<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>408</serviceExecutionTime><Trial id="107207"><TitleDisplay>Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer</TitleDisplay><TitleOfficial>A Phase II Trial Evaluating Efficacy and Safety of Opatin (Oxaliplatin)/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">10CT006A</Identifier><Identifier type="NCT">NCT01370876</Identifier></Identifiers><Indications><Indication id="3673">Metastatic head and neck cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>5-fluorouracil</Name></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="31219">Nang Kuang Pharmaceutical Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="31219" type="Company"><TargetEntity id="5035530541" type="organizationId">Nang Kuang Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="31219">Nang Kuang Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>46</PatientCountEnrollment><DateStart>2010-09-30T00:00:00Z</DateStart><DateEnd type="actual">2011-08-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:34:27Z</DateChangeLast><DateAdded>2013-02-05T10:11:03Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Taipei Mackay Memorial Hospital</Affiliation><Name>Chang Yi Fan, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have been histologically confirmed squamous cell carcinoma of the head             and neck (SCCHN) except nasopharyngeal cancer&lt;/li&gt;&lt;li&gt;Patients must have recurrent or metastatic disease and for which curative surgery or             radiotherapy do not exist or are no longer effective&lt;/li&gt;&lt;li&gt;Prior to entering the protocol treatment, it has to be &gt; 6 months interval             between previous systemic chemotherapy and protocol treatment&lt;/li&gt;&lt;li&gt;The disease must have been measurable by computed tomographic (CT) scan or magnetic resonance imaging (MRI; done             within 30 days of study entry) and the diameter of the target tumor is at least &gt; 1 cm&lt;/li&gt;&lt;li&gt;Patients must be between 20 to 75 years of age&lt;/li&gt;&lt;li&gt;Patients must have an ECOG performance status score 2&lt;/li&gt;&lt;li&gt;Patient's hematologic function, liver function and renal function must meet the             eligibility requirements&lt;/li&gt;&lt;li&gt;Patients must sign the informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with known hypersensitivity history to platinum compounds or to             5-FU&lt;/li&gt;&lt;li&gt;Patients with brain metastases&lt;/li&gt;&lt;li&gt;Patients with bone metastases only&lt;/li&gt;&lt;li&gt;Patients with pregnancy or breast-feeding&lt;/li&gt;&lt;li&gt;Patient with CTC (National Cancer Institute Common Toxicity Criteria) grade 2 peripheral neuropathy of any             cause that is clinically detectable&lt;/li&gt;&lt;li&gt;Patients who have serious concomitant illness that might be aggravated by             chemotherapy and other conditions which will be judged by physician's discretion&lt;/li&gt;&lt;li&gt;Patients who are receiving other anticancer cancer drug(s) for SCCHN&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Objective response rate: to evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer</Description><Timeframe>Every 12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety: to assess number of participants with adverse events of these treatment regimen</Description><Timeframe>Each patient will be followed for 30 days after the last dose of study medication</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the objective response rate of &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; combined with 5-fluorouracil  (5-FU) in patients with      recurrent or metastatic head and neck cancer and to assess the safety profile of these      treatment regimen.The study also aimed to evaluate the duration of      response of &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;/5-FU.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  receive &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; as a 2-h infusion first on day 1, followed by 5-FU intravenous infusion for 48-h (day 1 and 2), repeated every 2 weeks, 4 weeks as a cycle. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was terminated due to company policy.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Taiwan"><Sites><Site><Name>Taipei Mackay Memorial Hospital</Name><Address1>Taipei</Address1><Address3>104</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Head and neck tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3774">Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3777">Subjects with Specific Histological Sub-type of HNC</PatientSegment><SubSegments><SubSegment id="3778">Subjects with squamous cell carcinoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3799">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3804">Subjects with Relapsed/Recurrent Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10290">Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment><SubSegments><SubSegment id="10293">Subjects with TNM stage IVc HNC</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01370876</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Head and neck tumor" id="7263"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7264">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Head and neck tumor" id="7312"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Head and neck tumor" id="4370"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4386"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4389">Subjects with TNM stage IV C HNC</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4396"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4399">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4414"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4416">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Head and neck tumor" id="4417">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4441"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4443">Subjects with progressive/refractory HNC to radiotherapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="5237">Subjects with progressive/refractory HNC to surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4451"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4793"><Criterion>Subjects with Specific Histological Sub-type of Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4794">Subjects with squamous cell head and neck carcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="7086"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="34017"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4419">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Head and neck tumor" id="5712"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5715">Subjects with TNM stage IV C HNC</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5744"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5751"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5771"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5772">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="6479"><Criterion>Subjects on Other Non-Chemotherapeutic Medications</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="6732"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="8710"><Criterion>Subjects with Pharyngeal Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5694">Subjects with nasopharyngeal cancer</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-03-28T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-05T10:11:03Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-12-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="108619"><TitleDisplay>A double-blind, placebo-controlled, randomized study to assess the efficacy of cetirizine in pediatric patients with perennial allergic rhinitis</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="1107">Allergic rhinitis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cetirizine</Name><Drug id="2752">cetirizine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2752">cetirizine</Drug><IndicationsPioneer><Indication id="1107">Allergic rhinitis</Indication></IndicationsPioneer><Companies><Company><Company id="1036331">Hacettepe University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2752" type="Drug"><TargetEntity id="136227" type="siDrug">Cetirizine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1036331" type="Company"><TargetEntity id="5035541213" type="organizationId">Hacettepe Universitesi</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"/><TargetEntity id="-600684678" type="omicsDisease"/><TargetEntity id="298" type="siCondition"/></SourceEntity><SourceEntity id="199" type="Action"><TargetEntity id="196" type="Mechanism">Histamine H1 Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1036331">Hacettepe University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="199">Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15180">Topical antipruritic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateStart>1995-12-31T00:00:00Z</DateStart><DateChangeLast>2013-02-08T08:36:36Z</DateChangeLast><DateAdded>2013-02-08T08:36:36Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Pediatric patients aged 5 to 14 years with perennial allergic rhinitis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this double-blind, placebo-controlled, randomized study was to assess the efficacy of &lt;ulink linkType="Drug" linkID="2752"&gt;cetirizine&lt;/ulink&gt; in pediatric patients with perennial allergic rhinitis [&lt;ulink linkType="Reference" linkID="1360687"&gt;1360687&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 1995, results were published. &lt;ulink linkType="Drug" linkID="2752"&gt;Cetirizine&lt;/ulink&gt; was effective for the treatment of allergic rhinitis in children [&lt;ulink linkType="Reference" linkID="1360687"&gt;1360687&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were treated with &lt;ulink linkType="Drug" linkID="2752"&gt;cetirizine&lt;/ulink&gt;, 10 mg p.o. o.d. x 7 d; Placebo  [&lt;ulink linkType="Reference" linkID="1360687"&gt;1360687&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-08T08:36:36Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="113300"><TitleDisplay>An open-label study to evaluate the improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nateglinide</Name><Drug id="2375">nateglinide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2375">nateglinide</Drug><IndicationsPioneer/><Companies><Company><Company id="1079711">Saitama-ken Saiseikai Kurihashi Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2375" type="Drug"><TargetEntity id="127137" type="siDrug">Nateglinide</TargetEntity></SourceEntity><SourceEntity id="1079711" type="Company"><TargetEntity id="5038078198" type="organizationId">Saiseikai Kurihashi Hospital</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity><SourceEntity id="314" type="Action"><TargetEntity id="367" type="Mechanism">Potassium Channel Blockers</TargetEntity><TargetEntity id="372" type="Mechanism">K(ATP) Channel Blockers</TargetEntity><TargetEntity id="1642" type="Mechanism">Calcium-Activated K(Ca) Channel Blockers</TargetEntity><TargetEntity id="4392" type="Mechanism">Potassium Channel Subfamily K Blockers</TargetEntity></SourceEntity><SourceEntity id="92" type="Action"><TargetEntity id="360" type="Mechanism">Calcium Channel Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1079711">Saitama-ken Saiseikai Kurihashi Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="314">Potassium channel inhibitor</Action><Action id="92">Calcium channel stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="3246">Insulin release stimulator</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><PatientCountEvaluable>10</PatientCountEvaluable><DateStart>2002-01-31T00:00:00Z</DateStart><DateChangeLast>2013-03-04T03:47:09Z</DateChangeLast><DateAdded>2013-03-04T03:47:09Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with untreated type 2 diabetes with good insulin secreting ability and no diabetic complications&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the the improvement of glucose tolerance by &lt;ulink linkType="Drug" linkID="2375"&gt;nateglinide&lt;/ulink&gt; occurs through enhancement of early phase insulin secretion [&lt;ulink linkType="Reference" linkID="1371998"&gt;1371998&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results published in January 202, showed that &lt;ulink linkType="Drug" linkID="2375"&gt;nateglinide&lt;/ulink&gt; increased early phase insulin secretion. This was the factor that contributed more to postprandial hyperglycemia improvement in type 2 diabetes [&lt;ulink linkType="Reference" linkID="1371998"&gt;1371998&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="2375"&gt;nateglinide&lt;/ulink&gt;, 90 mg, po, tid  for  7 days [&lt;ulink linkType="Reference" linkID="1371998"&gt;1371998&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-04T03:47:09Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="117584"><TitleDisplay>An Open-Label Trial of Atomoxetine For Attention Deficit Hyperactivity Disorder (ADHD) in Children With 22q11.2 Deletion Syndrome (22qDS)</TitleDisplay><TitleOfficial>OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2010-024551-82</Identifier><Identifier type="Secondary Organisational">ATOM_22qDS/2011</Identifier><Identifier type="Trial Acronym">Atomoxetine in 22qDS</Identifier></Identifiers><Indications><Indication id="34">Attention deficit hyperactivity disorder</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atomoxetine</Name><Drug id="16905">atomoxetine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="16905">atomoxetine</Drug><IndicationsPioneer/><Companies><Company><Company id="1084103">South London and Maudsley NHS Foundation Trust</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1085386">NIHR Central Commissioning Facility</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23507">King's College London</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="16905" type="Drug"><TargetEntity id="90043" type="siDrug">Atomoxetine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1084103" type="Company"><TargetEntity id="5039587505" type="organizationId">South London and Maudsley NHS Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="1085386" type="Company"><TargetEntity id="5063321530" type="organizationId">NIHR Central Commissioning Facility</TargetEntity></SourceEntity><SourceEntity id="23507" type="Company"><TargetEntity id="4296365401" type="organizationId">King's College London</TargetEntity></SourceEntity><SourceEntity id="34" type="ciIndication"><TargetEntity id="F90" type="ICD10"/><TargetEntity id="10003736" type="MEDDRA"/><TargetEntity id="D001289" type="MeSH"/><TargetEntity id="-197354408" type="omicsDisease"/><TargetEntity id="87" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1084103">South London and Maudsley NHS Foundation Trust</Company><Company id="23507">King's College London</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1085386">NIHR Central Commissioning Facility</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="285">Norepinephrine uptake inhibitor</Class><Class id="2939">CNS modulator</Class><Class id="2941">Antidepressant</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Dose Comparison</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2012-03-07T00:00:00Z</DateStart><DateEnd type="actual">2013-03-22T00:00:00Z</DateEnd><DateChangeLast>2019-03-29T09:22:20Z</DateChangeLast><DateAdded>2013-03-27T11:34:16Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Institute of Psychiatry, King s College London;  Department of Child and Adolescent Psychiatry SE5 8AF London United Kingdom</Affiliation><Email>emily.simonoff@kcl.ac.uk</Email><Name>Emily Simonoff</Name><Phone>00440207848 5369</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children and adolescents of both genders, aged 7 to 17 years inclusive at the beginning of trial, with a genetically confirmed diagnosis of 22qDS&lt;/li&gt;&lt;li&gt;Diagnosis of attention deficit hyperactivity disorder&lt;/li&gt;&lt;li&gt;Access allowed to medical records&lt;/li&gt;&lt;li&gt;Participant is in a stable care situation&lt;/li&gt;&lt;li&gt;Informed consent is obtained&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Children currently receiving&lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; will not be included (those who have received &lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; in the past regardless of response, may be included, provided they did not demonstrate frank intolerance, ie, moderate to severe adverse effects at low doses)&lt;/li&gt;&lt;li&gt;A clear-cut history of intolerance to&lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; (defined as serious or moderate adverse events at very low doses eg, 10 mg qd)&lt;/li&gt;&lt;li&gt;Concomitant use of MAO inhibitor or narrow angle glaucoma (due to increased risk of mydriasis) represent absolute contradictions to the use of&lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; and constitute exclusion to the trial. MAOI use within the last 2 weeks or other drugs that affect brain monamine concentrations are also an exclusion&lt;/li&gt;&lt;li&gt;Severe limitation of mobility&lt;/li&gt;&lt;li&gt;Dementia or degenerative disorder&lt;/li&gt;&lt;li&gt;Poorly controlled or uncontrolled epilepsy&lt;/li&gt;&lt;li&gt;Presence of significant cardiovascular disease (medical notes will be reviewed by a consulant pediatrician and further investigations undertaken, if necessary, to exclude any reason for inclusion)&lt;/li&gt;&lt;li&gt;Psychotic disorder or bipolar disorder&lt;/li&gt;&lt;li&gt;Child has severe obsessive-compulsive disorder severe enough to require special treatment&lt;/li&gt;&lt;li&gt;Child is being treated with neuroleptic or stimulant medication (children have to be off neuroleptic medication for at least 1 month and 1 week off stimulant medication prior to randomization)&lt;/li&gt;&lt;li&gt;Child poses a significant risk of suicidal or homicidal behavior&lt;/li&gt;&lt;li&gt;Children without a full-time school/college placement that is expected to continue for the next 4 months&lt;/li&gt;&lt;li&gt;Another child the in family and/or household currently enrolled in this study&lt;/li&gt;&lt;li&gt;Children residing in a home without a telephone (land line or mobile)&lt;/li&gt;&lt;li&gt;Ongoing child protection concerns&lt;/li&gt;&lt;li&gt;For female participants, pregnancy or not wishing to have a pregnancy test at baseline, will be an exclusion criterion&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Reduction in symptoms of hyperactive behavior (overactivity, poor concentration and impulsivity) as rated by parents and teachers on the ADHD index of the short version of the conners scale: baseline ratings will be compared to ratings taken during week 16. The proportion of 'responders' will be estimated using the following three definitions of a 'responder': At least a 30% decrease in symptoms in week 16 score compared to baseline score based on parent ratings on the ADHD index of the CRS-S; at least a 30% decrease in symptoms in week 16 score compared to baseline score based on teacher ratings on the ADHD index of the CRS-S; where a child is classified as a responder on the basis of both parent and teacher ratings on the ADHD index of the CRS-S as defined above. Additionally, participants achieving at least 50% decrease in symptoms will be considered good responders</Description><Timeframe>16 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Parent and teacher hyperactivity scale ratings on the conners rating scales: clinicians' ratings of improvement in relation to symptoms and impairment as rated on the clinical global impressions scale at the end of the trial ('clinical global impressions scale,' 1985)</Description><Timeframe>At the end of the trial</Timeframe></Measure><Measure><Description>Changes in other behaviors commonly seen in children with learning disabilities will be evaluated by parent and teacher ratings on the aberrant behavior checklist</Description><Timeframe>At baseline and at week 16</Timeframe></Measure><Measure><Description>Adverse events will be primariy recorded using the 'other behaviors questonnaire'</Description><Timeframe>At baseline, during tiration and weeks 8, 12, 16</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of the trial was to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) among children with 22qDS who also have ADHD. Secondary objectives of this trial to evaluate the  adverse effects profile associated with &lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; treatment amongst children with a specific deletion in the 22qDS gene and ADHD [&lt;ulink linkType="Reference" linkID="1395866"&gt;1395866&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive  &lt;ulink linkType="Drug" linkID="16905"&gt;atomoxetine&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1395866"&gt;1395866&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Attention deficit hyperactivity disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="10179">Subjects with comorbid conditions</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="20253">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-275743253" id="21720">Chr22_HUMAN_del(22)(q11.2)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2010-024551-82</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Attention deficit hyperactivity disorder" id="15527"><Endpoint>Assessment of ADHD Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15529">Assessment of symptoms of impulsivity</SubEndpoint><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15530">Assessment of symptoms of hyperactivity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Attention deficit hyperactivity disorder" id="15532"><Endpoint>Assessment of ADHD Symptoms with Protocol Specified Scales</Endpoint><SubEndpoints><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15534">Assessment by Conners ADHD rating scale</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Attention deficit hyperactivity disorder" id="15620"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Attention deficit hyperactivity disorder" id="15527"><Endpoint>Assessment of ADHD Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15530">Assessment of symptoms of hyperactivity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Attention deficit hyperactivity disorder" id="15532"><Endpoint>Assessment of ADHD Symptoms with Protocol Specified Scales</Endpoint><SubEndpoints><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15534">Assessment by Conners ADHD rating scale</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Attention deficit hyperactivity disorder" id="15552"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15541">Assessment by Clinical Global Impression (CGI)</SubEndpoint><SubEndpoint disease="Attention deficit hyperactivity disorder" id="15556">Assessment of behavior</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Attention deficit hyperactivity disorder" id="15611"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Attention deficit hyperactivity disorder" id="14051"><Criterion>Subjects with Diagnosis of ADHD</Criterion></Inclusion><Inclusion disease="Attention deficit hyperactivity disorder" id="14091"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Attention deficit hyperactivity disorder" id="11488"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Attention deficit hyperactivity disorder" id="11491">Subjects with mood disorders</SubCriterion><SubCriterion disease="Attention deficit hyperactivity disorder" id="11492">Subjects with anxiety disorders</SubCriterion><SubCriterion disease="Attention deficit hyperactivity disorder" id="11493">Subjects co-morbid with psychotic disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Attention deficit hyperactivity disorder" id="11498"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Attention deficit hyperactivity disorder" id="11499">Subjects with other central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Attention deficit hyperactivity disorder" id="11508">Subjects with ocular diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Attention deficit hyperactivity disorder" id="11500"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Attention deficit hyperactivity disorder" id="11511"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Attention deficit hyperactivity disorder" id="11521"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Attention deficit hyperactivity disorder" id="11523">Hypersensitivity/Contra-Indication to atomoxetine</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Attention deficit hyperactivity disorder" id="11532"><Criterion>Subjects with History of  ADHD Therapy</Criterion><SubCriteria><SubCriterion disease="Attention deficit hyperactivity disorder" id="11533">Subjects with history of psychostimulants</SubCriterion><SubCriterion disease="Attention deficit hyperactivity disorder" id="11534">Subjects with history of atmoxetine</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Attention deficit hyperactivity disorder" id="26793"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Attention deficit hyperactivity disorder" id="11536">Subjects with history of antidepressants</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-27T11:34:16Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2019-03-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="123840"><TitleDisplay>Evaluation of Endoscopic Mucosal Activity, Non-Relapsing Rates and Detection Rates of Both Colonic Cancer and Dysplasia by Using FICE System for Patients With Ulcerative Colitis</TitleDisplay><TitleOfficial>Evaluation of endoscopic mucosal activity, non-relapsing rates and detection rates of both colonic cancer and dysplasia by using FICE (flexible spectral imaging color enhancement) system for patients with ulcerative colitis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000005074</Identifier></Identifiers><Indications><Indication id="337">Ulcerative colitis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="2054" role="Therapeutic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="4522" role="Therapeutic effect marker" type="Cellular">Erythrocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Flexible spectral imaging color enhancement</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25996" type="Company"><TargetEntity id="5035524339" type="organizationId">Saitama Medical University</TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"/><TargetEntity id="10009900" type="MEDDRA"/><TargetEntity id="D003093" type="MeSH"/><TargetEntity id="-1993209976" type="omicsDisease"/><TargetEntity id="396" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25996">Saitama Medical University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>500</PatientCountEnrollment><DateStart>2011-03-01T00:00:00Z</DateStart><DateChangeLast>2018-01-04T03:03:17Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Saitama Medical Center, Saitama medical University, Department og gastroenterology and Hepatology; 1981 Kamoda, Kawagoe City, Saitama, Japan</Affiliation><Email>skato@saitama-med.ac.jp</Email><Name>Shingo Kato</Name><Phone>+81-49-228-3564</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who can receive colonoscopic examination&lt;/li&gt;&lt;li&gt;Patients who receive informed consents&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who cannot receive colonoscopic examination because of their poor clinical condition and bad diagnostic imaging&lt;/li&gt;&lt;li&gt;Patients who refuse informed consents&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Vascular grading</Description></Measure><Measure><Description>Non-relapsing rates</Description></Measure><Measure><Description>Detection rates of both colonic cancer and dysplasia</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Clinical activity index</Description></Measure><Measure><Description>White blood cell count, platelet count, erythrocyte sedimentation rates, CRP</Description></Measure><Measure><Description>Pathological Matts grading</Description></Measure><Measure><Description>Endoscopic ultrasonographic evaluation</Description></Measure><Measure><Description>Concordance of FICE appearance and pathological specimens</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to investigate the relation of endoscopic mucosal activity and non-relapsing rates, and detection rates of both colonic cancer and dysplasia by using flexible spectral imaging color enhancement (FICE) in patients with ulcerative colitis [&lt;ulink linkType="Reference" linkID="1408739"&gt;1408739&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would undergo magnifing endoscopic examination with FICE (flexible spectral imaging color enhancement) system [&lt;ulink linkType="Reference" linkID="1408739"&gt;1408739&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000005074</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ulcerative colitis" id="15895"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Ulcerative colitis" id="15918"><Endpoint>Assessment of complications</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15919">Assessment of dysplastic/neoplastic changes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Ulcerative colitis" id="15898"><Endpoint>Ulcerative Colitis Assessed by Activity Indices</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15900">Assessment by Clinical Activity Index (CAI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15914"><Endpoint>Assessment of Biopsy/Cytology/Histology</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15915">Assessment by matt's grading system</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15950"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15961">Assessment by other imaging techniques </SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="16721"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="16724">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ulcerative colitis" id="15826"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15828">Subjects assessed by/indicated for endoscopic examination</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ulcerative colitis" id="13151"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="149708"><TitleDisplay>Safety and Immunogenicity of Rabies Vaccine (Chick Embryo Cell) for Human Use Produced in Germany and India</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">PMID:20084974</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rabies chick embryo cell vaccine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1050286" type="Company"><TargetEntity id="5040202586" type="organizationId">Jiangsu Provincial Center for Disease Control and Prevention</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1050286">Jiangsu Province Centers for Disease Control and Prevention</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2015-09-30T17:07:45Z</DateChangeLast><DateAdded>2013-08-12T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy subjects&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2009, results were published. Severe systemic and local reactions were not observed in trial group (Rabipur produced in India)  [&lt;ulink linkType="Reference" linkID="1464017"&gt;1464017&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose was to assess the safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India [&lt;ulink linkType="Reference" linkID="1464017"&gt;1464017&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2009, results were published. Significant difference was not observed between trial and control group. The seroconversion rates of the two groups were 100% and GMC of the two groups increased obviously and highly beyond 0.5 TU/ml, 14 and 45 days after the first dose  [&lt;ulink linkType="Reference" linkID="1464017"&gt;1464017&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects received rabies vaccine (chick embryo cell) [&lt;ulink linkType="Reference" linkID="1464017"&gt;1464017&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Rabies Vaccine" id="14491"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Rabies Vaccine" id="14493">Assessment of anti-rabies antibodies</SubEndpoint><SubEndpoint disease="Rabies Vaccine" id="14495">Assessment of seropositivity/seroconversion rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Rabies Vaccine" id="14496"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Rabies Vaccine" id="34749"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Rabies Vaccine" id="13592">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-08-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="15661"><TitleDisplay>A phase I safety and pharmacokinetic study of palivizumab in healthy volunteers</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers/><Indications><Indication id="287">Respiratory syncytial virus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>palivizumab</Name><Drug id="8747">palivizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8747">palivizumab</Drug><IndicationsPioneer><Indication id="287">Respiratory syncytial virus infection</Indication></IndicationsPioneer><Companies><Company><Company id="18008">MedImmune LLC</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8747" type="Drug"><TargetEntity id="218833" type="siDrug">Palivizumab</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="287" type="ciIndication"><TargetEntity id="10061603" type="MEDDRA"/><TargetEntity id="D018357" type="MeSH"/><TargetEntity id="-1462311917" type="omicsDisease"/><TargetEntity id="866" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="18008">MedImmune LLC</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="52108">Respiratory syncytial virus protein F modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>38</PatientCountEnrollment><PatientCountEvaluable>38</PatientCountEvaluable><DateStart>1997-03-10T00:00:00Z</DateStart><DateChangeLast>2008-06-10T11:52:49Z</DateChangeLast><DateAdded>2008-06-10T11:52:49Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy adults&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure><Measure><Description>Pharmacokinetics</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;There were no drug-related serious adverse events [&lt;ulink linkType="Reference" linkID="237303"&gt;237303&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A phase I safety and pharmacokinetic study of &lt;ulink linkType="Drug" linkID="8747"&gt;palivizumab&lt;/ulink&gt; in healthy volunteers [&lt;ulink linkType="Reference" linkID="237303"&gt;237303&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="8747"&gt;palivizumab&lt;/ulink&gt; was well tolerated at doses ranging from 1 to 15 mg/kg. Low level and transient immune responses to &lt;ulink linkType="Drug" linkID="8747"&gt;palivizumab&lt;/ulink&gt; were observed in a small number of subjects. The duration of the antibody in the bloodstream (half-life ranging from 13 to 26 days) was similar to that of natural human antibodies. Within 7 days after the first intramuscular dose, blood levels increased to those levels attained by intravenous dosing and remained approximately superimposable until the next dose [&lt;ulink linkType="Reference" linkID="237303"&gt;237303&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-06-10T11:52:49Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="157641"><TitleDisplay>A Phase 1b Clinical Trial of Syn-1002 to Demonstrate Its Proof of Concept in Validated Human Pain Models</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Syn-1002</Name><Drug id="45278">Syn-1002</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pregabalin</Name><Drug id="17814">pregabalin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17814">pregabalin</Drug><IndicationsPioneer/><Companies><Company><Company id="18010">Laboratories Leurquin-Mediolanum SA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="27663">CLL Pharma</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="45278">Syn-1002</Drug><IndicationsPioneer/><Companies><Company><Company id="18010">Laboratories Leurquin-Mediolanum SA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="27663">CLL Pharma</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17814" type="Drug"><TargetEntity id="194644" type="siDrug">Pregabalin</TargetEntity></SourceEntity><SourceEntity id="45278" type="Drug"><TargetEntity id="370898" type="siDrug">Syn-1002</TargetEntity></SourceEntity><SourceEntity id="18010" type="Company"><TargetEntity id="5035528166" type="organizationId">Laboratories Leurquin Mediolanum SA</TargetEntity></SourceEntity><SourceEntity id="27663" type="Company"><TargetEntity id="4296726920" type="organizationId">CLL Pharma SA</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="17217" type="Action"><TargetEntity id="5031" type="Mechanism">GABA(A) Receptor Subunit alpha-2 (GABRA2) Positive Allosteric Modulators</TargetEntity><TargetEntity id="5343" type="Mechanism">GABA(A) Receptor Subunit alpha-2 Agonists</TargetEntity></SourceEntity><SourceEntity id="17247" type="Action"><TargetEntity id="5227" type="Mechanism">GABA(A) Receptor Subunit delta Positive Allosteric Modulators</TargetEntity></SourceEntity><SourceEntity id="173" type="Action"><TargetEntity id="961" type="Mechanism">GABAergic Transmission Enhancers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="18010">Laboratories Leurquin-Mediolanum SA</Company><Company id="27663">CLL Pharma</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="17217">GABA A receptor alpha-2 subunit stimulator</Action><Action id="17247">GABA A receptor delta subunit stimulator</Action><Action id="173">GABA receptor agonist</Action><Action id="3411">Thymulin receptor agonist</Action><Action id="50960">CACNA2D calcium channel subunit modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class><Class id="70">Anticonvulsant agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2013-07-15T00:00:00Z</DateStart><DateChangeLast>2013-10-15T08:18:46Z</DateChangeLast><DateAdded>2013-10-18T00:00:00Z</DateAdded><Contacts/><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>To evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of Syn-1002 administered at three dose levels in comparison with pregabalin</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of &lt;ulink linkType="Drug" linkID="45278"&gt;Syn-1002&lt;/ulink&gt; administered at three dose levels in comparison with &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;  [&lt;ulink linkType="Reference" linkID="1487540"&gt;1487540&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  received either &lt;ulink linkType="Drug" linkID="45278"&gt;Syn-1002&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; or placebo    [&lt;ulink linkType="Reference" linkID="1487540"&gt;1487540&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="34745"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22260">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-10-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="160780"><TitleDisplay>A Study of Effectiveness and Safety of Delayed Release Prednisolone in Patients With Newly Diagnosed Giant Cell Arteritis</TitleDisplay><TitleOfficial>A study of efficacy and safety of delayed release prednisolone in newly diagnosed cases of Giant Cell Arthritis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2011-005090-22</Identifier><Identifier type="ISRCTN">ISRCTN40911426</Identifier><Identifier type="Secondary Organisational">UKCRN ID: 12529</Identifier><Identifier type="Secondary Organisational">001</Identifier></Identifiers><Indications><Indication id="1850">Temporal arteritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="781" role="Therapeutic effect marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName><BiomarkerName id="12058" role="Toxic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>prednisolone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1059947" type="Company"><TargetEntity id="5035526568" type="organizationId">Southend Hospital</TargetEntity></SourceEntity><SourceEntity id="18449" type="Company"><TargetEntity id="4298440557" type="organizationId">Napp Pharmaceutical Group Ltd</TargetEntity></SourceEntity><SourceEntity id="1850" type="ciIndication"><TargetEntity id="10043207" type="MEDDRA"/><TargetEntity id="D013700" type="MeSH"/><TargetEntity id="397" type="ORPHANET"/><TargetEntity id="-693410461" type="omicsDisease"/><TargetEntity id="1618" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1059947">Southend Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="18449">Napp Pharmaceutical Group Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2011-12-01T00:00:00Z</DateStart><DateEnd type="actual">2012-12-01T00:00:00Z</DateEnd><DateChangeLast>2018-02-20T10:51:11Z</DateChangeLast><DateAdded>2013-11-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, SS0 0RY, United Kingdom</Affiliation><Name>Mark Williams</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 50 years&lt;/li&gt;&lt;li&gt;New diagnosis of Giant Cell Arteritis (GCA) within last 4 weeks&lt;/li&gt;&lt;li&gt;Erythrocyte sedimentation rate (ESR)&amp;gt; 30 mm/h or CRP &amp;gt; 10 mg/l&lt;/li&gt;&lt;li&gt;Unequivocal clinical and laboratory picture of GCA either fulfilling American College of Rheumatology (ACR) criteria or typical features, as assessed by a clinician, including one or several of the following:&lt;ul&gt;&lt;li&gt;New onset localised pain in the head after 50 years of age&lt;/li&gt;&lt;li&gt;Jaw or tongue claudication&lt;/li&gt;&lt;li&gt;Visual symptoms (amaurosis fugax, blurring and diplopia)&lt;/li&gt;&lt;li&gt;Systemic symptoms not attributable to other causes&lt;/li&gt;&lt;li&gt;Limb claudication&lt;/li&gt;&lt;li&gt;Polymyalgia&lt;/li&gt;&lt;li&gt;Abnormal temporal artery (tender, thickened, beading, decreased pulsation)&lt;/li&gt;&lt;li&gt;Scalp tenderness&lt;/li&gt;&lt;li&gt;Decreased visual acuity/visual field defect&lt;/li&gt;&lt;li&gt;Anterior ischemic optic neuropathy or central retinal artery occlusion&lt;/li&gt;&lt;li&gt;Upper cranial nerve palsies&lt;/li&gt;&lt;li&gt;Symptoms and signs of GCA with typical ischemic complications (eg, Anterior ischemic optic neuropathy - AION). The American College of Rheumatology classification criteria for GCA (three out of five items fulfilled)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;New onset of or new type of localized pain in the&lt;/li&gt;&lt;li&gt;Temporal artery abnormality: tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries&lt;/li&gt;&lt;li&gt;Elevated erythrocyte sedimentation rate (ESR &gt;/= 50 mm/h by the Westergren method)&lt;/li&gt;&lt;li&gt;Abnormal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;GCA on steroid therapy longer than 4 weeks&lt;/li&gt;&lt;li&gt;Previous exposure to DMARD/biological therapy&lt;/li&gt;&lt;li&gt;Serious or chronic infection in the last 3 months&lt;/li&gt;&lt;li&gt;Diagnostic doubt&lt;/li&gt;&lt;li&gt;Failure to respond to high dose steroids within 5 days&lt;/li&gt;&lt;li&gt;Known other vasculitis&lt;/li&gt;&lt;li&gt;Patients with evolving ischemic symptoms requiring intravenous methylprednisolone&lt;/li&gt;&lt;li&gt;Malignancy&lt;/li&gt;&lt;li&gt;Patients lacking capacity to consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportion of patients achieving persistent disease control (without features of active disease and remaining flare free) in each arm. Disease control: primary response criteria for assessing remission in patients will be as follows: patients maintaining a global improvement &gt; 70% (compared to pre-steroid state), absence of signs and symptoms of new, recurrent, worsening features of GCA, CRP &lt; 10 mg/l or ESR&lt; 30 mm/h, complete control: patients fulfilling all three criteria items, partial control: fulfilling two out of three</Description><Timeframe>At 26 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Relapse free subjects in each arm</Description><Timeframe>At 26 weeks</Timeframe></Measure><Measure><Description>Time to the first flare</Description></Measure><Measure><Description>Time to second flare</Description></Measure><Measure><Description>Cumulative steroid dosage</Description></Measure><Measure><Description>Patient global VAS of disease activity</Description></Measure><Measure><Description>Reduction of erythrocyte sedimentation rate (ESR)</Description></Measure><Measure><Description>Reduction of C-reactive protein (CRP)</Description></Measure><Measure><Description>Improvement in HAQ and Euro QOL 5D</Description></Measure><Measure><Description>Visual Function Questionnaire (VFQ-25) in patients with vision loss</Description></Measure><Measure><Description>Improvement in sleep and fatigue scores</Description></Measure><Measure><Description>Proportion with steroid related toxicity in each arm with particular reference to weight gain, fluid retention, bruising, glucose tolerance, hypertension, dyspepsia</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether delayed release prednisolone, in doses equivalent to standard of care immediate release prednisolone, can effectively maintain disease control in new cases of giant cell arteritis and to  investigate the duration of the observed clinical response and safety and tolerance of said treatment.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be treated with high dose standard prednisolone (40 to 60 mg) daily for 4 weeks. Thereafter they would be randomized to two open arms with 15 cases in each arm to continue tapering steroid treatment with either standard (IR) or modified release (MR) prednisolone.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts/></Site><Site><Contacts/></Site><Site><Name>Southend University Hospital</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8431">Subjects with Other Types of Pain</PatientSegment><SubSegments><SubSegment id="8432">Subjects with other types of headache</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2011-005090-22</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN40911426</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21865"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21868">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21893"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25894"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25988"><Endpoint>Assessment of Underlying Conditions</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25993">Vascular disease related outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26007"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26019">Assessment of hematological function</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26023">Endothelial function assessments</SubEndpoint><SubEndpoint disease="Pain" id="26024">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26045"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26049"><Endpoint>Assessment of Remission</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25986">Assessment by Patient Global Impression Scale (PGI)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="26273">Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</SubEndpoint><SubEndpoint disease="Peripheral vascular disease" id="26279">Health assessment questionnaire (HAQ)</SubEndpoint><SubEndpoint disease="Peripheral vascular disease" id="26298">Other patient reported outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21865"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21868">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21893"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21936"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21937">Assessment of adverse effects</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25889"><Endpoint>Assessment of Other Measures of Pain Quality</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25890">Assessment of acute pain flare</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25983"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26023">Endothelial function assessments</SubEndpoint><SubEndpoint disease="Pain" id="26024">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26049"><Endpoint>Assessment of Remission</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19201"><Criterion>Subjects with Peripheral Arterial Disease</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19207">Subjects with intermittent claudication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19260"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19270">Subjects co-morbid with inflammatory diseases/disorders</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="19274">Subjects with neuropathy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22120"><Criterion>Subjects with Other Headaches</Criterion><SubCriteria><SubCriterion disease="Pain" id="22124">Subjects with headache attributed to a secondary cause</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22181"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="22187">Subjects with normal/acceptable hematopoietic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22196">Subjects with infectious/inflammatory/immunological disease/disorder associated pain</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15981"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16023">Subjects with history/requiring corticosteroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20122">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20119"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20135">Subjects with history/scheduled to receive steroids</SubCriterion><SubCriterion disease="Pain" id="20152">Subjects with history/scheduled to receive biologics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion></Exclusion><Exclusion disease="Pain" id="20179"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25907"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16007">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2012-12-01T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.03 Months</EnrollmentPeriod><EnrollmentRate>2.49 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-11-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="175889"><TitleDisplay>Randomized, Controlled Trials of the Effects of Decadron on Swallowing, Airway, and Arthrodesis</TitleDisplay><TitleOfficial>Prospective, Randomized, Controlled Trail of the Effects of Steroids on Swallowing, Airway and Arthrodesis Related to Multi-Level Anterior Cervical Reconstruction</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01065961</Identifier><Identifier type="Organisational Study">D-01</Identifier></Identifiers><Indications><Indication id="2085">Dysphagia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Decadron</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="24139" type="Company"><TargetEntity id="4298209044" type="organizationId">Albany Medical College</TargetEntity></SourceEntity><SourceEntity id="2085" type="ciIndication"><TargetEntity id="R13.0" type="ICD10"/><TargetEntity id="R13.1" type="ICD10"/><TargetEntity id="787.2" type="ICD9"/><TargetEntity id="10013950" type="MEDDRA"/><TargetEntity id="D003680" type="MeSH"/><TargetEntity id="-1314452377" type="omicsDisease"/><TargetEntity id="1592" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="24139">Albany Medical College</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><PatientCountEvaluable>112</PatientCountEvaluable><DateStart>2008-11-30T00:00:00Z</DateStart><DateEnd type="estimated">2016-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-01-18T22:09:30Z</DateChangeLast><DateAdded>2014-03-05T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>dirisi@mail.amc.edu</Email><Name>Darryl DiRisio, MD</Name><Phone>518 262-5088</Phone></Contact><Contact type="Public contact"><Email>czerwim@mail.amc.edu</Email><Name>Margaret Czerwinski, BSN, RN</Name><Phone>518 262-0034</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age of &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Cervical spondylosis requiring surgical treatment at two or more motion segments&lt;/li&gt;&lt;li&gt;Ventrally - approachable vertebral levels&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Minors (under 18 years old)&lt;/li&gt;&lt;li&gt;Pregnant women&lt;/li&gt;&lt;li&gt;Patients currently taking steroids&lt;/li&gt;&lt;li&gt;Patients requiring surgical treatment at only one segment&lt;/li&gt;&lt;li&gt;Comatose or incapacitated patients who cannot consent to participate&lt;/li&gt;&lt;li&gt;Wards of the state&lt;/li&gt;&lt;li&gt;Persons with an allergy to dexamethasone or related drugs&lt;/li&gt;&lt;li&gt;Persons employed at Albany Medical Center&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Complications/reoperations</Description><Timeframe>Follow-up was performed at 1, 3, 6, 12, and 24 months</Timeframe></Measure><Measure><Description>Subjects will demonstrate good bony fusion</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Functional status: modified Japanese Orthopedic Association myelopathy score</Description><Timeframe>Follow-up was performed at 1, 3, 6, 12, and 24 months</Timeframe></Measure><Measure><Description>Functional status: neck disability index</Description><Timeframe>Follow-up was performed at 1, 3, 6, 12, and 24 months</Timeframe></Measure><Measure><Description>Functional status: 12-Item Short-Form Health Survey score</Description><Timeframe>Follow-up was performed at 1, 3, 6, 12, and 24 months</Timeframe></Measure><Measure><Description>Functional status: patient-reported visual analog scale score of axial and radiating pain</Description><Timeframe>Follow-up was performed at 1, 3, 6, 12, and 24 months</Timeframe></Measure><Measure><Description>Functional outcome: swallowing scale score, interval postoperative imaging, fusion status</Description><Timeframe>Follow-up was performed at 1, 3, 6, 12, and 24 months  and CT was performed 6, 12, and 24 months after surgery for fusion assessment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The investigators hypothesis was that the use of steroids intraoperatively provides a      significant benefit to the patient, in terms of reduced incidence of dysphagia and airway      compromise.&lt;br/&gt;The purpose of this trial was to access the effects of steroids on swallowing, airway and arthrodesis related to multi-level anterior cervical reconstruction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in August 2015.  No differences were reported in the steroid and placebo groups, in terms of patient-reported functional and pain-related outcomes. Compared to the placebo group,  the severity of dysphagia in the postoperative period up to 1 month proved to be significantly lower in the steroid group than in the placebo group (p = 0.027). Airway difficulty and a need for intubation were reported to be significant in the placebo group (p = 0.057). At 6 months, fusion rates at 6 months were significantly lower in the steroid group but lost significance at 12 months (p = 0.048 and 0.57, respectively) [&lt;ulink linkType="Reference" linkID="1696607"&gt;1696607&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized into two arms:&lt;br/&gt;Arm A: subject would be given Decadron 0.2 mg/kg intraoperatively. This dose would be followed by 4 mg every 6 h for the first 24 h.&lt;br/&gt;Arm B: subject would be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 h for 24 h.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects ( n = 112) were enrolled and randomized to receive  either saline or dexamethasone [&lt;ulink linkType="Reference" linkID="1696607"&gt;1696607&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Albany Medical Center</Name><Address1>Albany</Address1><Address2>New York</Address2><Address3>12208</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Osteoarthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="8845">Subjects With Disc Degeneration (Spinal Osteoarthritis)</PatientSegment><SubSegments><SubSegment id="8925">Subjects with cervical osteoarthritis</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8866">Subjects With History of /Scheduled For Surgical Procedures</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01065961</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoarthritis" id="13937"><Endpoint>Assessment of Implant/Prosthesis Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13945">Assessment of bone fusion rate</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoarthritis" id="14150"><Criterion>Subjects With Disc Degeneration (Spinal Osteoarthritis)</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14152">Subjects with cervical osteoarthritis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="14227"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14242">Subjects with specific range of motion flexion</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Osteoarthritis" id="11602"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11631"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11645"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11646">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="26814"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11625">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-11-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-02-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-03-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-09-29T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="176505"><TitleDisplay>Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty</TitleDisplay><TitleOfficial>Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): a Randomized, Masked, Placebo-Controlled Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00485108</Identifier><Identifier type="Organisational Study">DJ1</Identifier></Identifiers><Indications><Indication id="134">Glaucoma</Indication><Indication id="3147">Open angle glaucoma</Indication></Indications><BiomarkerNames><BiomarkerName id="10753" role="Therapeutic effect marker" type="Physiological">Intraocular pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ketorolac (ophthalmic), Allergan</Name><Drug id="3423">ketorolac (ophthalmic), Allergan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>prednisolone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3423">ketorolac (ophthalmic), Allergan</Drug><IndicationsPioneer><Indication id="3147">Open angle glaucoma</Indication></IndicationsPioneer><Companies><Company><Company id="1043097">Glaucoma Research Society of Canada</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1050299">Queen's University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3423" type="Drug"><TargetEntity id="158396" type="siDrug">Ketorolac tromethamine</TargetEntity></SourceEntity><SourceEntity id="1043097" type="Company"><TargetEntity id="5035544176" type="organizationId">Glaucoma Research Society Of Canada</TargetEntity></SourceEntity><SourceEntity id="1050299" type="Company"><TargetEntity id="4297020324" type="organizationId">Queen's University</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="134" type="ciIndication"><TargetEntity id="H40" type="ICD10"/><TargetEntity id="365" type="ICD9"/><TargetEntity id="10018304" type="MEDDRA"/><TargetEntity id="D005901" type="MeSH"/><TargetEntity id="-1306155249" type="omicsDisease"/><TargetEntity id="777" type="siCondition"/></SourceEntity><SourceEntity id="3147" type="ciIndication"><TargetEntity id="H40.1" type="ICD10"/><TargetEntity id="10030348" type="MEDDRA"/><TargetEntity id="D005902" type="MeSH"/><TargetEntity id="-1400643513" type="omicsDisease"/><TargetEntity id="779" type="siCondition"/></SourceEntity><SourceEntity id="132" type="Action"><TargetEntity id="405" type="Mechanism">Cyclooxygenase (COX) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1050299">Queen's University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1043097">Glaucoma Research Society of Canada</Company><Company id="18767">Pfizer Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="132">Cyclooxygenase inhibitor</Action><Action id="406">Oxidoreductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2946">Analgesic</Class><Class id="2955">Non-steroidal anti-inflammatory</Class><Class id="329">Prostaglandin synthesis inhibitor</Class></Class><Technologies><Technology id="620">Ophthalmic formulation</Technology><Technology id="659">Ophthalmic liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2007-01-31T00:00:00Z</DateStart><DateEnd type="actual">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-05-16T08:11:05Z</DateChangeLast><DateAdded>2014-03-07T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Queen's University</Affiliation><Name>Delan Jinapriya, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Queen's University</Affiliation><Name>Rob J Campbell, MD, MSc</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Primary open angle glaucoma, pseudo exfoliation glaucoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous incisional glaucoma surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Intraocular pressure lowering effect</Description><Timeframe>1 h, 2 days, 1, 3, 6 months and one year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Intraocular pressure elevation</Description><Timeframe>1 h, 2 days, 1 month</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study       evaluated the intra-ocular pressure (IOP) lowering effect of selective laser trabeculoplasty (SLT) following the topical administration of  prednisolone 1% or &lt;ulink linkType="Drug" linkID="3422"&gt;ketorolac&lt;/ulink&gt; 0.5% or artificial tears (methyl cellulose drops).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  be randomized to receive  prednisolone 1% or &lt;ulink linkType="Drug" linkID="3423"&gt;ketorolac&lt;/ulink&gt; 0.5% or artificial tears qid for 5 days following      administration of the laser treatment.  The IOP will be measured at various time points      following SLT (1 h, 2 days, 1 week, 1, 3, 6 months, and one year).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Queen's University</Name><Address1>Kingston</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Queen s University</Name><Address1>Kingston</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Glaucoma</Disease><PatientSegments><PatientSegment><PatientSegment id="9163">Subjects with Primary Open-Angle Glaucoma(POAG)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9168">Subjects with Secondary Glaucoma</PatientSegment><SubSegments><SubSegment id="9172">Subjects with pseudoexfoliative glaucoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Ocular hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="11708">Subjects with primary open-angle glaucoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11711">Subjects with secondary glaucoma</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00485108</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Glaucoma" id="16648"><Endpoint>Assessment of ocular function</Endpoint><SubEndpoints><SubEndpoint disease="Glaucoma" id="16634">Assessment of intraocular pressure(IOP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Ocular hypertension" id="25612"><Endpoint>Assessment of ocular function</Endpoint><SubEndpoints><SubEndpoint disease="Ocular hypertension" id="25600">Assessment of intraocular pressure(IOP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Glaucoma" id="16648"><Endpoint>Assessment of ocular function</Endpoint><SubEndpoints><SubEndpoint disease="Glaucoma" id="16634">Assessment of intraocular pressure(IOP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ocular hypertension" id="25612"><Endpoint>Assessment of ocular function</Endpoint><SubEndpoints><SubEndpoint disease="Ocular hypertension" id="25600">Assessment of intraocular pressure(IOP)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Glaucoma" id="15601"><Criterion>Subjects with Secondary Glaucoma</Criterion><SubCriteria><SubCriterion disease="Glaucoma" id="15605">Subjects with pseudoexfoliative glaucoma(PXFG)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ocular hypertension" id="21863"><Criterion>Subjects with Specific Type of Glaucoma</Criterion><SubCriteria><SubCriterion disease="Ocular hypertension" id="21864">Subjects with primary open-angle glaucoma(POAG)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ocular hypertension" id="21867"><Criterion>Subjects with secondary glaucoma</Criterion></Inclusion><Inclusion disease="Glaucoma" id="35000"><Criterion>Subjects with Specific Type of Glaucoma</Criterion><SubCriteria><SubCriterion disease="Glaucoma" id="15596">Subjects with Primary Open-Angle Glaucoma (POAG)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Glaucoma" id="13946"><Criterion>Subjects with History of/Scheduled for Ocular Therapy</Criterion><SubCriteria><SubCriterion disease="Glaucoma" id="13948">Subjects with history of/scheduled for ocular procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ocular hypertension" id="19798"><Criterion>Subjects with History of/Scheduled for Ocular Therapy</Criterion><SubCriteria><SubCriterion disease="Ocular hypertension" id="19800">Subjects with history of/scheduled for ocular procedures</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>24.03 Months</EnrollmentPeriod><EnrollmentRate>4.99 Patients/Month</EnrollmentRate><DateFirstReceived>2007-06-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-03-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="187186"><TitleDisplay>OsseoFix Spinal Fracture Reduction System in Treating Spinal Compression Fracture</TitleDisplay><TitleOfficial>Evaluation of Safety and Effectiveness of the OsseoFix Spinal Fracture Reduction System in Treating Spinal Compression Fracture</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00961714</Identifier><Identifier type="Organisational Study">08-02-A</Identifier><Identifier type="Trial Acronym">OsseoFix</Identifier></Identifiers><Indications><Indication id="3136">Spinal cord compression</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>OsseoFix spinal fracture reduction system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1022706" type="Company"><TargetEntity id="4295164959" type="organizationId">Alphatec Spine Inc</TargetEntity></SourceEntity><SourceEntity id="3136" type="ciIndication"><TargetEntity id="10041549" type="MEDDRA"/><TargetEntity id="D013117" type="MeSH"/><TargetEntity id="-1553141350" type="omicsDisease"/><TargetEntity id="177" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><NumberOfSites>11</NumberOfSites><CompaniesSponsor><Company id="1022706">Alphatec Spine Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>15</PatientCountEnrollment><DateStart>2009-08-31T00:00:00Z</DateStart><DateEnd type="actual">2013-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:32:43Z</DateChangeLast><DateAdded>2014-05-16T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Integrative Treatment Centers</Affiliation><Name>Daniel Bennett, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Yale University</Affiliation><Name>James Yue, MD</Name></Contact><Contact type="Scientific contact"><Email>harambula@alphatecspine.com</Email><Name>Heidi Arambula</Name><Phone>760-494-6637</Phone></Contact><Contact type="Scientific contact"><Affiliation>Clinical Radiology Of Oklahoma; Edmond; Oklahoma; 73034; United States</Affiliation><Name>Douglas Beall</Name></Contact><Contact type="Scientific contact"><Affiliation>Scripps; La Jolla; California; 92037; United States</Affiliation><Name>James Bruffey</Name></Contact><Contact type="Scientific contact"><Affiliation>Boulder Neurosurgery Associates; Boulder; Colorado; 80304; United States</Affiliation><Email>sigitab@bnasurg.com</Email><Name>Sigita Burneikiene</Name><Phone>303-938-5700</Phone></Contact><Contact type="Scientific contact"><Affiliation>Neurospine Solutions, PC; Bristol; Tennessee; 37620; United States</Affiliation><Email>kim@neurospinesolutions.net</Email><Name>Kim Butterworth</Name><Phone>423-844-0501</Phone></Contact><Contact type="Scientific contact"><Affiliation>Lyerly Neurosurgery; Jacksonville; Florida; 32207; United States</Affiliation><Email>rcurtright@lyerlyneuro.com</Email><Name>Roxanne Curtright</Name><Phone>904.388.6518</Phone></Contact><Contact type="Scientific contact"><Affiliation>Scripps; La Jolla; California; 92037; United States</Affiliation><Email>daneshvari.suzanne@scrippshealth.org</Email><Name>Suzanne Daneshvari</Name><Phone>858-332-0133</Phone></Contact><Contact type="Scientific contact"><Affiliation>Southwestern Orthopedic Center; Savannah; Georgia; 31405; United States</Affiliation><Name>James Dewberry</Name></Contact><Contact type="Scientific contact"><Affiliation>Scripps; La Jolla; California; 92037; United States</Affiliation><Name>Robert Eastlack</Name></Contact><Contact type="Scientific contact"><Affiliation>SIU Phyysicians and Surgeons Division of Orthopaedics and Rehabilitation; Springfield; Illinois; 62702; United States</Affiliation><Name>Per Freitag</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age of 50 years&lt;/li&gt;&lt;li&gt;Legal US citizen with ability to read and write&lt;/li&gt;&lt;li&gt;Acute painful fracture (&amp;lt;/= 2 months) between T6 to L5 as evidenced by plain radiography, CT / Bone scan, and/or magnetic resonance imaging&lt;/li&gt;&lt;li&gt;Subject is:&lt;ul&gt;&lt;li&gt;Non-standard treatment:&lt;ul&gt;&lt;li&gt;Inability to tolerate prolonged conservative care due to intractable pain (VAS 70/100) with maximum tolerated medication for at least 2 weeks, but&amp;lt; 6 weeks&lt;/li&gt;&lt;li&gt;Inability to tolerate prolonged immobilization due to other comorbid conditions aggravated by immobility for at least 2 weeks, but&amp;lt; 6 weeks&lt;/li&gt;&lt;li&gt;Intolerance of or adverse reaction to available pain medications for at least 2 weeks, but&amp;lt; 6 weeks&lt;/li&gt;&lt;li&gt;Hospitalization secondary to pain for at least 2 weeks, but&amp;lt; 6 weeks&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Standard treatment:&lt;ul&gt;&lt;li&gt;Has undergone at least 6 weeks of conservative care&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Have a self assessment VAS score &gt;/= 50 mm at the baseline visit&lt;/li&gt;&lt;li&gt;Have 30% or greater disability score on ODI at the baseline visit&lt;/li&gt;&lt;li&gt;Anterior wedge deformity with no&amp;lt; 5 and no &gt; 75% loss of anterior cortical height as compared to the posterior cortical height of the same vertebral body&lt;/li&gt;&lt;li&gt;Bone mineral density (BMD) T-score of -1.5 or less, as determined by a DEXA scan&lt;/li&gt;&lt;li&gt;Intact posterior cortical vertebral body wall&lt;/li&gt;&lt;li&gt;Type A compression fractures according to AO classification of spinal vertebral fractures&lt;/li&gt;&lt;li&gt;If a transpedicular approach is utilized the pedicle diameter must be &gt;/= 6.5 mm; however, if an extrapedicular approach is utilized there is not a minimum pedicle width requirement&lt;/li&gt;&lt;li&gt;Subject is willing and able to provide informed consent and agrees to release medical information for purposes of this study (HIPAA authorization) and to return for scheduled follow-up evaluations&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Significant vertebral collapse defined as &gt; 75% of original vertebral height or&amp;lt; 5% or a burst or pedicle fracture with posterior cortical wall disruption&lt;/li&gt;&lt;li&gt;Presence of healed fracture at the intended treatment level(s) based on a CT / bone scan or MRI&lt;/li&gt;&lt;li&gt;Compression fractures requiring treatment at 3 or more levels&lt;/li&gt;&lt;li&gt;Spinal/foraminal canal compromised&lt;/li&gt;&lt;li&gt;Significant deformity/instability indicated by:&lt;ul&gt;&lt;li&gt;Segmental kyphosis &gt; 30 deg, or&lt;/li&gt;&lt;li&gt;Translation &gt; 4 mm&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;VAS back pain score of&amp;lt; 50 mm&lt;/li&gt;&lt;li&gt;ODI score of&amp;lt; 30%&lt;/li&gt;&lt;li&gt;Have a documented active systemic or local infection, such as AIDS, hepatitis, with a WBC &gt; 11.5 and a temperature &gt; 101.5 degF&lt;/li&gt;&lt;li&gt;Spinal surgery in the thoracic and/or lumbar region within the past year&lt;/li&gt;&lt;li&gt;Previous kyphoplasty or vertebroplasty at involved level or level above or below treated level&lt;/li&gt;&lt;li&gt;Spinal arthrodesis within two adjacent levels of fracture&lt;/li&gt;&lt;li&gt;Non-ambulatory prior to fracture&lt;/li&gt;&lt;li&gt;Greater than grade 1 spondylolisthesis at level of fracture&lt;/li&gt;&lt;li&gt;Scoliosis &gt; 10 deg&lt;/li&gt;&lt;li&gt;BMI &gt; 40&lt;/li&gt;&lt;li&gt;Severe cardiopulmonary deficiencies&lt;/li&gt;&lt;li&gt;Pregnant&lt;/li&gt;&lt;li&gt;Type 1 or 2 diabetes without controlled A1C level&lt;/li&gt;&lt;li&gt;Achondrogenesis disorders&lt;/li&gt;&lt;li&gt;Active malignancy, hemangiomas at the operative level(s), or multiple myeloma&lt;/li&gt;&lt;li&gt;No generally accepted medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy with a threshold for INR at 1.5 or less, and platelet count 100,000&lt;/li&gt;&lt;li&gt;A life expectancy less than the study duration or undergoing palliative care&lt;/li&gt;&lt;li&gt;Trauma injuries aside from vertebral compression fracture(s)&lt;/li&gt;&lt;li&gt;Injuries that violate the posterior vertebral cortex and/or posterior column&lt;/li&gt;&lt;li&gt;Active litigation&lt;/li&gt;&lt;li&gt;Currently on workman's compensation&lt;/li&gt;&lt;li&gt;Autoimmune disorders&lt;/li&gt;&lt;li&gt;Non-spine pain that requires daily opioids&lt;/li&gt;&lt;li&gt;Systemic long-term steroid use - &gt; 6 months&lt;/li&gt;&lt;li&gt;Active multiple sclerosis or neurologic deficit caudal to fracture&lt;/li&gt;&lt;li&gt;Currently an alcohol, solvent, or drug abuser&lt;/li&gt;&lt;li&gt;Psychiatric or cognitive impairment that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements&lt;/li&gt;&lt;li&gt;History of allergies to any of the device components including but not limited to commercially pure titanium, titanium alloy, polymethylmethacrylate or zirconium oxide (ZrO2)&lt;/li&gt;&lt;li&gt;Incarcerated&lt;/li&gt;&lt;li&gt;Are currently participating in another investigational study&lt;/li&gt;&lt;li&gt;Having had another device implanted in the thoracic and/or lumbar area that would interfere with the surgical approach, study device, or follow-up evaluations&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>No device related surgical intervention/retreatment at treated level during 12m</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Reduction in functional disability at 12m f/u by &gt;/= 15 pnts from baseline</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Reduction of back pain at 12-m f/u by ≥ 20mm from baseline measured by VAS</Description><Timeframe>12 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Any cement extravasation before discharge</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Any new VCF during 12m</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Change ODI at 12m</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Change VAS at 12m</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Change neuro status at 12m f/u</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Proportion of subject free device related surgical intervention during 12m</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>QOL improvement</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Vertical height and spine alignment by X-ray at 12m f/u</Description><Timeframe>12 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to provide reasonable assurance on safety and effectiveness of      the OsseoFix spinal fracture reduction system for market release approval in the US.&lt;br/&gt;The study was designed to evaluate safety and effectiveness of the OsseoFix spinal fracture reduction system used with polymethylmethacrylate (PMMA) bone cement relative to the clinical expectations for treatment of vertebral compression fractures (VCFs).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Baseline screening would be completed to determine eligible subjects. VCFs would be confirmed      by magnetic resonance imaging (MRI), or by a CT / bone scan.  These diagnostic tests would be      utilized to confirm that there were no retropulsed bone fragments. Subjects who meet all      inclusion criteria and do not have any exclusion criteria wouldl be scheduled to receive the      OsseoFix spinal fracture reduction system.&lt;br/&gt;Subjects that were enrolled would be implanted with the OsseoFix spinal fracture reduction      system through a postero-lateral approach to the anterior vertebral body using instruments      specifically designed for this procedure.&lt;br/&gt;Radiographs would be taken at each follow-up visit, including baseline and post-operatively.      Subject's perception of pain would be assessed using the visual analogue scale (VAS).      Functional outcomes would be measured using the Oswestry Disability Index (ODI) and Short      Form- 36 (SF-36) questionnaires as well as their neurological status. The VAS, ODI, SF-36 and      neurological status would be measured at baseline, 4-week, 3-, 6- and 12-month      follow-up visits. Overall patient-satisfaction would be evaluated at all post-implant      scheduled follow-up visits. Adverse event would be the recorded in all scheduled and      non-scheduled visits.&lt;br/&gt;The endpoint analysis would be performed and submitted when all implanted subjects had      completed their 12-months follow-up.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was terminated    as sponsor withdrew study.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Boulder Neurosurgery Associates</Name><Address1>Boulder</Address1><Address2>Colorado</Address2><Address3>80304</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Clinical Radiology of Oklahoma</Name><Address1>Edmond</Address1><Address2>Oklahoma</Address2><Address3>73034</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts/></Site><Site><Name>Jewish Hospital for Advanced Medicine</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40202</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Lyerly Neurosurgery</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32207</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>NeuroSpine Institute, LLC</Name><Address1>Eugene</Address1><Address2>Oregon</Address2><Address3>97401</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts/></Site><Site><Name>Neurospine Solutions, PC</Name><Address1>Bristol</Address1><Address2>Tennessee</Address2><Address3>37620</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Orthopaedic Associates of the Greater Lehigh Valley Easton Hospital</Name><Address1>Easton</Address1><Address2>Pennsylvania</Address2><Address3>18045</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>SIU Phyysicians and Surgeons Division of Orthopaedics and Rehabilitation</Name><Address1>Springfield</Address1><Address2>Illinois</Address2><Address3>62702</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Scripps</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3>92037</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>South Denver Neurosurgery</Name><Address1>Littleton</Address1><Address2>Colorado</Address2><Address3>80122</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Southwestern Orthopedic Center</Name><Address1>Savannah</Address1><Address2>Georgia</Address2><Address3>31405</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>NeuroSpine Institute LLC</Name><Address1>Eugene</Address1><Address2>Oregon</Address2><Address3> 97401</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts/></Site><Site><Name>NeuroSpine Solutions, P.C.</Name><Address1>Bristol</Address1><Address2>Tennessee</Address2><Address3> 37620</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8386">Subjects with Acute Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment><SubSegments><SubSegment id="8416">Subjects with back pain</SubSegment><SubSegment id="8418">Subjects with trauma related pain</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8430">Subjects with Intractable Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00961714</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26039">Assessment of efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25894"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25974">Assessment by Oswestry Disability Index (ODI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25982"><Endpoint>Assessment of Neuropsychological Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26015">Imaging assessments</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22087"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22088">Subjects with acute pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22091"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Pain" id="22093">Subjects with moderate pain</SubCriterion><SubCriterion disease="Pain" id="22094">Subjects with severe pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion><SubCriteria><SubCriterion disease="Pain" id="22149">Based on Visual analog scale[VAS]</SubCriterion><SubCriterion disease="Pain" id="22164">Based on Oswestry Disability Index (ODI)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22180">Subjects with pre-specified imaging assessments</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22207">Subjects with musculoskeletal disorder/injury associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22253">Subjects with history/scheduled to receive other drug therapies</SubCriterion><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22258"><Criterion>Subjects with Intractable Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20052"><Criterion>Subjects with Somatic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20058">Subjects with trauma related pain</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20095"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="20100">Subjects with pre-specified life-expectancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20098"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Pain" id="20104"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Pain" id="20110">Subjects with abnormal/unacceptable hematopoietic/marrow function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20121">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20119"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20132">Subjects with history/scheduled to receive opioids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20128">Hypersensitivity/ contraindication to general anaesthesia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26026"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Pain" id="20168">Subjects with history/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>31.03 Months</EnrollmentPeriod><EnrollmentRate>0.48 Patients/Month</EnrollmentRate><DateFirstReceived>2009-08-17T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="188376"><TitleDisplay>CLINICAL STUDY OPEN, 2 PERIODS, 2 TREATMENTS, 2 SEQUENCES, CROSS RANDOMISED SINGLE DOSE ASSESSMENT OF LANSOPRAZOL BIOEQUIVALENCE CAPSULES 15 mg: DITIL VS ULPAX under fasting conditions</TitleDisplay><TitleOfficial>Open clinical study, 2 periods, 2 treatments, 2 sequences, crossover, randomized, single dose to assess the bioequivalence of Lansoprazole 15 mg capsules: Ditil vs Ulpax ® under fasting conditions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">BE13049</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lansoprazole from Biomep, SA de CV</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>lansoprazole</Name><Drug id="6104">lansoprazole</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1096208" type="Company"><TargetEntity id="5037846847" type="organizationId">Biomep SA de CV</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1096208">Biomep, SA de CV</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>44</PatientCountEnrollment><DateChangeLast>2018-01-22T22:07:23Z</DateChangeLast><DateAdded>2014-05-19T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>RESEARCH, SCIENCE AND TECHNOLOGY INTERNATIONAL, SA DE CV</Affiliation><Email>vmancera @ ictinternacional.com</Email><Name>Victor M Mancera Reyes</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects must meet all the following inclusion criteria to be eligible to participate in the study:&lt;/li&gt;&lt;li&gt; Gender Indistinct.&lt;/li&gt;&lt;li&gt; Aged from 18 to 55 years (inclusive)&lt;/li&gt;&lt;li&gt; Status health: Clinically healthy. (Healthy is defined as no clinically relevant abnormalities identified by a medical history, physical examination, including blood pressure and pulse measurement a 12-lead electrocardiogram, chest radiography and laboratory tests).&lt;/li&gt;&lt;li&gt; Without consuming any medicine.&lt;/li&gt;&lt;li&gt; Formal Informed Consent signed and dated.&lt;/li&gt;&lt;li&gt; Índex body mass 20-26 kg / m 2. Failure to comply with this requirement may be entered if your body weight is within the limits of ± 10% of their ideal weight. (5)&lt;/li&gt;&lt;li&gt; Abdominal circumference&amp;lt;/= 102 cm in men and in women &amp;lt;/=88 cm&lt;/li&gt;&lt;li&gt; Letter signed undertaking not to pregnancy (for female volunteers). Pregnancy test will be performed to female volunteers before each session.&lt;/li&gt;&lt;li&gt; Who has been released from the database system COFEPRIS bioequivalence.&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt; Evidence or clinical history of hematological disease, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or severe allergic reactions.&lt;/li&gt;&lt;li&gt; Any condition that may affect drug absorption (eg gastrectomy, Sprue, e.g.).&lt;/li&gt;&lt;li&gt; Positive urine test substances of abuse.&lt;/li&gt;&lt;li&gt; Positive pregnancy test.&lt;/li&gt;&lt;li&gt; Use of products containing snuff or nicotine.&lt;/li&gt;&lt;li&gt; Smoker (&gt; than 1 cigarette per day), or difficulty to abstain from consumption of snuff for the duration of the study.&lt;/li&gt;&lt;li&gt; Consumption of grapefruit juice and / or grapes or products containing grapefruit or citrus derived at least 2 days prior to the first session of the study.&lt;/li&gt;&lt;li&gt; History of hypersensitivity to the study drug or its derivatives.&lt;/li&gt;&lt;li&gt; History of frequent excessive drinking 7 drinks per week for female subjects or 14 drinks per week for male subjects (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 4 months before the election.&lt;/li&gt;&lt;li&gt; Consumption of alcohol prior (48 hours) and during the study. (For this purpose, the breath test was performed with a breath-analyzer).&lt;/li&gt;&lt;li&gt; Treatment with study drug 30 days prior.&lt;/li&gt;&lt;li&gt; Be participating in another study or participating in another study without time elapsed at least equivalent to 7 half-lives of the drug administered in the previous study.&lt;/li&gt;&lt;li&gt; Electrocardiogram A 12-lead resting demonstrating absence of clinically significant findings.&lt;/li&gt;&lt;li&gt; Subjects Female: The female subjects who are in the period of pregnancy, or who are unable or unwilling to use an acceptable method of non-hormonal contraception for at least 14 days before the first session of the study and throughout the duration of the study. Intrauterine devices that release progesterone, postcoital contraception and hormone replacement should be suspended at least 28 days before the first session of the study. Depo-Provera must be suspended at least 6 months prior to the first session of the study&lt;/li&gt;&lt;li&gt; Use of prescription or non-prescription, dietary supplements, coffee, chocolate, cola, meat, coal, or vegetarian diet with less than 4 days before the test or herbal supplements and hormonal methods of contraception (including oral contraceptives, transdermal, injectable, injectable progesterone, progestin implants). Women are expected to take appropriate measures to prevent pregnancy and fetal exposure to a potentially toxic agent for the duration of the study (the screening visit to the end of the study) precautions. -Women of childbearing age should be informed to take appropriate measures to prevent pregnancy during the study as the following steps: Do not have a desire to become pregnant (after menopause or hysterectomy); Determined to maintain abstinence (not having sex) from 21 days before the start of the study until 28 days after the end of the study; Be willing to use two effective methods of birth control (condom, diaphragm, cervical cap, vaginal sponge, spermicides, non-hormonal IUD, tubal ligation, vasectomy ) from 21 days before the start of the study until 28 days after its completion; If a pregnancy test (for female subjects) is positive, the subject will be immediately removed from the study.&lt;/li&gt;&lt;li&gt; Shall be permitted limited use of non-prescription drugs that do not affect the safety of the subject and do not affect the results of the study based on an individual approval by the investigator and sponsor use.&lt;/li&gt;&lt;li&gt; Donation of blood about 1 unit (500 mL) in less than 56 days before the first session of the study period.&lt;/li&gt;&lt;li&gt; History of sensitivity to heparin or heparin-induced thrombocytopenia.&lt;/li&gt;&lt;li&gt; Inability or refusal to comply with the instructions described in this protocol.&lt;/li&gt;&lt;li&gt; Any other acute or chronic medical or psychiatric, or laboratory conditions that might increase the risk associated with the share of product to manage or that could interfere with the interpretation of the findings and judgment of the investigator would compromise participation subject in the study.&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>AUC</Description></Measure><Measure><Description>Cmax</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this Phase 1 study was to determine the safety and bioequivalence of lansoprazole 15 mg capsule from Biomep, SA de CV as test drug vs. &lt;ulink linkType="Drug" linkID="6104"&gt;lansoprazole&lt;/ulink&gt; 15 mg capsule as reference drug in healthy volunteers.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects were randomized to receive a single dose of one of the two following formulations:&lt;br/&gt;&lt;br/&gt;- lansoprazole 15 mg capsule from Biomep, SA de CV [test]&lt;br/&gt;&lt;br/&gt;- &lt;ulink linkType="Drug" linkID="6104"&gt;lansoprazole&lt;/ulink&gt; 15 mg capsule [reference]&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Mexico"><Sites><Site><Name>Research, Science and Technology, International SA de CV</Name><Address1>Coyoacan</Address1><Address2>Mexico</Address2><CountrySubDivision>Mexico</CountrySubDivision><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1033">Federal Commission for Protection against Health Risks (COFEPRIS) Clinical Trials Registry</Name><Identifiers><Identifier>BE13049</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Gastroesophageal reflux" id="17662"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peptic ulcer" id="21678"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Gastroesophageal reflux" id="16541"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="16542">Subjects with normal/acceptable vital signs</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastroesophageal reflux" id="16543"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Peptic ulcer" id="19070"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="19071">Subjects with normal/acceptable vital signs</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peptic ulcer" id="19073"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Gastroesophageal reflux" id="34517"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="16581">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peptic ulcer" id="34746"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="19103">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Gastroesophageal reflux" id="13690"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13691">Subjects with neurological/neuropsychiatric diseases/disorders</SubCriterion><SubCriterion disease="Gastroesophageal reflux" id="13697">Subjects with infectious/inflammatory disorders</SubCriterion><SubCriterion disease="Gastroesophageal reflux" id="13700">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13692"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13695"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13696"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13698"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13701"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13703"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13721"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13723">Subjects with hypersensitivity/contraindication to pump inhibitors (PPI) therapy</SubCriterion><SubCriterion disease="Gastroesophageal reflux" id="13726">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13736"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="17043"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="17056"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17057">Subjects with infectious/inflammatory disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="17058"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="17066"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17068">Subjects with hypersensitivity/contraindication to H. Pylori eradication therapy</SubCriterion><SubCriterion disease="Peptic ulcer" id="17069">Subjects with hypersensitivity/contraindications to proton pump inhibitors</SubCriterion><SubCriterion disease="Peptic ulcer" id="17071">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="17079"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17084">Subjects with history of major surgery for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="26041"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13694">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="27070"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13693">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="190210"><TitleDisplay>Treatment of Bacterial Vaginosis (BV) With Tinidazole</TitleDisplay><TitleOfficial>Tinidazole for the Treatment of Bacterial Vaginosis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00334633</Identifier><Identifier type="Organisational Study">F040329003</Identifier><Identifier type="Secondary Organisational">R01AI058033</Identifier></Identifiers><Indications><Indication id="2240">Bacterial vaginosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>metronidazole</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tinidazole</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20520" type="Company"><TargetEntity id="5035523514" type="organizationId">National Institute of Allergy and Infectious Diseases</TargetEntity></SourceEntity><SourceEntity id="20524" type="Company"><TargetEntity id="5001998137" type="organizationId">University of Alabama at Birmingham</TargetEntity></SourceEntity><SourceEntity id="2240" type="ciIndication"><TargetEntity id="D016585" type="MeSH"/><TargetEntity id="-1361925730" type="omicsDisease"/><TargetEntity id="912" type="siCondition"/><TargetEntity id="5612" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20524">University of Alabama at Birmingham</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20520">National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>593</PatientCountEnrollment><DateStart>2004-11-30T00:00:00Z</DateStart><DateEnd type="actual">2009-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T16:53:22Z</DateChangeLast><DateAdded>2014-05-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Alabama at Birmingham</Affiliation><Name>Jane Schwebke, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Women be at least 18 years of age&lt;/li&gt;&lt;li&gt;Have symptoms of vaginal odor and or/discharge&lt;/li&gt;&lt;li&gt;Meet the clinical (Amsel) criteria for BV&lt;/li&gt;&lt;li&gt;Willing to participate in research&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Presence of another vaginal infection or STD&lt;/li&gt;&lt;li&gt;Allergy to metronidazole&lt;/li&gt;&lt;li&gt;Pregnant or nursing&lt;/li&gt;&lt;li&gt;Use of oral or intravaginal antibiotics within the past 2 weeks&lt;/li&gt;&lt;li&gt;HIV or other chronic disease&lt;/li&gt;&lt;li&gt;Inability to keep return appointments&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cure of bacterial vaginosis: resolution of Amsel criteria for bacterial vaginosis</Description><Timeframe>1 month</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Recurrence of BV</Description><Timeframe>Baseline to 4 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the study was to determine if treatment of bacterial vaginosis with &lt;ulink linkType="Drug" linkID="72842"&gt;tinidazole&lt;/ulink&gt; is better      than treatment with metronidazole. The specific aims of this study were:&lt;br/&gt;To compare the efficacy of two different doses of &lt;ulink linkType="Drug" linkID="72842"&gt;tinidazole&lt;/ulink&gt; with oral metronidazole           for the initial treatment of symptomatic BV as well as short-term recurrence rates.&lt;br/&gt;To compare the side effect profiles of &lt;ulink linkType="Drug" linkID="72842"&gt;tinidazole&lt;/ulink&gt; versus metronidazole in the treatment           of BV.&lt;br/&gt;To compare drug levels of &lt;ulink linkType="Drug" linkID="72842"&gt;tinidazole&lt;/ulink&gt; and metronidazole in the vaginal secretions and           correlate with microbiological cure of BV as well as rates of recurrence.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would either receive metronidazole 500 mg, &lt;ulink linkType="Drug" linkID="72842"&gt;tinidazole&lt;/ulink&gt; 500 mg or &lt;ulink linkType="Drug" linkID="72842"&gt;tinidazole&lt;/ulink&gt; 1 gm, bid for 7 days. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Jefferson County Department of Health STD Clinic</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35294</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00334633</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2006-06-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="190579"><TitleDisplay>Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01374776</Identifier><Identifier type="Organisational Study">VERSION NUMBER 2 FRO</Identifier></Identifiers><Indications><Indication id="3191">Iron deficiency anemia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ferric carboxymaltose</Name><Drug id="61205">ferric carboxymaltose</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="61205">ferric carboxymaltose</Drug><IndicationsPioneer/><Companies><Company><Company id="25713">University of Zurich</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="61205" type="Drug"><TargetEntity id="447690" type="siDrug">Ferric carboxymaltose</TargetEntity></SourceEntity><SourceEntity id="25713" type="Company"><TargetEntity id="4298324199" type="organizationId">University of Zurich</TargetEntity></SourceEntity><SourceEntity id="3191" type="ciIndication"><TargetEntity id="D50" type="ICD10"/><TargetEntity id="10022972" type="MEDDRA"/><TargetEntity id="D018798" type="MeSH"/><TargetEntity id="-533542915" type="omicsDisease"/><TargetEntity id="1249" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25713">University of Zurich</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1546">Blood system agent</Class><Class id="493">Iron uptake stimulator</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>24</PatientCountEnrollment><DateStart>2013-02-28T00:00:00Z</DateStart><DateEnd type="estimated">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2014-06-13T07:51:17Z</DateChangeLast><DateAdded>2014-05-28T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Name>01 Studienregister MasterAdmins</Name><Phone>+41 (0)44 255 11 11</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Zurich</Affiliation><Name>Pierre-Alexandre Krayenbuehl, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy female subjects, age&amp;gt; 18 years, premenopausal, regularly menstruating&lt;/li&gt;&lt;li&gt;BMI 18 to 25 kg/m2&lt;/li&gt;&lt;li&gt;Serum ferritin level&amp;lt; 15 microg/ml&lt;/li&gt;&lt;li&gt;Recreationally active with = 1.5 h/w structured activity&lt;/li&gt;&lt;li&gt;Adequate contraception during the study period&lt;/li&gt;&lt;li&gt;Informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Anemia with Hb level&amp;lt; 120 g/l&lt;/li&gt;&lt;li&gt;Known hypersensitivity to iron carboxymaltose, iron sucrose or iron sulfate&lt;/li&gt;&lt;li&gt;Intake of iron preparations (also multivitamins containing iron) during the last 8 weeks before the start of the trial protocol&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Any cardiovascular or pulmonary disease&lt;/li&gt;&lt;li&gt;Any orthopedic or rheumatological disease which affects exercise performance&lt;/li&gt;&lt;li&gt;Presence of muscle disease&lt;/li&gt;&lt;li&gt;Acute or chronic infection/inflammation or malignancy&lt;/li&gt;&lt;li&gt;Known mental disorders (eg, depression)&lt;/li&gt;&lt;li&gt;Intake of concurrent medication, except oral contraceptives&lt;/li&gt;&lt;li&gt;CRP&amp;gt; 10 mg/l&lt;/li&gt;&lt;li&gt;TSH out of normal range&lt;/li&gt;&lt;li&gt;Elevated CK (&amp;gt; 167 U/l)&lt;/li&gt;&lt;li&gt;Any concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients&lt;/li&gt;&lt;li&gt;Participation in any other therapeutic trial within the previous month&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mitochondrial capacity (phosphocreatine recovery rate assessed by 31P-MR-spectroscopy of the lower leg muscle)</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to determine the effect of intravenous iron substitution (iron carboxymaltose [&lt;ulink linkType="Drug" linkID="61205"&gt;Ferinject&lt;/ulink&gt;], total dose 15 mg/      kg [maximal dose: 1000 mg] in 250 ml 0.9% NaCl; intravenous infusion in 20 min)in non-anemic      premenopausal women with iron deficiency.&lt;/para&gt;&lt;para&gt;Primary objective of the study  is to determine the  mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of      the lower leg muscle).&lt;/para&gt;&lt;para&gt;Secondary objectives of the study  are:&lt;br/&gt;Maximal oxygen uptake during a graded cycling exercise test and time to exhaustion at           submaximal power during a constant-load cycling exercise test.&lt;br/&gt;Plantarflexor muscle fatiguability as assessed by isokinetic dynamometry.&lt;br/&gt;Trial with medicinal product.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The patients will be randomized to one of the  two  treatment groups (n = 12  in each group).  &lt;br/&gt;Group I (intravenous iron): &lt;ulink linkType="Drug" linkID="61205"&gt;Ferinject&lt;/ulink&gt; will be applied via a short infusion. Patients will receive 15 mg/kg of iron as iron carboxymaltose &lt;ulink linkType="Drug" linkID="61205"&gt;Ferinject&lt;/ulink&gt; in 250 ml 0.9% NaCl intravenously (time of infusion 20 min), in a single-dose. The maximum dose is limited to 1000 mg iron. &lt;br/&gt;Group II (intravenous placebo): intravenous placebo (250 ml 0.9% NaCl ) will be administrated in the same manner and time schedule than group I.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Switzerland"><Sites><Site><Name>University Hospital Zurich, Clinic and Policlinic of Internal Medicine</Name><Address1>Zurich</Address1><Address2>ZH</Address2><Address3>8091</Address3><CountrySubDivision>ZH</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01374776</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anemia" id="17319"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17324">Assessment of efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Restless legs syndrome" id="25302"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Restless legs syndrome" id="25303">Assessment of efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anemia" id="14431"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Anemia" id="34601"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14453">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Restless legs syndrome" id="34750"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Restless legs syndrome" id="21679">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11816">Subjects with central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Anemia" id="11823">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11817"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11824"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11846"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Anemia" id="11848"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11851">Subjects with hypersensitivity/contraindication to iron supplementation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11855"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11868">Subjects with history of dietary supplements</SubCriterion><SubCriterion disease="Anemia" id="20190">Subjects with history of iron therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11871"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Anemia" id="11925"><Criterion>Subjects with Abnormal/Unacceptable Hemoglobin Count</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="19364"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Restless legs syndrome" id="19365">Subjects with pregnancy as a risk factor</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Restless legs syndrome" id="19393"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="19399"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Restless legs syndrome" id="19402">Subjects co-morbid with respiratory disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Restless legs syndrome" id="19408"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="19411"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="19425"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="19427"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Restless legs syndrome" id="19432">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Restless legs syndrome" id="19441"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="19459"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Restless legs syndrome" id="25896"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Restless legs syndrome" id="19410">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="27098"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11818">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2014-09-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="192283"><TitleDisplay>Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery</TitleDisplay><TitleOfficial>Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01220739</Identifier><Identifier type="Organisational Study">STELLAR</Identifier><Identifier type="Other">P50NS044148</Identifier><Identifier type="Trial Acronym">StELLAR</Identifier></Identifiers><Indications><Indication id="3676">Ischemic stroke</Indication></Indications><BiomarkerNames><BiomarkerName id="1735" role="Not determined" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="12058" role="Not determined" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Not determined" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>NeuroThera laser system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rt-PA</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>rt-PA</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1036091" type="Company"><TargetEntity id="5035525570" type="organizationId">National Institute of Neurological Disorders and Stroke</TargetEntity></SourceEntity><SourceEntity id="25451" type="Company"><TargetEntity id="4296621839" type="organizationId">University of California San Diego</TargetEntity></SourceEntity><SourceEntity id="3676" type="ciIndication"><TargetEntity id="10061256" type="MEDDRA"/><TargetEntity id="96" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="25451">University of California San Diego</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1036091">National Institute of Neurological Disorders and Stroke</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateStart>2011-06-30T00:00:00Z</DateStart><DateEnd type="actual">2013-04-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:32:09Z</DateChangeLast><DateAdded>2014-05-31T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Santa Barbara Cottage Hospital; Santa Barbara; California; 93105; United States</Affiliation><Name>Philip Delio</Name></Contact><Contact type="Public contact"><Affiliation>Swedish Medical Center; Englewood; Colorado; 80113; United States</Affiliation><Name>Chris Fanale</Name></Contact><Contact type="Public contact"><Affiliation>Providence Medical Research Center; Spokane; Washington; 99204; United States</Affiliation><Name>Madeleine Geraghty</Name></Contact><Contact type="Public contact"><Affiliation>UCSD Medical Center; San Diego; California; 92093; United States</Affiliation><Name>Thomas Hemmen</Name></Contact><Contact type="Public contact"><Affiliation>Hospital of the Univ. of Pennsylvania; Philadelphia; Pennsylvania; 19104; United States</Affiliation><Email>jjurf@ucsd.edu</Email><Name>Julie Jurf</Name><Phone>858-657-7185</Phone></Contact><Contact type="Public contact"><Email>jjurf@ucsd.edu</Email><Name>Julie Jurf</Name><Phone>858-657-7185</Phone></Contact><Contact type="Public contact"><Affiliation>Palmetto Health Richland; Columbia; South Carolina; 29203; United States</Affiliation><Email>jjurf@ucsd.edu</Email><Name>Julie Jurf</Name><Phone>858-657-7185</Phone></Contact><Contact type="Public contact"><Affiliation>Swedish Medical Center; Englewood; Colorado; 80113; United States</Affiliation><Email>jjurf@ucsd.edu</Email><Name>Julie Jurf</Name><Phone>858-657-7185</Phone></Contact><Contact type="Public contact"><Affiliation>Providence Medical Research Center; Spokane; Washington; 99204; United States</Affiliation><Email>jjurf@ucsd.edu</Email><Name>Julie Jurf</Name><Phone>858-657-7185</Phone></Contact><Contact type="Public contact"><Affiliation>Santa Barbara Cottage Hospital; Santa Barbara; California; 93105; United States</Affiliation><Email>jjurf@ucsd.edu</Email><Name>Julie Jurf</Name><Phone>858-657-7185</Phone></Contact><Contact type="Public contact"><Affiliation>Hospital of the University of Pennsylvania; Philadelphia; Pennsylvania; 19104; United States</Affiliation><Name>Scott Kashner</Name></Contact><Contact type="Public contact"><Affiliation>Huntington Memorial Hospital; Pasadena; California; 91105; United States</Affiliation><Name>Arbi Ohanian</Name></Contact><Contact type="Public contact"><Affiliation>Palmetto Health Richland; Columbia; South Carolina; 29203; United States</Affiliation><Name>Souvik Sen</Name></Contact><Contact type="Public contact"><Affiliation>UCSD Medical Center; San Diego; California; 92093; United States</Affiliation><Email>jzivin@ucsd.edu</Email><Name>Justin Zivin</Name><Phone>858-534-3525</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of California, San Diego</Affiliation><Name>Thomas Hemmen, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject is at least 40 years of age at screening, but has not had their 81st birthday&lt;/li&gt;&lt;li&gt;Subject has received intravenous rt-PA per the NINDS rt-PA protocol guidelines within 3 h of symptom onset for an acute ischemic stroke.&lt;/li&gt;&lt;li&gt;Subject is diagnosed with acute ischemic stroke and presents to the health care facility at a time such that initiation of NTS procedure is feasible within 6 h of the time of stroke onset. The time of stroke onset is defined as the time at which a change in the baseline neurological function occurred. If the time is not known (eg, the subject awakens from sleep with new symptoms), the last time the patient was observed to be neurologically intact must be considered to be the time of onset&lt;/li&gt;&lt;li&gt;Documented baseline NIHSS score of &gt; 7 and&amp;lt;/= 17 prior to intravenous rt-PA administration. Subjects who transfer from other facilities after receiving intravenous rt-PA must have a documented NIHSS by a certified examiner prior to initiation of rt-PA treatment. Documentation of NIHSS score via telemedicine is acceptable if performed by a certified examiner. Subjects who improve prior to NTS procedure will still be treated, unless their NIHSS improves to 0&lt;/li&gt;&lt;li&gt;Full functional independence just prior to the present stroke episode as defined by the following criteria:&lt;ul&gt;&lt;li&gt;Estimated prestroke mRS score 0 or 1&lt;/li&gt;&lt;li&gt;Ambulates independently, may need a cane or walker, but does not need the assistance of another person&lt;/li&gt;&lt;li&gt;Absence of a medical/physical/mental condition that substantially limits the subject's ability to work, study, participate in leisure activities, or look after family at home&lt;/li&gt;&lt;li&gt;Completely independent, does not need supervision (may live with other individuals, but could live alone if necessary)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Negative serum or urine pregnancy test in females of childbearing potential&lt;/li&gt;&lt;li&gt;Subject (or legally authorized representative) provides written informed consent in compliance with local regulations prior to enrollment into this study&lt;/li&gt;&lt;li&gt;The subject (and caregiver, if applicable) is willing to participate in this study for at least 90 days after the onset of stroke&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Evidence on from a pre-tPA head CT of an intracranial, subdural, or subarachnoid hemorrhage or clinical presentation suggestive of subarachnoid hemorrhage even if the initial neuroimaging scan is normal&lt;/li&gt;&lt;li&gt;Clinical presentation consistent with a brainstem or cerebellar stroke&lt;/li&gt;&lt;li&gt;A rapidly improving neurological status that in the opinion of the investigator will make the subject unsuitable for participation in this study or patient rapidly improves to NIHSS of 0 by start of NTS procedure&lt;/li&gt;&lt;li&gt;The subject had a seizure at stroke onset or within the 7 days prior to stroke onset&lt;/li&gt;&lt;li&gt;Sustained blood glucose &gt; 300 mg/dl or&amp;lt;/= 60 mg/dl&lt;/li&gt;&lt;li&gt;Subjects who, on repeated measurement, have a systolic blood pressure &gt; 185, or a diastolic blood pressure &gt; 110 mmHg, post rt-PA administration, or it is the opinion of the investigator that aggressive treatment to reduce blood pressure post thrombolysis is required to keep pressure within these limits&lt;/li&gt;&lt;li&gt;Presumed and/or confirmed septic embolus&lt;/li&gt;&lt;li&gt;The subject has a history of CNS vascular wall disease (eg, aneurysm, AVM)&lt;/li&gt;&lt;li&gt;The subject has a history of CNS disease or damage (eg, neoplasm or dementia) which may influence the subject's outcome assessment&lt;/li&gt;&lt;li&gt;The subject has a significant skin condition (ie, hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on their scalp that is found to be directly below three or more TLT procedure sites&lt;/li&gt;&lt;li&gt;Planned or actual use of any intra-arterial thrombolytic medication or a clot retrieval device, or any diagnostic or therapeutic interventional neurovascular procedure, including mechanical recanalization, whether successful or unsuccessful, during this stroke episode&lt;/li&gt;&lt;li&gt;Subject previously participated in another investigational drug or device trial within the preceding four weeks&lt;/li&gt;&lt;li&gt;Subject is a female who is pregnant or lactating (within the previous 30 days), or who is of child-bearing potential unless she is surgically sterile or she and/or her partner are using a medically acceptable method of birth control&lt;/li&gt;&lt;li&gt;The subject has an implant of any kind in the head (i.e. clipped aneurysm, embolised AVM, implantable shunt - Hakim valve)&lt;/li&gt;&lt;li&gt;Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment&lt;/li&gt;&lt;li&gt;The subject participated in the NEST-1, NEST-2, or NEST-3 study&lt;/li&gt;&lt;li&gt;The subject has any co-existing or terminal disease that may limit life expectancy or any medical condition (eg, morbid obesity, substance abuse) that may, in the clinical judgment of the Investigator, independently influence the subject's outcome during the course of the study&lt;/li&gt;&lt;li&gt;The subject is otherwise determined, based on the opinion of the Investigator,to be an unsuitable candidate for enrollment in this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Symptomatic intracerebral hemorrhage</Description><Timeframe>36 h from tPA initiation</Timeframe></Measure><Measure><Description>Percentage of participants with modified Rankin Scale (0 to 1): measures the degree of disability or dependence in the daily activities. Minimum score = 0 (best outcome - No symptoms); Maximum Score = 6 (worse outcome - dead)</Description><Timeframe>90 days from stroke onset</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Hemorrhagical transformation without clinical consequences (asymptomatic)</Description><Timeframe>Within 36 to 48 h</Timeframe></Measure><Measure><Description>Mortality</Description></Measure><Measure><Description>The modified Rankin Scale (mRS) score dichotomized as 0 to 1 versus an mRS score of 2 to 6</Description><Timeframe>At 90 days or the last rating in patients that develop intracerebral hemorrhages</Timeframe></Measure><Measure><Description>Frequency of SAEs and AEs</Description></Measure><Measure><Description>Preliminary efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In May 2014,  results of this study were presented. Symptomatic intracranial hemorrhage was not reported in any of the patients. There was no prominent different between groups in terms of frequency of patients experiencing at least one serious AE (3 versus 2). Recurrent stroke within 90 days was not observed and one patient in the TLT group died [&lt;ulink linkType="Reference" linkID="1600948"&gt;1600948&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to assess the safety and preliminary efficacy of combining intravenous rt-PA with      transcranial laser therapy (TLT) with the NeuroThera laser system      (NTS) in subjects treated for acute ischemic stroke.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2014,  results of this study were presented. Good 90-day (mRS 0 to 1) outcome with rt-PA alone and in combination with TLT was noted in three and two patients (42.9 versus 40%), respectively [&lt;ulink linkType="Reference" linkID="1600948"&gt;1600948&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would be a phase II (n = 200), prospective, double-blind, randomized, sham-controlled, multicenter, safety study of intravenous  rt-PA alone versus intravenous rt-PA plus TLT (transcranial laser therapy) at approximately ten investigational sites (United States only). The primary endpoint for this safety study would be occurrence of symptomatic intracranial hemorrhages at 36 to 48 h after stroke symptom onset.&lt;/para&gt;&lt;para&gt;Symptomatic hemorrhage would be defined as deterioration of &amp;gt; 4 points on the NIHSS lasting at least 72 h accompanied by intracranial hemorrhage in the distribution of the neurological deficit as identified by neuroimaging scans. All follow up neuroimaging scans would be reviewed centrally by an independent reviewer for the presence or absence of hemorrhage on the 36 to 48 h scan.&lt;/para&gt;&lt;para&gt;The secondary endpoints for this study would be as follows:&lt;br/&gt;Hemorrhagical transformation without clinical consequences (asymptomatic) within 36 to 48 h. All follow-up neuroimaging scans would be reviewed centrally by an independent reviewer for the presence or absence of hemorrhage on the 36 to 48 h scan.&lt;br/&gt;Mortality.&lt;br/&gt;The modified Rankin Scale (mRS) score dichotomized as 0 to 1 versus an mRS score of 2 to 6 at 90 days or the last rating in patients that develop intracerebral hemorrhages.&lt;br/&gt;Frequency of SAEs and AEs.&lt;/para&gt;&lt;para&gt;The study population would be randomized into two arms. One group will receive a sham TLT procedure (Sham control group or SCG) and the second group will receive an active TLT procedure (TLTG).&lt;/para&gt;&lt;para&gt;The randomization ratio of SCG and TLTG would be 1 : 1 and would be stratified in order to ensure balanced patient distribution between the treatment and sham-controlled groups for the following factors:&lt;br/&gt;Stroke severity as measured by National Institute of Health Stroke Scale (NIHSS) at baseline (stratified as 7 to 9, 10 to 13, 14 to 17).&lt;br/&gt;Sham comparator: patients in this treatment arm would receive intravenous tPA within 3 h of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 h after tPA and no &amp;gt; 24 h from stroke onset.&lt;br/&gt;Active comparator: patients in this treatment arm would receive intravenous tPA within 3 h of stroke symptom onset followed by transcranial laser therapy no sooner than 12 h after tPA and no greater than 24 h from stroke onset. Transcranial laser therapy would be administered with the NeuroThera laser system.&lt;/para&gt;&lt;para&gt;Study site: there would be six visits in the study. The purpose of the visit 1 would be to determine and confirm the eligibility of patients for participation in the StELLAR study and document baseline information about the patient and their stroke event. This would include all of the following standard of care tests and procedures: a non contrast head CT scan performed prior to rt-PA administration, vital signs, height , weight ,physical exam, finger stick or blood glucose, serum or urine pregnancy test (if women of childbearing potential). In addition, the following data would be obtained: prestroke mRS, NIHSS, presumed location of stroke and vascular territory, start and stop date and time of the intravenous rt-PA treatment and dose given, date and time of stroke onset, date and time of arrival to the hospital, demographic data (date of birth, gender, ethnicity),sociodemographic data (education, marital status, social support prior to stroke),medical and surgical history (specific cardiovascular, neurological, endocrine, and other standard questions asked), method of contraception use (for women of child bearing potential), prior (three days prior to screening) and current concomitant medication use, smoking history, adverse events from the time of obtaining informed consent. To be eligible for the study, the administration of rt-PA should follow the guidelines outlined by the National Institutes of Neurological Disorders. Patients meeting the inclusion/exclusion criteria would be enrolled into the study after written informed consent is obtained by the patient or their legally authorized representative.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects were randomized to receive intravenous rt-PA plus sham TLT procedure (n = 7) or intravenous rt-PA in combination with active TLT (n = 5) [&lt;ulink linkType="Reference" linkID="1600948"&gt;1600948&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial was terminated because device sponsor was no longer in business.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Palmetto Health Richland</Name><Address1>Columbia</Address1><Address2>South Carolina</Address2><Address3>29203</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Providence Medical Research Center</Name><Address1>Spokane</Address1><Address2>Washington</Address2><Address3>99204</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Swedish Medical Center</Name><Address1>Englewood</Address1><Address2>Colorado</Address2><Address3>80113</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Hospital of the Univ. of Pennsylvania</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3> 19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stroke</Disease><PatientSegments><PatientSegment><PatientSegment id="11631">Subjects with Ischemic Stroke</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11632">Subjects with Acute Stroke</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01220739</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stroke" id="24197"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24199">Assessment of intracerebral hemorrhage (ICH)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stroke" id="24177"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24180"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24197"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24199">Assessment of intracerebral hemorrhage (ICH)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24091">Assessment by Modified Rankin Scale (MRS) Score</SubEndpoint><SubEndpoint disease="Stroke" id="27532">Assessment by Short Form Health Survey (SF-36)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stroke" id="20936"><Criterion>Stroke Subjects</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20938">Subjects with ischemic stroke</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20939"><Criterion>Subjects with Acute Stroke</Criterion></Inclusion><Inclusion disease="Stroke" id="20957"><Criterion>Inclusion Based on Time Post Stroke</Criterion></Inclusion><Inclusion disease="Stroke" id="20985"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20987">Inclusion based on modified rankin scale (mRS) </SubCriterion><SubCriterion disease="Stroke" id="20988">Inclusion based on NIHSS</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stroke" id="18634"><Criterion>Subjects with Specified Type of Stroke</Criterion></Exclusion><Exclusion disease="Stroke" id="18662"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Stroke" id="18667"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Stroke" id="18671"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Stroke" id="18681"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Stroke" id="18686"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18689">Subjects with abnormal blood glucose level</SubCriterion><SubCriterion disease="Stroke" id="18690">Subjects with abnormal blood pressure values</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="18693"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Stroke" id="25988"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18659">Subjects co-morbid with aneurysm</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="26680"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18672">Subjects co-morbid with epilepsy/seizures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="27030"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18639">Subjects co-morbid with subarachnoid haemorrhage</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-10-13T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-10-10T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="207280"><TitleDisplay>Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient</TitleDisplay><TitleOfficial>Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01365741</Identifier><Identifier type="Trial Acronym">TTISUE</Identifier></Identifiers><Indications><Indication id="224">Myocardial infarction</Indication></Indications><BiomarkerNames><BiomarkerName id="2054" role="Therapeutic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="11096" role="Disease marker" type="Physiological">ST segment</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>prasugrel</Name><Drug id="19001">prasugrel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="19001">prasugrel</Drug><IndicationsPioneer/><Companies><Company><Company id="1043344">Rigshospitalet, Denmark</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="19001" type="Drug"><TargetEntity id="273686" type="siDrug">Prasugrel hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1043344" type="Company"><TargetEntity id="5035555022" type="organizationId">Rigshospitalet  Denmark</TargetEntity></SourceEntity><SourceEntity id="224" type="ciIndication"><TargetEntity id="10028596" type="MEDDRA"/><TargetEntity id="D009203" type="MeSH"/><TargetEntity id="-998451372" type="omicsDisease"/><TargetEntity id="226" type="siCondition"/></SourceEntity><SourceEntity id="4913" type="Action"><TargetEntity id="613" type="Mechanism">P2Y12 (P2T) Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1043344">Rigshospitalet, Denmark</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4913">P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2011-02-28T00:00:00Z</DateStart><DateEnd type="actual">2016-04-30T00:00:00Z</DateEnd><DateChangeLast>2019-04-17T02:04:44Z</DateChangeLast><DateAdded>2014-08-04T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bispebjerg Hospital</Affiliation><Name>Jacob Antonsen, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age: 20 to 30 years&lt;/li&gt;&lt;li&gt;Healthy&lt;/li&gt;&lt;li&gt;Male&lt;/li&gt;&lt;li&gt;Ability to give informed consent&lt;/li&gt;&lt;li&gt;Non-smoker&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known with reflux or dysphagia&lt;/li&gt;&lt;li&gt;Ingestion of medicine, beside paracetamol&amp;lt; 14 prior to the trial&lt;/li&gt;&lt;li&gt;Hematological diseases&lt;/li&gt;&lt;li&gt;Diabetes&lt;/li&gt;&lt;li&gt;Known kidney disease&lt;/li&gt;&lt;li&gt;Known liver disease&lt;/li&gt;&lt;li&gt;Recent trauma&lt;/li&gt;&lt;li&gt;Scheduled operation within 7 days after the trial&lt;/li&gt;&lt;li&gt;Former apoplexia&lt;/li&gt;&lt;li&gt;Known gastro-intestinal disease&lt;/li&gt;&lt;li&gt;Weight&amp;lt; 60 kg&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in inhibition of ADP-receptors on thrombocytes: the primary outcome will be the difference between the time to sufficient/maximal inhibition of the ADP-receptors on the test-persons thrombocytes compared between supine and upright ingestion of Efient; inhibition will be verified bedside by VerifyNow analyses</Description><Timeframe>Blood will be drawn from the test person at 0, 20, 40, 60, 80, 100 min post ingestion</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to clarify whether body posture during ingestion of 60 mg &lt;ulink linkType="Drug" linkID="19001"&gt;Efient&lt;/ulink&gt;,      a thrombocytic inhibitor, had influence on the time to thrombocytic inhibition.&lt;/para&gt;&lt;para&gt;The study aims to mimic the treatment Danish subjects receive when admitted to the hospital      with a ST-elevation myocardial infarction since these subjects are refereed to acute      Percutaneous Coronary Intervention (PCI) necessitating fast and efficient thrombocytic      inhibition.&lt;/para&gt;&lt;para&gt;The study hypothesis was that by making the subjects ingest the tablets in a 90 degrees upright      position and making them sit up for 2 min after ingestion, the effect of the pills would      commence faster than if taken in a supine position. This would possibly lead to faster      inhibition of the thrombocytes, which the researchers believe would lead to a lower incidence of clotting      issues during and after the procedure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consists of two arms:&lt;br/&gt;Arm A (standard administration of Efient): the subject would ingest Efient in supine position, and remain supine during 2 h, mimicing the way Efient is used for pre-PCI treatment today.&lt;br/&gt;Arm B (upright administration of Efient): after 14 days of ingestion of Efient in supine position, the subjectwould ingest Efient in an upright position, and remain upright for 2 min. After 2 min, the test person would lie down, and remain supine for 2 h, the same way as the person did in the control arm.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Denmark"><Sites><Site><Name>Nordsjællands Hospital</Name><Address1>Hillerød</Address1><Address3>2100</Address3><Contacts/></Site><Site><Name>Righospitalet</Name><Address1>Copenhagen</Address1><Address3> 2100</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="173">Subjects with Unstable Coronary Artery Disease</PatientSegment><SubSegments><SubSegment id="178">ST elevation myocardial infarction (STEMI)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="369">Subjects on /Indicated for/History of Cardiovascular Therapy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Acute coronary syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="302">ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="321">Subjects with History of Cardiac Intervention</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="373">Subjects with History of Treatment</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01365741</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2598"><Endpoint>Assessment of Platelet Function Tests (PFT) Findings</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2606">Evaluation of PFT by Accumetrics Verify Now TM P2Y12 Assay</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Acute coronary syndrome" id="2904"><Endpoint>Assessment of Platelet Function Tests (PFT)</Endpoint><SubEndpoints><SubEndpoint disease="Acute coronary syndrome" id="2905">Assessment of PFT by accumetrics verifynow P2Y12 assay</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3871">Subjects with acute coronory syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1078"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1082">ST segment elevation myocardial infarction (STEMI)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1134"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1147">Thrombolytic therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acute coronary syndrome" id="1285"><Criterion>ST Segment Elevation Myocardial Infarction(STEMI) Subjects</Criterion></Inclusion><Inclusion disease="Acute coronary syndrome" id="1384"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="1397">Thrombolytic therapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1696"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1740"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1760"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2031"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2070"><Criterion>Subjects on  Other Systemic Medications</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2102"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2113"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2119"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2149"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2150">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2195"><Criterion>Subjects with History of Other Procedure/Intervention</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2203">General Surgery/Organ transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="5591"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>32.13 Months</EnrollmentPeriod><EnrollmentRate>0.62 Patients/Month</EnrollmentRate><DateFirstReceived>2010-12-21T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-04-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="213221"><TitleDisplay>A Study of Baricitinib in Healthy Japanese Participants</TitleDisplay><TitleOfficial>Relative Bioavailability of the Baricitinib (LY-3009104) Commercial Tablet Compared to the Phase II Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02263911</Identifier><Identifier type="Organisational Study">14612</Identifier><Identifier type="Secondary Organisational">I4V-MC-JAGO</Identifier><Identifier type="Other">JapicCTI-142687</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>baricitinib</Name><Drug id="59098">baricitinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59098">baricitinib</Drug><IndicationsPioneer/><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59098" type="Drug"><TargetEntity id="472088" type="siDrug">Baricitinib</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="3562" type="Action"><TargetEntity id="1506" type="Mechanism">Jak1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3564" type="Action"><TargetEntity id="1505" type="Mechanism">Jak2 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3562">Jak1 tyrosine kinase inhibitor</Action><Action id="3564">Jak2 tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioavailability</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>16</PatientCountEnrollment><DateStart>2014-11-30T00:00:00Z</DateStart><DateEnd type="actual">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:20:14Z</DateChangeLast><DateAdded>2014-10-16T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Overtly healthy Japanese male and female (women not of child-bearing potential or after menopause), as determined by medical history and physical examination&lt;/li&gt;&lt;li&gt;Have a Body mass index (BMI) of 18.5 to 29.9 kg/m2&lt;/li&gt;&lt;li&gt;Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study&lt;/li&gt;&lt;li&gt;Have an abnormal blood pressure as determined by the investigator&lt;/li&gt;&lt;li&gt;Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data&lt;/li&gt;&lt;li&gt;Are women who are pregnant or lactating&lt;/li&gt;&lt;li&gt;Have used or intend to use over-the-counter or prescription medication, including herbal medications, within 14 days prior to dosing and during the study&lt;/li&gt;&lt;li&gt;Have donated blood of &gt; 400 ml in the last 12 weeks (males) or in the last 16 weeks (females) or any blood donation (including apheresis) within the last 4 weeks, or total volume of blood donation within 12 months is 1200 ml (males) or 800 ml (females) at screening&lt;/li&gt;&lt;li&gt;Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to abide by alcohol restrictions&lt;/li&gt;&lt;li&gt;Are subjects who currently smoke &gt; 10 cigarettes per day (or equivalent in tobacco or nicotine products) or are unwilling to abide by smoking restrictions&lt;/li&gt;&lt;li&gt;Have a current or recent history of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis) or mycobacterial infection&lt;/li&gt;&lt;li&gt;Have an absolute neutrophil count (ANC)&amp;lt; 2000 cells/microl&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>PK: maximum Concentration (Cmax) of Baricitinib</Description><Timeframe>Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 h Post-dose</Timeframe></Measure><Measure><Description>Pharmacokinetics (PK): area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 to infinity]) of Baricitinib</Description><Timeframe>Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 h Post-dose</Timeframe></Measure><Measure><Description>PK: area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0 to tlast]) of Baricitinib</Description><Timeframe>Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 h Post-dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to understand the relationship of three different dosage forms of      &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt;.  This study would also explore  the effect of food on how the body absorbs       &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt;. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized to one of the following arms:&lt;br/&gt;Arm 1: subjects would receive single oral dose of &lt;ulink linkType="Drug" linkID="59098"/&gt; 2 x 4 mg (test 1) &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt; commercial formulation  tablet fasted on day 1 in one of five periods.&lt;br/&gt;Arm 2: subjects would receive single oral dose of &lt;ulink linkType="Drug" linkID="59098"/&gt; 1 x 4 mg (test 1) &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt; commercial formulation  tablet fasted on day 1 in one of five periods.&lt;br/&gt;Arm 3: subjects would receive single oral dose of &lt;ulink linkType="Drug" linkID="59098"/&gt; 1 x 4 mg (test 2F) &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt; commercial formulation  tablet after food intake on day 1 in one of five periods.&lt;br/&gt;Arm 4: subjects would receive single oral dose of &lt;ulink linkType="Drug" linkID="59098"/&gt; 1 x 8 mg (reference 1)  &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt; phase II tablet fasted on day 1 in one of five periods.&lt;br/&gt;Arm 5: subjects would receive single oral dose of &lt;ulink linkType="Drug" linkID="59098"/&gt; 1 x 4 mg (reference 2)  &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt; phase II tablet fasted on day 1 in one of five periods.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Hachioji</Address1><Address2>Tokyo</Address2><Address3>192-0071</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3462">Others</PatientSegment><SubSegments><SubSegment id="3463">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Rheumatoid arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="3740">Others</PatientSegment><SubSegments><SubSegment id="535">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02263911</Identifier></Identifiers></Registry><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier>JapicCTI-142687</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6626"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Rheumatoid arthritis" id="6891"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="33280"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="3391">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="34532"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1968">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="34928"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1970">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Psoriasis" id="34934"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="3425">Subjects likely to be compliant to the protocol</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Rheumatoid arthritis" id="2870"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2885"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2891"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2894"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2898"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2903"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2906"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2909">Uncontrolled endocrine/metabolic diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2922"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2924">Subjects co-morbid with bacterial infections</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2926">Subjects co-morbid with viral infection</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2927">Subjects with history of / current fungal infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2931"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2936"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2877">History of ECG abnormalities</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2942">Subjects with history of drug/alcohol abuse</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2967">Recent/Planned blood loss or donation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4532"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4541">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Psoriasis" id="4551">Subjects co-morbid with respiratory disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4534"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4536"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4538"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4539"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4552"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4556"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4557">Subjects with history of / current bacterial infections</SubCriterion><SubCriterion disease="Psoriasis" id="4558">Subjects co-morbid with viral infection</SubCriterion><SubCriterion disease="Psoriasis" id="4559">Subjects with history of / current fungal infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4586"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4587">Abnormal hematology/blood chemistry findings</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4590"><Criterion>Subjects with abnormal ECG</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4591"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4605">Subjects with history of blood donation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="25118"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2953">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="25762"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4615">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="26004"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2965">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="26080"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4542">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="27143"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2912">Abnormal differential cell counts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="29367"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4596">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-10-08T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-10-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-11-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2014-12-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-01-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="21647"><TitleDisplay>Study of Daclizumab in Patients With Chronic, Persistent Asthma</TitleDisplay><TitleOfficial>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">DAC-1003</Identifier><Identifier type="NCT">NCT00028288</Identifier></Identifiers><Indications><Indication id="31">Asthma</Indication></Indications><BiomarkerNames><BiomarkerName id="1979" role="Therapeutic effect marker" type="Genomic;Proteomic">Eosinophil cationic protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>daclizumab (intravenous, transplant rejection), PDL/Roche</Name><Drug id="2546">daclizumab (intravenous, transplant rejection), PDL/Roche</Drug></Intervention><Intervention type="InterventionPrimary"><Name>triamcinolone acetate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2546">daclizumab (intravenous, transplant rejection), PDL/Roche</Drug><IndicationsPioneer><Indication id="31">Asthma</Indication></IndicationsPioneer><Companies><Company><Company id="1044720">AbbVie Biotherapeutics Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2546" type="Drug"><TargetEntity id="198590" type="siDrug">Daclizumab</TargetEntity></SourceEntity><SourceEntity id="1044720" type="Company"><TargetEntity id="4298116075" type="organizationId">Abbvie Biotherapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="488" type="Action"><TargetEntity id="1750" type="Mechanism">IL-2 Receptor Antagonists</TargetEntity><TargetEntity id="6684" type="Mechanism">Anti-IL2 (Interleukin 2)</TargetEntity></SourceEntity><SourceEntity id="5100" type="Action"><TargetEntity id="1558" type="Mechanism">Anti-CD25 (IL-2 Receptor)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>18</NumberOfSites><CompaniesSponsor><Company id="1044720">AbbVie Biotherapeutics Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="488">IL-2 receptor antagonist</Action><Action id="5100">IL-2 receptor alpha subunit inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="396">Immunosuppressant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="7748">Lymphocyte inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><PatientCountEvaluable>115</PatientCountEvaluable><DateStart>2001-09-30T00:00:00Z</DateStart><DateEnd type="actual">2003-12-01T00:00:00Z</DateEnd><DateChangeLast>2014-01-15T09:22:10Z</DateChangeLast><DateAdded>2008-07-24T10:21:04Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;History of asthma for 6  or more months&lt;/li&gt;&lt;li&gt;History of chronic persistent asthma requiring daily high dose inhaled corticosteroid  (1200 microg triamcinolone acetate or equivalent inhaled corticosteroids) for 3 or more months prior to enrollment&lt;/li&gt;&lt;li&gt;FEV1 of 50 to 80% of predicted&lt;/li&gt;&lt;li&gt;Reversibility of at least 12% with inhaled short-acting beta2-agonist&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment&lt;/li&gt;&lt;li&gt;No significant disease other than asthma&lt;/li&gt;&lt;li&gt;Oral or parenteral corticosteroids within 30 days&lt;/li&gt;&lt;li&gt;Hospitalization for asthma within 60 days&lt;/li&gt;&lt;li&gt;Current allergen immunotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The change in pulmonary function as assessed by the percentage change from baseline FEV1</Description><Timeframe>At day 84</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Time to asthma exacerbation</Description></Measure><Measure><Description>Diary symptom scores</Description></Measure><Measure><Description>Morning and nighttime peak expiratory flow rates</Description></Measure><Measure><Description>Rescue medication use</Description></Measure><Measure><Description>Daytime/nighttime asthma symptoms</Description></Measure><Measure><Description>Asthma-free days</Description></Measure><Measure><Description>Pharmacokinetics</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results presented in March 2004 have shown that &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; was generally well tolerated. The overall frequency and severity of adverse events was similar between &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; and placebo groups [&lt;ulink linkType="Reference" linkID="527285"&gt;527285&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results  presented in November 2008 showed that  more serious adverse events were seen in  patients treated with &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt;, although the adverse events were evenly distributed between groups. The frequency of patients reporting adverse events was similar for both groups (87.4%, &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; versus 88.9%, placebo). Majority of the adverse events were mild or moderate in severity with six patients reporting  seven serious adverse events. The most commonly observed adverse events among patients treated with &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; included upper respiratory tract infection (18.4%), nasopharyngitis (16.1%), nasal congestion (9.2%), rash (9.2%), and nausea (9.2%)  [&lt;ulink linkType="Reference" linkID="969868"&gt;969868&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was to  evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; to treat chronic persistent asthma.  The research would be   conducted at up to 22 clinical research sites in the US and would be open to both men and women ages 18 to 70 years old.  Participants in the study  would have a number of visits to a research site over a 10-month period. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results presented in March 2004 have shown that patients receiving &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; showed a mean increase in FEV1 of 4.4% of baseline, compared to placebo patients who experienced a mean decrease of 1.5% (p = 0.05) during  treatment period 1 (ie, initial 12-week treatment period). Patients receiving &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; also showed  a  significant increase in the time to asthma exacerbation requiring oral corticosteroid rescue (p = 0.024). Peripheral eosinophil counts were  reduced in the &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; treatment group compared to the placebo group (p = 0.04). Changes in the &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; group showed improvements (p &amp;lt;/= 0.007) from baseline in diary symptom scores, as well as morning and nighttime peak expiratory flow rates compared to placebo group [&lt;ulink linkType="Reference" linkID="527285"&gt;527285&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Similar results were presented in November 2008. The daytime asthma symptoms (P = 0.018) and short-acting inhaled beta2-agonist use (P = 0.009) were reduced by &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; compared to placebo during treatment period 1. There were no significant differences in patients treated with &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; compared to placebo  for nighttime asthma symptoms (P = 0.136) and asthma-free days (P = 0.35).  During  treatment period 2, there were no significant differences between the two groups for changes in daytime and nighttime asthma symptoms, short-acting inhaled beta2-agonist use, or asthma-free days. FEV1 values were decreased for patients in both treatment groups during  treatment period 2 (ie, from 12 to 20 weeks). The percent change difference in FEV1  between &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; and placebo was not significant  (&lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt;: –5.37%; placebo: –4.3%; P = 0.61). There were no significant differences between the two groups  for changes in morning and evening PEF rates during treatment period 2. A significant reduction in the mean peripheral blood eosinophil count from baseline to day 84 (26% decrease) was seen by &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; therapy compared to placebo (9% increase)  (P = 0.04), with a peak reduction by day 28 [&lt;ulink linkType="Reference" linkID="969868"&gt;969868&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A total of 32 patients were evaluable  for  pharmacokinetic analysis. A long elimination half-life of 20 days, with no accumulation of drug was observed after the initial loading dose of daclizumab. At approximately 24 microg/ml, the average steady-state serum daclizumab concentrations were maintained. For at least 2 months after the last infusion, serum levels were maintained at &amp;gt;  1 microg/ml  [&lt;ulink linkType="Reference" linkID="969868"&gt;969868&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were randomized to receive &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; or placebo in a 3 : 1 ratio. Patients were given &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; at 2-week intervals, for a total of 10 doses. During the initial 12-week treatment period, &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; or placebo was used in combination with a stable dose of inhaled corticosteroids (triamcinolone acetate). Patients in the &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; treatment group received an initial dose of 2 mg/kg iv, followed by subsequent doses of 1 mg/kg iv,   every 2 weeks. The use of inhaled corticosteroids was gradually reduced, while patients continued receiving &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; or placebo during the final 8 weeks. Patients were followed for a period of 16 weeks at the end of treatment [&lt;ulink linkType="Reference" linkID="527285"&gt;527285&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="969868"&gt;969868&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; or placebo in a 3 : 1 ratio. Patients were given &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; at 2-week intervals, for a total of 10 doses. During the initial 12-week treatment period, &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; or placebo was used in combination with a stable dose of inhaled corticosteroids (triamcinolone acetate). Patients in the &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; treatment group received an initial dose of 2 mg/kg iv, followed by subsequent doses of 1 mg/kg iv,   every 2 weeks. The use of inhaled corticosteroids was gradually reduced, while patients continued receiving &lt;ulink linkType="Drug" linkID="2546"&gt;daclizumab&lt;/ulink&gt; or placebo during the final 8 weeks. Patients were followed for a period of 16 weeks at the end of treatment [&lt;ulink linkType="Reference" linkID="527285"&gt;527285&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="969868"&gt;969868&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>daclizumab (intravenous, transplant rejection), PDL/Roche</Name><Drug id="2546">daclizumab (intravenous, transplant rejection), PDL/Roche</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>9.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>16.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3006">Nasal congestion</Indication><CountPatientsAffectedPercentage>9.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>9.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="516">Upper respiratory tract infection</Indication><CountPatientsAffectedPercentage>18.4</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="33218">daclizumab (intravenous, transplant rejection), PDL/Roche</Intervention><Treatments><Treatment><Dose>1 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>2 milligram/kg</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Bensch Research Associates</Name><Address1>Stockton</Address1><Address2>California</Address2><Address3>95207</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Southern California Research</Name><Address1>Mission Viejo</Address1><Address2>California</Address2><Address3>92691</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Institute of Health Care Assessment, Inc.</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92120</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Medical Research Associates</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3>90806</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>National Jewish Medical and Research Center</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3>80206</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Clinical Reserch Centers of Colorado</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3>80230</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Florida Center for Allergy and Asthma Reserch</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33176</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Rx Research</Name><Address1>Woodstock</Address1><Address2>Georgia</Address2><Address3>30188</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>ICSL Clinical Studies</Name><Address1>Bloomington</Address1><Address2>Illinois</Address2><Address3>61704</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Asthma and Allergy Center of Chicago, S.C.</Name><Address1>River Forest</Address1><Address2>Illinois</Address2><Address3>60305</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>New England Clinical Studies</Name><Address1>North Dartmouth</Address1><Address2>Massachusetts</Address2><Address3>02747</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Clinical Research Institute</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55402</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Princeton Center for Clinical Research</Name><Address1>Princeton</Address1><Address2>New Jersey</Address2><Address3>08540</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Allergy, Asthma, and Dermatology Research Center, LLC</Name><Address1>Lake Oswego</Address1><Address2>Oregon</Address2><Address3>97035</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts/></Site><Site><Name>Valley Clinical Research Center</Name><Address1>Easton</Address1><Address2>Pennsylvania</Address2><Address3>18045</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Pharmaceutical Research and Consulting, Inc.</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75231</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>University of Wisconsin Medical School</Name><Address1>Madison</Address1><Address2>Wisconsin</Address2><Address3>53792</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site><Site><Name>Allergy and Respiratory Care Center</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3>53209</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Asthma</Disease><PatientSegments><PatientSegment><PatientSegment id="3314">Subjects with History of/Scheduled for Therapy</PatientSegment><SubSegments><SubSegment id="11963">Subjects with history of/scheduled for asthma drugs</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11959">Subjects with Persistent Asthma</PatientSegment><SubSegments><SubSegment id="11960">Subjects with mild persistent asthma</SubSegment><SubSegment id="11961">Subjects with moderate persistent asthma</SubSegment><SubSegment id="11962">Subjects with severe persistent asthma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00028288</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="5939"><Endpoint>Assessment of Forced Expiratory Volume in One Second (FEV1)</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5941">Change from baseline in FEV1</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Asthma" id="5918"><Endpoint>Assessment of Pulmonary Function</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5922">FEV1/FVC ratio</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="5933"><Endpoint>Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5934">Assessment of morning/evening PEFR</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="5939"><Endpoint>Assessment of Forced Expiratory Volume in One Second (FEV1)</Endpoint></OtherEndpoint><OtherEndpoint disease="Asthma" id="5957"><Endpoint>Assessment of Forced Expiratory Flow (FEF)</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5959">Forced expiratory flow 25-75%</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="5966"><Endpoint>Assessment of Asthma Symptoms/Symptoms Score</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5967">Daytime asthma symptom score</SubEndpoint><SubEndpoint disease="Asthma" id="5969">Nighttime asthma symptom score</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="5983"><Endpoint>Assessment of Exacerbations</Endpoint></OtherEndpoint><OtherEndpoint disease="Asthma" id="5997"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6000">Blood eosinophils</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="6048"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Asthma" id="6049"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6051">Antibody assays</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="6064"><Endpoint>Assessment of use of Rescue Medication</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6065">Beta agonist usage</SubEndpoint><SubEndpoint disease="Asthma" id="6067">Corticosteroid usage</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="6082"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6083">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Asthma" id="45555"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6087">Infection</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2765"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Asthma" id="22368">Subjects with history of/scheduled for asthma drugs</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Asthma" id="4322"><Criterion>Subjects with Diagnosis of Asthma</Criterion></Inclusion><Inclusion disease="Asthma" id="22363"><Criterion>Subjects with Persistent Asthma</Criterion><SubCriteria><SubCriterion disease="Asthma" id="22364">Subjects with mild persistent asthma</SubCriterion><SubCriterion disease="Asthma" id="22365">Subjects with moderate persistent asthma</SubCriterion><SubCriterion disease="Asthma" id="22366">Subjects with severe persistent asthma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="25070"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Asthma" id="3954">Smokers</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2003-12-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-07-24T10:21:04Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="223494"><TitleDisplay>Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria</TitleDisplay><TitleOfficial>Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Comparison to Placebo in Patients With Hypertension and Albuminuria</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02376075</Identifier><Identifier type="Secondary Organisational">2012-004300-35</Identifier><Identifier type="Organisational Study">IKFE-LINA-003</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication><Indication id="2285">Albuminuria</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="120" role="Therapeutic effect marker" type="Genomic;Proteomic">Cystatin C</BiomarkerName><BiomarkerName id="166" role="Therapeutic effect marker" type="Genomic;Proteomic">Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="319" role="Therapeutic effect marker" type="Genomic;Proteomic">Transforming growth factor beta 1</BiomarkerName><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="363" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-18</BiomarkerName><BiomarkerName id="429" role="Therapeutic effect marker" type="Biochemical">N,N-dimethylarginine</BiomarkerName><BiomarkerName id="430" role="Therapeutic effect marker" type="Genomic;Proteomic">Acetylglucosaminidase</BiomarkerName><BiomarkerName id="1183" role="Therapeutic effect marker" type="Biochemical">Urinary albumin to creatinine ratio</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="2662" role="Therapeutic effect marker" type="Biochemical">Sodium</BiomarkerName><BiomarkerName id="5596" role="Therapeutic effect marker" type="Physiological">Blood flow</BiomarkerName><BiomarkerName id="7001" role="Therapeutic effect marker" type="Biochemical">Cyclic GMP</BiomarkerName><BiomarkerName id="8395" role="Therapeutic effect marker" type="Genomic;Proteomic">Podocin</BiomarkerName><BiomarkerName id="8590" role="Therapeutic effect marker" type="Genomic;Proteomic">Nephrin</BiomarkerName><BiomarkerName id="11304" role="Therapeutic effect marker" type="Structural (imaging)">Retina</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>linagliptin</Name><Drug id="55852">linagliptin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="55852">linagliptin</Drug><IndicationsPioneer><Indication id="178">Hypertension</Indication><Indication id="2285">Albuminuria</Indication></IndicationsPioneer><Companies><Company><Company id="1048708">ikfe-CRO GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1103499">Profil Mainz GmbH &amp; Co KG</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1106578">MLM Medical Labs</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="55852" type="Drug"><TargetEntity id="365734" type="siDrug">Linagliptin</TargetEntity></SourceEntity><SourceEntity id="1048708" type="Company"><TargetEntity id="5035547301" type="organizationId">ikfe CRO GmbH</TargetEntity></SourceEntity><SourceEntity id="1103499" type="Company"><TargetEntity id="5044167969" type="organizationId">Profil Mainz GmbH &amp; Co KG</TargetEntity></SourceEntity><SourceEntity id="1106578" type="Company"><TargetEntity id="5045505219" type="organizationId">Mlm Medical Labs GmbH</TargetEntity></SourceEntity><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity><SourceEntity id="2285" type="ciIndication"><TargetEntity id="10001580" type="MEDDRA"/><TargetEntity id="D000419" type="MeSH"/><TargetEntity id="997" type="siCondition"/></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1048708">ikfe-CRO GmbH</Company><Company id="1103499">Profil Mainz GmbH &amp; Co KG</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1106578">MLM Medical Labs</Company><Company id="14881">Boehringer Ingelheim International GmbH</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="38439">DPP IV inhibitor antidiabetic product</Class><Class id="399">Hypoglycemic agent</Class><Class id="7292">Vulnerary agent</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>43</PatientCountEnrollment><PatientCountEvaluable>43</PatientCountEvaluable><DateStart>2013-01-31T00:00:00Z</DateStart><DateEnd type="actual">2014-09-30T00:00:00Z</DateEnd><DateChangeLast>2016-03-18T05:47:40Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Profil GmbH Mainz</Affiliation><Name>Thomas Forst, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient has signed and dated written informed consent to participate in the trial&lt;/li&gt;&lt;li&gt;Arterial hypertension&lt;/li&gt;&lt;li&gt;Stable antihypertensive treatment within the last 3 months&lt;/li&gt;&lt;li&gt;Age &gt;/=  45 to&amp;lt;/= 80 years&lt;/li&gt;&lt;li&gt;Micro- or macroalbuminuria defined as UACR in morning urine&amp;gt; 20 mg/g in female and &amp;gt; 30 mg/g in male and/or arterial hypertension for more than five years currently treated with two or more antihypertensive drugs to control blood pressure and a history of cardiovascular disease or stroke&lt;/li&gt;&lt;li&gt;Patient consents that his/her family physician will be informed of trial participation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of type 1 diabetes&lt;/li&gt;&lt;li&gt;History of type 2 diabetes&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension (systolic blood pressure&amp;gt;180 mmHg and/or diastolic blood pressure &amp;gt;100 mmHg)&lt;/li&gt;&lt;li&gt;Acute infections&lt;/li&gt;&lt;li&gt;Any history of glomerulonephritis&lt;/li&gt;&lt;li&gt;Any kidney disease not caused by hypertension as judged by the Investigator&lt;/li&gt;&lt;li&gt;Glomerular filtration rate (GFR)&amp;lt; 30 ml/min (estimated by use of the Modification of Diet in Renal Disease (MDRD) formula)&lt;/li&gt;&lt;li&gt;Medical history of hypersensitivity to the study drugs or to drugs with similar chemical structures&lt;/li&gt;&lt;li&gt;History of severe or multiple allergies&lt;/li&gt;&lt;li&gt;Treatment with any other investigational drug within 3 months before trial entry&lt;/li&gt;&lt;li&gt;Progressive fatal disease&lt;/li&gt;&lt;li&gt;History of drug or alcohol abuse in the past two years&lt;/li&gt;&lt;li&gt;Condition after kidney transplantation&lt;/li&gt;&lt;li&gt;Serum potassium&amp;gt; 5.5 mmol/l&lt;/li&gt;&lt;li&gt;Pregnancy or breast feeding&lt;/li&gt;&lt;li&gt;Sexually active woman of childbearing age not practicing a highly effective method of birth control as defined as those which result in a low failure rate (ie,&amp;lt; 1% per year) when used  consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomised partner&lt;/li&gt;&lt;li&gt;Acute myocardial infarction, open heart surgery or cerebral event (stroke/TIA) within the previous 3 months&lt;/li&gt;&lt;li&gt;Any elective surgery during study participation&lt;/li&gt;&lt;li&gt;Uncontrolled unstable angina pectoris&lt;/li&gt;&lt;li&gt;Intake of Coumarin or coumarin derived compounds such as phenprocoumon (Marcumar) or warfarin (Coumadin, Warfant)&lt;/li&gt;&lt;li&gt;Intake of rifampicin or carbamazepine&lt;/li&gt;&lt;li&gt;HbA1c &gt;/= 6,5%&lt;/li&gt;&lt;li&gt;A body mass index of&amp;gt; 35 kg/m2&lt;/li&gt;&lt;li&gt;CHF NYHA stage III to IV&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Albumin/creatinine ratio (UACR) in 24 h urine change between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Blood pressure, urine sampling, and retinal microvascular assessments: UACR, systolic blood pressure, diastolic blood pressure, retinal capillary perfusion, arterial flow, retinal endothelial function and the arterial wall to lumen ratio</Description><Timeframe>At baseline, after 6 and 12 weeks of treatment</Timeframe></Measure><Measure><Description>Collection of blood samples for measurement of HbA1c, asymmetric dimethylarginine, C-reactive peptide, cyclic guanosinmonophosphate, transforming growth factor beta (TGF-beta1) and cystatin C</Description></Measure><Measure><Description>24 hour urinary sodium excretion change between baseline and visit 4</Description><Timeframe>After 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Blood pressure measurements change at 24 h between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Adverse events during study participation</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Body weight change during study participation</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Fasting TGF-beta1 change between baseline and visit 4</Description><Timeframe>After 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Fasting cGMP change between baseline and visit 4</Description><Timeframe>After 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Fasting cystatin C change between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Fasting hsCRP change between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Fasting serum ADMA change between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>HbA1c change between Baseline and Visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Retinal endothelial function change between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Retinal microvascular blood flow change between baseline and visit 4</Description><Timeframe>Up to 14 weeks of study drug intake</Timeframe></Measure><Measure><Description>Fasting serum and urinary neutrophil gelatinase-associated lipocalin (NGAL)</Description><Timeframe>After approximately 16 weeks of treatment</Timeframe></Measure><Measure><Description>Urinary N-acetyl-beta-D-glucosaminidase</Description><Timeframe>After approximately 16 weeks of treatment</Timeframe></Measure><Measure><Description>Urinary nephrin</Description><Timeframe>After approximately 16 weeks of treatment</Timeframe></Measure><Measure><Description>Urinary podocin</Description><Timeframe>After approximately 16 weeks of treatment</Timeframe></Measure><Measure><Description>Fasting serum and urinary IL-18</Description><Timeframe>After approximately 16 weeks of treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this trial was to investigate the effect of &lt;ulink linkType="Drug" linkID="55852"&gt;linagliptin&lt;/ulink&gt; in comparison to      placebo on the UACR in patients with high blood pressure and an increased albumin excretion.      Numerous, equivalent endothelial, renal, and retinal parameters serve as objectives of the      study. All study parameters would be handled in an exploratory sense for the generation of      models to further discuss the role of DPP-IV inhibition on renal and retinal physiology.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2015 results were presented. In linagliptin versus placebo groups, the urinary albumin creatinine ratios (UACR) at baseline, 6 and 12 weeks values were 8.1, 9.4 and 12.5 versus 19.5, 12.7 and 11.9 mg/g creatinine, respectively. Similarly, the mean 24 h systolic blood pressure values were 129.8, 126 and 127.1 versus 133.2, 129.4 and 128.5 mmHg; mean 24 h diastolic blood pressure values were 75.8, 73.9 and 73.9 versus 76.9, 74.7 and 73.9 mmHg; retinal capillary perfusion vales were 247.6, 253.7 and 290.7 versus 235.8, 248.6 and 269.7 AU; arterial flow values were 74.2, 75.8 and 77.3 versus 76.1, 74.6 and 75.5 AU; flicker response values were 32.4, 36.9 and 54.1 versus 39.6, 29.5 and 27.8 AU; and areteriolar wall/lumen ratios were 0.400, 0.392 and 0.397 versus 0.415, 0.416 and 0.413 in linagliptin versus placebo groups, respectively [&lt;ulink linkType="Reference" linkID="1667957"&gt;1667957&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, results were published. Assessment of retinal microcirculation and arterial blood pressure profiles was performed at baseline, after 6 and 12 weeks, respectively. During treatment with &lt;ulink linkType="Drug" linkID="55852"&gt;linagliptin&lt;/ulink&gt;, increase in retinal capillary perfusion by 23.7 % (p &amp;lt;  0.05), retinal arterial flow by 7.6 % (p &amp;lt;  0.05) and the retinal hyperemic response by 290 % (p &amp;lt;  0.05) was observed. In the placebo group, no change in retinal blood flow was observed. Blood pressure decline was observed in both groups, and in the  linagliptin group, a significant reduction in TGF-beta1 by 9.3 % (p &amp;lt;  0.05) was observed. In both groups, no significant change in other laboratory parameters was reported  [&lt;ulink linkType="Reference" linkID="1743239"&gt;1743239&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive linagliptin (5 mg) or placebo once-daily as add on to pre-existing anti-hypertensive treatment for 6 weeks. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 43) were randomized to receive linagliptin qd (5 mg; n = 21) or placebo (n = 22) [&lt;ulink linkType="Reference" linkID="1667957"&gt;1667957&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1743239"&gt;1743239&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="510853">linagliptin</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Profil Mainz GmbH &amp; Co. KG</Name><Address1>Mainz</Address1><Address2>Rhineland-Palatinate</Address2><Address3>55116</Address3><CountrySubDivision>Rhineland-Palatinate</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="1">Subjects with Primary/Essential Hypertension</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="14">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="47">Subjects with renal disorders/diseases/dysfunction</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7709">Subjects with Hypertensive Nephropathy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11420">Subjects with Proteinuria/Albuminuria</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02376075</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2012-004300-35</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="155"><Endpoint>Assessment of Vascular Endothelial Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="171"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="176">High-sensitivity C-reactive protein (hsCRP)</SubEndpoint><SubEndpoint disease="Hypertension" id="179">Interleukin-18 (IL-18)</SubEndpoint><SubEndpoint disease="Hypertension" id="195">Transforming growth factor-beta (TGF-beta)</SubEndpoint><SubEndpoint disease="Hypertension" id="199">Asymmetric dimethylarginine [ADMA]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="242"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="252">Urinary albumin to creatinine ratio (UACR)</SubEndpoint><SubEndpoint disease="Hypertension" id="257">Urinary sodium excretion</SubEndpoint><SubEndpoint disease="Hypertension" id="260">Serum cystatin C levels</SubEndpoint><SubEndpoint disease="Hypertension" id="469">Urinary podocyte excretion</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="285"><Endpoint>Assessment of Renal Hemodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="288">Renal plasma flow (RPF)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22509"><Endpoint>Assessment of Urinary Protein Excretion/Proteinuria</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22511">Assessment of proteinuria/albuminuria/macroalbuminuria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22513"><Endpoint>Assessment of Urine Creatinine</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22521"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22522">Assessment of asymmetric dimethylarginine(ADMA)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22523">Assessment of cystatin</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22524">Assessment of neutrophil gelatinase-associated lipocalin(NGAL)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22526">Assessment of interleukin(IL-6/8/10/18)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22529">Assessment of N-acetyl-ß-D-glucosaminidase(NAG)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22532">Assessment of other inflammatory/oxidative stress markers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22539"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22540">Assessment of blood pressure</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22549"><Endpoint>Assessment of Serum Electrolytes</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22551">Assessment of sodium</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="242"><Endpoint>Assessment of Renal Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypertension" id="1"><Criterion>Subjects with Primary/Essential Hypertension</Criterion></Inclusion><Inclusion disease="Hypertension" id="79"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="92">Subjects on stable antihypertensive medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hypertension" id="126"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="133">Subjects co-morbid with microalbuminuria</SubCriterion><SubCriterion disease="Hypertension" id="134">Subjects with macroalbuminuria/proteinuria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17665"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17666">Subjects with hypertensive nephropathy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17687"><Criterion>Subjects with Proteinuria/Albuminuria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypertension" id="1"><Criterion>Subjects with Primary/Essential Hypertension</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="344">Uncontrolled blood pressure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="36"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="40">Subjects co-morbid with stroke</SubCriterion><SubCriterion disease="Hypertension" id="42">Subjects co-morbid with transient ischemic attack</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="101"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="104">Current/recent use of antipsychotics/antidepressants/antimaniac drugs</SubCriterion><SubCriterion disease="Hypertension" id="120">Subjects with history/scheduled to receive anticoagulants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="125"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="140">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="150"><Criterion>Obese Subjects</Criterion></Exclusion><Exclusion disease="Hypertension" id="167"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="367">Post-renal transplant/one functioning kidney</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="203"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Hypertension" id="222"><Criterion>Subjects with Electrolyte Imbalances</Criterion></Exclusion><Exclusion disease="Hypertension" id="248"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hypertension" id="351"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="46">Subjects co-morbid with unstable/variant angina</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="385"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17508"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17512">Subjects with glomerular disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17515"><Criterion>Subjects with Renal Function Outside of Protocol Specified Limits</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17516">Subjects with GFR outside of protocol specified limits</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17524"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17525">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17527"><Criterion>Subjects with Fluid/Electrolyte Imbalance</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17535"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17536"><Criterion>Subjects with History of/Scheduled for Renal Replacement Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17539">Subjects with protocol specified transplantation related criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17541"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17549">Subjects with history of/scheduled for anticoagulants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17551"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17552"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17553"><Criterion>Subjects with Contraindications to Study Procedure</Criterion></Exclusion><Exclusion disease="Hypertension" id="25139"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="60">Subjects co-morbid with type 1 diabetes mellitus</SubCriterion><SubCriterion disease="Hypertension" id="61">Subjects co-morbid with type 2 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="27039"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="47">Subjects co-morbid with myocardial infarction</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-03-18T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="228156"><TitleDisplay>Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis</TitleDisplay><TitleOfficial>A Randomized, Double-blind, Placebo-controlled Study With an Open-Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02429882</Identifier><Identifier type="Secondary Organisational">2014-003701-15</Identifier><Identifier type="Organisational Study">20101228</Identifier></Identifiers><Indications><Indication id="2921">Spondylarthritis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>brodalumab</Name><Drug id="59585">brodalumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59585">brodalumab</Drug><IndicationsPioneer><Indication id="2921">Spondylarthritis</Indication></IndicationsPioneer><Companies><Company><Company id="14109">Amgen Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59585" type="Drug"><TargetEntity id="474135" type="siDrug">Brodalumab</TargetEntity></SourceEntity><SourceEntity id="14109" type="Company"><TargetEntity id="4295905537" type="organizationId">Amgen Inc</TargetEntity></SourceEntity><SourceEntity id="2921" type="ciIndication"><TargetEntity id="D025241" type="MeSH"/><TargetEntity id="-172791506" type="omicsDisease"/><TargetEntity id="753" type="siCondition"/></SourceEntity><SourceEntity id="55653" type="Action"><TargetEntity id="5286" type="Mechanism">Interleukin-17 Receptor A (IL-17RA) Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><NumberOfSites>16</NumberOfSites><CompaniesSponsor><Company id="14109">Amgen Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="55653">Interleukin receptor 17A antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="168">Monoclonal antibody human</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><DateStart>2015-05-01T00:00:00Z</DateStart><DateEnd type="actual">2015-05-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:33:56Z</DateChangeLast><DateAdded>2015-05-14T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Amgen</Affiliation><Name>MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject fulfills the ASAS classification criteria of axial spondyloarthritis (except Crohn's disease criterion) for&amp;gt; 3 months with age of onset &amp;lt; 45 years of age&lt;/li&gt;&lt;li&gt;Subject has Bath Ankylosing Spondylitis DIsease Activity Index (BASDAI) score &gt;/=  4 at screening and baseline&lt;/li&gt;&lt;li&gt;Subject has spinal pain score (BASDAI question #2) &gt;/= 4 at screening and baseline&lt;/li&gt;&lt;li&gt;Subject has had adequate therapeutic trial (at least 4 weeks) of &gt;/= 2 non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum recommended dose unless contraindicated or subject is intolerant&lt;/li&gt;&lt;li&gt;For subjects receiving non-biologic DMARDS subject has received treatment for &gt;/= 3 months with a stable dose for &gt;/= 4 weeks prior to initiation of IM&lt;/li&gt;&lt;li&gt;For subjects receiving oral corticosteroids: the subject must be on a stable dose (not to exceed the equivalent of 10 mg of prednisone per day) for &gt;/= 4 weeks prior to initiation of IMP&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Complete ankylosis (fusion) of the spine&lt;/li&gt;&lt;li&gt;Subject has a positive test for tuberculosis&lt;/li&gt;&lt;li&gt;Subject has a planned surgical intervention between baeline and week 16&lt;/li&gt;&lt;li&gt;Subject has an active infection or history of infections as follows (any active infection for which systemic anti-infectives were used within 28 day prior to the first MP dose&lt;/li&gt;&lt;li&gt;A serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first IMP dose&lt;/li&gt;&lt;li&gt;Recurrent or chronic infections or other active infection that, in the opinion ofthe investigator might cause this study to be detrimental to the subject)&lt;/li&gt;&lt;li&gt;Subject has active Crohn's disease or a history of Crohn's disease&lt;/li&gt;&lt;li&gt;Subject has active ulcerative colitis requiring daily use of immunosuppressive therapy&lt;/li&gt;&lt;li&gt;Subject has had active fibromyalgia within the past 12 months&lt;/li&gt;&lt;li&gt;Subject has a prior history of &gt; 1 anti-TNF therapy for ankylosing spondylitis&lt;/li&gt;&lt;li&gt;Subject has used commercially available or investigational biologic therapies for ankylosing spondylitis as follows&lt;/li&gt;&lt;li&gt;Anti-tumor necrosis factor (TNF) therapy as follows: within 1 month prior to IMP initiation for etanercept and within 2 months prior to IMP initiation for other anti-TNF agents&lt;/li&gt;&lt;li&gt;Other experimental or commercially available biologic therapies for ankylosing spondylitis within 3 months prior to IMP initiation&lt;/li&gt;&lt;li&gt;Anti-IL17 biologics (eg, brodalumab, secukinumab, ixekizumab) or anti-IL12/IL23 biologic therapy (eg, ustekinumab, briakinumab) at any time&lt;/li&gt;&lt;li&gt;Rituximab at any time&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Assessment of SpondyloArthritis international Society (ASAS): achievement of Assessment of SpondyloArthritis international Society (ASAS) 20 response</Description><Timeframe>Week 16</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>ASDAS-CRP change from baseline in AS subjects</Description><Timeframe>At week 16</Timeframe></Measure><Measure><Description>ASAS 20 in the pooled population (AS and nr-axSpA subjects)</Description><Timeframe>At week 16</Timeframe></Measure><Measure><Description>ASAS 40 in AS subjects</Description><Timeframe>At week 16</Timeframe></Measure><Measure><Description>ASAS 20 in anti-TNF-naive AS subjects</Description><Timeframe>At week 16</Timeframe></Measure><Measure><Description>ASAS 20 in anti-TNF-experienced AS subjects</Description><Timeframe>At week 16</Timeframe></Measure><Measure><Description>ASAS 20 in nr-axSpA subjects</Description><Timeframe>At week 16</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to assess the safety and efficacy of &lt;ulink linkType="Drug" linkID="59585"&gt;brodalumab&lt;/ulink&gt; compared with      placebo in participants with axial spondyloarthritis.&lt;/para&gt;&lt;para&gt;The main objective of the study was to evaluate the efficacy of brodalumab in ankylosing spondylitis (AS) compared to placebo, as measured by the proportion of AS subjects achieving an Assessment of SpondyloArthritis international Society (ASAS) 20 response at week 16.&lt;/para&gt;&lt;para&gt;The secondary objective of the study were:&lt;br/&gt;To evaluate the efficacy of brodalumab in AS subjects on Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) change from baseline at week 16.&lt;br/&gt;To evaluate the efficacy of brodalumab in the pooled population (AS and non-radiographic axial spondyloarthritis [nr-axSpA] subjects) on ASAS 20 at week 16.&lt;br/&gt;To evaluate the efficacy of brodalumab in AS subjects as measured by ASAS 40 at week 16.&lt;br/&gt;To evaluate the efficacy of brodalumab in the anti-TNF-experienced and anti-TNF-naïve subgroups as measured by ASAS 20 at week 16.&lt;br/&gt;To describe the effect of brodalumab in subjects with nr-axSpA as measured by ASAS 20 at week 16.&lt;br/&gt;This study contains  sub study: &lt;br/&gt;Pharmacokinetic substudy:  to better characterize the pharmacokinetics of brodalumab in AS subjects following subcutaneous administration, additional pharmacokinetic samples will be collected with sparse sampling to determine the steady-state PK area under the concentration-time profile (AUC) in a small subset of subjects (n= 28).&lt;br/&gt;Longitudinal MRI substudy of the axial spine will be assessed in approximately 40 AS subjects at baseline and week 16.&lt;/para&gt;&lt;para&gt;Biomarker development: blood samples are to be assessed for biomarker development. A cell pellet from the blood plasma tube may be utilized to assess the impact of brodalumab on circulating immune cells via DNA methylation analysis, a pharmacodynamics assessment of methylation patterns of relevant gene.&lt;/para&gt;&lt;para&gt;Pharmacogenetic studies:  focus on inherited genetic variations to evaluate their possible correlation to the disease and/or responsiveness to the therapies used in this study. The goals of the optional studies include the use of genetic markers to help in the investigation of inflammatory disease and/or to identify subjects who may have positive or negative responses to brodalumab.&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized in a 1:1      ratio to brodalumab , 210 mg or placebo sc for the first part of the study. Subjects would then  receive      open-label brodalumab for the remainder of the study. The entire study would be 312 weeks in      duration for each subject.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab, study was being cancelled/closed.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Research Site</Name><Address1>Winnipeg</Address1><Address2>Manitoba</Address2><Address3>R3A 1M3</Address3><CountrySubDivision>Manitoba</CountrySubDivision><Contacts/></Site><Site><Name>Research Site</Name><Address1>Winnipeg</Address1><Address2>Manitoba</Address2><Address3>R3N 0K6</Address3><CountrySubDivision>Manitoba</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>MedinfoInternational@amgen.com</Email><Name>IHQ Medical Info - Clinical Trials</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Name>State Autonomous Institution of Health of the Novosibirsk Region "Clinical Polyclinic number 1"</Name><Address1>Novosibirsk</Address1><Address3>630099</Address3><Contacts/></Site><Site><Name>Federal State Institution "Research Institute of Rheumatology, the VA Nasonova "of the Russian Academy of Medical Sciences</Name><Address1>Moscow</Address1><Address3>115522</Address3><Contacts/></Site><Site><Name>State Budget Institution of Health in Moscow City Clinical Hospital named after SP Botkin Moscow Health Department</Name><Address1>Moscow</Address1><Address3>125284</Address3><Contacts/></Site><Site><Name>Limited Liability Company Town neurological center "Sibneyromed"</Name><Address1>Novosibirsk</Address1><Address3>630091</Address3><Contacts/></Site><Site><Name>State Health Care Institution "Regional Hospital"</Name><Address1>Saratov</Address1><Address3>410053</Address3><Contacts/></Site><Site><Name>Federal State Institution of Health «Health Service Central Internal Affairs Directorate in Kemerovo region»</Name><Address1>Kemerovo</Address1><Address3>650099</Address3><Contacts/></Site><Site><Name>Regional Budget Institution of Health «Ivanovo Clinical Hospital Kuvaeva"</Name><Address1>Ivanovo</Address1><Address3>153025</Address3><Contacts/></Site><Site><Name>Non-state health care facility "of departmental hospital at Smolensk Station Joint Stock Company" Russian Railways "</Name><Address1>Smolensk</Address1><Address3>214025</Address3><Contacts/></Site><Site><Name>State Educational Institution of Higher Professional Education "Voronezh State Medical Academy named after NN Burdenko" Ministry of Health and Social Development of the Russian Federation</Name><Address1>Voronezh</Address1><Address3>394036</Address3><Contacts/></Site><Site><Name>State Autonomous Institution of Health of the Yaroslavl region "Clinical Emergency Hospital named NV Solovyov</Name><Address1>Yaroslavl</Address1><Address3>150003</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Research Site</Name><Address1>Duncansville</Address1><Address2>Pennsylvania</Address2><Address3>16635</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Research Site</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73103</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts/></Site><Site><Name>Research Site</Name><Address1>Scottsdale</Address1><Address2>Arizona</Address2><Address3>85258</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ankylosing spondylitis</Disease><PatientSegments><PatientSegment><PatientSegment id="552">Subjects with History of Use of Ankylosing Spondylitis Medications</PatientSegment><SubSegments><SubSegment id="3715">DMARDs</SubSegment><SubSegment id="3717">NSAIDs</SubSegment><SubSegment id="3718">Stable medication</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02429882</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2014-003701-15</Identifier></Identifiers></Registry><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ankylosing spondylitis" id="3192"><Endpoint>Response to Therapy (ASAS criteria)</Endpoint><SubEndpoints><SubEndpoint disease="Ankylosing spondylitis" id="3193">Assessments in Ankylosing Spondylitis (ASAS) 20</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Ankylosing spondylitis" id="3295"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ankylosing spondylitis" id="1456"><Criterion>Severe Ankylosing Spondylitis</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="1457">Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) = or &gt; 4</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ankylosing spondylitis" id="1459"><Criterion>Active Ankylosing Spondylitis</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2037">Axial Involvement</SubCriterion><SubCriterion disease="Ankylosing spondylitis" id="4251">Spinal pain/Back pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ankylosing spondylitis" id="1547"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="1511">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ankylosing spondylitis" id="1895"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="1508">DMARDs</SubCriterion><SubCriterion disease="Ankylosing spondylitis" id="1510">Subjects with history of/scheduled to receive NSAIDs</SubCriterion><SubCriterion disease="Ankylosing spondylitis" id="4252">Subjects with history of/ scheduled to receive corticosteroids</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ankylosing spondylitis" id="2274"><Criterion>Complete Ankylosis</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2275"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="5631">Subjects with hypersensitivity/Contraindication to non steroidal antiinflammatory drugs (NSAIDs)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2278"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2279">Anti-TNF therapy</SubCriterion><SubCriterion disease="Ankylosing spondylitis" id="2285">Subjects with history of/current use of a prohibited immunosuppressant/immunomodulator</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2307"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2327"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2299">Subjects co-morbid with tuberculosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2335"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2336">Subjects co-morbid with fibromyalgia syndrome</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2353"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2370">History of/current hospitalization for any condition</SubCriterion><SubCriterion disease="Ankylosing spondylitis" id="2382">Unsuitable to participate as per the investigator's opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="5641"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-04-24T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-05-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-06-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-01-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-01-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="22859"><TitleDisplay>Trial of IC-351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction</TitleDisplay><TitleOfficial>Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC-351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">0220013701</Identifier><Identifier type="NCT">NCT00707187</Identifier></Identifiers><Indications><Indication id="1105">Scleroderma</Indication><Indication id="1276">Female sexual dysfunction</Indication><Indication id="478">Raynauds disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tadalafil</Name><Drug id="4119">tadalafil</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4119">tadalafil</Drug><IndicationsPioneer><Indication id="1105">Scleroderma</Indication><Indication id="478">Raynauds disease</Indication></IndicationsPioneer><Companies><Company><Company id="20638">University of Medicine and Dentistry of New Jersey</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4119" type="Drug"><TargetEntity id="251999" type="siDrug">Tadalafil</TargetEntity></SourceEntity><SourceEntity id="20638" type="Company"><TargetEntity id="4296715677" type="organizationId">University of Medicine and Dentistry of New Jersey</TargetEntity></SourceEntity><SourceEntity id="1105" type="ciIndication"><TargetEntity id="10039710" type="MEDDRA"/><TargetEntity id="732" type="siCondition"/></SourceEntity><SourceEntity id="1276" type="ciIndication"><TargetEntity id="10057671" type="MEDDRA"/><TargetEntity id="572" type="siCondition"/></SourceEntity><SourceEntity id="478" type="ciIndication"><TargetEntity id="I73.0" type="ICD10"/><TargetEntity id="10037912" type="MEDDRA"/><TargetEntity id="D011928" type="MeSH"/><TargetEntity id="-140562337" type="omicsDisease"/><TargetEntity id="263" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20638">University of Medicine and Dentistry of New Jersey</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="778">PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class><Class id="388">Vasodilator</Class><Class id="5557">Muscle relaxant</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><PatientCountEvaluable>39</PatientCountEvaluable><DateStart>2001-07-31T00:00:00Z</DateStart><DateEnd type="actual">2002-07-31T00:00:00Z</DateEnd><DateChangeLast>2013-09-14T15:36:28Z</DateChangeLast><DateAdded>2008-08-14T13:49:35Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Female with diagnosis of scleroderma&lt;/li&gt;&lt;li&gt;Stable sexual relationship with male partner or be sexually active&lt;/li&gt;&lt;li&gt;Raynaud phenomenon at least six times per week&lt;/li&gt;&lt;li&gt;Willing to attempt sexual activity 1/month during study period&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Severe internal organ problems related to scleroderma&lt;/li&gt;&lt;li&gt;Other gynecologic problems&lt;/li&gt;&lt;li&gt;Serious depression&lt;/li&gt;&lt;li&gt;Receiving other experimental and Raynaud treatments&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of Raynaud attacks</Description><Timeframe>16 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the effectiveness and safety of  &lt;ulink linkType="Drug" linkID="4119"&gt;IC-351&lt;/ulink&gt;.  The study was designed to gather information regarding the possible usefulness of      &lt;ulink linkType="Drug" linkID="4119"&gt;IC-351&lt;/ulink&gt; as a treatment of several blood vessel features of scleroderma including Raynaud      phenomenon as well as the vaginal dryness and discomfort associated with scleroderma.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results showed that &lt;ulink linkType="Drug" linkID="4119"&gt;IC-351&lt;/ulink&gt; was well-tolerated in 39 evaluable patients. No statistically significant differences in Raynaud Condition Score (RCS), frequency of RP episodes or duration of RP episodes were observed between the treatment groups [&lt;ulink linkType="Reference" linkID="1051467"&gt;1051467&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients received either &lt;ulink linkType="Drug" linkID="4119"&gt;IC-351&lt;/ulink&gt; (20 mg) or placebo, daily for 4 weeks. This was followed by a crossover to the alternate treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received either &lt;ulink linkType="Drug" linkID="4119"&gt;IC-351&lt;/ulink&gt; (20 mg) or placebo, daily for 4 weeks. This was followed by a crossover to the alternate treatment.&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="35828">tadalafil</Intervention><Treatments><Treatment><Dose>20 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>UMDNJ</Name><Address1>New Brunswick</Address1><Address2>New Jersey</Address2><Address3>08903</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10155">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="10161">Subjects with raynaud's disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Female sexual dysfunction</Disease><PatientSegments><PatientSegment><PatientSegment id="9030">Subjects with Sexual Pain Disorder</PatientSegment><SubSegments><SubSegment id="9031">Subjects with dyspareunia</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11125">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00707187</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Female sexual dysfunction" id="14034"><Endpoint>Assessment of Underlying Condition</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="44735"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21843">Assessment by Raynaud Condition Score (RCS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Female sexual dysfunction" id="13241"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="19201"><Criterion>Subjects with Peripheral Arterial Disease</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19208">Subjects with raynaud"s disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19260"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19263">Subjects co-morbid with connective tissue disease</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15458"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Female sexual dysfunction" id="15844"><Criterion>Subjects with History of Other Genitourinary Disorder</Criterion></Exclusion><Exclusion disease="Female sexual dysfunction" id="15846"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Female sexual dysfunction" id="15863"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15939"><Criterion>Subjects with Peripheral Arterial Diseases</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15949">Subjects with raynaud disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15989"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2002-07-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-08-14T13:49:35Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="255382"><TitleDisplay>Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients</TitleDisplay><TitleOfficial>A Phase I, Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Solid Tumors in Asians</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02703298</Identifier><Identifier type="Organisational Study">CVM-002</Identifier></Identifiers><Indications><Indication id="2876">Paraganglioma</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>foslinanib</Name><Drug id="91251">foslinanib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="91251">foslinanib</Drug><IndicationsPioneer><Indication id="2876">Paraganglioma</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication></IndicationsPioneer><Companies><Company><Company id="1095999">TaiRx Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1095999" type="Company"><TargetEntity id="5042385530" type="organizationId">TaiRx Inc</TargetEntity></SourceEntity><SourceEntity id="2876" type="ciIndication"><TargetEntity id="D010235" type="MeSH"/><TargetEntity id="-699384684" type="omicsDisease"/><TargetEntity id="2506" type="siCondition"/></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"/><TargetEntity id="3229" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1095999">TaiRx Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="86576">Mitochondrial Heat shock protein 75 kDa modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="695">Metastasis inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>19</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateStart>2016-03-25T00:00:00Z</DateStart><DateEnd type="actual">2018-05-03T00:00:00Z</DateEnd><DateChangeLast>2019-04-01T08:12:21Z</DateChangeLast><DateAdded>2016-03-16T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>National Cheng-Kung University Hospital</Affiliation><Name>Wu-Chou Su, M.D</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Tumor eligibility: histologically or cytologically confirmed advanced, non resectable, and/or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available, or who were not amenable to established forms of treatment&lt;/li&gt;&lt;li&gt;Solid tumors must have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy&lt;/li&gt;&lt;li&gt;Female or male, &gt;/= 20 years of age&lt;/li&gt;&lt;li&gt;ECOG performance status 0 to 2. Resolution of all acute toxic effects of prior therapy or surgical procedures to grade 1 (except alopecia)&lt;/li&gt;&lt;li&gt;Adequate organ function as defined by the following criteria:&lt;ul&gt;&lt;li&gt;Serum aspartate transaminase (AST) and serum alanine transaminase (ALT)&amp;lt;/= 3 x upper limit of normal (ULN), or AST and ALT &amp;lt;/= 5 x ULN if liver function abnormalities are due to underlying malignancy&lt;/li&gt;&lt;li&gt;Total serum bilirubin&amp;lt;/= 1.5 x ULN (except for patients with documented Gilbert's syndrome) &lt;/li&gt;&lt;li&gt;Absolute neutrophil count (ANC)&amp;gt;/= 1500/microl&lt;/li&gt;&lt;li&gt;Platelets&amp;gt;/= 90000/microl&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt;/= 9.0 g/dl&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 2.0 x ULN &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment&lt;/li&gt;&lt;li&gt;Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with leukemia, lymphomas, multiple myeloma, or other type of hematologic cancers&lt;/li&gt;&lt;li&gt;Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of starting study treatment&lt;/li&gt;&lt;li&gt;Prior high-dose chemotherapy requiring hematopoietic stem cell rescue&lt;/li&gt;&lt;li&gt;Current treatment on another clinical trial&lt;/li&gt;&lt;li&gt;Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks&lt;/li&gt;&lt;li&gt;Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the 6 month post-event-free period for a patient with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted&lt;/li&gt;&lt;li&gt;Hypertension that cannot be controlled by medications (&amp;gt; 150/100 mmHg despite optimal medical therapy)&lt;/li&gt;&lt;li&gt;Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg po daily for deep vein thrombosis prophylaxis is allowed)&lt;/li&gt;&lt;li&gt;Human immunodeficiency virus (HIV)-positive and is receiving anti-retroviral therapy&lt;/li&gt;&lt;li&gt;Hepatitis B virus (HBV) or hepatitis C virus (HCV) with evidence of chronic active disease or receiving/requiring antiviral therapy&lt;/li&gt;&lt;li&gt;History of receiving organ transplantation or immune disorders that require continuous immunosuppressant agent therapy&lt;/li&gt;&lt;li&gt;Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to the use of effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate&lt;/li&gt;&lt;li&gt;Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Dose limiting toxicity (DLT) of TRX-818 in Asians: toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0</Description><Timeframe>Up to 28 days</Timeframe></Measure><Measure><Description>Maximum tolerated dose (MTD) of TRX-818 in Asians: the MTD will be defined as the dose level at which at most one of six patients experiences a DLT after 28 days of treatment have occurred, with the next higher dose having at least 2/3 or 2/6 patients experiencing a DLT</Description><Timeframe>Up to 28 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Composite measure of pharmacokinetics (PK) parameters of TRX-818: AUC (0 to last): area under the plasma concentration versus time curve to the time of the last measurable concentration</Description><Timeframe>Days 1, 8, 15 for cycle 1 only (each cycle is 28 days)</Timeframe></Measure><Measure><Description>Composite measure of pharmacokinetics (PK) parameters of TRX-818: T(1/2) terminal elimination half-life</Description><Timeframe>Days 1, 8, 15 for cycle 1 only (each cycle is 28 days)</Timeframe></Measure><Measure><Description>Composite measure of pharmacokinetics (PK) parameters of TRX-818: Tmax: time to maximum plasma concentration</Description><Timeframe>Days 1, 8, 15 for cycle 1 only (each cycle is 28 days)</Timeframe></Measure><Measure><Description>Composite measure of pharmacokinetics (PK) parameters of TRX-818: Cmax: maximum plasma concentration</Description><Timeframe>Days 1, 8, 15 for cycle 1 only (each cycle is 28 days)</Timeframe></Measure><Measure><Description>Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)</Description><Timeframe>Up to 112 days</Timeframe></Measure><Measure><Description>Time to tumor progression (TTP)</Description><Timeframe>Up to 112 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2017, results were presented. DLTs and serious adverse events (AEs) were not observed at doses &amp;lt;/= 600 mg/day and escalation was continued. Compared to patients in &lt;ulink linkType="Protocol" linkID="235753"&gt;CVM-001&lt;/ulink&gt;, CVM-002 patients had better tolerability for TRX-818 which was likely due to lower drug exposure at the same dose level. Grade I diarrhea (2 in 600 mg), abdominal distension (1 in 600 mg), nausea (1 in 100 mg), vomiting (1 in 100 mg), regurgitation (1 in 200 mg), dysgeusia (1 in 200 mg) and dry skin (1 in 200 mg) were the drug related adverse events.  No drug-related serious AEs were reported  [&lt;ulink linkType="Reference" linkID="1932150"&gt;1932150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, pooled results from two studies (CVM-001 and CVM-002) were presented. Limited drug-related AEs were seen during treatment. GI toxicity and fatigue were the most commonly seen drug-related AEs. Laboratory abnormality was not seen [&lt;ulink linkType="Reference" linkID="1932150"&gt;1932150&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objectives of this study were to determine the pharmacokinetics and safety profile of &lt;ulink linkType="Drug" linkID="91251"&gt;TRX-818&lt;/ulink&gt;      including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) in      Asians and determine the recommended dose and regimen(s) to initiate phase II [&lt;ulink linkType="Reference" linkID="1724067"&gt;1724067&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1978159"&gt;1978159&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2017, results were presented. Stable disease was observed in paraganglioma patient treated with 200 mg/day post completion of 4 cycles, and in a renal cell carcinoma patient treated with 600 mg/day (at that time, patient was continuing treatment on cycle 3). Progressive disease was seen in 3, 1, 2 and 1 patients in 100, 200, 400 and 600 mg groups, respectively. Disease control rate (complete response + partial response + stable disease) was 30% and objective response rate (complete response + partial response) was 0% [&lt;ulink linkType="Reference" linkID="1932150"&gt;1932150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, pooled results from two studies (CVM-001 and CVM-002) were presented. TRX-818 was rapidly absorbed with Tmax of &amp;lt; 2 h. TRX-818 was rapidly and almost completely converted to its active metabolite (CVM-1125). With increasing dose levels, drug exposure also increased [&lt;ulink linkType="Reference" linkID="1932150"&gt;1932150&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive TRX-818 capsules [&lt;ulink linkType="Reference" linkID="1724067"&gt;1724067&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 12) received TRX-818 capsules of 100 mg qd, 100 mg bid, 200 mg bid, 300 mg bid and 400 mg bid (cohorts 1 to 5) in a 28-day cycle for 4 cycles [&lt;ulink linkType="Reference" linkID="1932150"&gt;1932150&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>foslinanib</Name><Drug id="91251">foslinanib</Drug><Dose unit="milligram dose">100.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>3</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsTotal>3</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>foslinanib</Name><Drug id="91251">foslinanib</Drug><Dose unit="milligram dose">200.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2576">Dysgeusia</Indication><CountPatientsTotal>3</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="3868">Xerosis</Indication><CountPatientsTotal>3</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>foslinanib</Name><Drug id="91251">foslinanib</Drug><Dose unit="milligram dose">600.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsTotal>3</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="588562">foslinanib</Intervention><Treatments><Treatment><Dose>100 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>200 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>300 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>400 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Taiwan"><Sites><Site><Name>National Cheng Kung University Hospital</Name><Address1>Tainan City</Address1><Address2>Tainan</Address2><Address3>704</Address3><CountrySubDivision>Tainan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7961">Subjects with Advanced/Metastatic Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7962">Subjects with Unresectable Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7967">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02703298</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15288">Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</SubEndpoint><SubEndpoint disease="Solid tumor" id="15293">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15209"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15206">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15276"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="26827">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15315"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15318">Assessment of Anti-tumor Activity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13096"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13098"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13109"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13110">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Solid tumor" id="13111">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Solid tumor" id="13112">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13119"><Criterion>Subjects with Unresectable Solid Tumors</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13129"><Criterion>Subjects with Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13130"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13131">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Solid tumor" id="13132">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13137"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13141">Subjects recovered from prior therapy/therapies</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34030"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13133">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34423"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13138">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34896"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13140">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion><SubCriterion disease="Solid tumor" id="13142">Subjects willing/able to complete follow up period</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10705"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10706">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Solid tumor" id="10707">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10731"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10732">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Solid tumor" id="10736">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Solid tumor" id="10737">Patient with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10739"><Criterion>Subjects with History of Other Non Anti-cancer Drugs/Agents</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10743"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10746">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Solid tumor" id="10753">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="12316"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Solid tumor" id="25667"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10747">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Solid tumor" id="10748">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="26453"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10761">Subjects with brain/CNS metastasis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="26970"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10754">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-01-23T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>24.23 Months</EnrollmentPeriod><EnrollmentRate>0.78 Patients/Month</EnrollmentRate><DateFirstReceived>2016-02-22T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-04-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-09-06T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2017-09-06T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-06T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-06T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-06T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-06T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2018-03-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-08-14T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="256567"><TitleDisplay>A Single-Arm, Open-Label, Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer</TitleDisplay><TitleOfficial>Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single-arm, Open-label, Multicenter Clinical Trial</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02717923</Identifier><Identifier type="Organisational Study">TJCC005</Identifier></Identifiers><Indications><Indication id="3658">Metastatic colorectal cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="52" role="Disease marker" type="Genomic;Proteomic">GTPase KRas</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>capecitabine + cetuximab</Name></Intervention><Intervention type="InterventionPrimary"><Name>cetuximab</Name><Drug id="10388">cetuximab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10388">cetuximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1058888">Henan Province Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059119">Hunan Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1082172">The First Affiliated Hospital of Nanchang University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="CM27909">Huazhong University of Science and Technology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1058888">Henan Province Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059119">Hunan Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1082172">The First Affiliated Hospital of Nanchang University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="CM27909">Huazhong University of Science and Technology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="10388" type="Drug"><TargetEntity id="230562" type="siDrug">Cetuximab</TargetEntity></SourceEntity><SourceEntity id="1058888" type="Company"><TargetEntity id="5035564988" type="organizationId">Henan Provincial Hospital</TargetEntity></SourceEntity><SourceEntity id="1059119" type="Company"><TargetEntity id="5035552305" type="organizationId">Hunan Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="1082172" type="Company"><TargetEntity id="5039631567" type="organizationId">First Affiliated Hospital of Nanchang University</TargetEntity></SourceEntity><SourceEntity id="CM27909" type="Company"><TargetEntity id="5000047779" type="organizationId">Huazhong University of Science and Technology</TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"/><TargetEntity id="595" type="siCondition"/></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="CM27909">Huazhong University of Science and Technology</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1058888">Henan Province Hospital</Company><Company id="1059119">Hunan Cancer Hospital</Company><Company id="1082172">The First Affiliated Hospital of Nanchang University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2946">Analgesic</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="751">Film coating</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="167">Monoclonal antibody murine</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><PatientCountEvaluable>28</PatientCountEvaluable><DateStart>2014-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T16:48:31Z</DateChangeLast><DateAdded>2016-03-28T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>yxl@medmail.com.cn</Email><Name>Xianglin Yuan, Professional</Name><Phone>13667241722</Phone></Contact><Contact type="Public contact"><Email>zhaoben0609@163.com</Email><Name>Ben Zhao, Master</Name><Phone>15071206621</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients has been fully understand this research and volunteered to sign the consent form&lt;/li&gt;&lt;li&gt;Histologically and/or cytologically diagnosed with RAS wild-type metastatic metastatic colorectal cancer (phase IIIc/IV), any other histological type is excluded&lt;/li&gt;&lt;li&gt;Patients with stable disease or better after induction treatment with eight to twelve 2-weekly cycles of 5FU-based  standard chemotherapy&lt;/li&gt;&lt;li&gt;ECOG performance status (ECOG PS)&amp;lt;/= 1 (0 to 1)&lt;/li&gt;&lt;li&gt;Evident measurable lesion(s) that meets the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)&lt;/li&gt;&lt;li&gt;Expected survival＞16 weeks&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with presence of clinically detectable second primary malignant tumors at the enrollment, or other malignant tumors within the last five years (excluding adequately treated skin basal cell carcinoma or carcinoma in situ of cervix)&lt;/li&gt;&lt;li&gt;Clinical refractory diseases(including uncontrolled epilepsy),and affect survivor&lt;/li&gt;&lt;li&gt;Central nervous system (CNS) metastatic disease or prior cerebral metastasis&lt;/li&gt;&lt;li&gt;Researchers think that the patients exist any clinical or laboratory abnormalities or compliance issues and not suitable to participate in this clinical study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free survival of maintaining treatment (mPFS): mPFS defined as time from randomization to progression after maintenance</Description><Timeframe>Five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To assess the disease status</Description><Timeframe>Every 6 weeks</Timeframe></Measure><Measure><Description>Overall survival</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2018, interim analysis results were presented. Patients  reported grade 3 AEs were skin reactions and hand-foot syndrome in 18 and 11%, respectively, without any other severe toxicity. Among 28 patients, no one discontinued maintenance treatment due to toxic effects. During maintenance treatment, the global quality of life did not deteriorate [&lt;ulink linkType="Reference" linkID="2039218"&gt;2039218&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a single-arm, open-label clinical trial to evaluate the efficacy and safety of      maintenance treatment with &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; after first-line 5-fluorouracil based standard chemotherapy plus cetuximab for patients with KRAS      wild-type metastatic colorectal cancer.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2018, interim analysis results were presented. The median follow-up was found to be 17.5 months and the median progression free survival was 6.6 months [&lt;ulink linkType="Reference" linkID="2039218"&gt;2039218&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be administered with maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received maintenance treatment with capecitabine (1000 mg/m2 po bid on days 1 to 14 q3w), and cetuximab (400 mg/m2 on day 1 of the first week, then 250 mg/m2 on day 1 every week or 500 mg/mA on day 1 q2w) and the treatment was continued until disease progression or unacceptable toxicity [&lt;ulink linkType="Reference" linkID="2039218"&gt;2039218&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>capecitabine + cetuximab</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="6832">Acral erythema</Indication><CountPatientsAffectedPercentage>11.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="95">Dermatological disease</Indication><CountPatientsAffectedPercentage>18.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="591834">capecitabine</Intervention><Treatments><Treatment><Dose>1000 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="591852">cetuximab</Intervention><Treatments><Treatment><Dose>250 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>400 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>500 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Huazhong University of Science and Technology</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><Address3>430000</Address3><CountrySubDivision>Hubei</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>yxl@medmail.com.cn</Email><Name>Xianglin Yuan, Professional</Name><Phone>13667241722</Phone></Contact><Contact type="Facility contact backup"><Email>zhaoben0609@163.com</Email><Name>Ben Zhao, Master</Name><Phone>15071206621</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3814">Subjects with Colon Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3824">Subjects with TNM  stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7874">Subjects with KRAS Wild-type Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02717923</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8163"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Colorectal tumor" id="8182"><Endpoint>Assessment of Disease Progression</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4468"><Criterion>Subjects with Colon Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4470"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4471">Subjects with measurable disease as per modified RECIST Criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4509"><Criterion>Subjects with Histologically Confirmed Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4511"><Criterion>Subjects with KRAS Wild-type Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4519"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4523">Subjects with life expectancy of four months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4544"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4545">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="34341"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4578">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="34919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4579">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5825"><Criterion>Subjects with Metastatic Colorectal Cancer</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5826">Subjects with brain metastases or leptomeningeal carcinomatosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5841"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5889"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5973"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5979"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5996">Subjects unsuitable for study as per investigator's assessment</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="27793"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5981">Subjects who are unable to follow study procedures/comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-03-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-08-01T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2018-08-01T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-08-01T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="261139"><TitleDisplay>Central Glutathione Levels in Women With Late Life Depression: a Cross-Sectional, Pilot, Feasibility Study</TitleDisplay><TitleOfficial>Central Glutathione Levels in Women With Late Life Depression: a Cross-Sectional, Pilot, Feasibility Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02757833</Identifier><Identifier type="Organisational Study">10012689</Identifier></Identifiers><Indications><Indication id="93">Depression</Indication></Indications><BiomarkerNames><BiomarkerName id="2175" role="Disease marker" type="Biochemical">Glutathione</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>A 3 tesla MRI scanner</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1043527" type="Company"><TargetEntity id="4297906117" type="organizationId">Lawson Health Research Institute</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043527">Lawson Health Research Institute</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Female</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>26</PatientCountEnrollment><DateStart>2018-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T02:37:29Z</DateChangeLast><DateAdded>2016-05-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>akshya.vasudev@lhsc.on.ca</Email><Extension>77507</Extension><Name>Akshya Vasudev, MD</Name><Phone>519-685-8500</Phone></Contact><Contact type="Public contact"><Email>rbartha@robarts.ca</Email><Extension>24039</Extension><Name>Robert Bartha, PhD</Name><Phone>519-663-5777</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Late-life depression population:&lt;ul&gt;&lt;li&gt;Patients in the LLD study arm will be females 60 to 85 years of age with a general good bill of health&lt;/li&gt;&lt;li&gt;Patients in the LLD study arm will be presenting with mild to moderate MDD. Diagnosis of MDD will be confirmed through a structured clinical interview for DSM-5-TR (SCID) axis I disorder&lt;/li&gt;&lt;li&gt;LLD patients will have a Hamilton Depression Rating Scale (17 item version) score between 8 to 22&lt;/li&gt;&lt;li&gt;LLD patients if being treated with any antidepressant agent, will be at a minimum of 4 weeks at therapeutic dosage of medication&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Healthy control (HC) population:&lt;ul&gt;&lt;li&gt;HC participants will be females between 60 to 85 years of age and in good general health&lt;/li&gt;&lt;li&gt;HC participants will have no history of depression&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;A primary diagnosis of any other mental health disorder (including substance dependence, post traumatic stress disorder, obsessive compulsive disorder, bipolar disorder, neurocognitive disorders, personality disorder, etc)&lt;/li&gt;&lt;li&gt;High risk of suicide as elicited by clinical interview&lt;/li&gt;&lt;li&gt;History of head trauma&lt;/li&gt;&lt;li&gt;History of severe vascular disease or cerebrovascular infarcts&lt;/li&gt;&lt;li&gt;Any history of neurological disease (including Parkinson's disease or seizures)&lt;/li&gt;&lt;li&gt;An ongoing acute episode of systemic inflammatory disease (eg, rheumatoid arthritis, ulcerative colitis, crohn's disease)&lt;/li&gt;&lt;li&gt;Any contraindications to MRI&lt;/li&gt;&lt;li&gt;Additionally for healthy control participants only, a diagnosis of any mental health disorder&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of potential participants approached per month: at two years the number of potential participants approached per month will be calculated. This information will be used to determine if a larger randomized controlled trial is likely to succeed</Description><Timeframe>two years</Timeframe></Measure><Measure><Description>Number of potential participants screened: at two years the number of potential participants screened will be assessed. This information will be used to determine if a larger randomized controlled trial is likely to succeed</Description><Timeframe>two years</Timeframe></Measure><Measure><Description>Proportion of screened participants who enroll: at two years the number of potential participants screened who enroll will be calculated. This information will be used to assess if a larger randomized controlled trial is likely to succeed</Description><Timeframe>two years</Timeframe></Measure><Measure><Description>Rate of participant retention: at two years the rate of participant retention will be calculated. This information will be used to assess if a larger randomized controlled trial is likely to succeed</Description><Timeframe>two years</Timeframe></Measure><Measure><Description>Cost per participant: at two years the cost per participant will be calculated. This information will be used to assess if a larger randomized controlled trial is likely to succeed</Description><Timeframe>two years</Timeframe></Measure><Measure><Description>Quality of data available for analysis: at two years the quality of the data available for analysis will be assessed. This information will be used to determine if a larger randomized controlled trial is likely to succeed</Description><Timeframe>two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Central glutathione levels in the brain: participants will attend only one assessment. During this assessment central glutathione levels in the brain will be assessed</Description><Timeframe>week 0</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to determine the central glutathione levels in participants with late life depression (LLD) using a 3  tesla MRI scanner.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This will be a pilot/feasibility, single-center, open-label, cross-sectional study. Research      participants will be women aged 60 to 85 years. This study seeks to recruit 26 female      participants; 13 participants with a confirmed diagnosis of LLD and 13      control participants with no history of mental illness. This pilot study will be used to      determine if a larger randomized, controlled trial will be feasible. The results of this pilot study, and subsequent large-scale studies,      will allow the investigators to identify novel targets for therapeutic intervention in LLD.&lt;/para&gt;&lt;para&gt;This study will consists of two arms :&lt;br/&gt;Group 1: participants with LLD.&lt;br/&gt;Group 2: participants  having no history of mental illness will be considered as control.&lt;br/&gt;Female participants  will attend a 1 h magnetic resonance      imaging (MRI). A 3 tesla MRI scanner (&lt;ulink linkType="Company" linkID="31035"&gt;Siemens&lt;/ulink&gt;, Erlangen Germany) will be used to measure levels of glutathione (GSH) in      the brain via magnetic resonance spectroscopy (1H MRS).&lt;/para&gt;&lt;para&gt;Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high gray/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl beta-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>London Health Sciences Centre</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A 5W9</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Depression</Disease><PatientSegments><PatientSegment><PatientSegment id="7449">Subjects with Major Depressive Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7453">Subjects Based on Severity of Depression</PatientSegment><SubSegments><SubSegment id="7455">Subjects with moderate depression</SubSegment><SubSegment id="11945">Subjects with mild depression</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02757833</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Depression" id="10809"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="34517"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="35771"><Endpoint>Health Economic Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Depression" id="10792"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Depression" id="6402"><Criterion>Subjects with Major Depressive Disorder</Criterion></Inclusion><Inclusion disease="Depression" id="6416"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Depression" id="6417">Subjects with mild depression</SubCriterion><SubCriterion disease="Depression" id="6418">Subjects with moderate depression</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6420"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Depression" id="6432"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Depression" id="6436">Subjects with specified Hamilton depression rating score (HDRS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6474"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Depression" id="6477">Subjects with history of tricyclic antidepressants (TCAs)/heterocyclics</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="34715"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="6509">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Depression" id="8069"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Depression" id="8071">Subjects with cognitive impairment as a clinical manifestation</SubCriterion><SubCriterion disease="Depression" id="8075">Subjects with suicidal ideation/suicide attempts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8086"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Depression" id="8091">Subjects with personality disorders</SubCriterion><SubCriterion disease="Depression" id="8092">Subjects with substance related disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8093"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Depression" id="8088">Subjects co-morbid with bipolar disorder</SubCriterion><SubCriterion disease="Depression" id="8094">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8102"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Depression" id="24915"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Depression" id="8158">Subjects with Hypersensitivity/Contraindication to MRI</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-04-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-05-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="268811"><TitleDisplay>Comparative Study With Different Tracers (18F-FDG and 68 Gallium Citrate) in the Diagnosis of Periprosthetic Joint Infection</TitleDisplay><TitleOfficial>Pilot, Comparative Study of PET/MR and PET/CT With Different Tracers (18F-FDG and 68 Gallium Citrate) in the Diagnosis of Periprosthetic Joint Infection</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02855190</Identifier><Identifier type="Organisational Study">103-7226A</Identifier></Identifiers><Indications><Indication id="3918">Joint infection</Indication></Indications><BiomarkerNames><BiomarkerName id="213" role="Disease marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="1211" role="Disease marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="10684" role="Disease marker" type="Cellular">Blood cells</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>18F-FDG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>68 Ga-citrate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET scan</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1003827" type="Company"><TargetEntity id="5035509911" type="organizationId">Chang Gung Memorial Hospital</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1003827">Chang Gung Memorial Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2015-11-30T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-01-28T22:06:14Z</DateChangeLast><DateAdded>2016-08-31T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Chang Gung Memorial Hospital</Affiliation><Name>Yen MD Tzu-Chen, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with clinically-proved or -suspicious periprosthetic joint infection and treated with two-stage exchange arthroplasty&lt;/li&gt;&lt;li&gt;Age &gt;/= 20 years&lt;/li&gt;&lt;li&gt;Willing to sign the informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unable to tolerate PET/MR or PET/CT scan, such as those with magnetic implants (eg, those received intracranial aneurysm surgery, cardiac pacemaker, artificial valves replacement, artificial ears), renal impairment (glomerular filtration rate&amp;lt; 30 ml/min/1.73 m2), claustrophobia, unable to lie still, allergy to medium contrast&lt;/li&gt;&lt;li&gt;Unable to give informed consent&lt;/li&gt;&lt;li&gt;Patient who is pregnant or lactating&lt;/li&gt;&lt;li&gt;Unwilling to use contraceptives during nuclide medicine examinations&lt;/li&gt;&lt;li&gt;Allergy history to FDG or Ga68-citrate, significant abnormal lab data, and high risk to conduct examination after evaluations of PI&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Sensitivity and specificity of the two PET/CT tracers (18F-FDG and 68 Gallium citrate) in detecting periprosthetic joint infection</Description><Timeframe>Three years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is an open-labelled, two-arm, pilot, comparative, prospective study to compare PET/MR and PET/CT with different tracers (18F-FDG and 68 gallium citrate) in the diagnosis of periprosthetic joint infection.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The recruited  patient with  surgery/pathology proved periprosthetic joint infection will undergo total four      PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga 68 citrate      PET/CT scans on different two days will be arranged before infective prosthesis will be removed. A total of       8 to 12 weeks after the first stage operation, patient will receive two subsequent      PET/MR scans using Ga 68 Citrate and FDG on different 2 days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.&lt;br/&gt;The PET images      will be visually examined by a nuclear medicine physician and will be reported if any      abnormal uptake higher than background by their location and standard uptake value (SUV).      The CT/MR images will be reported by a radiologist using standard reading procedures,      respectively. The lesions on the PET scan will be correlated to the computed tomography and      magnetic resonance images, and the final sensitivity, specificity, and accuracy will be      calculated according to the histopathology results or composite clinical and laboratory      data.&lt;br/&gt;On the scan day using Ga 68-Citrate, baseline electrocardiogram, complete blood count (CBC),      and biochemistry profiles including serum alanine transaminase (ALT) and creatinine (Cre)      level will be done prior to injection of the radio-pharmaceutical (Ga 68-Citrate). Vital      signs will be measured before the scan beginning. After completing exam, the      electrocardiogram and vital signs will be measured again, and the patient will be released if      there is no discomfort. The patient will return to the clinic within 1 week after      Ga 68-citrate scan. CBC, biochemistry profiles will be checked again for safety monitoring.&lt;br/&gt;All patients will      undergo image assessment in the two stages of exchange arthroplasty surgery. At the first      stage, each enrolled patient will receive both FDG and Ga 68 citrate PET/CT scans before the      first operation for periprosthetic joint infection (PJI). Thus, the test results of FDG and      Ga 68 for each individual will be obtained. After the first operation, the surgery/biopsy      proof can be obtained as the gold standard. The patients those with PJI negative will      complete the process at the first stage.&lt;br/&gt;And the second stage of this study will be based on the patients with positive PJI from the      first operation. They will receive both FDG and Ga 68 citrate PET/MR scans after antibiotic      bone cement will be implanted. The sensitivity/accuracy of the two tracers for PET/MR can be      calculated and compared. This stage will answer whether PET/MR scan will be  a feasible      imaging tool to provide diagnostic information of infection control status after the      resection arthroplasty of hip/knee PJIs, especially with the implantation of antibiotic      loaded bone cement.&lt;br/&gt;In the second stage, the investigators shift the imaging modality to PET/MR based on the      following reasons:&lt;br/&gt;MRI itself will have  no radiation burden.&lt;br/&gt;MRI will provide more accurate      tissue contrast information and therefore better anatomic delineation.&lt;br/&gt;Currently      there will be no study indicating the existence of ABLC may hamper the interpretation of images.&lt;br/&gt;The study duration will be  a period of three years. It will plan to enroll a      total of 50 patients with suspicious infection. And the investigators expect the PJI      prevalence will be around 60%, ie, the anticipated number of patients of true PJI will be  around      30. The sample size and the prevalence will be  given based on the clinical availability and      consideration.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02855190</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="43038"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="43701"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="43702">Assessment of bones/joints/muscles infections</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other musculoskeletal disease" id="42923"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Other musculoskeletal disease" id="43038"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="43254">Assessment by electromyography (EMG)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other musculoskeletal disease" id="43536"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="34307"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32740">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24173"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24183"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24185"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24090">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="27146"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24169">Subjects with renal failure/renal insufficiency</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-07-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-08-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="280426"><TitleDisplay>EC-95 of Remifentanil for Preventing Cough</TitleDisplay><TitleOfficial>Predicted EC-95 of Effect-site Concentration of Remifentanil for Preventing Cough After Laryngomicrosurgery From Propofol Anesthesia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02973724</Identifier><Identifier type="Organisational Study">AJIRB-MED-CT4-16-349</Identifier></Identifiers><Indications><Indication id="82">Cough</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>anesthesia</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>laryngomicrosurgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>propofol, AstraZeneca/Fresenius</Name><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug></Intervention><Intervention type="InterventionPrimary"><Name>remifentanil</Name><Drug id="4208">remifentanil</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4208">remifentanil</Drug><IndicationsPioneer/><Companies><Company><Company id="1055023">Ajou University School of Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug><IndicationsPioneer/><Companies><Company><Company id="1055023">Ajou University School of Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4208" type="Drug"><TargetEntity id="185000" type="siDrug">Remifentanil hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44308" type="Drug"><TargetEntity id="90057" type="siDrug">Propofol</TargetEntity></SourceEntity><SourceEntity id="1055023" type="Company"><TargetEntity id="5035550008" type="organizationId">Ajou University School Of Medicine</TargetEntity></SourceEntity><SourceEntity id="82" type="ciIndication"><TargetEntity id="R05" type="ICD10"/><TargetEntity id="10011224" type="MEDDRA"/><TargetEntity id="D003371" type="MeSH"/><TargetEntity id="-62743552" type="omicsDisease"/><TargetEntity id="283" type="siCondition"/></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1055023">Ajou University School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1668">General anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="2944">Hypnotic</Class><Class id="2946">Analgesic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="597">Injectable emulsion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Prevention</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2016-11-30T00:00:00Z</DateStart><DateEnd type="actual">2017-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:21:06Z</DateChangeLast><DateAdded>2016-11-28T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;ASA I to II patients undergoing general anesthesia for laryngomicrosurgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Anticipated difficult airway&lt;/li&gt;&lt;li&gt;COPD, asthma&lt;/li&gt;&lt;li&gt;Recent URI (&amp;lt; 2 weeks)&lt;/li&gt;&lt;li&gt;Severe cardiac, hepatic renal disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of cough: number of cough or a strong and sudden contraction of the abdomen during periextubation periods</Description><Timeframe>From end of surgery to 5 min after tracheal extubation</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the trial was  to investigate &lt;ulink linkType="Drug" linkID="4208"&gt;remifentanil&lt;/ulink&gt; effect-site concentration      in 95% of patients (EC-95) for preventing cough after laryngomicrosurgery from &lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt;      anesthesia.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 40 patients would be enrolleld in the study. At the end of the surgery, propofol infusion would be  stopped and remifentanil was titrated to      predetermined (initial concentration 1.0 ng/ml for the first patient [0.4 ng/ml as a step size]). Anesthesia would be  induced with propofol target-controlled infusion at an effect-site concentration of 5.0 microg/ml. Extubation would be       performed when the patients opened their eyes and spontaneous respiration and adequate tidal      volume and ventilatory frequency would be  confirmed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Ajou University Hospital</Name><Address1>Suwon</Address1><Address2>Gyeonggi-do</Address2><Address3>443-721</Address3><CountrySubDivision>Gyeonggi-do</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02973724</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other respiratory disease" id="43450"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other respiratory disease" id="43461"><Endpoint>Assessment of Procedure and Procedure Related Events</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other respiratory disease" id="32992"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other respiratory disease" id="32995"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other respiratory disease" id="24309"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24430"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="estimated">2017-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.06 Months</EnrollmentPeriod><EnrollmentRate>5.67 Patients/Month</EnrollmentRate><DateFirstReceived>2016-11-21T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-06-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="283635"><TitleDisplay>Efficacy of oral immunotherapy combinated Kakkonto</TitleDisplay><TitleOfficial>Efficacy of Kakkonto in oral immunotherapy for food allergy: randomized, controlled Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000025470</Identifier></Identifiers><Indications><Indication id="3612">Food hypersensitivity</Indication></Indications><BiomarkerNames><BiomarkerName id="1937" role="Therapeutic effect marker" type="Proteomic">Immunoglobulin E</BiomarkerName><BiomarkerName id="3451" role="Therapeutic effect marker" type="Genomic;Proteomic">Immunoglobulin G</BiomarkerName><BiomarkerName id="4806" role="Therapeutic effect marker" type="Cellular">Lymphocytes</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Kakkonto</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>anti-allergic drug therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>immunotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1003470" type="Company"><TargetEntity id="5035524544" type="organizationId">University of Toyama</TargetEntity></SourceEntity><SourceEntity id="3612" type="ciIndication"><TargetEntity id="10016946" type="MEDDRA"/><TargetEntity id="D005512" type="MeSH"/><TargetEntity id="-291885503" type="omicsDisease"/><TargetEntity id="1183" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1003470">Toyama University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2016-12-26T00:00:00Z</DateStart><DateChangeLast>2019-03-07T16:21:29Z</DateChangeLast><DateAdded>2017-01-02T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Toyama University Hospital ; Pediatrics</Affiliation><Email>yaitto-tym@umin.net</Email><Name>Yasunori Ito</Name><Phone>81.76.434.2281</Phone></Contact><Contact type="Scientific contact"><Affiliation>Toyama University Hospital ; Pediatrics</Affiliation><Email>toyamakoit-group@umin.ac.jp</Email><Name>Yuichi Adachi</Name><Phone>81.76.434.2281</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Food allergy diagnosised by oral food challenge without tendency of natural outgrow&lt;/li&gt;&lt;li&gt;Children who obtain the informed consent of the study&lt;/li&gt;&lt;li&gt;Those who can take medicine of kakkonto&lt;/li&gt;&lt;li&gt;Patients who have secured medical institutions in emergency&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Complication or past history of heart, liver and kidney diseases&lt;/li&gt;&lt;li&gt;Uncontrolled asthma, atopic dermatitis, allergic rhinitis&lt;/li&gt;&lt;li&gt;Children who were judged as inappropriate by the study director&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Efficacy of oral immunotherapy induced acute reactions and side reaction by Kakkonto</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change of dose threshold in oral food challenge after 24 weeks of treatment</Description><Timeframe>After 24 weeks of treatment</Timeframe></Measure><Measure><Description>Compliance of kakkonto</Description></Measure><Measure><Description>Induced reactions during the maintenance</Description></Measure><Measure><Description>Prick test</Description></Measure><Measure><Description>Specific IgE/IgG4 antibody, cytokines, lymphocytes subsets</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this study, investigators would evaluate the efficacy and safety of Kakkonto in combination with food allergy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study consist of two groups:&lt;br/&gt;Group 1: patients would receive combination of anti-allergic drug and Kakkonto at introduction of oral immunotherapy for 5 weeks.&lt;br/&gt;Group 2: patients would receive combination of anti-allergic drug at introduction of oral immunotherapy for 5 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Toyama University Hospital ; Pediatrics</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other immune disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18262">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16802">Subjects with food allergy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000025470</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other immune disease" id="42927"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Other immune disease" id="43099">Assessment of treatment-emergent adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other immune disease" id="42927"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other immune disease" id="43089"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other immune disease" id="43114"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other immune disease" id="32767"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other immune disease" id="34306"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other immune disease" id="32769">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other immune disease" id="35076"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other immune disease" id="24027"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other immune disease" id="24100"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other immune disease" id="24130"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-09-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="292444"><TitleDisplay>Effect of endoscopic vantris injection in comparison with before treatment in children with primary vesicoureteral reflux</TitleDisplay><TitleOfficial>Effect of endoscopic vantris injection in comparison with before treatment in children with primary vesicoureteral reflux: a before-after clinical trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201610259014N126</Identifier><Identifier type="Secondary Organisational">IR.UMSHA.REC.1395.146</Identifier></Identifiers><Indications><Indication id="3218">Vesicoureteral reflux</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Vantris</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1063134" type="Company"><TargetEntity id="5036354143" type="organizationId">Hamadan University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="3218" type="ciIndication"><TargetEntity id="N13.7" type="ICD10"/><TargetEntity id="D014718" type="MeSH"/><TargetEntity id="-325419901" type="omicsDisease"/><TargetEntity id="2364" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1063134">Hamadan University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>32</PatientCountEnrollment><DateStart>2015-09-23T00:00:00Z</DateStart><DateChangeLast>2018-03-14T22:04:53Z</DateChangeLast><DateAdded>2017-04-06T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Shahid Beheshti Hospital</Affiliation><Email>n9shams @ gmail.com</Email><Name>Dr Naser Shams</Name><Phone>00988138380283 00989133877109</Phone></Contact><Contact type="Scientific contact"><Affiliation>Shahid Beheshti Hospital</Affiliation><Email>shmbahar@umsha.ac.ir</Email><Name>Dr Habibolah Moosavi Bahar</Name><Phone>00988138380283 00989181113612</Phone></Contact><Contact type="Public contact"><Affiliation>Department of Epidemiology</Affiliation><Email>poorolajal@umsha.ac.ir</Email><Name>Dr Jalal Poorolajal</Name><Phone>00988138380090 00</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age of 1 to 8 years&lt;/li&gt;&lt;li&gt;Vesicoureteral reflux with grade 1 to 3&lt;/li&gt;&lt;li&gt;New scar in renal parenchyma&lt;/li&gt;&lt;li&gt;Unsuccessful medical treatment&lt;/li&gt;&lt;li&gt;Repeated urinary tract infection&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous history of vantris injection&lt;/li&gt;&lt;li&gt;Previous surgery of vesicoureteral reflux&lt;/li&gt;&lt;li&gt;Nourogenis bladder&lt;/li&gt;&lt;li&gt;Urinary abnormality such as uretrocell, complete duplicate system, ectopic ureter or bladder diverticulitis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Measuring grade of reflux: using nuclear scan</Description><Timeframe>Before treatment and 3 and 6 month after treatment</Timeframe></Measure><Measure><Description>Assessing recurrence of reflux: using nuclear scan</Description><Timeframe>One year after intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Assessing hematuria: using urine analysis</Description><Timeframe>1 month after surgery</Timeframe></Measure><Measure><Description>Assessing infection: using urine culture</Description><Timeframe>1 month after surgery</Timeframe></Measure><Measure><Description>Measuring duration of hospitalization: through checking medical record</Description><Timeframe>After intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Study objective is to assess the effect of endoscopic Vantris injection in comparison with before treatment in children with primary vesicoureteral reflux.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this before-after clinical trial, eligible children with primary vesicoureteral reflux who were  refered  to Shahid Beheshti Hospital during the study period will be enrolled into the trial. &lt;br/&gt;Intervention group: endoscopic Vantris injection 1 ml submucosal in ureter once.&lt;br/&gt;Control group: in comparison with before intervention.&lt;/para&gt;&lt;para&gt;Primary outcome: measuring grade of reflux before treatment and 3 and 6 month after treatment using nuclear scan; assessing recurrence of reflux one year after intervention using nuclear scan.&lt;br/&gt;Secondary outcome: assessing infection 1 month after surgery using urine culture; assessing hematuria 1 month after surgery using urine analysis; measuring duration of hospitalization after intervention through checking medical record.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Shahid Beheshti Hospital</Name><Address1>Hamadan</Address1><Address2>Hamadan</Address2><CountrySubDivision>Hamadan</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr Naser Shams</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other genitourinary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18253">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201610259014N126</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other genitourinary disease" id="43587"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other genitourinary disease" id="43587"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other genitourinary disease" id="43007"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other genitourinary disease" id="33052"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other genitourinary disease" id="35072"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other genitourinary disease" id="24057"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other genitourinary disease" id="24302"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2018-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.29 Months</EnrollmentPeriod><EnrollmentRate>1.09 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-04-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="30176"><TitleDisplay>A trial to evaluate the safety and efficacy of zoledronic acid in patients with rheumatoid arthritis</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>zoledronic acid</Name><Drug id="2765">zoledronic acid</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2765">zoledronic acid</Drug><IndicationsPioneer><Indication id="291">Rheumatoid arthritis</Indication></IndicationsPioneer><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2765" type="Drug"><TargetEntity id="144428" type="siDrug">Zoledronic acid monohydrate</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="23137">Novartis AG</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="12596">Osteoclast inhibitor</Class><Class id="1545">Anticancer</Class><Class id="695">Metastasis inhibitor</Class><Class id="89">Bone resorption inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>39</PatientCountEnrollment><PatientCountEvaluable>39</PatientCountEvaluable><DateStart>2004-07-09T00:00:00Z</DateStart><DateChangeLast>2008-10-15T10:34:05Z</DateChangeLast><DateAdded>2008-10-15T10:34:05Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with  rheumatoid arthritis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Mean change of hand and wrist erosions</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This trial  evaluated the safety and efficacy of &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; in patients with rheumatoid arthritis [&lt;ulink linkType="Reference" linkID="546527"&gt;546527&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results have shown that there was  a 61% decrease in the mean change of hand and wrist erosions among patients in the treatment group. The drug was generally well tolerated  [&lt;ulink linkType="Reference" linkID="546527"&gt;546527&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were given 5 mg &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; parenterally or placebo at the start of the 6-month trial and again after 13 weeks. Patients also received weekly methotrexate  [&lt;ulink linkType="Reference" linkID="546527"&gt;546527&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were given 5 mg &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; parenterally or placebo at the start of the 6-month trial and again after 13 weeks. Patients also received weekly methotrexate  [&lt;ulink linkType="Reference" linkID="546527"&gt;546527&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="60217">zoledronic acid</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-10-15T10:34:05Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="305036"><TitleDisplay>Patient-ventilator Asynchrony in Patients With Brain Injury</TitleDisplay><TitleOfficial>Patient-ventilator Asynchrony in Patients With Brain Injury</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03212482</Identifier><Identifier type="Organisational Study">KY 2017-028-02</Identifier></Identifiers><Indications><Indication id="834">Brain injury</Indication></Indications><BiomarkerNames><BiomarkerName id="46338" role="Disease marker" type="Physiological">Esophageal pressure</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1019333" type="Company"><TargetEntity id="5035535752" type="organizationId">Capital Medical University</TargetEntity></SourceEntity><SourceEntity id="834" type="ciIndication"><TargetEntity id="10067967" type="MEDDRA"/><TargetEntity id="D001930" type="MeSH"/><TargetEntity id="-564913240" type="omicsDisease"/><TargetEntity id="2453" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1019333">Capital Medical University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2017-06-15T00:00:00Z</DateStart><DateEnd type="estimated">2019-07-30T00:00:00Z</DateEnd><DateChangeLast>2017-07-31T16:08:51Z</DateChangeLast><DateAdded>2017-07-17T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Acute Brain Injury and Critical Care Research Collaboration, ABC Research Collaboration</Affiliation><Name>Jian-Xin Zhou, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt; 18 years&lt;/li&gt;&lt;li&gt;With brain injury in the ICU&lt;/li&gt;&lt;li&gt;Mechanical ventilated for at least 72 h&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;ICU length of stay&amp;lt; 24 h&lt;/li&gt;&lt;li&gt;Enrolled in another trial&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The incidence of patient-ventilator asynchrony in brain-injured patients: the incidence of different types of patient-ventilator asynchrony in brain-injured patients</Description><Timeframe>3 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The risk factors of patient-ventilator asynchrony in brain-injured patients: the risk factors of different types of patient-ventilator asynchrony in brain-injured patients</Description><Timeframe>3 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Investigators conduct a prospective, observational study among      brain-injured patients to determine the prevalence, risk factors and outcomes of      patient-ventilator asynchrony. Esophageal pressure monitoring, a surrogate for pleural      pressure, combined with airway pressure and flow waveforms is used to detect      patient-ventilator asynchrony.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Adult patients with brain injury and receiving mechanical ventilation for at least 72 h in the intensive care unit, will be enrolled and observed in the study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Jian-Xin Zhou</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><Address3>100050</Address3><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03212482</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="46419"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="46419"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33192"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24094"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24096">Subjects participating in any investigational drug/device study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="27919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24149">Subjects unwilling/unable to comply with the study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-07-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-07-04T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-07-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="307804"><TitleDisplay>Investigating the Most Appropriate Dose and Effectiveness of Thiotepa in Combination With Ifosphamide, Etoposide and Rituximab in Patients with Lymphoma Arising in the Brain or Spinal Cord</TitleDisplay><TitleOfficial>A Study of Thiotepa, Ifosfamide, Etoposide and Rituximab for the Treatment of Relapsed or Refractory Primary Central Nervous System Lymphoma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2014-000227-24</Identifier><Identifier type="ISRCTN">ISRCTN12857473</Identifier><Identifier type="Secondary Organisational">RG_13-320</Identifier><Identifier type="Secondary Organisational">HM1020</Identifier><Identifier type="Other">UKCRN 17668</Identifier><Identifier type="Other">148036</Identifier><Identifier type="Other">14/LO/1568</Identifier><Identifier type="Other">17668</Identifier><Identifier type="Other">12857473</Identifier><Identifier type="Trial Acronym">TIER</Identifier></Identifiers><Indications><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="203">Lymphoma</Indication><Indication id="759">Central nervous system tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="1731" role="Disease marker" type="Genomic;Proteomic">B-lymphocyte antigen CD20</BiomarkerName><BiomarkerName id="6663" role="Disease marker" type="Cellular">B-lymphocytes</BiomarkerName><BiomarkerName id="46244" role="Therapeutic effect marker" type="Genomic">Circulating tumor DNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>etoposide phosphate</Name><Drug id="3072">etoposide phosphate</Drug></Intervention><Intervention type="InterventionPrimary"><Name>ifosfamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>rituximab</Name><Drug id="6736">rituximab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>thiotepa</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3072">etoposide phosphate</Drug><IndicationsPioneer/><Companies><Company><Company id="1057645">Leukaemia and Lymphoma Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20537">The University of Birmingham</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6736">rituximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1057645">Leukaemia and Lymphoma Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20537">The University of Birmingham</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6736" type="Drug"><TargetEntity id="204337" type="siDrug">Rituximab</TargetEntity></SourceEntity><SourceEntity id="1057645" type="Company"><TargetEntity id="5035526716" type="organizationId">Bloodwise</TargetEntity></SourceEntity><SourceEntity id="20537" type="Company"><TargetEntity id="5000700736" type="organizationId">University of Birmingham</TargetEntity></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"/><TargetEntity id="10012818" type="MEDDRA"/><TargetEntity id="D016403" type="MeSH"/><TargetEntity id="544" type="ORPHANET"/><TargetEntity id="-308083648" type="omicsDisease"/><TargetEntity id="1741" type="siCondition"/></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity><SourceEntity id="759" type="ciIndication"><TargetEntity id="10007958" type="MEDDRA"/><TargetEntity id="D016543" type="MeSH"/></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="20537">The University of Birmingham</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1057645">Leukaemia and Lymphoma Research</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="142">Topoisomerase II inhibitor</Action><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="50">Anticancer alkylating agent</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2014-12-12T00:00:00Z</DateStart><DateEnd type="estimated">2021-10-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-20T04:29:01Z</DateChangeLast><DateAdded>2017-08-09T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Cancer Research UK Clinical Trials Unit</Affiliation><Email>TIER@trials.bham.ac.uk</Email><Name>Louise Hopkins</Name><Phone>01213714366</Phone></Contact><Contact type="Public contact"><Affiliation>University of Birmingham</Affiliation><Email>tier@trials.bham.ac.uk</Email><Name>Ms Kathryn Paterson</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/=  16 years of age&lt;/li&gt;&lt;li&gt;Histologically confirmed CD20 + Diffuse Large B-Cell Lymphoma (DLBCL) confined to the central nervous system&lt;/li&gt;&lt;li&gt;Relapsed or refractory primary central nervous system lymphoma (PCNSL) according to the following definition:&lt;ul&gt;&lt;li&gt;One or two prior chemotherapy regimen(s), of which at least one regimen contained high-dose methotrexate at a dose of&amp;gt;  1 g/m2&lt;/li&gt;&lt;li&gt;Minimum of one cycle containing highdose methotrexate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;ECOG performance status 0, 1 or 2 (or 3 if attributed to lymphoma)&lt;/li&gt;&lt;li&gt;Adequate organ function:&lt;ul&gt;&lt;li&gt;Bone marrow: platelets&amp;gt; 80 x 10(9)/l, neutrophils &amp;gt; 1 x 10(9)/l, haemoglobin &amp;gt; 80 g/l&lt;/li&gt;&lt;li&gt;Hepatic: bilirubin&amp;lt; 1.5 x upper limit of normal (ULN) (unless isolated unconjugated hyperbilirubinemia attributable to Gilbert's syndrome)&lt;/li&gt;&lt;li&gt;Renal: eGFR &gt;/= 40 ml/min (Cockcroft-Gault)&lt;/li&gt;&lt;li&gt;Cardiorespiratory (as judged by the Local Investigator): clinically relevant cardiac or pulmonary function tests must be performed if there is a previous history of significant cardiac or pulmonary impairment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Able to comply with the scanning requirements of the study&lt;/li&gt;&lt;li&gt;Valid Informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Systemic involvement with lymphoma&lt;/li&gt;&lt;li&gt;Active infection requiring intravenous antimicrobials&lt;/li&gt;&lt;li&gt;Chemotherapy for lymphoma within 4 weeks registration&lt;/li&gt;&lt;li&gt;Whole-brain radiotherapy within 6 months of registration&lt;/li&gt;&lt;li&gt;Relapse within one  year of a thiotepa-based autologous stem cell transplant&lt;/li&gt;&lt;li&gt;Prior therapy with the R-IE (rituximab - ifosphamide and etoposide) regimen with the last year&lt;/li&gt;&lt;li&gt;Evidence of HIV or Hepatitis C infection&lt;/li&gt;&lt;li&gt;Hepatitis B infection&lt;/li&gt;&lt;li&gt;Serum albumin&amp;lt; 25 g/l&lt;/li&gt;&lt;li&gt;Pregnant and lactating patients (patients of childbearing potential must have a negative pregnancy test prior to study entry)&lt;/li&gt;&lt;li&gt;Competent patients and competent patients with partners of childbearing potential not willing to use effective contraception during and for 12 months after therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Phase I: Maximum Tolerated Dose (MTD) of thiotepa in combination with ifosphamide, etoposide and rituximab (TIER)</Description><Timeframe>End of two cycles of treatment</Timeframe></Measure><Measure><Description>Phase II: overall response rate (Complete Response [CR] + Complete Response: unconfirmed [CRu] + Partial Response [PR]) after two cycles of TIER treatment, as assessed by the international workshop to standardise baseline evaluation and response criteria for primary CNS lymphoma</Description><Timeframe>The phase II outcome will be measured after 28 patients have completed one cycle of TIER treatment at the maximum tolerated dose of thiotepa; end of two cycles of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A two years event free survival (EFS)</Description><Timeframe>Two years after trial treatment</Timeframe></Measure><Measure><Description>A two years overall survival (OS)</Description><Timeframe>Two years after trial treatment</Timeframe></Measure><Measure><Description>A two years progression free survival (PFS)</Description><Timeframe>Two years after trial treatment</Timeframe></Measure><Measure><Description>Complete response rate after two cycles of TIER</Description><Timeframe>End of two cycles of treatment</Timeframe></Measure><Measure><Description>Proportion of patients proceeding to high-dose therapy and autologous stem cell transplant (HDT-ASCT)</Description><Timeframe>Following trial treatment</Timeframe></Measure><Measure><Description>Rate of successful stem cell harvest</Description><Timeframe>After completing trial treatment</Timeframe></Measure><Measure><Description>Toxicity of TIER using the National Cancer Institute common terminology criteria for adverse events (CTCAE) version 4</Description><Timeframe>All cycles of trial treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of the trial:&lt;br/&gt;The first phase (phase I) of the study is to find the maximum safe dose (maximum tolerated dose) of thiotepa which is safe to give in combination with ifosfamide, &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; in patients with primary central nervous system lymphoma (PCNSL).&lt;/para&gt;&lt;para&gt;The second phase (phase II) is to look at how effective the combinastion of drugs are in treating (PCNSL). The investigators  will assess this by determining the overall response rate (complete response (CR) + complete response: unconfirmed (CRu) + partial response (PR)) after two  cycles of TIER treatment, as assessed by the 'International Workshop to Standardise Baseline Evaluation and Response Criteria for Primary CNS Lymphoma'.&lt;/para&gt;&lt;para&gt;The Secondary objectives of the trial are to determine:&lt;br/&gt;The toxicity of the TIER treatment using common terminology criteria for adverse events (CTCAE) version 4.&lt;br/&gt;The complete response rate after two cycles of TIER.&lt;br/&gt;The two years progression free survival (PFS).&lt;br/&gt;The two years event free survival (EFS).&lt;br/&gt;The two years overall survival (OS).&lt;br/&gt;The proportion of patients proceeding to high-dose therapy and autologous stem cell transplant (HDT-ASCT).&lt;br/&gt;The rate of successful stem cell harvest for patients proceeding to transplant&lt;/para&gt;&lt;para&gt;The exploratory outcome measures are:&lt;br/&gt;Analyzing the MRI scans to look for MRI-based prognostic and response parameters.&lt;br/&gt;Analyzing the pathobiological features of relapsed/refractory primary central nervous system lymphoma cases.&lt;/para&gt;&lt;para&gt;Substudy:&lt;br/&gt;Blood sample collection, as detailed in main protocol.&lt;br/&gt;Analysis of ctDNA at Royal Marsden Institute of Cancer Research.&lt;/para&gt;&lt;para&gt;This study hypothesis that the phase I dose finding component is a 3+3 cohort design which will recruit up to 18 patients in order to find the MTD of thiotepa in combination with ifosphamide, etoposide and rituximab (TIER). All patients recruited into phase I at the MTD will also contribute towards phase II. The phase II study is based on an A'Hern's design to assess the activity of thiotepa in combination with ifosphamide, etoposide and rituximab (TIER). 28 patients will be recruited in total in phase II (including some patients from phase I).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The phase I dose finding component is a 3 + 3 cohort design which will recruit up to 18 patients. All patients recruited into phase I at the MTD will also contribute towards phase II. A total of 28 patients will be recruited in phase II (including some patients from phase I).&lt;/para&gt;&lt;para&gt;Patients will receive thiotepa , chemotherapy 20 to 50 mg/m2 iv in combination with ifosfamide 2 g/m2/day iv on days 2 to 4, etoposide 250 mg/m2 iv on day 2 and rituximab 375 mg/m2/day iv on days 1 to 2  for each 21 day cycle.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts><Contact type="Facility contact"><Name>Louise Hopkins</Name></Contact><Contact type="Facility contact backup"><Email>TIER@trials.bham.ac.uk</Email><Name>Louise Hopkins</Name><Phone>01213714366</Phone></Contact></Contacts></Site><Site><Name>Cancer Research UK Clinical Trials Unit, School of Cancer Sciences University of Birmingham Edgbaston</Name><Address1>Birmingham</Address1><Address2>England</Address2><CountrySubDivision>England</CountrySubDivision><Contacts/></Site><Site><Name>Aberdeen Royal Infirmary</Name><Contacts/></Site><Site><Name>Aintree University Hospital</Name><Contacts/></Site><Site><Name>Beatson West of Scotland Cancer Centre</Name><Contacts/></Site><Site><Name>Cancer Research UK Clinical Trials Unit</Name><Contacts/></Site><Site><Name>Churchill Hospital</Name><Contacts/></Site><Site><Name>Derriford Hospital</Name><Contacts/></Site><Site><Name>Freeman Hospital</Name><Contacts/></Site><Site><Name>King's College Hospital</Name><Contacts/></Site><Site><Name>New Cross Hospital</Name><Contacts/></Site><Site><Name>Nottingham City Hospital</Name><Contacts/></Site><Site><Name>Queen Elizabeth Hospital</Name><Contacts/></Site><Site><Name>Royal Hallamshire Hospital</Name><Contacts/></Site><Site><Name>Southampton General Hospital</Name><Contacts/></Site><Site><Name>St James University Hospital</Name><Contacts/></Site><Site><Name>The Christie</Name><Contacts/></Site><Site><Name>The Royal Marsden Hospital</Name><Contacts/></Site><Site><Name>University College Hospital</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3489">Subjects with B Cell Non Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3472">Subjects with diffuse large B cell lymphoma</SubSegment><SubSegment id="3482">Subjects with central nervous system (CNS) lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3525">Subjects with Relapse/Recurrent Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3530">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2014-000227-24</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN12857473</Identifier></Identifiers></Registry><Registry><Name id="1023">UK Clinical Research Network (UKCRN)</Name><Identifiers><Identifier>UKCRN 17668</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7591"><Endpoint>Assessment of Response by Specific Scales</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7597">Assessment by international workshop to standardize response criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7563">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Lymphoma" id="7564">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7567">Assessment of complete response/unconfirmed (CRu)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7569">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="9133">Assessment of maximum tolerated dose (MTD)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7538"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7547"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7554"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7558">Assessment of event free survival (EFS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7563">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7651"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="28749">Assessment by Common Terminology Criteria for Adverse Events (CTCAE)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7845"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3464"><Criterion>Subjects with B Cell Non Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3447">Subjects with diffuse large B cell lymphoma</SubCriterion><SubCriterion disease="Lymphoma" id="3457">Subjects with central nervous system B Cell Non Hodgkin's lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3537">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lymphoma" id="3538">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Lymphoma" id="3539">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3609"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3612">Subjects with relapsed lymphoma after chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3614"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3615">Subjects with progressive/refractory lymphoma to chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3633">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Lymphoma" id="3637">Subjects with normal/acceptable pulmonary function</SubCriterion><SubCriterion disease="Lymphoma" id="3642">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3628">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34439"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3659">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34915"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3660">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4686"><Criterion>Subjects with Other Lymphoid Malignancies</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4690">Subjects with systemic lymphoma</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4717"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4718">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4762">Subject with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4794"><Criterion>Subjects with Relapsed/Recurrent Lymphoma</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4825"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4831">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26332"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4730">Subjects with abnormal/unacceptable liver function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26955"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4830">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2019-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>52.65 Months</EnrollmentPeriod><EnrollmentRate>0.76 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-08T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="321345"><TitleDisplay>Comparison of PVI-guided Fluid Management With Traditional Fluid Management in Colorectal Surgery</TitleDisplay><TitleOfficial>Comparison of PVI-guided Fluid Management With Traditional Fluid Management in Colorectal Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03339895</Identifier><Identifier type="Organisational Study">KOU KAEK 2015/99</Identifier></Identifiers><Indications><Indication id="2979">Surgical procedure</Indication></Indications><BiomarkerNames><BiomarkerName id="118" role="Therapeutic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="159" role="Therapeutic effect marker" type="Biochemical">Lactic Acid</BiomarkerName><BiomarkerName id="213" role="Therapeutic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName><BiomarkerName id="2098" role="Therapeutic effect marker" type="Biochemical">Potassium</BiomarkerName><BiomarkerName id="2662" role="Therapeutic effect marker" type="Biochemical">Sodium</BiomarkerName><BiomarkerName id="2689" role="Therapeutic effect marker" type="Physiological">Partial pressure of oxygen</BiomarkerName><BiomarkerName id="2699" role="Therapeutic effect marker" type="Physiological">Partial pressure of carbon dioxide</BiomarkerName><BiomarkerName id="3247" role="Therapeutic effect marker" type="Biochemical">Chlorides</BiomarkerName><BiomarkerName id="4529" role="Therapeutic effect marker" type="Biochemical">Bicarbonates</BiomarkerName><BiomarkerName id="11268" role="Therapeutic effect marker" type="Physiological">Urinary flow</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PVI guided goal-directed fluid management</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>Gelofusine</Name></Intervention><Intervention type="InterventionPrimary"><Name>ephedrine</Name></Intervention><Intervention type="InterventionPrimary"><Name>sodium chloride</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>traditional fluid management</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="duo"><Interventions><Intervention type="InterventionControl"><Name>Gelofusine</Name></Intervention><Intervention type="InterventionControl"><Name>ephedrine</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1033742" type="Company"><TargetEntity id="5035540482" type="organizationId">Kocaeli University</TargetEntity></SourceEntity><SourceEntity id="2979" type="ciIndication"><TargetEntity id="10042613" type="MEDDRA"/><TargetEntity id="D013514" type="MeSH"/><TargetEntity id="1036" type="siCondition"/><TargetEntity id="3645" type="siCondition"/><TargetEntity id="1043" type="siCondition"/><TargetEntity id="1381" type="siCondition"/><TargetEntity id="1045" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1033742">Kocaeli University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="596">Injectable formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>70</PatientCountEnrollment><DateStart>2016-01-01T00:00:00Z</DateStart><DateEnd type="actual">2017-01-25T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T17:06:07Z</DateChangeLast><DateAdded>2017-12-04T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Specialist: Kocaeli University</Affiliation><Name>Sevim Cesur, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Specialist</Affiliation><Name>Tülay Hoşten, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt; 18 years old&lt;/li&gt;&lt;li&gt;Elective colorectal suregry&lt;/li&gt;&lt;li&gt;ASA 1 to 2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Chronic renal disease&lt;/li&gt;&lt;li&gt;Ejection fraction&amp;lt; 30&lt;/li&gt;&lt;li&gt;Arthmia&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Fluid management: total fluid given during colorectal surgery</Description><Timeframe>two hours</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The first objective of this study was to compare the traditional fluid management (TFM) with      PVI guided goal-directed fluid management (GDFM) in terms of controlled intraoperative fluid      volume, surgical end-point fluid balance, blood lactate and serum creatinine levels. ASA I to II      70 patients included in this prospective study. Our secondary purpose was to compare the effects of different fluid regimens on the return of bowel function and the duration of hospital stay.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The      study included 70 American Society of Anesthesiologists (ASA) grade I and II patients, aged      above 18 and undergoing elective colorectal surgery. After premedication with 0.03 mg/kg      iv &lt;ulink linkType="Drug" linkID="44303"&gt;midazolam&lt;/ulink&gt;, all patients were started an iv infusion of 500 ml 0.9 % NaCl until the end      of anesthesia induction.&lt;br/&gt;After the anesthesia induction, while 0.9 % NaCl at rate of 2 ml/kg/h was infused in PVI-      guided GDFM group, a 250 ml bolus gelatin injection (Gelofusine, Barun) was administered      when PVI was &amp;gt; 13 % over 5 min. While 0.9 % NaCl at rate of 4 to 8 ml/kg/h was      infused in TFM group, a 250 ml bolus gelatin injection (Gelofusine, Barun) would be administered      when the mean arterial blood pressure (MAP) decreased &amp;lt; 65 mmHg. In both groups, when MAP      was still &amp;lt; 65 mmHg after fluid bolus infusion, 5 mg iv bolus ephedrine would be administered.      The data collected during intraoperative period, such as heart rate, MAP, arterial blood gas      samples (Ph, arterial oxygen pressure (PaO2), arterial carbon dioxide pressure (PaCO2), HCO3      level, hemoglobin, blood lactate level) would be recorded. Hemoglobin, Na, K, Cl, serum      creatinine, blood lactate and serum albumin scores would be measured preoperatively, and up to 24      h postoperative.&lt;br/&gt;In the first 24 h after surgery, oliguria (&amp;lt; 0.5 ml/kg urine output), need for blood      transfusion and the time of first bowel movement (depending on the days after surgery),      length of hospital stay would be recorded.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Turkey"><Sites><Site><Name>Kocaeli University</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18739">Subjects Undergoing Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03339895</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gastrointestinal disease" id="43393"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other gastrointestinal disease" id="46262"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other gastrointestinal disease" id="43393"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="43401"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43403">Assessment of hemoglobin levels</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="43662"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43663">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="43672"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="43804"><Endpoint>Assessment of Serum Electrolytes</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43412">Assessment of plasma potassium</SubEndpoint><SubEndpoint disease="Other gastrointestinal disease" id="43413">Serum sodium</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="44829"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43399">Assessment of creatinine</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="46262"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Other gastrointestinal disease" id="46346"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="32960"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="34647"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gastrointestinal disease" id="24021"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24301"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24468"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25174"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-01-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-01-30T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-12-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="350062"><TitleDisplay>Does eating oranges reduce inflammatory and other risk markers related to cardiovascular diseases</TitleDisplay><TitleOfficial>Effects of the consumption of oranges on gene expression and other biomarkers of disease and intake in a healthy population in a randomized intervention trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN17330010</Identifier><Identifier type="Organisational Study">UV111</Identifier><Identifier type="Trial Acronym">ORANGOMICS</Identifier></Identifiers><Indications><Indication id="57">Cardiovascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>oranges</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="23325" type="Company"><TargetEntity id="5000005176" type="organizationId">University of Valencia</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23325">University of Valencia</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Prevention</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2015-04-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-08-22T11:00:36Z</DateChangeLast><DateAdded>2018-08-20T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Prof Corella</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy men and women&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diseased&lt;/li&gt;&lt;li&gt;Allergic to oranges&lt;/li&gt;&lt;li&gt;Immunodeficiency or HIV-positive status&lt;/li&gt;&lt;li&gt;Liver cirrhosis or chronic renal failure&lt;/li&gt;&lt;li&gt;Serious psychiatric disorders: schizophrenia, bipolar disease, eating disorders, depression, etc&lt;/li&gt;&lt;li&gt;Any severe co-morbid condition&lt;/li&gt;&lt;li&gt;Alcohol abuse or addition&lt;/li&gt;&lt;li&gt;History of major organ transplantation&lt;/li&gt;&lt;li&gt;Concurrent therapy with immunosuppressive drugs or cytotoxic agents&lt;/li&gt;&lt;li&gt;Current treatment with systemic corticosteroids&lt;/li&gt;&lt;li&gt;Current use of weight loss medication&lt;/li&gt;&lt;li&gt;Patients with an acute infection or inflammation&lt;/li&gt;&lt;li&gt;Any other condition that may interfere with the completion of the study protocol&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Classical biochemical parameters related to cardiovascular risk at baseline and 4 h/1 month, also including novel omics markers (in plasma and/or urine) analyzed by metabolomics (also including markers of intake), gene expression and other omics</Description><Timeframe>At baseline and 4 h/1 month</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Anthropometric variables (weight, height, waist circumference and body composition by bioimpedance)</Description><Timeframe>At baseline and 4 h, 1 month</Timeframe></Measure><Measure><Description>Blood pressure</Description><Timeframe>At baseline and 4 h, 1 month</Timeframe></Measure><Measure><Description>Food intake measured by a validated food frequency questionnaire</Description><Timeframe>At baseline and 4 h</Timeframe></Measure><Measure><Description>Genetic polymorphisms</Description><Timeframe>At baseline and 4 h, 1 month</Timeframe></Measure><Measure><Description>Taste perception tests with standardized tastants for bitter, sour, sweet, umami and salty</Description><Timeframe>At baseline and 4 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to analyze the effects of the consumption of oranges on cardiovascular risk biomarkers (biological molecules found in the blood, other body fluids, or tissues that are a sign of heart disease).&lt;/para&gt;&lt;para&gt;This study hypothesize the short-term intake of oranges will have a favorable effect on biochemical markers related with cardiovascular risk, also including gene expression, metabolomic and epigenomic markers. As a secondary aim, metabolomic studies will provide a panel of markers for intake.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This is a short-term cross-over randomized trial. In a computer generated random order, 15 of the 30 study subjects will be assigned to the intervention with oranges. 500 g of peeled oranges will be administered after a minimum of 8 h fasting. No other food will be administered or ingested during 4 h. The other 15 subjects will be the control arm and after a minimum of 8 h fasting will receive an isocaloric (same energy than the oranges) solution of sucrose in water. No other food will be administered or ingested during 4 h. &lt;/para&gt;&lt;para&gt;At baseline and after 4 h plasma, urine, serum and buffy coat samples will be obtained as well as blood pressure, anthropometric and questionnaire data. The DNA and RNA will be isolated. RNA is used for the study of gene expression and biomarkers are determined in plasma and urine samples, including metabolomic analyses. The wash-out period will be 1 week and the interventions cross-over.  Subsequently, a longer intervention study is carried out with nutritional advice to increase the consumption of oranges in a subgroup of the initial volunteers. It is a parallel and randomized design of 1 month. &lt;/para&gt;&lt;para&gt;Subjects will be randomly allocated to two groups (oranges and control group) and the intervention arm consisted of the advice of eating oranges all days during a month. The control arm will recieve advise of a reduced intake of oranges during a month. At baseline and monthly, biological samples of plasma, urine, serum and buffy coat are also taken for subsequent measurements.   In parallel, a metabolomic study is proposed to identify markers of the intake of oranges since the short-term intervention study provides a unique intervention with this food. The subsequent longer-term study along with other foods in the diet will also allow validation of the use of metabolomic markers for consumption of oranges and secondary analyses of metabolomic biomarkers of other foods.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Universidad de Valencia</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other cardiovascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16529">Others</PatientSegment><SubSegments><SubSegment id="14550">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN17330010</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other cardiovascular disease" id="46584"><Endpoint>Gene variants involved in outcome measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43088"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43505"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Other cardiovascular disease" id="43507">Blood pressure assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="46584"><Endpoint>Gene variants involved in outcome measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other cardiovascular disease" id="43645"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other cardiovascular disease" id="32809"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="34636"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="32811">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other cardiovascular disease" id="23962"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="25811"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="26268"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27423"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27909"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="29170"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="29932"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-05-05T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>1.16 Months</EnrollmentPeriod><EnrollmentRate>25.86 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="35641"><TitleDisplay>Avastin (Bevacizumab) and RAD-001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma</TitleDisplay><TitleOfficial>Exploratory Study of Avastin (Bevacizumab) and RAD-001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">2006-0954</Identifier><Identifier type="NCT">NCT00607113</Identifier></Identifiers><Indications><Indication id="1128">Neuroendocrine tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>everolimus</Name><Drug id="13340">everolimus</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>everolimus</Name><Drug id="13340">everolimus</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13340">everolimus</Drug><IndicationsPioneer/><Companies><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13340">everolimus</Drug><IndicationsPioneer/><Companies><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="13340" type="Drug"><TargetEntity id="210424" type="siDrug">Everolimus</TargetEntity><TargetEntity id="210424" type="siDrug">Everolimus</TargetEntity></SourceEntity><SourceEntity id="8047" type="Drug"><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="1128" type="ciIndication"><TargetEntity id="C7A" type="ICD10"/><TargetEntity id="209" type="ICD9"/><TargetEntity id="10052399" type="MEDDRA"/><TargetEntity id="D018358" type="MeSH"/><TargetEntity id="-1333045072" type="omicsDisease"/><TargetEntity id="1422" type="siCondition"/></SourceEntity><SourceEntity id="10240" type="Action"><TargetEntity id="1705" type="Mechanism">Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="76090" type="Action"><TargetEntity id="3739" type="Mechanism">mTOR Complex 1 (mTORC1) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="19453">Genentech Inc</Company><Company id="23137">Novartis AG</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10240">mTOR inhibitor</Action><Action id="12521">VEGF ligand inhibitor</Action><Action id="76090">mTOR complex 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="70">Anticonvulsant agent</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>41</PatientCountEnrollment><DateStart>2008-01-22T00:00:00Z</DateStart><DateEnd type="actual">2011-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-14T09:42:01Z</DateChangeLast><DateAdded>2008-12-01T08:40:35Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>U.T.M.D. Anderson Cancer Center</Affiliation><Name>James Yao</Name></Contact><Contact type="Scientific contact"><Affiliation>M.D. Anderson Cancer Center</Affiliation><Name>James Yao, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have histologically or cytologically confirmed low or intermediate grade             neuroendocrine carcinoma. Patients with neuroendocrine tumors associated with MEN1             syndrome will be eligible &lt;/li&gt;&lt;li&gt;Patients must have at least one measurable site of disease according to recist that             has not been previously irradiated. If the patient has had previous radiation to the             target lesion(s), there must be evidence of progression in the lesion(s) since the             radiation&lt;/li&gt;&lt;li&gt;Patients must have at least one lesion suitable for perfusion CT. The lesion should be             &gt;/= 3 cm in size in the cranial caudal direction&lt;/li&gt;&lt;li&gt;Patients who are on a somatostatin analogue must be on a stable dose (no change in mg             dose of long acting octreotide or lanreotide, changes in dosing interval of +/- 1 week             is allowed) for 2 months prior to start of protocol&lt;/li&gt;&lt;li&gt;Prior radiation therapy is permitted. A recovery period of at least 4 weeks after             completion of radiotherapy is required prior to enrollment&lt;/li&gt;&lt;li&gt;Patients may have received prior interferon or cytotoxic chemotherapy. There are no             limitations on the number of prior regimens. Patients who had no prior therapy are             eligible. At least 28 days must have elapsed since last treatment&lt;/li&gt;&lt;li&gt;Patients may have received prior therapy targeting c-kit, abl, PDGFR, or EGFR             (imatinib, gefitinib, erlotinib, cetuximab)&lt;/li&gt;&lt;li&gt;Age&amp;gt;/= 18 years of age, because no dosing or adverse event data are currently             available on the use of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; in patients &amp;lt; 18 years of age&lt;/li&gt;&lt;li&gt;Patients must have unresectable or metastatic disease&lt;/li&gt;&lt;li&gt;Zubrod performance status of 0 or 1&lt;/li&gt;&lt;li&gt;Patients must have adequate organ and marrow function as defined below&lt;ul&gt;&lt;li&gt;Leukocytes&amp;gt;/=             3000/microl&lt;/li&gt;&lt;li&gt;Absolute neutrophil count&amp;gt;/= 1500/microl&lt;/li&gt;&lt;li&gt;Platelets&amp;gt;/= 120,000/microl&lt;/li&gt;&lt;li&gt;Total             bilirubin&amp;lt;/= 1.5 times the institutional upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;AST(SGOT)/ALT(SGPT)&amp;lt;/= 3.0 times institutional ULN (&amp;lt;/= 5 X ULN in patients with liver             metastases) &lt;/li&gt;&lt;li&gt;Creatinine&amp;lt;/= 2.0 or, creatinine clearance &amp;gt;/= 60 ml/min/1.73 m(2) for             patients with creatinine levels above institutional normal&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients not on anticoagulation must have PT/PTT within 1.2 X the upper limit of             normal&lt;/li&gt;&lt;li&gt;Patients on full-dose anticoagulation (warfarin or low molecular weight heparin) are             eligible provided that both of the following criteria are met&lt;ul&gt;&lt;li&gt;The patient has an             in-range INR (between 2 and 3) on a stable (no change in the prior 2 weeks) dose of             oral anticoagulant or on a stable (no change in the prior 2 weeks) dose of low             molecular weight heparin&lt;/li&gt;&lt;li&gt;The patient has no active bleeding or known pathological             condition that carries a high risk of bleeding such as varices&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients must have resting blood pressure (BP) no &gt; 140 mmHg (systolic) or             90 mmHg (diastolic) for eligibility. Initiation or adjustment of BP medication is             permitted prior to study entry&lt;/li&gt;&lt;li&gt;Women of child-bearing potential must have a negative urine pregnancy test within 7             days prior to study entry. Women who have had menses within the past two years, who have             not had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy are             considered to be of child-bearing potential&lt;/li&gt;&lt;li&gt;Ability to understand and the willingness to sign a written informed consent document             and ability to comply with study and/or follow-up procedures&lt;/li&gt;&lt;li&gt;Men and women of reproductive potential must use effective means of contraception.             Oral, implantable, or injectable contraceptives may be affected by cytochrome P450             interactions, and are therefore not considered effective for this study. Barrier             method of contraception is required during the study. Contraception should continue             for 6 months after the last dose of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Current, recent (within 4 weeks of the first infusion of this study), or planned             participation in an experimental drug study&lt;/li&gt;&lt;li&gt;Prior treatment with a mTOR inhibitor or&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Chronic treatment with systemic steroids or another immunosuppressive agent&lt;/li&gt;&lt;li&gt;A known history of immunocompromise, including a positive HIV test. An HIV test will             not be required; however, previous medical history will be reviewed&lt;/li&gt;&lt;li&gt;Inadequately controlled hypertension (defined as systolic blood pressure&amp;gt; 140 and/or             diastolic blood pressure &amp;gt; 90 mmHg on antihypertensive medications)&lt;/li&gt;&lt;li&gt;Any prior history of hypertensive crisis or hypertensive encephalopathy&lt;/li&gt;&lt;li&gt;New York Heart Association (NYHA) Grade II or greater congestive heart failure&lt;/li&gt;&lt;li&gt;History of myocardial infarction or unstable angina within 6 months prior to study             enrollment&lt;/li&gt;&lt;li&gt;History of stroke or transient ischemic attack within 6 months prior to study             enrollment&lt;/li&gt;&lt;li&gt;Known history of brain or leptomeningeal metastases&lt;/li&gt;&lt;li&gt;Significant vascular disease (eg, aortic aneurysm, aortic dissection)&lt;/li&gt;&lt;li&gt;Symptomatic peripheral vascular disease&lt;/li&gt;&lt;li&gt;Evidence of bleeding diathesis or coagulopathy&lt;/li&gt;&lt;li&gt;Major surgical procedure, open biopsy, or significant traumatic injury within 28 days             prior to study enrollment or anticipation of need for major surgical procedure during             the course of the study&lt;/li&gt;&lt;li&gt;Minor surgical procedure, excluding placement of a vascular access device, within 7             days prior to study enrollment&lt;/li&gt;&lt;li&gt;History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess             within 6 months prior to study enrollment&lt;/li&gt;&lt;li&gt;Serious, non-healing wound, ulcer, or bone fracture&lt;/li&gt;&lt;li&gt;Proteinuria at screening as demonstrated by either: urine protein:creatinine (UPC)             ratio&amp;gt;/= 1.0 at screening, or, urinalysis for proteinuria &amp;gt;/= 2+ (patients discovered             to have&amp;gt;/= 2+ proteinuria on urinalysis at baseline should undergo a 24 h urine             collection and must demonstrate &amp;lt;/= 1g of protein in 24 h to be eligible)&lt;/li&gt;&lt;li&gt;Known hypersensitivity to any component of&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Pregnant or lactating. Should a woman become pregnant or suspect she is pregnant while             participating in this study, she should inform her treating physician immediately&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Tumor Blood Flow determined by functional computed tomography (CT)</Description><Timeframe>Functional CT at baseline after first and third cycles</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objectives of the study are to:&lt;br/&gt;Determine the effect of &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; on tumor blood flow as determined by functional           computed tomography (CT) in patients with low or intermediate grade neuroendocrine           carcinoma.&lt;br/&gt;Determine the effect of &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; on tumor blood flow as determined by functional CT in           patients with low or intermediate grade neuroendocrine carcinoma.&lt;br/&gt;Determine the effect of adding the second agent (&lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt;) to the first           agent (&lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt;) on tumor blood flow as determined by functional CT.&lt;/para&gt;&lt;para&gt;The      secondary objectives of the study are to:&lt;br/&gt;Determine the clinical activity (objective response rate and progression free           survival duration) of &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; in patients with low or intermediate grade           neuroendocrine carcinoma.Determine the biochemical response rate of &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; in patients with low or           intermediate grade neuroendocrine carcinoma. &lt;br/&gt;Determine the safety and tolerability of &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; in patients with low or           intermediate grade neuroendocrine carcinoma.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Eligible patients will be randomly assigned  to one of two treatment groups.  During cycle 1, one group will      receive &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; and the other group will receive &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt;.  Each study cycle is 3 weeks long.      In cycle 2 and every cycle after that, participants in both groups will receive both study      drugs.  There is an equal chance of being assigned to either group.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; administration:&lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; 10 mg tablets are taken qd  po, followed by a large glass of water.  The patients may either take &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; on an empty stomach or after a low-fat meal.  One should avoid taking &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; after large fatty meals because this will lower      the amount of &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; the body absorbs.  Dietary habits around the time patients take &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt;      should be as consistent as possible throughout the study.&lt;br/&gt;The patients should take &lt;ulink linkType="Drug" linkID="13340"&gt;RAD-001&lt;/ulink&gt; at about the same time each day.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; administration: &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; 15 mg/ kg is given through a needle in a vein in the arm.  The first dose will be given over      about 90 min.  If no intolerable side effects occur, the second dose will be given over      about 60 min, and if again no intolerable side effects occur, each dose after that will      be given over about 30 min.&lt;/para&gt;&lt;para&gt;Up to 36 patients will be enrolled in this study.  &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>U.T.M.D. Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Neuroendocrine tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9903">Subjects with Well Differentiated (Low &amp; Intermediate-grade) NET</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9905">Subjects with Multiple Endocrine Neoplasia, Type 1</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00607113</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Neuroendocrine tumor" id="11644"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Neuroendocrine tumor" id="11653">Assessment of disease control rate</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Neuroendocrine tumor" id="7326"><Criterion>Subjects with Multiple Endocrine Neoplasia, Type 1</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7329"><Criterion>Subjects with Well Differentiated (Low &amp; Intermediate-grade) NET</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7345"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7357"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="7358">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="7359">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7366"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="7367">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="7370">Subjects with history of anti-cancer hormonal therapy</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="7371">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7376"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="7377">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="7378">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="7380">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Neuroendocrine tumor" id="34043"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="7379">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Neuroendocrine tumor" id="8916"><Criterion>Subjects with Advanced/Metastatic Neuroendocrine Tumor</Criterion></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8929"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8939"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8944">Subjects with abnormal hematological status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8948"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8950">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="8951">Subjects with hypersensitivity/contraindication to biological therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8956"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8958">Subjects with history of targeted therapy</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="8962">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8964"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Neuroendocrine tumor" id="26362"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8941">Subjects with abnormal/unacceptable renal function</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="8942">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Neuroendocrine tumor" id="26842"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8959">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>17.32 Months</EnrollmentPeriod><EnrollmentRate>2.37 Patients/Month</EnrollmentRate><DateFirstReceived>2008-01-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-12-01T08:40:35Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="357262"><TitleDisplay>Multicenter, double-blind, randomized, placebo-controlled trial of IDEC-C2B8 for the treatment of childhood-onset nephrotic syndrome</TitleDisplay><TitleOfficial>Multicenter, double-blind, randomized, placebo-controlled trial of IDEC-C2B8 for the treatment of childhood-onset nephrotic syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">JMA-IIA00380</Identifier><Identifier type="Other">JSKDC10</Identifier></Identifiers><Indications><Indication id="2315">Nephrotic syndrome</Indication></Indications><BiomarkerNames><BiomarkerName id="3736" role="Not determined" type="Proteomic">Human anti-chimeric antibodies</BiomarkerName><BiomarkerName id="6663" role="Therapeutic effect marker" type="Cellular">B-lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rituximab</Name><Drug id="6736">rituximab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6736">rituximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1004094">National Center for Child Health &amp; Development</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1080981">Kobe University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21022">Zenyaku Kogyo Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6736" type="Drug"><TargetEntity id="204337" type="siDrug">Rituximab</TargetEntity></SourceEntity><SourceEntity id="1004094" type="Company"><TargetEntity id="5035556430" type="organizationId">National Center For Child Health &amp; Development</TargetEntity></SourceEntity><SourceEntity id="1080981" type="Company"><TargetEntity id="5039147619" type="organizationId">Kobe University Hospital</TargetEntity></SourceEntity><SourceEntity id="21022" type="Company"><TargetEntity id="4296429830" type="organizationId">Zenyaku Kogyo Co Ltd</TargetEntity></SourceEntity><SourceEntity id="2315" type="ciIndication"><TargetEntity id="N04" type="ICD10"/><TargetEntity id="10029164" type="MEDDRA"/><TargetEntity id="D009404" type="MeSH"/><TargetEntity id="-1704539060" type="omicsDisease"/><TargetEntity id="343" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>8</NumberOfSites><CompaniesSponsor><Company id="1080981">Kobe University Hospital</Company><Company id="21022">Zenyaku Kogyo Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1004094">National Center for Child Health &amp; Development</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2018-11-01T00:00:00Z</DateStart><DateChangeLast>2018-10-25T09:18:39Z</DateChangeLast><DateAdded>2018-10-24T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Kobe University Hospital</Affiliation><Email>ctrcpj-jskdc10@med.kobe-u.ac.jp</Email><Name>Naoko Kashiwagi</Name><Phone>+81-78-382-6729</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kobe University Hospital</Affiliation><Email>iijima@med.kobe-u.ac.jp</Email><Name>Kazumoto Iijima</Name><Phone>+81-78-382-5111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosed as idiopathic nephrotic syndrome (INS) according to the ISKDC criteria&lt;/li&gt;&lt;li&gt;First onset of INS is under 18 years of age&lt;/li&gt;&lt;li&gt;Subjects who are diagnosed as frequent recurrence or steroid dependency with recurrence just before registration and who can confirm the date of recurrence as the basis for diagnosis&lt;/li&gt;&lt;li&gt;Subjects who have not been treated with immunosuppressive treatment for INS&lt;/li&gt;&lt;li&gt;Diagnosed as steroid-sensitive relapse&lt;/li&gt;&lt;li&gt;CD20 positive B-cells &gt;/= 5/microl in the peripheral blood&lt;/li&gt;&lt;li&gt;Subjects can be hospitalized for treatments&lt;/li&gt;&lt;li&gt;Subjects have ability to provide written informed consent form. The written informed consent form of legal representative is also required for subjects less than 20 years of age&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects who have been diagnosed with steroid resistance NS&lt;/li&gt;&lt;li&gt;History of inflammatory nephritis such as IgA nephritis&lt;/li&gt;&lt;li&gt;Subjects falling under any of the following infectious diseases:&lt;ul&gt;&lt;li&gt;Subjects who have had a history of severe infection (pneumonia, pyelonephritis, etc) requiring hospitalization within the past 6 months before registration&lt;/li&gt;&lt;li&gt;Subjects who have had a history of opportunistic infection (cytomegalovirus infection, systemic fungal infection, pneumocystis infection, nontuberculous mycobacterial infection etc) within 6 months before registration&lt;/li&gt;&lt;li&gt;Subjects with active tuberculosis&lt;/li&gt;&lt;li&gt;Subjects with or having suspected tuberculosis infection&lt;/li&gt;&lt;li&gt;Subjects complicated with active hepatitis B or active hepatitis C, or patients confirmed to be hepatitis B virus carriers&lt;/li&gt;&lt;li&gt;Subjects with confirmed HIV infection&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Presence or history of angina pectoris, cardiac failure, myocardial infarction and/or serious arrhythmia grade 4 in "Common Terminology Criteria for Adverse Events (ver. 4.0)"&lt;/li&gt;&lt;li&gt;Having received a live vaccine within 4 weeks prior to screening&lt;/li&gt;&lt;li&gt;Known hypertension which is uncontrollable with conventional anti-hypertensive&lt;/li&gt;&lt;li&gt;Deteriorated kidney function, eg, estimated GFR&amp;lt; 60ml/min/1.73m2&lt;/li&gt;&lt;li&gt;Presence or history of auto-immune diseases such as Hashimoto disease (Chronic thyroiditis), Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma or vascular purpura&lt;/li&gt;&lt;li&gt;Presence or history of cancer&lt;/li&gt;&lt;li&gt;History of organ transplantation&lt;/li&gt;&lt;li&gt;History of allergic reaction to acetaminophen and/or d-chlorpheniramine maleate&lt;/li&gt;&lt;li&gt;Subject falling under any of the following clinical laboratory findings:&lt;ul&gt;&lt;li&gt;WBC&amp;lt; 3,000/microl&lt;/li&gt;&lt;li&gt;Neutrophil&amp;lt; 1,500/microl &lt;/li&gt;&lt;li&gt;PLT&amp;lt; 50,000/microl &lt;/li&gt;&lt;li&gt;AST(GOT) &gt; 2.5 x ULN &lt;/li&gt;&lt;li&gt;ALT(GPT) &gt; 2.5 x ULN &lt;/li&gt;&lt;li&gt;Positive for HBs antigen, HBs antibody, HBc antibody and HCV antibody&lt;/li&gt;&lt;li&gt;Positive for HIV antibody &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;History of receiving any kinds of monoclonal antibody therapy&lt;/li&gt;&lt;li&gt;Having received any investigational agent within 6 months prior to enrollment, or participating other clinical studies&lt;/li&gt;&lt;li&gt;Subjects who do not agree with contraception during the study period (Negative HCG result is required at screening for female subjects after the first menstruation)&lt;/li&gt;&lt;li&gt;A female patient who is pregnant, has a possibility of pregnancy, or is breastfeeding&lt;/li&gt;&lt;li&gt;Judged inappropriate for this study by the physicians&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Relapse-free period</Description><Timeframe>Time of randomization to the time of first relapse after starting the study treatment</Timeframe></Measure><Measure><Description>Adverse event, Adverse drug reaction</Description><Timeframe>Time of randomization to the end of observational period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Time to treatment failure</Description><Timeframe>Time of randomization to the time of development of treatment failure</Timeframe></Measure><Measure><Description>Total steroid dose</Description><Timeframe>Time of randomization to the end of double-blind phase observational period</Timeframe></Measure><Measure><Description>Variation in B cell count during observational period</Description></Measure><Measure><Description>Measurement of B cell count</Description></Measure><Measure><Description>Duration of B-cell depletion</Description><Timeframe>Day 1 in double-blind period to the end of observational period</Timeframe></Measure><Measure><Description>Relapse-free period in open-label phase</Description><Timeframe>Time of enrollment to the time of first relapse during open-label phase</Timeframe></Measure><Measure><Description>Serum IDEC-C2B8 level</Description><Timeframe>Day 1 in open-label period to the end of observational period</Timeframe></Measure><Measure><Description>Anti-rituximab antibody (human anti-chimeric antibody, HACA) in subject serum</Description><Timeframe>Day 1 in open-label period to the end of observational period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to evaluate the efficacy and safety of &lt;ulink linkType="Drug" linkID="6736"&gt;IDEC-C2B8&lt;/ulink&gt; in comparison with placebo  in patients with childhood-onset nephrotic syndrome, and to evaluate IDEC-C2B8 blood levels, anti-rituximab antibody (human anti-chimeric antibody, HACA), and the association between B cells and relapse/adverse events.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive 375 mg/m2 (maximum 500 mg/body) of the study drug or placebo, given two times at an interval of 7 +/- 2 days.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Address1>Tochigi</Address1><Contacts/></Site><Site><Address1>Tokyo</Address1><Contacts/></Site><Site><Address1>Kanagawa</Address1><Contacts/></Site><Site><Address1>Shiga</Address1><Contacts/></Site><Site><Address1>Osaka</Address1><Contacts/></Site><Site><Address1>Hyogo</Address1><Contacts/></Site><Site><Address1>Wakayama</Address1><Contacts/></Site><Site><Address1>Fukuoka</Address1><Contacts/></Site><Site><Address1>Saga　</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7712">Subjects with Glomerular Disorder</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1005">Japan Medical Association - Center for Clinical Trials (JMACCT CTR)</Name><Identifiers><Identifier>JMA-IIA00380</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22586"><Endpoint>Overall Disease Activity Assessment</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22588">Assessment of disease relapse</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22593"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22595"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22534"><Endpoint>Assessment of Immune Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22544"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22586"><Endpoint>Overall Disease Activity Assessment</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22588">Assessment of disease relapse</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22598"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="44909"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17665"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17668">Subjects with glomerular kidney disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17700"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17703">Subjects with protocol specified other lab findings</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="34288"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="32209">Women with adequate contraception/Negative pregnancy test/Non-lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="35543"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="35544">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17508"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17515"><Criterion>Subjects with Renal Function Outside of Protocol Specified Limits</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17516">Subjects with GFR outside of protocol specified limits</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17521"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17524"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17528"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17529">Subjects co-morbid with anemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17533"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17535"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17536"><Criterion>Subjects with History of/Scheduled for Renal Replacement Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17539">Subjects with protocol specified transplantation related criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17555"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="24726"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="25463"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="26583"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="27307"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="27701"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="27790"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="28269"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-10-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="358996"><TitleDisplay>Evaluation of the Efficacy of Ropivacaine in Children and Young Adults With Hereditary Epidermolysis Bullosa</TitleDisplay><TitleOfficial>Evaluation of the Efficacy of a Topical Analgesic Treatment With Ropivacaine in Children and Young Adults With Hereditary Epidermolysis Bullosa</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03730584</Identifier><Identifier type="Secondary Organisational">2018-003334-33</Identifier><Identifier type="Organisational Study">D20180207</Identifier><Identifier type="Trial Acronym">EBROPI</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ropivacaine</Name><Drug id="4271">ropivacaine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4271">ropivacaine</Drug><IndicationsPioneer/><Companies><Company><Company id="23948">Assistance Publique Hopitaux de Paris</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4271" type="Drug"><TargetEntity id="129999" type="siDrug">Ropivacaine</TargetEntity><TargetEntity id="150269" type="siDrug">Ropivacaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="23948" type="Company"><TargetEntity id="4296543185" type="organizationId">Assistance Publique Hopitaux de Paris</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23948">Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1669">Local anesthetic</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="654">Intrathecal formulation</Technology><Technology id="767">Rectal formulation</Technology><Technology id="622">Rectal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2017-02-27T00:00:00Z</DateStart><DateEnd type="estimated">2020-08-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-25T12:13:52Z</DateChangeLast><DateAdded>2018-11-09T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>celine.greco@aphp.fr</Email><Name>Celine Greco, MD</Name><Phone>+33 1 42 19 27 28</Phone></Contact><Contact type="Scientific contact"><Affiliation>Assistance Publique - Hôpitaux de Paris</Affiliation><Name>Christine Bodemer, MD, PhD</Name></Contact><Contact type="Public contact"><Email>nelly.briand@aphp.fr</Email><Name>Nelly Briand, PhD</Name><Phone>+33 1 44 38 18 62</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Minor patient or adult&amp;lt;/=  21 years of age with hereditary epidermolysis bullosa&lt;/li&gt;&lt;li&gt;Presenting pain at the entrance of the bath with an average of EVA or FLACC &gt; 4/10 the week before the inclusion&lt;/li&gt;&lt;li&gt;Usually requiring premedication with weak or strong opioid&lt;/li&gt;&lt;li&gt;Parental consent if minor or patient consent&lt;/li&gt;&lt;li&gt;Affiliated with social security&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with a known allergy to ROPIVACAINE or other local anesthetics with amide binding or one of the excipients mentioned in the SPC&lt;/li&gt;&lt;li&gt;Severe renal insufficiency defined by DFG below 29 ml/min&lt;/li&gt;&lt;li&gt;Moderate to severe hepatic insufficiency defined by a Child-Pugh B or C score and AST or ALAT &gt; 3 times normal&lt;/li&gt;&lt;li&gt;Moderate to severe cardiac failure defined by FEGV less than 45% and/or NYHA class II to IV&lt;/li&gt;&lt;li&gt;Hypovolemia&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Efficacy on pain of ropivacaine at the bath entrance: evaluation performed by child with a visual analog scale (VAS) or by parents with the face legs activity cry consolability questionary (FLACC) - defined by a two points loss between day 1 and day 5</Description><Timeframe>Day 5</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy of ropivacaine on the reduction of benzodiazepines or hypnotics use: efficacy of ropivacaine on the reduction of of benzodiazepines or hypnotics consumption for premedication for the bath and dressing change</Description><Timeframe>Day 21</Timeframe></Measure><Measure><Description>Efficacy of ropivacaine on the reduction of opioids use: efficacy of ropivacaine on the reduction of weak or strong opioids consumption for premedication for the bath and dressing change</Description><Timeframe>Day 21</Timeframe></Measure><Measure><Description>Efficacy on pain of ropivacaine at home at bath entrance: evaluation performed by child with a VAS or by parents with FLACC at the time of bath entrance</Description><Timeframe>Day 21</Timeframe></Measure><Measure><Description>Efficacy on pain of ropivacaine at home at the time of dressing change: evaluation performed by child with a VAS or by parents with FLACC at the time of dressing changes after bathing</Description><Timeframe>Day 21</Timeframe></Measure><Measure><Description>Efficacy on pain of ropivacaine at the time of dressing change: evaluation performed by child with a VAS or by parents with FLACC at the time of dressing changes after bathing</Description><Timeframe>Day 5</Timeframe></Measure><Measure><Description>Measurement of local or systemic side effects: evaluation of tolerance of ropivacaine</Description><Timeframe>Day 5</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to determine whether topical application of &lt;ulink linkType="Drug" linkID="4271"&gt;ropivacaine&lt;/ulink&gt; is      effective for treating refractory pain during dressing changes and so improve quality of life      of patients (newborn, child, adolescent or adults under 21) suffering from hereditary      epidermal epidermolysis bullosa.&lt;/para&gt;&lt;para&gt;This clinical trial aims to determine the efficacy on pain of local application of      ropivacaine 0.2% on cutaneous lesions related to epidermolysis bullosa during dressing      change, associated with the standard premedication.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be hospitalized and will have several baths. The first bath will be done      according to usual protocol (usual premedication 1 h before the bath). Pain measurements      (visual analog scale or FLACC) will be done at the entry into the water, in the middle of      bath and at the time of the dressing change. &lt;br/&gt;The following baths will be done using local application of ropivacaine 15 min before      entering into the water on lesions identified by the patients as the most painful lesions due      to epidermolysis bullosa.&lt;/para&gt;&lt;para&gt;A blood test will be done during the first use of ropivacaine to determine plasmatic level of      ropivacaine.&lt;/para&gt;&lt;para&gt;After three baths in the dermatology unit, patients will continue such bath at home, every 48 h      during 15 days.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Hôpital Necker Enfants Malades</Name><Address1>Paris</Address1><Address3>75015</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>celine.greco@aphp.fr</Email><Name>Céline Gréco, MD</Name><Phone>+33 1 42 19 27 28</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15999">Subjects with Epidermolysis Bullosa</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03730584</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2018-003334-33</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22201">Subjects with dermatological disorder/disease associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="32832"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="33233"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Pain" id="34061"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22211">Subjects with history/scheduled to receive opioids</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other dermatological disease" id="34310"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="33091">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20127">Hypersensitivity/ contraindication to local anaesthesia/ blocks</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="23963"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24776">Subjects with cardiac diseases/disorders</SubCriterion><SubCriterion disease="Other dermatological disease" id="24777">Subjects with liver disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="24589"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24590">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="24773"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Pain" id="26300"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Pain" id="20105">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Pain" id="20106">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-02-29T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-11-02T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-11-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-04-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-22T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-22T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-29T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-29T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="367230"><TitleDisplay>China Diabetes Registry by Metabolic Management Center</TitleDisplay><TitleOfficial>China Diabetes Registry - a Prospective, Cohort Study of Patients With Diabetes in National Metabolic Management Centers in China</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03811470</Identifier><Identifier type="Organisational Study">CCEMD-2018-1201</Identifier><Identifier type="Trial Acronym">CDR-MMC</Identifier></Identifiers><Indications><Indication id="836">Insulin dependent diabetes</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Disease marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="289" role="Disease marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1735" role="Disease marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2586" role="Disease marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="12225" role="Disease marker" type="Structural (imaging)">Visceral adipose tissue</BiomarkerName><BiomarkerName id="14767" role="Disease marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1037695" type="Company"><TargetEntity id="4296702079" type="organizationId">Shanghai Jiao Tong University</TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"/><TargetEntity id="10067584" type="MEDDRA"/><TargetEntity id="D003922" type="MeSH"/><TargetEntity id="-686743471" type="omicsDisease"/><TargetEntity id="507" type="siCondition"/></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1037695">Shanghai Jiao Tong University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>500000</PatientCountEnrollment><DateStart>2017-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2039-05-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T13:17:33Z</DateChangeLast><DateAdded>2019-01-28T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>gning@sibs.ac.cn</Email><Extension>671817</Extension><Name>Guang Ning</Name><Phone>008621-64370045</Phone></Contact><Contact type="Scientific contact"><Affiliation>National Metabolic Management center</Affiliation><Name>Guang Ning</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/=  18 years old and&amp;lt;/= 75 years&lt;/li&gt;&lt;li&gt;Diagnosis of diabetes mellitus according to 1999&lt;ulink linkType="Company" linkID="20947"&gt;WHO&lt;/ulink&gt; criteria&lt;/li&gt;&lt;li&gt;Gender: males and females&lt;/li&gt;&lt;li&gt;Provide written informed consent&lt;/li&gt;&lt;li&gt;Satisfactory compliance&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with significantly reduced life expectancy (&amp;lt; five years)&lt;/li&gt;&lt;li&gt;With drug abuse&lt;/li&gt;&lt;li&gt;With AIDS or syphilis or infectious diseases such as viral hepatitis or tuberculosis in active phase at enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of all diabetes-related clinical endpoints; including: Macrovascular morbidity</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Microvascular morbidity</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Mortality</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Major infections - pulmonary and non-pulmonary requiring hospitalizations</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Heart failure: including hospitalized or treated heart failure, or heart failure death</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Neuropathy: defined as a composite score by the assessment of positive responses among symptoms (by a careful history), sensory signs, or absent or hypoactive reflexes consistent with a distal symmetrical polyneuropathy, and at least one abnormal nerve conduction</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>All cancers: The occurrence of any of the following cancers: prostate, breast, lung/bronchus, endometrial, colon, gastric, leukemia, lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma, etc</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Blood pressures (mmHg)</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Body mass index (BMI): Body weight (kg) and height (m) will be combined to report BMI in kg/m(2)</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Cognitive function: incidences of all-cause dementia and mild cognitive impairment, cognitive function assessed by cognitive function scale</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Cost-effectiveness: the incremental cost per quality adjusted life year (QALY) gained. QALYs will be measured by the EuroQol-5 Dimensions (EQ-5D) questionnaire</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Fasting and postprandial glucose (mmol/l)</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>HbA1c (%)</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Health related quality of life: evaluated with HQoL scales such as short form 12 health survey questionnaire</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Psychological well being: using physiological parameter, questionnaire</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Visceral fat (cm[2])</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure><Measure><Description>Lipids (mg/dl)</Description><Timeframe>Through study completion, up to 20 years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the Metabolic Management Center (MMC) will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;The objectives of this study are:&lt;br/&gt;The purpose of the present study is to establish a multicenter nationwide prospective           database of diabetes patients in MMCs, including clinical data, biological samples           library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and           prognostic methods related to diabetes and its complications, as well as other metabolic           diseases.&lt;br/&gt;To collect cross-sectional data from patients seen and treated at each MMC centers so as           to evaluate: the current status of care of patients with diabetes and its related           complications, as well as other risk factors treatment strategies at these centers.           Patients'costs and quality of life (QoL) will also be evaluated.&lt;br/&gt;To collect the prospective data of patients treated at each MMC centers in order to           evaluate the strategies for the achievement of treatment goals, changes in management,           control of risk factors, incidence and progression of all-diabetes related clinical           endpoints (including mortality), behavioral changes, psychological well being as well as           costs and QoL.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Methods: after obtaining informed consent, patients will be invited and initiated with a      comprehensive baseline evaluation at each MMC centers. Then patients will be followed by      clinical/laboratory visits at MMC every 3 to 6 month later on according to individualized      patient's treatment plans. A repeated comprehensive clinical and laboratory assessment for      glycemic and risk factors control, safety, as well as diabetes-specific complications will be      scheduled once a year. Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms will be observed and analyzed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>National Metabolic Management center</Name><Address1>Multiple Locations</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>gning@sibs.ac.cn</Email><Extension>671817</Extension><Name>Guang Ning</Name><Phone>8621-64370045</Phone></Contact><Contact type="Facility investigator"><Name>Guang Ning</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03811470</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1525"><Endpoint>Assessment of Diabetic Complications &amp; Events</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1528">Microvascular complications</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1535"><Endpoint>Assessment of Morbidity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1543"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1546">Heart failure</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1553"><Endpoint>Assessment of hospitalization</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1559"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1561">Cardiovascular mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="2413"><Endpoint>Neurological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="2417">Nerve conduction assessments</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="18169"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18171">Cardiovascular mortality</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="18172">Assessment of in-hospital mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="18210"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18211">Assessment of neuropathy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="18260"><Endpoint>Assessment of Pulmonary Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="32006"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="33857"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="45216"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="45340"><Endpoint>Assessment of Co-morbidity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="45518"><Endpoint>Assessment of hospitalization</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="45563"><Endpoint>Assessment of complications</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1529">Macrovascular complications</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1451"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1345">Assessment of fasting blood glucose</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1346">Assessment of postprandial glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1580"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="2413"><Endpoint>Neurological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="2416">Cognitive function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1502">Assessment of BMI</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1503">Assessment of body weight</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18118"><Endpoint>Assessment of Blood Glucose Levels</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18121">Assessment of postprandial plasma glucose (PPPG)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18173"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18174"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="32006"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="32007">Assessment by Health Related Quality of Life (HRQOL)</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="32008">European quality of life instrument(EuroQol)</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="32011">Assessment by Short Form Health Survey (SF-12)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="32072"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="32073">Assessment of cost effectiveness</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="33777"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33779">Assessment of cost effectiveness</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="33857"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33858">Assessment by Health Related Quality of Life (HRQOL)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33859">European quality of life instrument(EuroQol)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33863">Assessment by Short Form Health Survey (SF-12)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="44121"><Endpoint>Assessment of fat</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1508">Intraabdominal fat (Visceral fat)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="44211"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18123">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="44714"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18219">Assessment of weight</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="18222">Assessment of BMI</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="45216"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45340"><Endpoint>Assessment of Co-morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="45639"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18221">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45701"><Endpoint>Assessment of Neuropsychological Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="1624"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1692">Other metabolic disorders</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="2464">Pharmacogenetic/Pharmacogenomic Study</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="2426"><Endpoint>Assessment of Diabetic Events/Risk Factors</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="2429">Diabetic disease progression/regression</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Insulin dependent diabetes" id="18160"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Insulin dependent diabetes" id="18210"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18268">Change in diabetes management</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="43878"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint><OtherEndpoint disease="Insulin dependent diabetes" id="44035"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint><OtherEndpoint disease="Insulin dependent diabetes" id="44944"><Endpoint>Assessment of Metabolic Parameters</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="3846">Subjects with secondary diabetes</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="3847">Subjects with maturity onset diabetes of young (MODY)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="32042">Comply with ADA and WHO standards criteria for diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16356"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="34466"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16363">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34467"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="906">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="34875"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16358">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34922"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1042">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16827">Subjects with Type 1 Diabetes Mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="995"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5072"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5074"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5076">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13812"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13814">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13815"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13817"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13822">Substance-abuse disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13835"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13886"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="28259"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13771">Subjects co-morbid with hepatitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="28262"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="913">Subjects co-morbid with hepatitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="29284"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1003">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2037-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-20T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="376506"><TitleDisplay>Effects of Heating on Exercise Pressor Reflex in Peripheral Artery Disease: Exercise Ability</TitleDisplay><TitleOfficial>Effects of Heating on Exercise Pressor Reflex in Peripheral Artery Disease: Exercise Ability</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03900832</Identifier><Identifier type="Organisational Study">STUDY00005798</Identifier><Identifier type="Trial Acronym">EPR</Identifier></Identifiers><Indications><Indication id="260">Peripheral vascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="5596" role="Therapeutic effect marker" type="Physiological">Blood flow</BiomarkerName><BiomarkerName id="44216" role="Therapeutic effect marker" type="Physiological">Body temperature</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Gardner walking protocol</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>heating suit</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lower limb warm water immersion</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>treadmill walk</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>warm bath</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Gardner walking protocol</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>neutral bath</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>walk without heating procedure</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1062187" type="Company"><TargetEntity id="5035553622" type="organizationId">Milton S Hershey Medical Center</TargetEntity></SourceEntity><SourceEntity id="260" type="ciIndication"><TargetEntity id="10034636" type="MEDDRA"/><TargetEntity id="D016491" type="MeSH"/><TargetEntity id="-817414410" type="omicsDisease"/><TargetEntity id="260" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 0 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1062187">Milton S. Hershey Medical Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>32</PatientCountEnrollment><DateStart>2017-02-15T00:00:00Z</DateStart><DateEnd type="estimated">2024-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-11T05:24:20Z</DateChangeLast><DateAdded>2019-04-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>jcui@pennstatehealth.psu.edu</Email><Name>Jian Cui, PhD</Name><Phone>7175311799</Phone></Contact><Contact type="Scientific contact"><Affiliation>Penn State College of Medicine</Affiliation><Name>Jian Cui</Name></Contact><Contact type="Public contact"><Email>kgray1@pennstatehealth.psu.edu</Email><Name>Kris Gray, MS</Name><Phone>7175314589</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All subjects:&lt;ul&gt;&lt;li&gt;Capable of giving informed consent&lt;/li&gt;&lt;li&gt;Any race or ethnicity&lt;/li&gt;&lt;li&gt;Men and women age 21 to 85 years (inclusive)&lt;/li&gt;&lt;li&gt;Fluent in written and spoken English&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with peripheral arterial disease (PAD):&lt;ul&gt;&lt;li&gt;Diagnosed with PAD (ie, ankle-brachial index below 0.9)&lt;/li&gt;&lt;li&gt;Fontaine stage II or less - no pain while resting&lt;/li&gt;&lt;li&gt;Satisfactory history and physical exam&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Healthy subjects:&lt;ul&gt;&lt;li&gt;Satisfactory history and physical examination&lt;/li&gt;&lt;li&gt;Free of acute medical conditions&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;For patients with PAD and Healthy subjects:&lt;ul&gt;&lt;li&gt;Age&amp;lt; 21 years&lt;/li&gt;&lt;li&gt;Pregnant or nursing women&lt;/li&gt;&lt;li&gt;Decisional impairment&lt;/li&gt;&lt;li&gt;Prisoners&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For patients with PAD:&lt;ul&gt;&lt;li&gt;History of CAD with symptoms of unstable angina or myocardial infarction (&amp;lt; 6 months)&lt;/li&gt;&lt;li&gt;History of epilepsy or seizure disorders&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For healthy subjects:&lt;ul&gt;&lt;li&gt;Any other chronic diseases (heart, lung, neuromuscular disease or diabetes)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Walking time in minutes: walking time on treadmill using Gardner protocol</Description><Timeframe>Recording walking time to fatigue (up to 22 min maximum) during of every 3 to 4 h study visit</Timeframe></Measure><Measure><Description>Blood pressure in mmHg: cuffs placed on a finger and arm will monitor blood pressure</Description><Timeframe>Recorded continuously during the 3 to 4 h study visit</Timeframe></Measure><Measure><Description>Heart Rate in beats per minute: electrocardiogram (ECG) patches attached to a Cardiocap will monitor heart rat</Description><Timeframe>Recorded continuously during the 3 to 4 h study visit</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Internal Temperature in degrees C: the internal temperature (Tcore) will be measured from the stomach/intestines via a telemetry pill swallowed by subjects</Description><Timeframe>Recorded continuously during the 3 to 4 h study visit</Timeframe></Measure><Measure><Description>Near infrared spectroscopy (NIRS) in arbitrary units: this system is designed specifically for non-invasive measurements of muscle tissue. The system measures the tissue saturation of the investigated muscle, called the 'tissue saturation index' (TSI)</Description><Timeframe>Recorded continuously during the 3 to 4 h study visit</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study objectives of this projects are to examine the hypothesis that the sympathetic and      blood pressure responses to exercise will be attenuated during and after heat exposure in      patients with peripheral artery disease, via altering the sensitivity of the muscle afferent      receptors.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Participants will be assigned into ten groups:&lt;br/&gt;Group 1: PAD without heating: participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 2: PAD warm bath: participants will take a warm bath. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 3: PAD neutral bath: participants will take a neutral bath. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 4: PAD heating suit: whole body heating with the suit will be performed. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 5: PAD lower limb warm water immersion: participants will place their lower legs in warm water. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 6: healthy participants without heating: participants will walk on a treadmill using the Gardner protocol until the participants says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 7: healthy participants warm bath: participants will take a warm bath. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 8: healthy participants neutral bath: participants will take a neutral bath. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Gropup 9: healthy participants heat suit: whole body heating with the suit will be performed. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;br/&gt;Group 10: healthy participants lower limb immersion: participants will place their lower legs in warm water. Then, participants will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Penn State Milton S. Hershey Medical Center</Name><Address1>Hershey</Address1><Address2>Pennsylvania</Address2><Address3>17033</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>kgray1@pennstatehealth.psu.edu</Email><Name>Kristen Gray</Name><Phone>717-531-4589</Phone></Contact><Contact type="Facility contact backup"><Email>jcui@pennstatehealth.psu.edu</Email><Name>Jian Cui</Name><Phone>717-531-1799</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10159">Others</PatientSegment><SubSegments><SubSegment id="18685">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03900832</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21819"><Endpoint>Assessment of Cardiac Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21939"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="44735"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21893"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21939"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Peripheral vascular disease" id="21772"><Endpoint>Assessment of Vascular Endothelial Function</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21743">Assessment of blood flow</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19201"><Criterion>Subjects with Peripheral Arterial Disease</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="19236"><Criterion>Subjects with Specified Hemodynamic Parameters</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19237">Subjects with specified ankle brachial index</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19315"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19322">Subjects able to communicate in the language specified in the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="34464"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19328">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="34510"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19332">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15458"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15939"><Criterion>Subjects with Peripheral Arterial Diseases</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15947">Subjects with rest pain</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15950"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15951">Subjects co-morbid with angina</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15979"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15986"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15987">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15989"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16065"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16110">Vulnerable subjects</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25761"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16095">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="27035"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15954">Subjects co-morbid with myocardial infarction</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2024-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-03-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="377421"><TitleDisplay>A retrospective study to evaluate the association between the antitumor efficacy of regorafenib and hand-foot skin reaction (HFSR) in patients with metastatic colorectal cancer (mCRC)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="3658">Metastatic colorectal cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>regorafenib</Name><Drug id="54624">regorafenib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54624">regorafenib</Drug><IndicationsPioneer/><Companies><Company><Company id="23138">Japanese Foundation For Cancer Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="54624" type="Drug"><TargetEntity id="395674" type="siDrug">Regorafenib</TargetEntity><TargetEntity id="418407" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="23138" type="Company"><TargetEntity id="5035523431" type="organizationId">Japanese Foundation for Cancer Research</TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"/><TargetEntity id="595" type="siCondition"/></SourceEntity><SourceEntity id="168" type="Action"><TargetEntity id="1105" type="Mechanism">FGFR Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3832" type="Action"><TargetEntity id="1153" type="Mechanism">Tie Receptor Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3834" type="Action"><TargetEntity id="1154" type="Mechanism">Tie2 Receptor Inhibitors</TargetEntity><TargetEntity id="2853" type="Mechanism">Anti-Tie2</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="4548" type="Action"><TargetEntity id="2892" type="Mechanism">Raf kinase B Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4550" type="Action"><TargetEntity id="2963" type="Mechanism">Raf kinase C Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7303" type="Action"><TargetEntity id="1773" type="Mechanism">Caspase 3 Activators</TargetEntity><TargetEntity id="3033" type="Mechanism">Procaspase 3 Activators</TargetEntity></SourceEntity><SourceEntity id="7321" type="Action"><TargetEntity id="1775" type="Mechanism">Caspase 9 Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="23138">Japanese Foundation For Cancer Research</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="168">FGF receptor antagonist</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3832">TIE tyrosine kinase receptor inhibitor</Action><Action id="3834">Tek tyrosine kinase receptor inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="4548">Raf B protein kinase inhibitor</Action><Action id="4550">Raf 1 protein kinase inhibitor</Action><Action id="48490">PDGF receptor beta modulator</Action><Action id="7303">Caspase-3 stimulator</Action><Action id="7321">Caspase-9 stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>97</PatientCountEnrollment><PatientCountEvaluable>97</PatientCountEvaluable><DateChangeLast>2019-04-25T04:02:29Z</DateChangeLast><DateAdded>2019-04-22T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with metastatic colorectal cancer (mCRC)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>To evaluate the incidence of hand-foot skin reaction (HFSR)</Description></Measure><Measure><Description>To evaluate the estimates of overall survival and progression-free survival using the Kaplan-Meier method</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in February 2019. Out of 97 patients who received at least one dose of regorafenib, 81.4% experienced HFSR of any grade, and 34% (n = 33) had grade 3 HFSR. Among the patients with HFSR at any time during the study, a total of 66 patients underwent the first HFSR event (any grade) during cycle 1  [&lt;ulink linkType="Reference" linkID="2143729"&gt;2143729&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this retrospective study was to evaluate the association between the antitumor efficacy of &lt;ulink linkType="Drug" linkID="54624"&gt;regorafenib&lt;/ulink&gt; and hand-foot skin reaction (HFSR) in patients with metastatic colorectal cancer (mCRC) [&lt;ulink linkType="Reference" linkID="2143729"&gt;2143729&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in February 2019. In patients who had HFSR grade &gt;/= 2 at any time, both overall survival and progression-free survival improved when compared to patients who had HFSR grade &amp;lt;/= 1. A history of HFSR grade &gt;/= 2 induced by capecitabine was identified as a significant risk factor for severe HFSR (grade &gt;/=2), as evaluated by multivariate logistic regression analysis [&lt;ulink linkType="Reference" linkID="2143729"&gt;2143729&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received regorafenib 160 mg/day during the first 3 weeks of each 4-week cycle were evaluated [&lt;ulink linkType="Reference" linkID="2143729"&gt;2143729&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>regorafenib</Name><Drug id="54624">regorafenib</Drug><Dose unit="milligram dose">160.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="6832">Acral erythema</Indication><CountPatientsAffectedPercentage>81.4</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><ChangeHistory><Change type="added"><Date>2019-04-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="Added"><Date>2019-04-23T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="added"><Date>2019-04-25T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="updated"><Date>2019-04-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="377898"><TitleDisplay>Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer</TitleDisplay><TitleOfficial>Phase III, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Tislelizumab Combined With Chemotherapy Versus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03924986</Identifier><Identifier type="Organisational Study">BGB-A317-309</Identifier><Identifier type="Other">CTR20182534</Identifier></Identifiers><Indications><Indication id="1768">Nasopharyngeal carcinoma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tislelizumab</Name><Drug id="77347">tislelizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="duo"><Interventions><Intervention type="InterventionControl"><Name>cisplatin</Name></Intervention><Intervention type="InterventionControl"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1063251">BeiGene Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1154004">BeiGene Pharmaceuticals (Guangzhou) Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="77347">tislelizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="1063251">BeiGene Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1154004">BeiGene Pharmaceuticals (Guangzhou) Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1063251" type="Company"><TargetEntity id="5036210022" type="organizationId">BeiGene Beijing Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1154004" type="Company"><TargetEntity id="5046736714" type="organizationId">BeiGene Shanghai Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1768" type="ciIndication"><TargetEntity id="10061306" type="MEDDRA"/><TargetEntity id="D009303" type="MeSH"/><TargetEntity id="150" type="ORPHANET"/><TargetEntity id="-1434303133" type="omicsDisease"/><TargetEntity id="2134" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="1063251">BeiGene Co Ltd</Company><Company id="1154004">BeiGene Pharmaceuticals (Guangzhou) Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="67136">Programmed cell death protein 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="767">Cell cycle inhibitor</Class><Class id="7761">T-lymphocyte stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>256</PatientCountEnrollment><DateStart>2019-04-18T00:00:00Z</DateStart><DateEnd type="estimated">2022-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-07-02T03:28:25Z</DateChangeLast><DateAdded>2019-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sun Yat-sen University</Affiliation><Name>Li Zhang</Name></Contact><Contact type="Public contact"><Email>clinicaltrials@beigene.com</Email><Name>Feng Guo</Name><Phone>18510168801</Phone></Contact><Contact type="Public contact"><Affiliation>Baekje Shenzhou (Shanghai) Biotechnology Co., Ltd</Affiliation><Email>ClinicalTrails@beigene.com</Email><Name>Li Yue</Name><Phone>4008203159</Phone></Contact><Contact type="Scientific contact"><Affiliation>Sun Yat-sen University Cancer Center</Affiliation><Email>Zhangli@sysucc.org.cn</Email><Name>Tension, Master of Medicine</Name><Phone>020-87343088</Phone></Contact><Contact type="Scientific contact"><Affiliation>Peking University Cancer Hospital</Affiliation><Name>Sun Yan</Name></Contact><Contact type="Scientific contact"><Affiliation>The Fifth Affiliated Hospital of Zhongshan University</Affiliation><Name>Wang Siyang</Name></Contact><Contact type="Scientific contact"><Affiliation>Guangdong Medical University Affiliated Hospital</Affiliation><Name>Wen Jiyu</Name></Contact><Contact type="Scientific contact"><Affiliation>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</Affiliation><Name>Yang Kunyu</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments&lt;/li&gt;&lt;li&gt;Aged between 18 to 75 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)&lt;/li&gt;&lt;li&gt;Histologically or cytologically confirmed, recurrent or metastatic NPC&lt;/li&gt;&lt;li&gt;Patients must be able to provide fresh or archival tumor tissues (FFPE blocks or approximately 10 [&gt;/= 6] freshly cut unstained FFPE slides) with an associated pathological report. The archival tumor tissues must be collected within two years before screening. In the absence of sufficient archival tumor tissues, a fresh biopsy of a tumor lesion at baseline is mandatory&lt;/li&gt;&lt;li&gt;ECOG performance status&amp;lt;/= 1 &lt;/li&gt;&lt;li&gt;Patients must have &gt;/=  1 measurable lesions as defined per RECIST v1.1&lt;/li&gt;&lt;li&gt;Must be treatment-naive for recurrent or metastatic NPC&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with locally recurrence suitable for curative surgery or radiotherapy&lt;/li&gt;&lt;li&gt;Received any approved systemic anticancer therapy, including hormonal therapy, within 28 days prior to initiation of study treatment. The following exception is allowed:&lt;ul&gt;&lt;li&gt;Palliative radiotherapy for bone metastases or soft tissue lesions should be completed&amp;gt; 7 days prior to baseline imaging&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Has received any immunotherapy (including but not limited to interferons, interleukin 2, tumor necrosis factor interleukin, and thymoxin) or any investigational therapies within 14 days or five half-lives (whichever is longer) of randomization&lt;/li&gt;&lt;li&gt;Received prior therapies targeting PD-1 or PD-L1&lt;/li&gt;&lt;li&gt;Active leptomeningeal disease or uncontrolled, untreated brain metastasis&lt;/li&gt;&lt;li&gt;Active autoimmune diseases or history of autoimmune diseases that may relapse&lt;/li&gt;&lt;li&gt;Any active malignancy&amp;lt;/= two years before randomization except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free Survival: Progression-free survival as assessed by the Independent Review Committee: the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the Independent Review Committee per RECIST v1.1 in an Intent-to-Treat analysis set</Description><Timeframe>Up to two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Duration of response: duration of response as assessed by the Independent Review Committee: the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the Independent Review Committee per RECIST v1.1 in all randomized patients with documented objective responses</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>Overall Survival: the time from the date of randomization to the date of death due to any cause in an Intent-to-Treat analysis set</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>Overall response rate: overall response rate as assessed by the Independent Review Committee: the proportion of patients who had complete response or partial response as assessed by the Independent Review Committee per RECIST v1.1 in all randomized patients with measurable disease at baseline</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>Progression-free survival after next line of treatment as assessed by the investigator: the time from randomization to second/subsequent disease progression after initiation of new anticancer therapy, or death from any cause, whichever occurs first</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>Progression-free survival as assessed by the investigator: the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 in an Intent-to-Treat analysis set</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>Health-related quality of life</Description><Timeframe>Throughout the study period</Timeframe></Measure><Measure><Description>The incidence and severity of adverse events following treatment were graded according to the National Cancer Institute's Common Terminology Standard v5.0 for Adverse Events.</Description><Timeframe>Throughout the study period</Timeframe></Measure><Measure><Description>Mitigation duration as assessed by the Independent Review Board</Description><Timeframe>Throughout the study period</Timeframe></Measure><Measure><Description>Total response rate as assessed by the Independent Review Board</Description><Timeframe>Throughout the study period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a phase III, multicenter, double-blind, randomized, placebo-controlled study to compare      the eficacy and safety of &lt;ulink linkType="Drug" linkID="77347"&gt;tislelizumab&lt;/ulink&gt; (BGB-A317) combined with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; pus cisplatin      versus placebo combined with gemcitabine plus cisplatin as first line treatment for recurrent      or metastatic nasopharyngeal cancer [&lt;ulink linkType="Reference" linkID="2150173"&gt;2150173&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2158379"&gt;2158379&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2019, trial was initiated  [&lt;ulink linkType="Reference" linkID="2150173"&gt;2150173&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would be divided into two experimental arms:&lt;br/&gt;Arm 1: participants would receive tislelizumab combined with gemcitabine Plus cisplatin. Tislelizumab would be administered at a dose of 200 mg iv q3w; gemcitabine 1 g/m2, day 1, day 8 of each cycle, would be administered as an iv infusion within 30 min, for 4 to 6 cycles; cisplatin 80 mg/m2, day 1 of each cycle, would be administered as an iv infusion over 4 h for 4 to 6 cycles.&lt;br/&gt;Arm 2: participants would receive placebo combined with gemcitabine plus cisplatin. Placebo would be administered at a dose of 200 mg iv q3w; gemcitabine 1 g/m2, day 1, day 8 of each cycle, would be administered as an iv infusion within 30 min, for 4 to 6 cycles; cisplatin 80 mg/m2, day 1 of each cycle, would be administered as an iv infusion over 4 h for 4 to 6 cycles.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Beijing Cancer Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><Address3>100142</Address3><CountrySubDivision>Beijing</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yan Sun</Name></Contact></Contacts></Site><Site><Name>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>The Fifth Affiliated Hospital of Zhongshan University</Name><Address1>Zhuhai</Address1><Address2>Guangdong</Address2><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>The Fifth Affiliated Hospital of Zhongshan University</Name><Address1>Zhanjiang</Address1><Address2>Guangdong</Address2><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><CountrySubDivision>Hubei</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Head and neck tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3774">Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3804">Subjects with Relapsed/Recurrent Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7281">Subjects with Pharyngeal Cancer</PatientSegment><SubSegments><SubSegment id="7282">Subjects with nasopharyngeal cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10290">Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19046">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03924986</Identifier></Identifiers></Registry><Registry><Name id="1039">Center for Drug Evaluation</Name><Identifiers><Identifier>CTR20182534</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Head and neck tumor" id="7256"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7285"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7290">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7331"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7332">Assessment of all cause mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="26070"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7280">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Head and neck tumor" id="7244"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7263"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7264">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint><SubEndpoint disease="Head and neck tumor" id="7269">Assessment of response duration</SubEndpoint><SubEndpoint disease="Head and neck tumor" id="9140">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Head and neck tumor" id="9141">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7270"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7271">Assessment of time to recurrence</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7285"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7290">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7299"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7300">Assessment by EORTC QLQ-C30</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7331"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7332">Assessment of all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Head and neck tumor" id="7311"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Head and neck tumor" id="4370"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4371">Subjects with measurable disease as per RECIST criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4386"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4396"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4397">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Head and neck tumor" id="4398">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4451"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4455"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="7086"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="7093"><Criterion>Subjects with Pharyngeal Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4361">Subjects with nasopharyngeal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="34360"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4460">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="34809"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4457">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="35580"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Head and neck tumor" id="5744"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5751"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5777"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5780">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="5781">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="5784">Subjects with history of targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5792"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="26437"><Criterion>Subjects with Evidence of Metastasis</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="26845"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-03-21T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="removed"><Date>2019-05-30T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="updated"><Date>2019-06-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-06-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-06-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-06-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-06-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change></ChangeHistory></Trial><Trial id="382126"><TitleDisplay>A retrospective study to evaluate the 10-year drug retention rate of infliximab in Behcet's disease-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs on drug survival and differences according to the lines of biologic treatment</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="341">Uveitis</Indication><Indication id="768">Behcets disease</Indication></Indications><BiomarkerNames><BiomarkerName id="18315" role="Therapeutic effect marker" type="Physiological">Visual acuity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>infliximab</Name><Drug id="6850">infliximab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6850">infliximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1160598">Humanitas Clinical and Research Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6850" type="Drug"><TargetEntity id="198460" type="siDrug">Infliximab</TargetEntity></SourceEntity><SourceEntity id="1160598" type="Company"><TargetEntity id="5061136370" type="organizationId">Instituto Clinico Humanitas</TargetEntity></SourceEntity><SourceEntity id="341" type="ciIndication"><TargetEntity id="10046851" type="MEDDRA"/><TargetEntity id="D014605" type="MeSH"/><TargetEntity id="98715" type="ORPHANET"/><TargetEntity id="-1203341451" type="omicsDisease"/><TargetEntity id="798" type="siCondition"/></SourceEntity><SourceEntity id="768" type="ciIndication"><TargetEntity id="M35.2" type="ICD10"/><TargetEntity id="136.1" type="ICD9"/><TargetEntity id="10004213" type="MEDDRA"/><TargetEntity id="D001528" type="MeSH"/><TargetEntity id="117" type="ORPHANET"/><TargetEntity id="-1672179307" type="omicsDisease"/><TargetEntity id="730" type="siCondition"/></SourceEntity><SourceEntity id="381" type="Action"><TargetEntity id="663" type="Mechanism">TNF-alpha Antagonists</TargetEntity><TargetEntity id="1551" type="Mechanism">Anti-TNF-alpha</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1160598">Humanitas Clinical and Research Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="381">TNF alpha ligand inhibitor</Action><Action id="721">TNF binding agent</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="128">Cell culture technique</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="652">Intra-articular formulation</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>40</PatientCountEnrollment><PatientCountEvaluable>40</PatientCountEvaluable><DateChangeLast>2019-05-28T11:48:27Z</DateChangeLast><DateAdded>2019-05-30T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with Behcet's disease (BD)-related uveitis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose was to evaluate the 10-year drug retention rate of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (IFX) in Behcet's disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biological treatment [&lt;ulink linkType="Reference" linkID="2155219"&gt;2155219&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In 2019, results were published. At 12, 24, 60 and 120 month follow-up, the drug retention rates were 89.03, 86.16, 75.66 and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while there was a statistically significant difference in relation to the different lines of IFX treatment (p = 0.014). From baseline to the last follow-up visit, visual acuity improved (p = 0.047) and there was a corticosteroid-sparing effect (p &amp;lt; 0.0001) [&lt;ulink linkType="Reference" linkID="2155219"&gt;2155219&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received infliximab (IFX) were included and analyzed [&lt;ulink linkType="Reference" linkID="2155219"&gt;2155219&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="60530"><TitleDisplay>Celecoxib as a Chemopreventive Agent in Current and Former Smokers</TitleDisplay><TitleOfficial>A Randomized, Double-Blind Study of the Biological Effects and Tolerability of Celecoxib as a Chemopreventive Agent in Current and Former Smokers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ID00-230</Identifier><Identifier type="NCT">NCT00981201</Identifier></Identifiers><Indications><Indication id="235">Nicotine dependence</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>celecoxib</Name><Drug id="12135">celecoxib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12135">celecoxib</Drug><IndicationsPioneer><Indication id="235">Nicotine dependence</Indication></IndicationsPioneer><Companies><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12135" type="Drug"><TargetEntity id="228583" type="siDrug">Celecoxib</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="235" type="ciIndication"><TargetEntity id="F17" type="ICD10"/><TargetEntity id="F17.2" type="ICD10"/><TargetEntity id="10057852" type="MEDDRA"/><TargetEntity id="D012907" type="MeSH"/><TargetEntity id="-1170201411" type="omicsDisease"/><TargetEntity id="2624" type="siCondition"/></SourceEntity><SourceEntity id="1001" type="Action"><TargetEntity id="407" type="Mechanism">Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors</TargetEntity><TargetEntity id="5042" type="Mechanism">Anti-Prostaglandin G/H Synthase 2 (PTGS2; COX-2)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1001">Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2946">Analgesic</Class><Class id="2955">Non-steroidal anti-inflammatory</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>219</PatientCountEnrollment><DateStart>2001-11-30T00:00:00Z</DateStart><DateEnd type="actual">2009-09-01T00:00:00Z</DateEnd><DateChangeLast>2013-12-02T16:25:37Z</DateChangeLast><DateAdded>2009-09-23T08:06:57Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>M.D. Anderson Cancer Center</Affiliation><Name>Jonathan M. Kurie, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participants must be 18 to 74 years old&lt;/li&gt;&lt;li&gt;Participants must have at least a 20 pack-year history of smoking&lt;/li&gt;&lt;li&gt;Participants may have had a prior laryngeal cancer (Stage I or II) that was             completely resected or rendered disease-free by radiation therapy, or a prior lung             cancer (Stage I NSCLC) that was completely resected, without radiotherapy.             Participants must have been clinically free of any cancer for at least 6 months&lt;/li&gt;&lt;li&gt;Participants must have no contraindications for undergoing bronchoscopy&lt;/li&gt;&lt;li&gt;Participants must have no active pulmonary infections&lt;/li&gt;&lt;li&gt;Participants must not be taking inhaled steroids or oral non-steroidal             anti-inflammatory drugs on a regular basis (Low dose aspirin&amp;lt;/= 81 mg/day is             allowed)&lt;/li&gt;&lt;li&gt;Participants must have the following blood levels:&lt;ul&gt;&lt;li&gt;Total granulocyte count&amp;gt; 1500&lt;/li&gt;&lt;li&gt;Platelet count&amp;gt; 100,000&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;lt;/= 1.5 mg% and creatinine &amp;lt;/= 1.5 mg%&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Participants must complete the pretreatment evaluation and must consent to             bronchoscopy and to endobronchial biopsy for documentation of histological status&lt;/li&gt;&lt;li&gt;Participants must sign a study-specific informed consent form&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participants with active gastric or duodenal ulcers or a history of ulcers requiring             prophylactic H2 blockers&lt;/li&gt;&lt;li&gt;Participants with active pulmonary infections or recent history of pulmonary             infection (within 1 month)&lt;/li&gt;&lt;li&gt;Participants receiving inhaled steroid therapy on a regular basis&lt;/li&gt;&lt;li&gt;Participants with acute intercurrent illness, or participants who had surgery within             the preceding 4 weeks unless they have fully recovered&lt;/li&gt;&lt;li&gt;Participants requiring chronic ongoing treatment with NSAIDs&lt;/li&gt;&lt;li&gt;Participants who are allergic to aspirin or sulfanamides&lt;/li&gt;&lt;li&gt;Participants with history of stroke, transient ischemic attack, uncontrolled             hypertension, and/or angina pectoris&lt;/li&gt;&lt;li&gt;Participants who are pregnant and/or breast-feeding&lt;/li&gt;&lt;li&gt;Participants (men or women) of childbearing potential who are not using an effective             method of contraception&lt;/li&gt;&lt;li&gt;History of cardiovascular diseases that might include one of the following:             myocardial infarction, angina, coronary angioplasty, congestive heart failure,             stroke, or coronary bypass surgery&lt;/li&gt;&lt;li&gt;Diagnosis of diabetes&lt;/li&gt;&lt;li&gt;History of deep venous thrombosis, pulmonary embolism, systemic lupus erythematous,             family history of protein S or C deficiencies, prior heparin-induced             thrombocytopenia, or known Factor V Leiden mutation&lt;/li&gt;&lt;li&gt;Family history of premature CAD. This is defined as individuals with either:&lt;ul&gt;&lt;li&gt;Father with MI prior to age 55, or&lt;/li&gt;&lt;li&gt;Mother with MI prior to age 60&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The change of the proliferation marker Ki-67</Description><Timeframe>From baseline to 3-month visit</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The changes in tissue COX-2 expression, lavage PGE2 levels and genetic markers such as LOH, chromosome instability, and chromosome polysomy</Description><Timeframe>3 and 6-months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purposes of this study were to:&lt;br/&gt;Examine the effect of &lt;ulink linkType="Drug" linkID="12135"&gt;celecoxib&lt;/ulink&gt; treatment on Ki-67 expression, a marker of cell           proliferation, in the bronchial epithelium of current and former smokers.&lt;br/&gt;Examine the toxicity associated with &lt;ulink linkType="Drug" linkID="12135"&gt;celecoxib&lt;/ulink&gt; administration.&lt;br/&gt;Measure the effect of &lt;ulink linkType="Drug" linkID="12135"&gt;celecoxib&lt;/ulink&gt; treatment on arachidonic acid metabolites in the           bronchial epithelium of current and former smokers.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Before treatment begins, participants would have a bronchoscopy (tissue sample from the      lung).  This would be taken to see if different elements (biomarkers) in the tissue can predict      which individuals are at higher risk for developing cancer.  In a bronchoscopy, a tube will      be placed through the nose into the lung (while under sedation) to remove tissue samples for      laboratory analysis (biopsy).  Cells would also be collected during the bronchoscopy by      spraying the lungs with a small amount water and then removing the water (bronchial lavage,      bronchial washing).  In addition, a sputum sample would be taken and the inside of the cheek      would be scraped (buccal sample).&lt;/para&gt;&lt;para&gt;A complete physical exam would be performed before beginning treatment and at 1, 2, 3, 4, 5      and 6 months.  During these visits, participants would be asked questions about      tobacco/alcohol exposure.  Participants would have blood taken before beginning treatment and      at 1, 3, 4 and 6 months.  Urine samples would be taken before beginning treatment and at 3      and 6 months.  The research nurse would also ask participants about any adverse signs or      symptoms that they have experienced. Participants who smoke would be encouraged to stop      smoking.  Sources for assistance to stop smoking would be provided for all study participants      who continue to smoke.&lt;/para&gt;&lt;para&gt;In this study, participants would be randomly picked (as in the toss of a coin) to be in one      of four treatment groups.  Treatment in this study would last 6 months. Participants in the      first group would receive a placebo during all 6 months.  Participants in the second group would receive a      placebo during months 1 to 3 and &lt;ulink linkType="Drug" linkID="12135"&gt;celecoxib&lt;/ulink&gt; during months 4 to 6.  Participants in the third group      would receive &lt;ulink linkType="Drug" linkID="12135"&gt;celecoxib&lt;/ulink&gt; during months 1 to 3 and placebo during months 4 to 6.  Participants in the      fourth group would receive &lt;ulink linkType="Drug" linkID="12135"&gt;celecoxib&lt;/ulink&gt; during all 6 months. Neither the participant nor the      participant's doctor would know to which treatment group the participant was assigned.      Participants have an equal chance of being assigned to any of these groups.&lt;/para&gt;&lt;para&gt;Participants would take two capsules twice a day for the 6-month treatment period. The capsule      could be either a placebo or the study drug. At 3 and 6 months, participants would have a physical exam, blood tests and a bronchoscopy.      Participants should take their study medication with a sip of water 2 h before each      bronchoscopy with a sip of water. Sputum and buccal samples would also be taken at these      times. The research nurse would ask participants questions about changes and/or additions to      the medications.Up to 250 individuals would take part in this study. All would be enrolled at      the M. D. Anderson.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>U.T. M.D. Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3622">Subjects with Early Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3625">Subjects with stage I lung cancer</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="9000">Smoking Cessation and Continued Risk in Cancer Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Smoking Cessation</Disease><PatientSegments><PatientSegment><PatientSegment id="10615">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="10624">Subjects with cancer</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00981201</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8617"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8623">Assessment of cell proliferation markers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19341"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19342">Assessment of markers of proliferation</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Smoking Cessation" id="22450"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8605"><Endpoint>Assessment of Oncogenes/Oncoproteins</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8617"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8623">Assessment of cell proliferation markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19329"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Smoking Cessation" id="22450"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Smoking Cessation" id="22456">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Smoking Cessation" id="22459"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3900"><Criterion>Subjects with Non Small Cell Lung Cancer (NSCLC)</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3927">Subjects with stage I lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3988"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3993">Subjects with history of/scheduled for anti-cancer surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4060"><Criterion>Smokers (History of/Current)</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13330"><Criterion>Smoking Cessation and Continued Risk in Cancer Subjects</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13354"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13359">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13362"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13363">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Cancer supportive care" id="13364">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13373">At risk of developing Solid tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Smoking Cessation" id="18350"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Lung tumor" id="22378"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4004">Subjects with History of/Active Cancers Other Than Lung Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="22379"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4023">Subjects with history of/scheduled for other cancer therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Smoking Cessation" id="33315"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Smoking Cessation" id="18357">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Smoking Cessation" id="18359">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="33317"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4024">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Smoking Cessation" id="33939"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Smoking Cessation" id="18303">Current heavy smokers</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34001"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4032">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34024"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13365">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34403"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13377">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34876"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13379">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4074">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5132"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5149"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5168"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5236"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5291"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5365">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10882"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10900"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10916"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Smoking Cessation" id="16312"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Smoking Cessation" id="16318">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Smoking Cessation" id="16319">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Smoking Cessation" id="16320">Subjects co-morbid with metabolic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Smoking Cessation" id="16314"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Smoking Cessation" id="16317"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Smoking Cessation" id="16336"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Smoking Cessation" id="16350"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Smoking Cessation" id="16353">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion><SubCriterion disease="Smoking Cessation" id="16361">Subjects with history of/scheduled for surgery for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5128">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20282"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="26890"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5285">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="28316"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5366">Sexually active male or female unwilling to use adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2007-07-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-09-23T08:06:57Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="68685"><TitleDisplay>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK-2202083A Vaccine Administered as a Booster Dose</TitleDisplay><TitleOfficial>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK-2202083A Vaccine Administered as a Booster Dose in 12 to 18 Months Old Healthy Children</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">113978</Identifier><Identifier type="NCT">NCT01171989</Identifier><Identifier type="Other">2010-019253-18</Identifier><Identifier type="Other">DTPA-HBV-IPV=HIB-MENC-TT-004 BST: 002</Identifier></Identifiers><Indications><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="152">Hepatitis B virus infection</Indication><Indication id="272">Poliovirus infection</Indication><Indication id="389">Neisseria meningitidis infection</Indication><Indication id="47">Bordetella pertussis infection</Indication><Indication id="72">Clostridium tetani infection</Indication><Indication id="81">Corynebacterium diphtheriae infection</Indication></Indications><BiomarkerNames><BiomarkerName id="2633" role="Therapeutic effect marker" type="Proteomic">Anti-Bordetella pertussis antibodies</BiomarkerName><BiomarkerName id="2664" role="Therapeutic effect marker" type="Proteomic">Anti-Clostridium tetani antibodies</BiomarkerName><BiomarkerName id="8532" role="Therapeutic effect marker" type="Proteomic">Anti-HBs antigen antibodies</BiomarkerName><BiomarkerName id="33523" role="Therapeutic effect marker" type="Proteomic">Anti-polyribitol phosphate antibodies</BiomarkerName><BiomarkerName id="44182" role="Therapeutic effect marker" type="Proteomic">Anti-Corynebacterium diphtheriae antibodies</BiomarkerName><BiomarkerName id="44216" role="Toxic effect marker" type="Physiological">Body temperature</BiomarkerName><BiomarkerName id="44220" role="Therapeutic effect marker" type="Proteomic">Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies</BiomarkerName><BiomarkerName id="44623" role="Therapeutic effect marker" type="Proteomic">Anti-poliovirus type 1 antibodies</BiomarkerName><BiomarkerName id="44624" role="Therapeutic effect marker" type="Proteomic">Anti-poliovirus type 2 antibodies</BiomarkerName><BiomarkerName id="44625" role="Therapeutic effect marker" type="Proteomic">Anti-poliovirus type 3 antibodies</BiomarkerName><BiomarkerName id="44741" role="Therapeutic effect marker" type="Proteomic">Anti-Meningitis C antibodies</BiomarkerName><BiomarkerName id="44742" role="Therapeutic effect marker" type="Proteomic">Anti-Bordetella pertussis pertactin antibodies</BiomarkerName><BiomarkerName id="44744" role="Therapeutic effect marker" type="Proteomic">Anti-Pneoumococcal polysaccharide C antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>GSK-2202083A</Name><Drug id="63760">GSK-2202083A</Drug></Intervention><Intervention type="InterventionPrimary"><Name>Synflorix</Name><Drug id="11459">Synflorix</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>Infanrix HeXa</Name><Drug id="17821">Infanrix HeXa</Drug></Intervention><Intervention type="InterventionControl"><Name>NeisVac-C</Name><Drug id="10774">NeisVac-C</Drug></Intervention><Intervention type="InterventionControl"><Name>Synflorix</Name><Drug id="11459">Synflorix</Drug></Intervention><Intervention type="InterventionControl"><Name>meningococcal C/CRM-197 conjugate vaccine, Chiron</Name><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11459">Synflorix</Drug><IndicationsPioneer/><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="63760">GSK-2202083A</Drug><IndicationsPioneer/><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="11459" type="Drug"><TargetEntity id="291860" type="siDrug">GSK-1024850A</TargetEntity></SourceEntity><SourceEntity id="63760" type="Drug"><TargetEntity id="661803" type="siDrug">GSK-2202083A</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"/></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"/><TargetEntity id="D019694" type="MeSH"/><TargetEntity id="-1284790527" type="omicsDisease"/><TargetEntity id="429" type="siCondition"/></SourceEntity><SourceEntity id="272" type="ciIndication"><TargetEntity id="A80" type="ICD10"/><TargetEntity id="10036012" type="MEDDRA"/><TargetEntity id="D011051" type="MeSH"/><TargetEntity id="2912" type="ORPHANET"/><TargetEntity id="-250236249" type="omicsDisease"/><TargetEntity id="3005" type="siCondition"/></SourceEntity><SourceEntity id="47" type="ciIndication"><TargetEntity id="A37" type="ICD10"/><TargetEntity id="033" type="ICD9"/><TargetEntity id="10034738" type="MEDDRA"/><TargetEntity id="D014917" type="MeSH"/><TargetEntity id="1489" type="ORPHANET"/><TargetEntity id="-320620987" type="omicsDisease"/><TargetEntity id="2337" type="siCondition"/></SourceEntity><SourceEntity id="72" type="ciIndication"><TargetEntity id="10043376" type="MEDDRA"/><TargetEntity id="D013742" type="MeSH"/><TargetEntity id="3299" type="ORPHANET"/><TargetEntity id="-687302618" type="omicsDisease"/><TargetEntity id="816" type="siCondition"/></SourceEntity><SourceEntity id="81" type="ciIndication"><TargetEntity id="A36" type="ICD10"/><TargetEntity id="10013023" type="MEDDRA"/><TargetEntity id="D004165" type="MeSH"/><TargetEntity id="1679" type="ORPHANET"/><TargetEntity id="-360770994" type="omicsDisease"/><TargetEntity id="3234" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>9</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="12371">Subunit vaccine</Class><Class id="12378">Prophylactic vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="744">Liquid-based formulation technology</Technology><Technology id="159">Oligosaccharide</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="207">Protein conjugated</Technology><Technology id="745">Suspension</Technology></Technologies><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>391</PatientCountEnrollment><DateStart>2010-08-31T00:00:00Z</DateStart><DateEnd type="actual">2010-12-03T00:00:00Z</DateEnd><DateChangeLast>2018-04-22T00:43:46Z</DateChangeLast><DateAdded>2010-07-30T07:29:59Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects who the investigator believes that parent(s)/legally acceptable             representative(s) can and will comply with the requirements of the protocol&lt;/li&gt;&lt;li&gt;Subjects who have completed the full three-dose primary vaccination course according             to their group allocation in the primary study DTPa-HBV-IPV=Hib-MenC-TT-002 (&lt;ulink linkType="Protocol" linkID="60077"&gt;112157&lt;/ulink&gt;)&lt;/li&gt;&lt;li&gt;A male or female between, and including, 12 and 18 months of age at the time of             booster vaccination&lt;/li&gt;&lt;li&gt;Written informed consent obtained from the parent(s)/legally acceptable             representative(s) of the subject&lt;/li&gt;&lt;li&gt;Healthy subjects as established by medical history and clinical examination before             entering into the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Child in care&lt;/li&gt;&lt;li&gt;Use of any investigational or non-registered product other than the study vaccines             within 30 days preceding the dose of study vaccine, or planned use during the study             period&lt;/li&gt;&lt;li&gt;Chronic administration of immunosuppressants or other immune-modifying drugs within             6 months prior to the booster vaccination&lt;/li&gt;&lt;li&gt;Planned administration/administration of immunoglobulins and/or any blood products             within 3 months before the booster dose, or during the study period&lt;/li&gt;&lt;li&gt;Planned administration/administration of any vaccine not foreseen by the study             protocol during the period starting 30 days before and ending 30 days after the             booster dose&lt;/li&gt;&lt;li&gt;Participation in another clinical study since the primary study             DTPa-HBV-IPV/Hib-MenC-TT-002 (&lt;ulink linkType="Protocol" linkID="60077"&gt;112157&lt;/ulink&gt;) in which the subject has been or will be exposed to an             investigational or a non-investigational product&lt;/li&gt;&lt;li&gt;Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib,             pneumococcal and MenC vaccination or disease since the conclusion visit of study             DTPa-HBV-IPV/Hib-MenC-TT-002 (&lt;ulink linkType="Protocol" linkID="60077"&gt;112157&lt;/ulink&gt;)&lt;/li&gt;&lt;li&gt;Any confirmed or suspected immunosuppressive or immunodeficient condition, based on             medical history and physical examination&lt;/li&gt;&lt;/ul&gt;History of any reaction or hypersensitivity likely to be exacerbated by any component             of the vaccines&lt;ul&gt;&lt;li&gt;The following adverse event having occurred after previous administration of DTP             vaccine:&lt;ul&gt;&lt;li&gt;Encephalopathy&lt;/li&gt;&lt;li&gt;Temperature of&amp;gt;/= 40.5degC (rectal temperature) within 48 h of vaccination,                  not due to another identifiable cause&lt;/li&gt;&lt;li&gt;Collapse or shock-like state within 48 h of vaccination&lt;/li&gt;&lt;li&gt;Persistent, inconsolable crying occurring within 48 h of vaccination and                  lasting&amp;gt;/= 3 h&lt;/li&gt;&lt;li&gt;Seizures with or without fever occurring within 3 days of vaccination&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The following condition is temporary or self-limiting, and a subject may be vaccinated        once the condition has resolved if no other exclusion criteria is met:&lt;ul&gt;&lt;li&gt;Acute disease and/or fever at the time of enrollment:&lt;ul&gt;&lt;li&gt;Fever is defined as temperature &gt;/= 37.5degC on oral, axillary or tympanic setting, or&amp;gt;/=             38.0degC on rectal setting. The preferred route for recording temperature in this study will be axillary.&lt;/li&gt;&lt;li&gt;Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the             investigator&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP): A seroprotected subject was defined as a subject with anti-PRP antibody concentrations &gt;/= 0.15 microg/ml</Description><Timeframe>At Month 1, post-booster dose</Timeframe></Measure><Measure><Description>Number of Seroprotected Subjects Against Neisseria Meningitidis Serogroup C Using Baby Rabbit Completent (rSBA-MenC): a seroprotected subject was defined as a subject with anti-rSBA-MenC titers &gt;/= 1:8</Description><Timeframe>At Month 1, post-booster dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of Seropositive Subjects for Anti-rSBA-MenC: a seropositive subject for anti-rSBA-MenC was defined as a subject with antibody titers &gt;/= 1 : 128</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-rSBA-MenC Antibody Titres: antibody titers were expressed as geometric mean titers (GMTs) for the seroprotection cut-off value of &gt;/= 1 : 8</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Number of Subjects With Polysaccharide N Meningitidis Serogroup C (PSC) Antibody Concentrations &gt;/= Cut-off Values: the cut-off values assessed were &gt;/= 0.3 microg/ml and &gt;/= 2 microg/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-PSC Antibody Concentrations: Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off value of &gt;/= 0.3 microg/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Number of Seropositive Subjects for Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T): a seropositive subject was defined as a subject with anti-D and anti-T antibody concentrations &gt;/= 0.1 IU/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-D and Anti-T Antibody Concentrations: concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off value of &gt;/= 0.1 IU/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations &gt;/= Cut-off Values: the cut-off values assessed were 3.3, 10 and 100 mIU/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-HBs Antibody Concentrations: concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/ml</Description><Timeframe>At Month 0 and 1, before and after booster dose</Timeframe></Measure><Measure><Description>Number of Seropositive Subjects for Anti-poliovirus Types 1, 2 and 3: a seropositive subject was defined as a subject with anti-polio type 1, 2 or 3 &gt;/= 1 : 8</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-poliovirus Types 1, 2 and 3 Antibody Titres: titers were expressed as geometric mean titters (GMTs) for the seropositivity cut-off value of &gt;/= 1 : 8</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN): a seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations &gt;/= 5 EL.U/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations: concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off value &gt;/= 5 EL.U/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Number of Subjects With Any Solicited Local Symptoms: solicited local symptoms assessed included pain, redness and swelling. Any= all reports of the speecified symptom irrespective of intensity grade</Description><Timeframe>During the 8-day (Days 0 to 7) post-booster period</Timeframe></Measure><Measure><Description>Number of Subjects With Any Solicited General Symptoms: solicited general symptoms assessed included drowsiness, irritability, loss of appetite and fever (defined as axillary temperature &gt;/= 37.5degC). Any = all reports of the specified symptom irrespective of intensity grade and relationship to vaccination</Description><Timeframe>During the 8-day (Days 0 to 7) post-booster period</Timeframe></Measure><Measure><Description>Number of Subjects With Any Unsolicited Adverse Events (AEs): an unsolicited AE was any AE (ie, any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</Description><Timeframe>During the 31-day (Days 0 to 30) post-booster period</Timeframe></Measure><Measure><Description>Number of Subjects With Any Serious Adverse Events (SAEs): SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity</Description><Timeframe>After the booster dose of the study vaccine up to the study end (from Month 0 to 1)</Timeframe></Measure><Measure><Description>Number of Seropositive Subjects for Anti-PRP: a seropositive subject was defined as a subject with anti-PRP antibody concentrations &gt;/= 0.15 microg/ml</Description><Timeframe>At Month 0, before the booster dose</Timeframe></Measure><Measure><Description>Number of Subjects With Anti-PRP Antibody Concentrations &gt;/= the Cut-off: the cut-off value of the assay was an anti-PRP antibody concentration &gt;/= 1 microg/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Anti-PRP Antibody Concentrations: concentrations were expressed as geometric mean concentrations (GMCs) for the cut-off value of &gt;/= 0.15 microg/ml</Description><Timeframe>At Month 0 and 1, before and 1 month after booster dose</Timeframe></Measure><Measure><Description>Number of Seroprotected Subjects Against rSBA-MenC: a seroprotected subject was defined as a subject with anti-rSBA-MenC antibody titers &gt;/= 1 : 8</Description><Timeframe>At Month 0, before the booster dose</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  trial would evaluate the safety and immunogenicity of &lt;ulink linkType="Company" linkID="24166"&gt;GSK Biologicals'&lt;/ulink&gt;       &lt;ulink linkType="Drug" linkID="63760"&gt;GSK-2202083A&lt;/ulink&gt; vaccine when administered as a booster dose following priming in the first year      of life with the same vaccine.This protocol posting would deal  with objectives and outcome measures of the booster phase. The      objectives and outcome measures of the primary phase were presented in a separate protocol      posting (&lt;ulink linkType="Protocol" linkID="60077"&gt;NCT00970307&lt;/ulink&gt;).&lt;br/&gt;Main objective of the trial:&lt;br/&gt;To demonstrate that GSK Biologicals' DTPa-HBV-IPV/Hib-MenC-TT vaccine is non-inferior to Menjugate co-administered with Infanrix hexa in terms of seroprotection to MenC 1 month after the booster dose.&lt;br/&gt;To demonstrate that GSK Biologicals' DTPa-HBV-IPV/Hib-MenC-TT vaccine is non-inferior to Infanrix hexa co-administered with NeisVac-C in terms of seroprotection to PRP and MenC, 1 month after the booster dose.&lt;br/&gt;Secondary objectives of the trial:&lt;br/&gt;To demonstrate that GSK Biologicals' DTPa-HBV-IPV/Hib-MenC-TT vaccine is non-inferior to &lt;ulink linkType="Drug" linkID="17821"&gt;Infanrix hexa&lt;/ulink&gt; co-administered with &lt;ulink linkType="Drug" linkID="10774"&gt;NeisVac-C&lt;/ulink&gt; in terms of seroprotection to diphtheria, tetanus, hepatitis B, and poliovirus types 1, 2 and 3, and in terms of antibody GMCs to pertussis antigens 1 month after the booster dose.&lt;br/&gt;To assess the persistence of the immune response to the study vaccines in terms of seroprotection/seropositivity rates and geometric mean concentrations/titres (GMCs/Ts) for all antigens, before the booster dose.&lt;br/&gt;To assess the immune response to the study vaccines in terms of seroprotection/seropositivity, GMCs/Ts to all antigens, in terms of booster response to pertussis antigens and GMC fold change in rSBA-MenC titres and anti-PRP concentrations.&lt;br/&gt;To assess the safety and reactogenicity of the study vaccines in terms of solicited, unsolicited, local and general symptoms and serious adverse events.&lt;br/&gt;Note: Objectives are conditional to having met all the primary and secondary objectives in study DTPa-HBV-IPV=Hib-MenC-TT-002 (&lt;ulink linkType="Protocol" linkID="60077"&gt;112157&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist  of three arms:&lt;br/&gt;Arm 1 (GSK-2202083A + &lt;ulink linkType="Drug" linkID="11459"&gt;Synflorix&lt;/ulink&gt; group): Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with three doses of GSK-2202083A and Synflorix vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK-2202083A vaccine at Day 0 and of Synflorix vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.&lt;/para&gt;&lt;para&gt;Arm 2 (Infanrix hexa/&lt;ulink linkType="Drug" linkID="3612"&gt;Menjugate&lt;/ulink&gt; group): Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with three doses of Infanrix hexa vaccine and two doses of Menjugate vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa vaccine co-administered with Menjugate vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.&lt;/para&gt;&lt;para&gt;Arm 3 (Infanrix hexa/NeisVac-C + Synflorix group): Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with three doses of Infanrix hexa vaccine and Synflorix vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa vaccine co-administered with NeisVac-C vaccine at Day 0 and 1 dose of Synflorix vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Poland"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Bydgoszcz</Address1><Address3>85-021</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Debica</Address1><Address3>39-200</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Krakow</Address1><Address3>31-422</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Krakow</Address1><Address3>31-503</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Siemianowice Slaskie</Address1><Address3>41-103</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Tarnow</Address1><Address3>33-100</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Torun</Address1><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Trzebnica</Address1><Address3>55-100</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Wroclaw</Address1><Address3>50345</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis B virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10539">Subjects with Prior Other Vaccination</PatientSegment><SubSegments><SubSegment id="10118">Subjects with Prior Hepatitis B Vaccination</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Meningitis</Disease><PatientSegments><PatientSegment><PatientSegment id="10395">Subjects with Prior Vaccination</PatientSegment><SubSegments><SubSegment id="10398">Subjects with prior HIB vaccination</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>DTP Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="8193">Subjects with Prior Other Vaccination</PatientSegment><SubSegments><SubSegment id="8188">Subjects with prior DTPa vaccination</SubSegment><SubSegment id="8194">Subjects with prior hepatitis B vaccination(HBV)</SubSegment><SubSegment id="8195">Subjects with prior haemophilus influenzae B vaccination(HIB)</SubSegment><SubSegment id="8196">Subjects with prior meningococcal vaccination(MCV/MPSV)</SubSegment><SubSegment id="8197">Subjects with prior polio vaccination(IPV/OPV)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Hepatitis B Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="10284">Subjects with Prior Other Vaccination</PatientSegment><SubSegments><SubSegment id="10051">Subjects with Prior Hepatitis B Vaccination</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Polio Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="10895">Subjects with Prior Other Vaccination</PatientSegment><SubSegments><SubSegment id="10894">Subjects with Prior Polio Vaccination</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pneumococcal Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="8330">Subjects with Prior Other Vaccination</PatientSegment><SubSegments><SubSegment id="8331">Subjects with prior DTP vaccination</SubSegment><SubSegment id="8332">Subjects with prior hepatitis B vaccination(HBV)</SubSegment><SubSegment id="8333">Subjects with prior haemophilus influenzae B vaccination(HIB)</SubSegment><SubSegment id="8334">Subjects with prior polio vaccination(IPV/OPV)</SubSegment><SubSegment id="8335">Subjects with prior meningococcal vaccination(MCV/MPSV)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Meningococcal Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="8238">Subjects with Prior Other Vaccination</PatientSegment><SubSegments><SubSegment id="8235">Subjects with Prior Meningococcal Vaccination</SubSegment><SubSegment id="8239">Subjects with prior DTP vaccination</SubSegment><SubSegment id="8240">Subjects with prior hepatitis B vaccination(HBV)</SubSegment><SubSegment id="8241">Subjects with prior haemophilus influenzae B vaccination(HIB)</SubSegment><SubSegment id="8242">Subjects with prior polio vaccination(IPV/OPV)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01171989</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2010-019253-18</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="DTP Vaccine" id="10965"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="DTP Vaccine" id="10966">Assessment of anti-diphtheria antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10967">Assessment of anti-tetanus antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10968">Assessment of anti-pertussis antibody concentration (PT)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10971">Assessment of anti-hepatitis B antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10973">Assessment of anti-polio virus antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10974">Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10975">Assessment of anti-pneumococcal antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10976">Assessment of anti-meningococcal antibody concentration</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Meningococcal Vaccine" id="11028"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Meningococcal Vaccine" id="11029">Assessment of anti-meningococcal antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11030">Assessment of anti-diphtheria antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11031">Assessment of anti-tetanus antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11032">Assessment of anti-pertussis antibody concentration (PT)</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11035">Assessment of anti-hepatitis B antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11037">Assessment of anti-polio virus antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11038">Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11039">Assessment of anti-pneumococcal antibody concentration</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pneumococcal Vaccine" id="15078"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Pneumococcal Vaccine" id="15079">Assessment of anti-pneumococcal antibody concentration</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pneumococcal Vaccine" id="15086"><Endpoint>Assessment of Booster Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Meningitis" id="16252"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Meningitis" id="16253">Assessment of anti-meningococcal antibody concentration</SubEndpoint><SubEndpoint disease="Meningitis" id="16254">Assessment of immunogenic response to other vaccine/infectious agent</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pneumonia" id="16593"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Pneumonia" id="16594">Anti-pneumococcal antibodies</SubEndpoint><SubEndpoint disease="Pneumonia" id="16601">Immunogenic response to other vaccine/infectious agent</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hepatitis B virus infection" id="18301"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B virus infection" id="18302">Anti-hepatitis B antibody titers</SubEndpoint><SubEndpoint disease="Hepatitis B virus infection" id="18303">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Polio Vaccine" id="18508"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18509">Assessment of anti-polio antibody concentration</SubEndpoint><SubEndpoint disease="Polio Vaccine" id="18511">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Polio Vaccine" id="18516"><Endpoint>Assessment of Booster Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hepatitis B Vaccine" id="19041"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B Vaccine" id="19042">Anti-hepatitis B antibody titers</SubEndpoint><SubEndpoint disease="Hepatitis B Vaccine" id="19043">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="DTP Vaccine" id="10965"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="DTP Vaccine" id="10966">Assessment of anti-diphtheria antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10967">Assessment of anti-tetanus antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10968">Assessment of anti-pertussis antibody concentration (PT)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10971">Assessment of anti-hepatitis B antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10973">Assessment of anti-polio virus antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10974">Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10975">Assessment of anti-pneumococcal antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10976">Assessment of anti-meningococcal antibody concentration</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="DTP Vaccine" id="10996"><Endpoint>Assessment of Booster Response</Endpoint><SubEndpoints><SubEndpoint disease="DTP Vaccine" id="10997">Assessment of anti-diphtheria booster response</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10998">Assessment of anti-tetanus booster response</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10999">Assessment of anti-pertussis booster response (PT)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11002">Assessment of anti-poliovirus booster response</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11018">Assessment of anti-hepatitis B booster response</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11020">Assessment of anti-polyribosyl-ribitol-phosphate booster response (PRP)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11021">Assessment of anti-pneumococcal booster response</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11022">Assessment of anti-meningococcal booster response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="DTP Vaccine" id="11003"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="DTP Vaccine" id="11005">Assessment of local reactions</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11006">Assessment of systemic reactions</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11007">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="DTP Vaccine" id="11004"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Meningococcal Vaccine" id="11028"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Meningococcal Vaccine" id="11029">Assessment of anti-meningococcal antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11030">Assessment of anti-diphtheria antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11031">Assessment of anti-tetanus antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11032">Assessment of anti-pertussis antibody concentration (PT)</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11035">Assessment of anti-hepatitis B antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11037">Assessment of anti-polio virus antibody concentration</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11038">Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11039">Assessment of anti-pneumococcal antibody concentration</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Meningococcal Vaccine" id="11060"><Endpoint>Assessment of Booster Response</Endpoint><SubEndpoints><SubEndpoint disease="Meningococcal Vaccine" id="11061">Assessment of anti-meningococcal booster response</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11062">Assessment of anti-diphtheria booster response</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11063">Assessment of anti-tetanus booster response</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11064">Assessment of anti-pertussis booster response (PT)</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11067">Assessment of anti-hepatitis B booster response</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11069">Assessment of anti-poliovirus booster response</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11070">Assessment of anti-polyribosyl-ribitol-phosphate booster response (PRP)</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11071">Assessment of anti-pneumococcal booster response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Meningococcal Vaccine" id="11080"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Meningococcal Vaccine" id="11082">Assessment of local reactions</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11083">Assessment of systemic reactions</SubEndpoint><SubEndpoint disease="Meningococcal Vaccine" id="11084">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Meningococcal Vaccine" id="11081"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pneumococcal Vaccine" id="15078"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Pneumococcal Vaccine" id="15079">Assessment of anti-pneumococcal antibody concentration</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pneumococcal Vaccine" id="15083"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pneumococcal Vaccine" id="15084">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Pneumococcal Vaccine" id="15085">Reactogenicity(local/systemic reactions)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pneumococcal Vaccine" id="15086"><Endpoint>Assessment of Booster Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Meningitis" id="16252"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Meningitis" id="16253">Assessment of anti-meningococcal antibody concentration</SubEndpoint><SubEndpoint disease="Meningitis" id="16254">Assessment of immunogenic response to other vaccine/infectious agent</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Meningitis" id="16260"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Meningitis" id="16261">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Meningitis" id="16262">Reactogenicity(local/systemic reactions)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="16593"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Pneumonia" id="16594">Anti-pneumococcal antibodies</SubEndpoint><SubEndpoint disease="Pneumonia" id="16601">Immunogenic response to other vaccine/infectious agent</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="16604"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pneumonia" id="16605">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Pneumonia" id="16606">Reactogenicity(local/systemic reactions)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B virus infection" id="18301"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B virus infection" id="18302">Anti-hepatitis B antibody titers</SubEndpoint><SubEndpoint disease="Hepatitis B virus infection" id="18303">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B virus infection" id="18309"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B virus infection" id="18310">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Polio Vaccine" id="18508"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18509">Assessment of anti-polio antibody concentration</SubEndpoint><SubEndpoint disease="Polio Vaccine" id="18511">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Polio Vaccine" id="18513"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18514">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Polio Vaccine" id="18515">Reactogenicity(local/systemic reactions)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Polio Vaccine" id="18516"><Endpoint>Assessment of Booster Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B Vaccine" id="19041"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B Vaccine" id="19042">Anti-hepatitis B antibody titers</SubEndpoint><SubEndpoint disease="Hepatitis B Vaccine" id="19043">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B Vaccine" id="19056"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B Vaccine" id="19057">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Meningitis" id="15241"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Meningitis" id="15242">Subjects with prior meningococcal vaccination</SubCriterion><SubCriterion disease="Meningitis" id="15244">Subjects with prior HIB vaccination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="DTP Vaccine" id="33881"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="6726">Subjects with prior DTPa vaccination</SubCriterion><SubCriterion disease="DTP Vaccine" id="6732">Subjects with prior hepatitis B vaccination(HBV)</SubCriterion><SubCriterion disease="DTP Vaccine" id="6733">Subjects with prior haemophilus influenzae B vaccination(HIB)</SubCriterion><SubCriterion disease="DTP Vaccine" id="6734">Subjects with prior meningococcal vaccination(MCV/MPSV)</SubCriterion><SubCriterion disease="DTP Vaccine" id="6735">Subjects with prior polio vaccination(IPV/OPV)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis B Vaccine" id="33885"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Hepatitis B Vaccine" id="17634">Subjects with Prior Hepatitis B Vaccination</SubCriterion><SubCriterion disease="Hepatitis B Vaccine" id="17639">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Meningococcal Vaccine" id="33892"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Meningococcal Vaccine" id="6808">Subjects with Prior Meningococcal Vaccination</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="6812">Subjects with prior DTP vaccination</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="6813">Subjects with prior hepatitis B vaccination(HBV)</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="6814">Subjects with prior haemophilus influenzae B vaccination(HIB)</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="6815">Subjects with prior polio vaccination(IPV/OPV)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pneumococcal Vaccine" id="33893"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Pneumococcal Vaccine" id="13684">Subjects with prior DTP vaccination</SubCriterion><SubCriterion disease="Pneumococcal Vaccine" id="13685">Subjects with prior hepatitis B vaccination(HBV)</SubCriterion><SubCriterion disease="Pneumococcal Vaccine" id="13686">Subjects with prior haemophilus influenzae B vaccination(HIB)</SubCriterion><SubCriterion disease="Pneumococcal Vaccine" id="13687">Subjects with prior polio vaccination(IPV/OPV)</SubCriterion><SubCriterion disease="Pneumococcal Vaccine" id="13688">Subjects with prior meningococcal vaccination(MCV/MPSV)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Polio Vaccine" id="33894"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="16833">Subjects with Prior Polio Vaccination</SubCriterion><SubCriterion disease="Polio Vaccine" id="16834">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis B virus infection" id="33906"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="16803">Subjects with Prior Hepatitis B Vaccination</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="16806">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pneumonia" id="33909"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Pneumonia" id="15588">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Meningococcal Vaccine" id="34523"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Meningococcal Vaccine" id="22463">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="DTP Vaccine" id="34524"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="22461">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pneumococcal Vaccine" id="34688"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pneumococcal Vaccine" id="22464">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis B virus infection" id="34723"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="16820">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis B Vaccine" id="34724"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Hepatitis B Vaccine" id="17658">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Meningitis" id="34742"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Meningitis" id="15251">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pneumonia" id="34747"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pneumonia" id="15589">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Polio Vaccine" id="34748"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="16829">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="DTP Vaccine" id="8297"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="8298">Subjects with prior history of/scheduled to receive immunoglobulins/blood products for other indication</SubCriterion><SubCriterion disease="DTP Vaccine" id="8299">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="DTP Vaccine" id="8306"><Criterion>Subjects with Contraindication to Vaccine/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="DTP Vaccine" id="8308"><Criterion>Subjects at Risk/History of Infections</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="8309">Subjects at risk/history of diphtheria</SubCriterion><SubCriterion disease="DTP Vaccine" id="8310">Subjects at risk/history of tetanus</SubCriterion><SubCriterion disease="DTP Vaccine" id="8311">Subjects at risk/history of pertussis</SubCriterion><SubCriterion disease="DTP Vaccine" id="8313">Subjects at risk/history of hepatitis</SubCriterion><SubCriterion disease="DTP Vaccine" id="8314">Subjects at risk/history of haemophilus influenza</SubCriterion><SubCriterion disease="DTP Vaccine" id="8315">Subjects at risk/history of meningococcal meningitis</SubCriterion><SubCriterion disease="DTP Vaccine" id="8316">Subjects at risk/history of pneumonia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="DTP Vaccine" id="8334"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="8335">Subjects with immune dysfunction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Meningococcal Vaccine" id="8356"><Criterion>Subjects with Prior History of/Scheduled for Meningococcal Vaccination</Criterion></Exclusion><Exclusion disease="Meningococcal Vaccine" id="8372"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Meningococcal Vaccine" id="8373">Subjects with prior history of/scheduled to receive immunoglobulins/blood products for other indication</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8374">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Meningococcal Vaccine" id="8381"><Criterion>Subjects with Contraindication to Vaccine/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="Meningococcal Vaccine" id="8383"><Criterion>Subjects at Risk/History of Infections</Criterion><SubCriteria><SubCriterion disease="Meningococcal Vaccine" id="8384">Subjects at risk/history of meningococcal meningitis</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8385">Subjects at risk/history of diphtheria</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8386">Subjects at risk/history of tetanus</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8387">Subjects at risk/history of pertussis</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8388">Subjects at risk/history of poliomyelitis</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8389">Subjects at risk/history of hepatitis</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8390">Subjects at risk/history of haemophilus influenza</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8391">Subjects at risk/history of pneumonia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Meningococcal Vaccine" id="8409"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Meningococcal Vaccine" id="8410">Subjects with immune dysfunction</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8411">Subjects co-morbid with allergic disease/disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11882"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Meningitis" id="12608"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12973"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14280"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14319"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hepatitis B Vaccine" id="15262"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="DTP Vaccine" id="26525"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="8278">Subjects with Prior History of/Scheduled for DTP Vaccination</SubCriterion><SubCriterion disease="DTP Vaccine" id="8285">Subjects with Prior Other Vaccination</SubCriterion><SubCriterion disease="DTP Vaccine" id="8286">Subjects with prior history of/scheduled for hepatitis B vaccination(HBV)</SubCriterion><SubCriterion disease="DTP Vaccine" id="8288">Subjects with prior history of/scheduled for haemophilus influenzae B vaccination(HIB)</SubCriterion><SubCriterion disease="DTP Vaccine" id="8289">Subjects with prior history of/scheduled for meningococcal vaccination(MCV/MPSV)</SubCriterion><SubCriterion disease="DTP Vaccine" id="8290">Subjects with prior history of/scheduled for polio vaccination(IPV/OPV)</SubCriterion><SubCriterion disease="DTP Vaccine" id="8291">Subjects with prior history of/scheduled for pneumococcal vaccination(PCV/PPSV)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Meningococcal Vaccine" id="26536"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Meningococcal Vaccine" id="8359">Subjects with Prior Other Vaccination</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8360">Subjects with prior history of/scheduled for DTP vaccination</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8361">Subjects with prior history of/scheduled for hepatitis B vaccination(HBV)</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8364">Subjects with prior history of/scheduled for polio vaccination(IPV/OPV)</SubCriterion><SubCriterion disease="Meningococcal Vaccine" id="8365">Subjects with prior history of/scheduled for pneumococcal vaccination(PCV/PPSV)</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-12-03T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>3.13 Months</EnrollmentPeriod><EnrollmentRate>124.92 Patients/Month</EnrollmentRate><DateFirstReceived>2010-07-27T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-07-30T07:29:59Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="76522"><TitleDisplay>Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)</TitleDisplay><TitleOfficial>A Multicenter, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partical-Onset Seizures (Extension of Study RGB-113905)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">113413</Identifier><Identifier type="NCT">NCT01336621</Identifier><Identifier type="Secondary Organisational">RTG113413</Identifier><Identifier type="Other">2010-022777-34</Identifier></Identifiers><Indications><Indication id="119">Epilepsy</Indication><Indication id="3439">Partial seizure</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="148" role="Therapeutic effect marker" type="Physiological">QT interval</BiomarkerName><BiomarkerName id="154" role="Therapeutic effect marker" type="Genomic;Proteomic">Lactate dehydrogenase</BiomarkerName><BiomarkerName id="213" role="Therapeutic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="248" role="Therapeutic effect marker" type="Cellular">Eosinophils</BiomarkerName><BiomarkerName id="330" role="Toxic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Toxic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="1183" role="Therapeutic effect marker" type="Biochemical">Urinary albumin to creatinine ratio</BiomarkerName><BiomarkerName id="1211" role="Therapeutic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="1221" role="Therapeutic effect marker" type="Physiological">Hematocrit</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1296" role="Therapeutic effect marker" type="Physiological">Mean corpuscular volume</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1736" role="Therapeutic effect marker" type="Physiological">Mean corpuscular hemoglobin</BiomarkerName><BiomarkerName id="1904" role="Toxic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="1925" role="Therapeutic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="2044" role="Therapeutic effect marker" type="Physiological">R-R interval</BiomarkerName><BiomarkerName id="2054" role="Therapeutic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="2098" role="Therapeutic effect marker" type="Biochemical">Potassium</BiomarkerName><BiomarkerName id="2358" role="Therapeutic effect marker" type="Biochemical">Urea nitrogen</BiomarkerName><BiomarkerName id="2387" role="Therapeutic effect marker" type="Biochemical">Bilirubin</BiomarkerName><BiomarkerName id="2417" role="Therapeutic effect marker" type="Biochemical">Calcium</BiomarkerName><BiomarkerName id="2515" role="Therapeutic effect marker" type="Biochemical">Magnesium</BiomarkerName><BiomarkerName id="2527" role="Therapeutic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName><BiomarkerName id="2586" role="Toxic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="2626" role="Therapeutic effect marker" type="Biochemical">Total protein</BiomarkerName><BiomarkerName id="2662" role="Therapeutic effect marker" type="Biochemical">Sodium</BiomarkerName><BiomarkerName id="3247" role="Therapeutic effect marker" type="Biochemical">Chlorides</BiomarkerName><BiomarkerName id="3324" role="Therapeutic effect marker" type="Physiological">QRS complex</BiomarkerName><BiomarkerName id="3457" role="Therapeutic effect marker" type="Biochemical">Carbon dioxide</BiomarkerName><BiomarkerName id="4522" role="Therapeutic effect marker" type="Cellular">Erythrocytes</BiomarkerName><BiomarkerName id="4806" role="Therapeutic effect marker" type="Cellular">Lymphocytes</BiomarkerName><BiomarkerName id="8024" role="Therapeutic effect marker" type="Genomic;Proteomic">Creatine kinase</BiomarkerName><BiomarkerName id="8097" role="Therapeutic effect marker" type="Cellular">Monocytes</BiomarkerName><BiomarkerName id="9807" role="Therapeutic effect marker" type="Cellular">Basophils</BiomarkerName><BiomarkerName id="10930" role="Therapeutic effect marker" type="Physiological">Post-void residual urine</BiomarkerName><BiomarkerName id="12058" role="Toxic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="18236" role="Therapeutic effect marker" type="Physiological">PR interval</BiomarkerName><BiomarkerName id="18315" role="Toxic effect marker" type="Physiological">Visual acuity</BiomarkerName><BiomarkerName id="28899" role="Therapeutic effect marker" type="Genomic;Proteomic">Alkaline phosphatase</BiomarkerName><BiomarkerName id="50155" role="Therapeutic effect marker" type="Physiological">Urinary specific gravity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>retigabine</Name><Drug id="8197">retigabine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8197">retigabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1145220">GlaxoSmithKline Research &amp; Development Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8197" type="Drug"><TargetEntity id="188707" type="siDrug">Retigabine hydrochloride</TargetEntity><TargetEntity id="227505" type="siDrug">Retigabine</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"/><TargetEntity id="345" type="ICD9"/><TargetEntity id="10015037" type="MEDDRA"/><TargetEntity id="D004827" type="MeSH"/><TargetEntity id="-2005570698" type="omicsDisease"/><TargetEntity id="115" type="siCondition"/></SourceEntity><SourceEntity id="3439" type="ciIndication"><TargetEntity id="10061334" type="MEDDRA"/><TargetEntity id="D004828" type="MeSH"/><TargetEntity id="-569935387" type="omicsDisease"/><TargetEntity id="120" type="siCondition"/></SourceEntity><SourceEntity id="15565" type="Action"><TargetEntity id="1842" type="Mechanism">Voltage-Gated K(V) 7 (KCNQ) Channel Activators</TargetEntity><TargetEntity id="4084" type="Mechanism">Voltage-Gated K(V) 7.2/7.3 (KCNQ2/3) Channel Activators</TargetEntity></SourceEntity><SourceEntity id="175" type="Action"><TargetEntity id="186" type="Mechanism">GABA(A) Receptor Agonists</TargetEntity><TargetEntity id="1180" type="Mechanism">GABA(A) GABA Site Agonists</TargetEntity><TargetEntity id="2848" type="Mechanism">GABA(A) BZ Site 1 (Omega-1) Receptor Agonists</TargetEntity><TargetEntity id="5198" type="Mechanism">GABA(A) Receptor Subunits alpha1beta2gamma2L Positive Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>44</NumberOfSites><CompaniesSponsor><Company id="1145220">GlaxoSmithKline Research &amp; Development Ltd</Company><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="15565">KCNQ voltage-gated potassium channel stimulator</Action><Action id="175">GABA A receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="70">Anticonvulsant agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="661">Oral quick release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>98</PatientCountEnrollment><DateStart>2011-02-21T00:00:00Z</DateStart><DateEnd type="actual">2017-09-13T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T00:30:19Z</DateChangeLast><DateAdded>2011-04-20T05:51:22Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>GSK Investigational Site, Moscow, 117049</Affiliation><Name>Gagik Avakian</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Roma, Lazio, 00163</Affiliation><Name>Piero Barbanti</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Kazan, 420064</Affiliation><Name>Enver Bogdanov</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Belgorod, 308007</Affiliation><Name>Zhanna Chefranova</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Bangkok, 10400</Affiliation><Name>Yotin Chinvarun</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Torrette di Ancona, Marche, 60126</Affiliation><Name>Nicoletta Foschi</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Roma, Lazio, 00185</Affiliation><Name>Anna Giallonardo</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Strasbourg Cedex, 67098</Affiliation><Name>Edouard Hirsch</Name></Contact><Contact type="Public contact"><Affiliation>GSK Clinical Disclosure</Affiliation><Name>Cheri Hudson</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Pisa, Toscana, 56126</Affiliation><Name>Alfonso Iudice</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Warszawa, 00-453</Affiliation><Name>Zygmunt Jamrozik</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site Lugansk, 91045, Ukraine</Affiliation><Name>Svitlana Kazakova</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Bologna, Emilia-Romagna, 40139</Affiliation><Name>Roberto Michelucci</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site Oleksandrivka village, Odesa, 67513, Ukraine</Affiliation><Name>Oleksandr Mykhaylyukovych</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, St.-Petersburg, 193019</Affiliation><Name>Nikolay Neznanov</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site; Smolensk; 214 019; Russian Federation</Affiliation><Name>Alexander Okhapkin</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Samara, 443095</Affiliation><Name>Irina Poverennova</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site Poltava,, Ukraine</Affiliation><Name>Andriy Skrypnikov</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Foggia, Puglia, 71100</Affiliation><Name>Luigi Specchio</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Genova, Liguria, 16153</Affiliation><Name>Paolo Tanganelli</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Khon Kaen, 40002</Affiliation><Name>Somsak Tiamkao</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Krasnodar, 350007</Affiliation><Name>Irina Vakula</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site Odesa, 65014, Ukraine</Affiliation><Name>Anatolii Voloshchuk</Name></Contact><Contact type="Public contact"><Affiliation>GSK Investigational Site, Moscow, 107150</Affiliation><Name>Olga Vorobieva</Name></Contact><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The subject has successfully completed the 20 weeks (4 weeks titration and 16 weeks             of flexible dose evaluation phases) of treatment with&lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; as adjunctive             therapy to one of the pre-specified AED in the parent study &lt;ulink linkType="Protocol" linkID="71610"&gt;RGB-113905&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;The investigator and the subject, or caregiver, if applicable, should consider it             beneficial for the subject to receive continued&lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; therapy&lt;/li&gt;&lt;li&gt;The subject is able and willing to maintain an accurate and complete daily written             seizure calendar or has a caregiver who is able and willing to maintain an accurate             and complete daily written seizure calendar for the entire duration of the study&lt;/li&gt;&lt;li&gt;The subject has given written informed consent, or has a legally authorized             representative who has given written informed consent, prior to the performance of             any study assessments&lt;/li&gt;&lt;li&gt;A female subject is eligible to enter and participate in the study if she is of             non-childbearing potential (ie, physiologically incapable of becoming pregnant,             including any female who is pre-menarcheal or post-menopausal)&lt;ul&gt;&lt;li&gt;Pre-menopausal females with a documented (medical report verification) hysterectomy with or without oophorectomy or bi-lateral oophorectomy when reproductive status has been confirmed by hormone level assessment&lt;/li&gt;&lt;li&gt;Post-menopausal females defined as being amenorrhoeic for greater than one year with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). However, if indicated, this should be confirmed by estradiol and FSH levels consistent with menopause (according to local laboratory ranges). Women who have not been confirmed as post-menopausal should be advised to use contraception&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;A female subject is eligible to enter and participate in the study if she is             of childbearing potential and has a negative pregnancy test at screening, and agrees to             use one of the contraceptive methods &lt;/li&gt;&lt;li&gt;A female subject is eligible to enter and participate in the study if she not             pregnant or lactating or planning to become pregnant during the study&lt;/li&gt;&lt;li&gt;French subjects only: in France, a subject will be eligible for inclusion in this             study only if either affiliated to or a beneficiary of a social security category&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Has met any of the withdrawal criteria in the previous&lt;ulink linkType="Protocol" linkID="71610"&gt;RGB-113905&lt;/ulink&gt; study or has             clinically significant abnormal clinical laboratory or electrocardiogram (ECG) findings not resolved             prior to entry to the open-label extension (OLE) study&lt;/li&gt;&lt;li&gt;Is suffering from acute or progressive neurological disease, severe psychiatric             disease, or severe mental abnormalities that are likely to interfere with the study             objectives&lt;/li&gt;&lt;li&gt;Has any medical condition that, in the investigator's judgement, is considered to be             clinically significant and could potentially affect subject safety or study outcome,             including but not limited to: clinically significant cardiac, renal, hepatic             condition, or a condition that affects the absorption, distribution, metabolism or             excretion of drugs&lt;/li&gt;&lt;li&gt;Has any abnormality on 12-lead ECG at screening which is clinically significant in             the opinion of the investigator, or has QTc (either QTcB Bazett's correction or QTcF             Fridericia's correction) &amp;gt; 500 ms or &amp;gt; 530 ms for subjects with bundle branch block             or an increase in QTc of &amp;gt; 60 ms from baseline in the parent study&lt;/li&gt;&lt;li&gt;Is unwilling or inability to follow the study procedures or reporting of adverse events (AE)&lt;/li&gt;&lt;li&gt;Is planning on following a ketogenic diet or planning surgery or implantation of a             vagus nerve stimulator (VNS) to control seizures during the study. Note: subjects who             already have a VNS implanted which is functional may be permitted to enter the study&lt;/li&gt;&lt;li&gt;Has active suicidal plan/intent or has had active suicidal thoughts in the past 6             months. Has history of suicide attempt in the last two years or more than one lifetime             suicide attempt&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (TESAEs): Safety Population: an AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth defect or is associated with liver injury or impaired liver function. TEAE refers to an AE for which the onset was on or after the date of the first retigabine dose in this study and on or before 30 days after the last retigabine dose date. AEs that started in the parent study that increased in severity during this study were also considered treatment-emergent</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With AEs and SAEs: All SFUCP Subjects: an AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth defect or is associated with liver injury or impaired liver function. The following AEs were collected in the SFUCP: AEs related to the finding(s) of pigmentation/, discoloration of the eye/skin, AEs related to unexplained vision loss, SAEs, Deaths and Pregnancies. SFUCP collected AEs are those for which onset was 31 days or more after the last dose of retigabine. The analysis was performed on the All SFUCP Subjects population which comprised of all subjects who enter the SFUCP</Description><Timeframe>Up to 2.6 years</Timeframe></Measure><Measure><Description>Number of Participants Withdrawn Due to TEAEs: an AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolonged existing hospitalization, results in disability, is a congenital anomaly/birth defect or is associated with liver injury or impaired liver function. TEAE refers to an AE for which the onset was on or after the date of the first retigabine dose and on or before 30 days after the last retigabine dose date</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Retinal Pigmentary Abnormalities: number of participants with abnormal findings after eye examination were evaluated. Only retinal pigmentary abnormalities detected on-treatment with retigabine were presented. Retinal pigmentary abnormalities included abnormalities in the macula, peripheral retina and unspecified location</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Pigmentation of Non-retinal Ocular Tissue(s): number of participants with abnormal findings after eye examination were evaluated. Pigmentation of non-retinal ocular tissue (s) detected on-treatment with retigabine were presented. Non-retinal pigmentary abnormalities included abnormalities in the sclera and/ or conjunctiva, cornea, iris and lens</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Abnormal Discoloration of Skin: number of participants with Dermatologist-Confirmed abnormal discoloration of skin including skin around the eyes and eyelids, lips, nails, or mucosa were evaluated. Only abnormalities occurring on-treatment with retigabine were presented</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With a Clinically Significant Decrease in Visual Acuity From Initial Examination: number of participants with a clinically significant decrease in visual acuity from initial examination were evaluated. Only abnormalities occurring on-treatment with retigabine were presented.</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Decrease in Confrontational Visual Field From Initial Examination: number of participants with a clinically significant decrease in confrontational visual field from initial examination were evaluated. Only abnormalities occurring on-treatment with retigabine were presented</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Potential Clinical Concern (PCC) Values of Change From Baseline in Vital Signs and Weight: vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were measured after at least 5 minutes of rest. Body weight was measured without shoes and wearing light clothing. Baseline assessments in this OLE study were defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. Increase or decrease of &gt;=20 in SBP, increase or decrease of &gt;=15 in DBP and HR were considered as PCC values. Number of participants with PCC values of vital signs for any visit post-Baseline are presented</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Electrocardiogram (ECG) Parameter Including HR: single measurements of 12-lead ECG were obtained in supine position after at least 10 minutes of rest using an ECG machine to measure HR. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in ECG Parameter Including PR Interval, QRS Duration, Uncorrected QT Interval, Corrected QT by Bazett's Formula (QTcB), Corrected QT by Fridericia's Formula (QTcF) and RR Interval: Single measurements of 12-lead ECG were obtained in supine position after at least 10 minutes of rest using an ECG machine to measure parameters including PR interval, QRS duration, uncorrected QT interval, QTcB, QTcF and RR interval. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Clinical Chemistry Parameters of PCC: number of participants with chemistry parameters of PCC at 'any visit post-Baseline' are presented. Chemistry parameters for which PCC values were identified were alanine aminotransferase (ALT) (if value &gt;=3 * upper limit of normal [ULN]), alkaline phosphatase (alk.phosphatase) (if value &gt;=3*ULN), aspartate aminotransferase (AST) (if value &gt;=3*ULN), calcium (if value &lt;=1.8962 or &gt;=2.8692), carbon-di-oxide (CO2) (if value &lt;=18 or &gt;=36), chloride (if value &lt;=92 or &gt;=112), creatine kinase (if value &gt;=3*ULN), direct bilirubin (if value &gt;=1.5*ULN), glucose (if value &lt;=2.7755 or &gt;=11.102), lactate dehydrogenase (LD) (if value &gt;=3*ULN), magnesium (if value &lt;0.36 or &gt;2.50), potassium (if value &lt;=3.0 or &gt;=6.0), sodium (if value &lt;=127 or &gt;=153), total bilirubin (if value &gt;=1.5*ULN), total protein</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Hematology Parameters of PCC: blood samples were collected from participants to evaluate hematology parameters. Number of participants with clinical hematology parameters of PCC at 'any visit post-Baseline' are presented. Hematology parameters for which PCC values were identified were eosinophils (if value is &gt;0.8), hematocrit (if value is &lt;=0.32 for males and &lt;=0.28 for females), platelet count (if value is &lt;=100 or &gt;=550), total neutrophils (if value is &lt;=1.8), white blood cells (WBC) (if value is &lt;=2.8 or &gt;=16). Only those participants with data available at specific time points were analyzed (represented by n=X in the category titles)</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Urinalysis Parameters of PCC: urine samples were collected from participants at specific time points. Number of participants with urinalysis parameters of PCC at 'any visit post-Baseline' are presented. Urinalysis parameters for which PCC values were identified were albumin/creatinine ratio (if value is &gt;11.3), red blood cells (RBC) (if value is 3-5 or higher), WBC (if value is 5-10 or higher for male and 10-15 or higher for females), specific gravity (if value is &lt;1.001 or &gt;1.035) and potential of hydrogen (pH) (if value is &lt;4.6 or &gt;8.0). Only those participants with data available at specific time points were analyzed (represented by n=X in the category titles)</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Albumin and Total Protein: blood samples were collected from participants for evaluation of change from Baseline in clinical chemistry parameters including albumin and total protein. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Alk. Phosphatase, ALT, AST, Creatine Kinase and LD Levels: blood samples were collected from participants for evaluation of change from Baseline in clinical chemistry parameters including alk. phosphatase, ALT, AST, creatine kinase and LD. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Direct Bilirubin, Total Bilirubin and Creatinine: blood samples were collected from participants for evaluation of change from Baseline in clinical chemistry parameters including direct bilirubin, total bilirubin and creatinine. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in BUN/Creatinine Ratio: blood samples were collected from participants for evaluation of change from Baseline in clinical chemistry parameters including BUN/creatinine ratio. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Calcium, Chloride, CO2, Glucose, Potassium, Magnesium, Sodium and BUN: blood samples were collected from participants for evaluation of change from Baseline in clinical chemistry parameters including calcium, chloride, CO2, glucose, potassium, magnesium, sodium and BUN. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Absolute Basophils, Absolute Eosinophils, Absolute Lymphocytes, Absolute Monocytes, Absolute Total Neutrophils, Platelet Count and WBC Count: blood samples were collected from participants for evaluation of change from Baseline in clinical hematology parameters including absolute basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and WBC count. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Levels: blood samples were collected from participants for evaluation of change from Baseline in clinical hematology parameters including hemoglobin and MCHC. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Hematocrit, Mean Corpuscle Hemoglobin (MCH), Mean Corpuscle Volume (MCV) and Mean Platelet Volume (MPV), RBC Count, Percent Basophils, Percent Eosinophils, Percent Lymphocytes, Percent Monocytes, Percent Neutrophils and RBC Distribution Width (RDW) Levels : blood samples were collected from participants for evaluation of change from Baseline in clinical hematology parameters including Hematocrit, Mean Corpuscle Hemoglobin (MCH), Mean Corpuscle Volume (MCV) and Mean Platelet Volume (MPV), RBC Count, Percent Basophils, Percent Eosinophils, Percent Lymphocytes, Percent Monocytes, Percent Neutrophils and RBC Distribution Width (RDW) Levels. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Urine Albumin Creatinine Ratio, Albumin, Creatinine Levels: Urine samples were collected from participants for evaluation of change from Baseline in urinalysis parameters including Urine Albumin Creatinine Ratio, Albumin, Creatinine Levels. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Changes From Baseline in American Urological Association Symptom Scale (AUA SS) Score: the effect of retigabine on bladder function was assessed using AUA symptom index. It is a 7-item Likert-scored scale ranging from 0 (no symptom at all) to 5 (almost always symptoms present) with a total possible score of 35. AUA SS score is the sum of the responses to these seven questions. The total score for all questions was classified as mild (0 to 7), moderate (8 to 19), or severe (&gt;19). Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Change From Baseline in Post-Void Residual (PVR) Bladder Ultrasound Urine Volume: the PVR bladder ultrasound was used to assess urinary retention. Baseline was defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Change from Baseline was defined as post-Baseline value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles)</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Suicidal Ideation or Behavior Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Score: number of participants with suicidal ideation or behavior during treatment were assessed using the C-SSRS score scale. It is a brief questionnaire designed to assess severity and change in suicidality by integrating both behavior and ideation using a semi-structured interview to probe participant responses. Participants are classified with respect to extent of suicidal ideation, extent of suicidal behavior, and with respect to self-injurious behavior</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants Experiencing New Seizure Types: number of participants experiencing new seizure type that is seizure not experienced before were summarized. New seizure types were classified into 5 classes including type A (simple partial seizure), type B (complex partial seizure), type C (Partials, evolving to Secondary Generalized Seizures), type D (Generalized, excluding Myoclonic Seizures), type D2 (Myoclonic Seizures) and type E (Unclassified Seizures)</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants Experiencing Worsening of Seizures: worsening of seizures was defined as an increase in seizure frequency or the occurrence of a new, more severe seizure type, or status epilepticus occurring in a participant without a history of status epilepticus. An increase in seizure frequency was defined as doubling of the 28-day seizure frequency compared to the 28-day Baseline seizure frequency established in the parent study. Number of participants experiencing worsening of seizure during study period are presented</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Duration of Retigabine Exposure: duration of exposure was calculated from the first dose through the last dose during study including the Taper Phase and presented using median and full range</Description><Timeframe>Up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants With Resolution of Abnormal Eye Pigmentation After Discontinuation of Retigabine: the ophthalmologist/retina specialist determined the presence or absence of retinal and non-retinal ocular abnormalities. Retinal abnormalities included abnormalities in the macula and/or the peripheral retina and non-retinal ocular pigmentary abnormality</Description><Timeframe>Up to 2.6 years</Timeframe></Measure><Measure><Description>Number of Participants With Resolution of Dermatologist Confirmed Abnormal Discoloration After Discontinuation of Retigabine: participants who enter the SFUCP who had an on-treatment finding(s) of abnormal discoloration of skin, lips, nails or mucosa confirmed by a dermatologist entered the SFUCP and underwent assessments performed by a dermatologist at 6-monthly intervals. The assessment of the participant's skin included assessment of the skin around the eyes and the eyelids, lips, nails, and mucosa</Description><Timeframe>Up to 2.6 years</Timeframe></Measure><Measure><Description>Time From Discontinuation of Retigabine to Resolution of Abnormal Eye Pigmentation: retinal pigmentary abnormality was determined by either an ophthalmologist or retina specialist. Retinal pigmentary abnormality included abnormality of macula, peripheral retina and unspecified location. If a participant had pigmentary abnormality of macula and pigmentary abnormality of the peripheral retina both should be resolved in order for retinal pigmentary abnormality to be considered resolved. If a participant had non-retinal ocular pigmentary abnormality in more than one location (conjunctiva, sclera, cornea, iris or lens), all should be resolved for non-retinal pigmentary abnormality to be considered resolved</Description><Timeframe>Up to 2.6 years</Timeframe></Measure><Measure><Description>Time From Discontinuation of Retigabine to Resolution of All Dermatologist-confirmed Abnormal Discoloration: assessments were at approximately 6-monthly intervals (timed relative to the participants previous dermatology assessment) until the abnormal discoloration either resolved or stabilized (as defined by no changes over 2 consecutive 6-monthly assessments performed by the dermatologist over at least 12 months after discontinuation of retigabine). The assessment of the participant's skin included assessment of the skin around the eyes and the eyelids, lips, nails, and mucosa. Only participants with resolution of the specified tissue are included in this analysis</Description><Timeframe>Up to 2.6 years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of Participants Experiencing a 0 to &lt;25, 25 to &lt;50, 50 to &lt;75 and 75 to 100 Percent Reduction in 28 Day POS Frequency From Baseline: the seizure frequency was recorded in daily seizure calendar by participants during the treatment period. Baseline assessments in this OLE study are defined by and taken directly from the Baseline assessments in the parent study NCT01336621</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Percent Change From Baseline in 28-day Partial-onset Seizure Frequency: the seizure frequency was recorded in daily seizure calendar by participants during the treatment period. Percent change from Baseline in 28-day partial onset seizure frequency was presented as mean and standard deviation (SD). Baseline assessments in this OLE study are defined by and taken directly from the Baseline assessments in the parent study NCT01336621. Percent change from Baseline was calculated as post-Baseline value minus Baseline value divided by Baseline value into 100</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants Experiencing an Increase in 28-day Partial-onset Seizure Frequency From Baseline: the seizure frequency was recorded in daily seizure calendar by participants during the treatment period. Baseline assessments in this OLE study are defined by and taken directly from the Baseline assessments in the parent study NCT01336621</Description><Timeframe>Baseline and up to 5.8 years</Timeframe></Measure><Measure><Description>Number of Participants Who Remained Seizure-free: the seizure frequency was recorded in daily seizure calendar by participants during the treatment period. Number of participants who were treated retigabine for at least 6 months and who remained seizure free for any 6 continuous months as well as number of participants who were treated with retigabine for at least 12 months and who remained seizure free for any 12 continuous months are presented</Description><Timeframe>Up to 5.8 years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase III study was to assess the long-term safety, tolerability and      efficacy of flexibly dosed &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; as adjunctive therapy in adult      subjects with partial-onset seizures. In addition, those subjects who successfully completed      20 weeks of adjunctive treatment with &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; in the parent study, &lt;ulink linkType="Protocol" linkID="71610"&gt;RGB-113905&lt;/ulink&gt;,  and who      were thought to have benefited from  treatment were provided continued access to      &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Secondary objectives of the trial were:&lt;br/&gt;To assess long-term efficacy of flexibly dosed retigabine IR as adjunctive therapy in adults with partial-onset seizures (POS) who completed open-label flexible dose Study RGB113905.&lt;br/&gt;To evaluate whether retinal pigmentation, unexplained vision loss, pigmentation of non-retinal ocular tissues, and discolouration of nails, lips, skin or mucosa change over time after discontinuation of retigabine.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;RTG113413 would be  an open-label, multicenter extension study of &lt;ulink linkType="Protocol" linkID="71610"&gt;RGB-113905&lt;/ulink&gt;. This study would enroll      adult subjects with partial-onset seizures (POS) who successfully completed 20 weeks of      adjunctive treatment with &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; (4-weeks titration phase and 16-weeks flexible dose      evaluation phase) in the parent study, &lt;ulink linkType="Protocol" linkID="71610"&gt;RGB-113905&lt;/ulink&gt; and who were thought to have benefited      from the treatment.&lt;/para&gt;&lt;para&gt;The screening visit (visit 1) would be performed on the same day as the final visit of the      parent study (visit 7/week 20). Subjects entering the extension study would initially receive      the same dose of &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; and concurrent antiepileptic drug (AED) as they were      receiving on the final visit of the parent study. After the first week of the extension      study, the subject's &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; dose can be adjusted based on efficacy and tolerability. The      overall daily dose of &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; must be maintained between 300 mg/day (minimum) and 1200      mg/day (maximum). In addition, the dose and the number of concurrent AED can be adjusted to      meet the individual needs of the subject.  &lt;ulink linkType="Drug" linkID="8197"&gt;Retigabine IR&lt;/ulink&gt; monotherapy would not be  permitted. If      concurrent AED therapy is removed, the subject would be withdrawn from the study.&lt;/para&gt;&lt;para&gt;Subjects in this study would be eligible to receive &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; treatment until one of the      following criteria have been met: &lt;br/&gt;Regulatory approval and commercial availability of      &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt; or &lt;br/&gt;&lt;ulink linkType="Drug" linkID="8197"&gt;Retigabine IR&lt;/ulink&gt; is not approved by the regulatory authorities or &lt;br/&gt;The      study would be  terminated by the sponsor for reasons including, but not limited to, safety issues      or&lt;br/&gt;Subject is withdrawn or withdraws consent or&lt;br/&gt;Subject  received &lt;ulink linkType="Drug" linkID="8197"&gt;retigabine IR&lt;/ulink&gt;      treatment for a total of three years and all the above options  have not been met. After the screening      visit, subjects would be required to attend four further clinic visits at weeks 13, 26, 39, and      52 in the first year of the study and a total of three clinic visits at approximately 4-monthly      intervals during each of the second and third year of study.   Upon completion or early      withdrawal, subjects would begin a 3-week taper period and then return for a follow-up visit.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Gent</Address1><Address3>9000</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Bulgaria"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Plovdiv</Address1><Address3>4000</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Sofia</Address1><Address3>1113</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Sofia</Address1><Address3>1431</Address3><Contacts/></Site><Site><Address2>Bulgarian Drug Agency</Address2><CountrySubDivision>Bulgarian Drug Agency</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Bielefeld</Address1><Address2>Nordrhein-Westfalen</Address2><Address3>33617</Address3><CountrySubDivision>Nordrhein-Westfalen</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Kehl-Kork</Address1><Address2>Baden-Wuerttemberg</Address2><Address3>77694</Address3><CountrySubDivision>Baden-Wuerttemberg</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Stuttgart</Address1><Address2>Baden-Wuerttemberg</Address2><Address3>70372</Address3><CountrySubDivision>Baden-Wuerttemberg</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Limoges</Address1><Address3>87042</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Strasbourg Cedex</Address1><Address3>67098</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Bologna</Address1><Address2>Emilia-Romagna</Address2><Address3>40139</Address3><CountrySubDivision>Emilia-Romagna</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Foggia</Address1><Address2>Puglia</Address2><Address3>71100</Address3><CountrySubDivision>Puglia</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Genova</Address1><Address2>Liguria</Address2><Address3>16153</Address3><CountrySubDivision>Liguria</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Pisa</Address1><Address2>Toscana</Address2><Address3>56126</Address3><CountrySubDivision>Toscana</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Roma</Address1><Address2>Lazio</Address2><Address3>00163</Address3><CountrySubDivision>Lazio</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Roma</Address1><Address2>Lazio</Address2><Address3>00185</Address3><CountrySubDivision>Lazio</CountrySubDivision><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Torrette Di Ancona</Address1><Address2>Marche</Address2><Address3>60126</Address3><CountrySubDivision>Marche</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Heemstede</Address1><Address3>2103 SW</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trials Helpdesk</Name></Contact></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Warszawa</Address1><Address3>00-453</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Belgorod</Address1><Address3>308007</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Kazan</Address1><Address3>420064</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Krasnodar</Address1><Address3>350007</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Moscow</Address1><Address3>107150</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Moscow</Address1><Address3>117049</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Samara</Address1><Address3>443095</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Smolensk</Address1><Address3>214 019</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>St.-Petersburg</Address1><Address3>193019</Address3><Contacts/></Site><Site><Name>State Educational Institution of Higher Professional Education "Russian State Medical University", Department of Neurology and Neurosurgery, Faculty of Medicine number 1 (State Health Care Institution of Moscow "City Clinical Hospital № 1. Pirogov")</Name><Address1>Moscow</Address1><Address2>Ostrovityanova</Address2><Address3>117997</Address3><CountrySubDivision>Ostrovityanova</CountrySubDivision><Contacts/></Site><Site><Name>State Educational Institution of Higher Professional Education "Samara State Medical University" * Clinics of Samara State Medical University, ** Department of Neurology and Neurosurgery (State Health Care Institution "Samara Regional Clinical Hospital. Kalinin"), 443099, g . Samara, ul. Chapaevskaya, etc</Name><Address3>443099</Address3><Contacts/></Site><Site><Name>State educational institution of higher education ", Kazan State Medical University", Department of Neurology (State medical institution "Republican Clinical Hospital"),</Name><Address1>Kazan</Address1><Address3>420012</Address3><Contacts/></Site><Site><Name>Public health agency of the city of Moscow "City Clinical Hospital № 1. Pirogov</Name><Address1>Moscow</Address1><Address3>119049</Address3><Contacts/></Site><Site><Name>State Institution "St. Petersburg Research Institute of neuropsychiatric. VMBekhterev Health Institute</Name><Address1>St. Petersburg</Address1><Address3>192019</Address3><Contacts/></Site><Site><Name>Non-governmental health agency "Central Clinical Hospital № 2. NA Semashko Open Joint Stock Company "Russian Railways", Department of Rehabilitation Losinoostrovskaya d.43 107150</Name><Address1>Moscow</Address1><Address3>129128</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Thailand"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Bangkok</Address1><Address3>10400</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Khon Kaen</Address1><Address3>40002</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Ukraine"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Dnepropetrovsk</Address1><Address3>49005</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Lugansk</Address1><Address3>91045</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Lviv</Address1><Address3>79010</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Odesa</Address1><Address3>65014</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Oleksandrivka Village, Odesa</Address1><Address3>67513</Address3><Contacts/></Site><Site><Name>GSK Investigational Site</Name><Address1>Poltava</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Epilepsy</Disease><PatientSegments><PatientSegment><PatientSegment id="10306">Subjects with Partial Seizures</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01336621</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2010-022777-34</Identifier></Identifiers></Registry><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Epilepsy" id="17155"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17157">Assessment of serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Epilepsy" id="17156"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Epilepsy" id="17057"><Endpoint>Assessment of Seizure Activity</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17058">Assessment of seizure frequency</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17070"><Endpoint>Assessment of Seizure Freedom</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17071">Assessment of rate of seizure freedom</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17073"><Endpoint>Assessment of Partial Seizures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17131"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17140">Assessment of hematological function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17132"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17133"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17137"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17139"><Endpoint>Assessment of Renal Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17146"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17149">Assessment of biochemical parameters</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17156"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17159"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17164">Assessment of drop-out rate/withdrawal rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17172"><Endpoint>Assessment of Exacerbation of Seizures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Epilepsy" id="15256"><Criterion>Subjects with Diagnosis of Epilepsy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15257">Subjects with partial onset epilepsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15318"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15325">Subjects with history/ scheduled to receive potassium channel openers</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Epilepsy" id="12709"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12710">Subjects with other central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12711"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12712"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12748"><Criterion>Subjects with History/ Scheduled to receive Anti-epileptic Therapy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12759">Subjects with history/ scheduled for neurosurgery</SubCriterion><SubCriterion disease="Epilepsy" id="12760">Subjects with history/ scheduled to receive vagus nerve stimulation</SubCriterion><SubCriterion disease="Epilepsy" id="12762">Subjects with history/ scheduled to receive ketogenic diet</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12780"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion><Exclusion disease="Epilepsy" id="26069"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12713">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="26310"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12729">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-12-14T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>28.35 Months</EnrollmentPeriod><EnrollmentRate>3.46 Patients/Month</EnrollmentRate><DateFirstReceived>2011-03-10T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-04-20T05:51:22Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-10-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="84790"><TitleDisplay>Medical Research Council (MRC) Working Party on Leukemia in Children UK National Acute Lymphoblastic Leukemia (ALL) Trial</TitleDisplay><TitleOfficial>Medical Research Council Working Party on Leukemia in Children UK National Acute Lymphoblastic Leukemia (ALL) Trial: UKALL 2003</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">UKALL2003</Identifier><Identifier type="NCT">NCT00222612</Identifier><Identifier type="Secondary Organisational">ISRCTN07355119</Identifier><Identifier type="Other">G0300130</Identifier><Identifier type="Other">0301</Identifier><Identifier type="Other">UKCRN 1287</Identifier><Identifier type="Trial Acronym">MRC UKALL 2003</Identifier></Identifiers><Indications><Indication id="1728">Acute lymphoblastic leukemia</Indication></Indications><BiomarkerNames><BiomarkerName id="90" role="Therapeutic effect marker" type="Genomic;Proteomic">Neurogenic locus notch homolog protein 1</BiomarkerName><BiomarkerName id="323" role="Therapeutic effect marker" type="Genomic;Proteomic">CD40 ligand</BiomarkerName><BiomarkerName id="3451" role="Therapeutic effect marker" type="Genomic;Proteomic">Immunoglobulin G</BiomarkerName><BiomarkerName id="6557" role="Therapeutic effect marker" type="Genomic;Proteomic">F-box/WD repeat-containing protein 7</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>Augmented group (aspariginase)</Name></Intervention><Intervention type="InterventionPrimary"><Name>Augmented group (methotrexate)</Name></Intervention><Intervention type="InterventionPrimary"><Name>Standard group (aspariginase)</Name></Intervention><Intervention type="InterventionPrimary"><Name>Standard group (methotrexate)</Name></Intervention><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>cytarabine</Name></Intervention><Intervention type="InterventionPrimary"><Name>daunorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>intensification course</Name></Intervention><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention><Intervention type="InterventionPrimary"><Name>pegaspargase</Name><Drug id="2573">pegaspargase</Drug></Intervention><Intervention type="InterventionPrimary"><Name>vincristine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2573">pegaspargase</Drug><IndicationsPioneer/><Companies><Company><Company id="1042227">Leukemia Research Fund</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="18438">Medical Research Council</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21194">University of Sheffield</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22182">University of Oxford</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2573" type="Drug"><TargetEntity id="126670" type="siDrug">Pegaspargase</TargetEntity></SourceEntity><SourceEntity id="1042227" type="Company"><TargetEntity id="5035543779" type="organizationId">Leukemia Research Fund</TargetEntity></SourceEntity><SourceEntity id="18438" type="Company"><TargetEntity id="5035523380" type="organizationId">Medical Research Council</TargetEntity></SourceEntity><SourceEntity id="21194" type="Company"><TargetEntity id="4295977911" type="organizationId">University Of Sheffield</TargetEntity></SourceEntity><SourceEntity id="22182" type="Company"><TargetEntity id="5000698033" type="organizationId">University of Oxford</TargetEntity></SourceEntity><SourceEntity id="1728" type="ciIndication"><TargetEntity id="C91.0" type="ICD10"/><TargetEntity id="204" type="ICD9"/><TargetEntity id="513" type="ORPHANET"/><TargetEntity id="685" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="21194">University of Sheffield</Company><Company id="22182">University of Oxford</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1042227">Leukemia Research Fund</Company><Company id="18438">Medical Research Council</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="517">Asparaginase stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="72">Enzyme</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="348">PEGylated formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>2100</PatientCountEnrollment><PatientCountEvaluable>874</PatientCountEvaluable><DateStart>2003-10-31T00:00:00Z</DateStart><DateEnd type="actual">2013-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-25T13:02:49Z</DateChangeLast><DateAdded>2012-02-16T11:51:39Z</DateAdded><Contacts><Contact type="Public contact"><Email>Sue.Richards@ctsu.ox.ac.uk</Email><Name>Susan Richards, D Phil</Name></Contact><Contact type="Scientific contact"><Affiliation>Sheffield Children's Hospital</Affiliation><Name>Ajay Vora</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children with age between 1 and 25 years with acute lymphoblastic leukemia (ALL)&lt;/li&gt;&lt;li&gt;For entry into the randomizations:&lt;ul&gt;&lt;li&gt;Standard or intermediate risk as defined above&lt;/li&gt;&lt;li&gt;Morphological complete remission (BM1 Marrow) at day 29 of induction&lt;/li&gt;&lt;li&gt;Availability of MRD results at day 28 and after consolidation therapy&lt;/li&gt;&lt;li&gt;Informed consent obtained&lt;/li&gt;&lt;li&gt;Induction given as protocol&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Infants less than a year old should be entered onto the Interfant ALL study&lt;/li&gt;&lt;li&gt;Children with B-ALL (Burkitt-like, t[8;14], L3 morphology, SMIg positive). Patients             with this disease will be eligible for the current UKCCSG B cell NHL/ALL trial&lt;/li&gt;&lt;li&gt;Children with Philadelphia-positive ALL (t[9;22] or BCR/ABL positive) will start             induction therapy on this protocol but transfer to the European Intergroup Protocol             as soon as their Philadelphia status is known &lt;/li&gt;&lt;li&gt;For entry into the MRD randomization:&lt;ul&gt;&lt;li&gt;High risk as defined above. These patients will receive regimen C&lt;/li&gt;&lt;li&gt;Day 28 non-remitters. These patients will receive regimen C if BM2 or go off-protocol             if BM3 (see below for definitions of BM2 and BM3)&lt;/li&gt;&lt;li&gt;MRD indeterminate group (no result or MRD positive&amp;lt; 1 x 10[4] at day 28 and after             consolidation therapy) will continue on previously assigned therapy&lt;/li&gt;&lt;li&gt;Sub-optimal induction therapy. The clinical significance of day 28 MRD is uncertain             in patients who have received sub-optimal induction therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Event-free survival</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>Five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Survival</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Quality of life</Description><Timeframe>Three years</Timeframe></Measure><Measure><Description>Trough plasma asparaginase activity</Description></Measure><Measure><Description>IgG and IgM antibodies to PEG-asparaginase and native asparaginase were measured</Description></Measure><Measure><Description>Complete response (CR) rate</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>NOTCH1 and FBXW7 mutation screening of genomic DNA was carried out by heteroduplex analysis on the WAVE DNA Fragment Analysis System</Description></Measure><Measure><Description>Outcome was analyzed according to overall survival (OS), defined as the time to death, event-free survival (EFS) which was the time to relapse, secondary tumor or death, and relapse (RR)</Description></Measure><Measure><Description>Kaplan–Meier curves were used to assess survival, and differences between groups were compared using the log-rank test</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2013, results were published.  Death was seen in three patients who were given two delayed intensifications because of treatment-related causes compared with none in the group given one delayed intensification (p = 0.08). There were  no significant difference between groups for serious adverse events and grade 3 or 4 toxic effects, though   the second delayed intensification course was associated with one (&amp;lt; 1%) treatment-related death, and 74 episodes of grade 3 or 4 toxic effects in 45 patients (17%) [&lt;ulink linkType="Reference" linkID="1569060"&gt;1569060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, results from 75 patients were published. The five-year cumulative incidence of infection-related mortality (IRM) was 2.4% indicating  75 of 249 (30%) trial deaths and 75 of 117 (64%) treatment-related mortality (TRM) deaths. Greater risk of IRM as a proportion of TRM was observed in  induction than other phases (77 versus 56%, p = 0.02). Bacterial infection  and fungal infection were seen in 68 and 20% of patients. The most signiicant risk factor for IRM was the down syndrome (DS) (p &amp;lt; 0.0001). A trend towards increased IRM in girls (p = 0.04) and increasing treatment intensity (p = 0.02) was observed. A significant higher risk  of IRM was seen in DS patients  during maintenance (p = 0.048) [&lt;ulink linkType="Reference" linkID="1569077"&gt;1569077&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, results were published. Results showed that, in the augmented treatment group, more adverse events occurred  than in the standard group (asparaginase-related hypersensitivity in 18 [6.7%] in the augmented group versus two [0.8%] in the standard group and asparaginase-related pancreatitis in eight [3.0%] versus one [0.4%]; intravenous methotrexate-related mucositis in 11 [4.1%] versus three [1.1%] and methotrexate-related stomatitis in 48 [18.0%] versus 12 [4.5%]) [&lt;ulink linkType="Reference" linkID="1622659"&gt;1622659&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, results were published. Patients receiving regimen A had fewer problems with pain and nausea compared to regimen B (ie, additional doxorubicin during induction and additional cyclophosphamide and cytarabine during consolidation chemotherapy) [&lt;ulink linkType="Reference" linkID="1996024"&gt;1996024&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A randomized, open-label, parallel-group trial for patients with acute lymphoblastic leukemia (ALL), using the detection of      minimal residual disease (MRD) to define risk groups, aimed to assess: whether the treatment can be reduced without compromising efficacy in a MRD-defined low-risk group; whether  post-remission intensification can improve outcome for a MRD-defined high-risk           group; the Quality of Life (Qol) impact of the different treatment arms on the patients and           their families. A total of 2500 patients would be enrolled in the study [&lt;ulink linkType="Reference" linkID="1263463"&gt;1263463&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Study hypothesis was to optimize treatment of childhood acute lymphoblastic leukemia (ALL) by stratification according to on-treatment monitoring of minimal residual disease.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2011, results were presented. A total of 86% of samples had adequate activity throughout induction time points. A &amp;gt; 10-fold variation was observed in activity levels. A total of 309/706 samples had adequate activity &amp;gt; 3 times the therapeutic threshold, while 51/100 samples with inadequate activity had levels below the detection limit. It was observed that increasing the dose of &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt; in induction was unlikely to benefit patients with inadequate activity. NCI HR patients had a superior incidence of inadequate asparaginase activity in induction when compared with SR patients (p = 0.002). Inadequate asparaginase activity was associated with high MRD (&gt;/= 10[4]) in SR patients (p = 0.045), especially those with good risk cytogenetics (p = 0.012), and in particular the high hyperdiploid subgroup (p = 0.03). Throughout  induction, inadequate asparaginase activity  was not correlated with MRD in HR patients (p = 0.699), possibly because these patients received in addition daunorubicin. Patients (n = 81) were tested for anti-asparaginase antibodies. N antibodies were detected in those who demonstrated adequate activity throughout treatment (n = 18). Antibodies were detected in 18 of 63 patients with inadequate levels at any time point. All had anti-PEG and seven in addition also had anti-asparaginase antibodies. Though all antibody positive patients had inadequate asparaginase activity at the time of antibody assessment, 17 showed adequate activity at an earlier time point, suggesting immune-mediated post-exposure inactivation. Of 15 patients who had inadequate activity at first exposure, 14 did not have antibodies  [&lt;ulink linkType="Reference" linkID="1243616"&gt;1243616&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2013, the results were published. The study aimed to analyze the NOTCH1/FBXW7 mutations impact on outcome in T-cell acute lymphoblastic leukemia pediatric (n = 162) patients, and their role in refining risk stratification. A total of 119 mutations were detected in NOTCH1 gene in 62% of patients, 59% mutations in the HD-N and 14% in the HD-C domain, missense mutations (54%) or short in-frame insertions, deletions or indels (46%). In the PEST domain, 21% mutations were observed, which included 84% of insertions, deletions or indels causing a frameshift and 8% of non-sense mutations (Q2406X, S2487X), all predicted to result in a C-terminally truncated protein, and two missense mutations (F2510L, P2459T). Non-sense mutations (2%) were detected in the TAD (Q2392X, Q2395X), which also result in C-terminal protein truncation. Mutations (3%) were found in the JME domain, all large in-frame insertions of 24 bp or more. One missense mutation, C1528R, was found in the LNR-B domain. Overall, 83% of patients had single mutation (NOTCH1 Single) and 17% had more than one NOTCH1 mutation (NOTCH1 Double). Of the latter, 82% were mutated in both the HD (either HD-N or HD-C) and PEST domains, one of which also had an LNR-B mutation, two harbored mutations in both the HD-N and HD-C subunits, and one in both the PEST and TAD domains. A total of 31 mutations were detected in NOTCH1 gene in 18% patients. Everyone was missense mutations, 68% in exon 9, 26% in exon 10 and 2 in exon 12. Finally in all 162 patients, 35% patients were WT for both genes, 47% were NOTCH1 MUT only, and 38% and 9% with NOTCH1 Single and NOTCH1 Double, respectively, 3% were FBXW7 MUT only, and 15% had a mutation in both genes. Later on, everyone had NOTCH1 HD domain mutation coupled with the FBXW7 mutation; two patients also had a mutation in the NOTCH1 PEST domain. There was a positive correlation between a NOTCH1 HD domain mutation and an FBXW7 mutation, 32% patients with NOTCH1 HD-only mutations were FBXW7 MUT versus 7% other patients (p = 0.0003). On the other hand, cases with a NOTCH1 PEST domain mutation were less likely to have an FBXW7 mutation, 18% FBXW7WT patients had a NOTCH1 PEST domain mutation versus 6% FBXW7 MUT patients, but this did not reach statistical significance (p = 0.19). There was no significant difference in sex, WBC, age group, CNS disease or NCI risk group between the three combined genotype groups, excluding the four patients with FBXW7 mutations alone, nor in cytogenetic characteristics [&lt;ulink linkType="Reference" linkID="1394124"&gt;1394124&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The presence of either a NOTCH1 or FBXW7 mutation was related with a low incidence of SER, but the difference was of average significance, SER in NOTCH1 MUT versus NOTCH1 WT patients (21 versus 34%, p = 0.06) and FBXW7MUT versus FBXW7WT patients (14 versus 29%, p = 0.1). For the three combined genotype groups, the difference was similarly average significant, SER in 33% NOTCH1 WT/FBXW7 WT, 23% NOTCH1 Single/FBXW7 WT and 18% NOTCH1 +/- FBXW7 Double patients (P for trend across all groups = 0.08). At day 29, the MRD status post-diagnosis was available for 151 patients. Evaluation for individual genes showed that NOTCH1 MUT patients were more likely to be MRD negative than NOTCH1WT patients (59 versus 39%, p = 0.02), but FBXW7 mutational status alone had no significant effect (MRD negative in 58 FBXW7 MUT versus 50% FBXW7WT, p = 0.4). When the combined genotype status was measured, the frequency of MRD negativity was maximum in NOTCH1 +/- FBXW7 Double patients (71, 51 and 40% for NOTCH1 +/- FBXW7 Double, NOTCH1 Single/FBXW7 WT and NOTCH1 WT/FBXW7 WT, respectively, P for trend = 0.005). Of the 11 patients without MRD data, seven were NOTCH1 WT/FBXW7 WT, three NOTCH1 Single/FBXW7 WT and one NOTCH1 +/-FBXW7 Double. The genotype was extremely significant for favorable outcome in multivariate analysis adjusted for age and WBC as continuous variables (p = 0.0003). Outcome report were available for all 162 patients. EFS at five years was not significantly different from the 226 excluded patients without molecular data (84 versus 80%, p = 0.3). Median follow-up for the cohort studied was 4.5 years (range 2.3 to 7.8). At five years, there was no significant difference between NOTCH1 MUT and NOTCH1 WT patients in RR and EFS, 11 versus 16% (log-rank p = 0.4) and 87 versus 80% (p = 0.1) respectively, though NOTCH1 MUT patients did showed a trend to improve OS (93 versus 83%, p = 0.06). Outcome for FBXW7 MUT patients was generally enhanced than FBXW7 WT patients, RR 4 versus 15%, respectively (p = 0.08), EFS 93 versus 82% (p = 0.1), and OS 100 versus 87% (p = 0.02). Of 29 FBXW7 MUT patients, only one relapsed and no one had died. In the combined genotype groups, there was non-significantly low RR according to the mutation numbers, 17, 15 and 5% for NOTCH1 WT/FBXW7 WT, NOTCH1 Single/FBXW7 WT and NOTCH1 +/- FBXW7 Double patients, respectively (P for trend = 0.1), and significantly better EFS (78, 84, and 92%; p = 0.04) and OS (82, 88 and 100%; p = 0.005) [&lt;ulink linkType="Reference" linkID="1394124"&gt;1394124&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, results were published. There were no significant difference in event-free survival (EFS) between the group given one delayed intensification (94.4% at five years) and that given two delayed intensifications (95.5%, p = 0·99). The two groups showed a difference in five-year EFS of 1.1%. A total of 11 patients on one delayed intensification showed an actuarial relapse at five years of 5.6%and  six patients on  two delayed intensifications relapsed (p = 0.23) [&lt;ulink linkType="Reference" linkID="1569060"&gt;1569060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, results were published. Results showed that, compared to standard group, in the augmented treatment group, the five-year event-free survival was better, after a median follow-up of 70 months (p = 0.04). Than in the standard group, in the augmented treatment group, overall survival at five years was numerically, but not significantly higher (OR 0.67, p = 0.16) [&lt;ulink linkType="Reference" linkID="1622659"&gt;1622659&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, results were published. Generic HRQoL was found to be significantly lower than equivalent norm scores for healthy subjects at each time point. Before recovering gradually (but remained below pre-treatment levels), HRQoL decreased significantly at the start of treatment. Older patients worried more about side effects and their appearance, but compared to younger patients, showed less procedural anxiety. Compared to male patients, concern for appearance was found to be greater among female patients. No statistically significant differences were observed in HRQoL by number of DI blocks received [&lt;ulink linkType="Reference" linkID="1996024"&gt;1996024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;para&gt; &lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be  assigned to MRD risk groups based on day 29 and post consolidation MRD      results. Patients would be randomized as follows:&lt;br/&gt;MRD low risk group (MRD negative at day 29 and week 11 or positive &amp;lt; 1 x 10[4] at day 28           and negative at week 11) would continue on previously assigned regimens (A or B) but           would be randomized between two delayed intensifications and one delayed intensification.&lt;br/&gt;MRD high risk group (MRD positive &amp;gt; 1 x 10[4] at day 29) would be randomized between previously           assigned regimen (A or B) and regimen C.&lt;br/&gt;MRD indeterminate group (no MRD result or MRD positive &amp;lt; 1 x 10[4] at day 29 and at week           11) would continue on previously assigned regimen (A or B). In addition, patients in this group would receive two delayed           intensifications. &lt;/para&gt;&lt;para&gt;Patients  would receive  vincristine, &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt; and Capizzi maintenance (iv methotrexate and &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt;) as intensified treatment. Deletion of one 7-week treatment block containing dexamethasone, vincristine, doxorubicin, &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt;, intrathecal methotrexate, cyclophosphamide and cytarabine.&lt;/para&gt;&lt;para&gt;Initially, eligible patients would  be stratified into three risk groups based on the following criteria:&lt;br/&gt;Standard risk: all children with age between &amp;gt; 1 and &amp;lt; 10 years with a highest white cell count (WBC) before starting treatment of &amp;lt; 50 x 10(9)/l, and who do not have BCR-ABL, hypodiploidy (&gt;/= 44 chromosomes), or an MLL gene rearrangement.&lt;br/&gt;Intermediate risk: all children &gt;/= 10 years old, or with a diagnostic WBC &gt;/= 50 x 10(9)/l (or both) and who do not have BCR-ABL, hypodiploidy (&gt;/= 44 chromosomes), or an MLL gene rearrangement.&lt;br/&gt;High risk: all children, irrespective of initial risk category, who have a slow early response (SER) as defined below - together with those who have BCR-ABL (induction only), hypodiploidy (&gt;/= 44 chromosomes), or an MLL gene rearrangement. These patients would  not be eligible for MRD randomization.&lt;/para&gt;&lt;para&gt;Patients would then start treatment according to their risk group as follows:&lt;br/&gt;Standard risk, (around 60 to 65% of the total): regimen A - three-drug induction.&lt;br/&gt;Intermediate risk, (around 20 to 30% of the total): regimen B - four-drug induction.&lt;br/&gt;High risk (around 10 to 12% of the total): these patients would not be eligible for MRD randomization. They would be allocated regimen C - four drug induction, augmented BFM consolidation, Capizzi interim maintenance, and two further BFM-style intensification periods of extended duration.&lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Throughout therapy, patients enrolled in this trial were consented for trough asparaginase activity analysis. National Cancer Institute (NCI) standard risk (SR) patients with rapid early response and non-high risk (HR) cytogenetics were administered with regimen A, a three-drug induction (dexamethasone, vincristine, and &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt; [1000 U/m2]). All other patients were administered with additional daunorubicin throughout induction. NCI high risk (HR) patients were administered with regimen B. Patients on regimen A/B went on to regimen C as a result of either HR cytogenetics, slow early response or high MRD that randomized patients to continue the assigned regimen A/B or change to regimen C. Patients received &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt; (1000 U/m2) on days 4 and 18 of induction, and at least once post-induction [&lt;ulink linkType="Reference" linkID="1243616"&gt;1243616&lt;/ulink&gt;]. Compared with standard therapy, the augmented treatment regimen (regimen C) included an additional eight doses of  &lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt;, 18 doses of vincristine, and escalated-dose intravenous methotrexate without folinic acid rescue during interim maintenance courses [&lt;ulink linkType="Reference" linkID="1622659"&gt;1622659&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1996024"&gt;1996024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients were randomized to receive either one (n = 260) or two (n = 261) delayed intensification courses (&lt;ulink linkType="Drug" linkID="2573"&gt;PEG-asparaginase&lt;/ulink&gt; on day 4; vincristine, dexamethasone [alternate weeks], and doxorubicin for 3 weeks; and 4 weeks of cyclophosphamide and cytarabine) [&lt;ulink linkType="Reference" linkID="1569060"&gt;1569060&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>intensification course</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="104">Down syndrome</Indication></AdverseEvent><AdverseEvent><Indication id="124">Fungal infection</Indication></AdverseEvent><AdverseEvent><Indication id="40">Bacterial infection</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>Standard group (aspariginase)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="250">Pancreatitis</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="505">Hypersensitivity</Indication><CountPatientsAffectedPercentage>6.7</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>Augmented group (aspariginase)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="250">Pancreatitis</Indication><CountPatientsAffectedPercentage>0.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="505">Hypersensitivity</Indication><CountPatientsAffectedPercentage>0.8</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>Standard group (methotrexate)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>18.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1263">Mucositis</Indication><CountPatientsAffectedPercentage>4.1</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>Augmented group (methotrexate)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>4.5</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1263">Mucositis</Indication><CountPatientsAffectedPercentage>1.1</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Sheffield Children's Hospital</Name><Address1>Sheffield</Address1><Address3>S10 2TH</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ajay.vora@sch.nhs.uk</Email><Name>Ajay Vora</Name></Contact></Contacts></Site><Site><Contacts/></Site><Site><Name>Sheffield Children's Hospital</Name><Contacts/></Site><Site><Name>Sheffield Children s Hospital</Name><Address1>Sheffield</Address1><Address3> S10 2TH</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3975">Subjects with Acute Leukemia Unspecified Type</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3979">Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3986">Pediatric Leukemia Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00222612</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="Secondary Organisational">ISRCTN07355119</Identifier></Identifiers></Registry><Registry><Name id="1023">UK Clinical Research Network (UKCRN)</Name><Identifiers><Identifier>UKCRN 1287</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="7897"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7898">Assessment of event free survival (EFS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="7879"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7952"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8147">Assessment of minimal residual disease</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="7921"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7923">Assessment of relapse incidence (RI) </SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8079">Assessment of serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8109"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="4973"><Criterion>Subjects with Acute Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4985"><Criterion>Subjects with Acute Lymphocytic Leukemia (ALL)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5157"><Criterion>Subjects with Response to Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5163">Subjects in complete response/remission</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="7092"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5102">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Leukemia" id="6486"><Criterion>Subjects with BCR-ABL Positive/Philadelphia Positive Leukemia</Criterion></Exclusion><Exclusion disease="Leukemia" id="6492"><Criterion>Subjects with Specific Sub-type of Lymphoid Leukemia</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6495">Subjects with B-cell leukemia</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>152.03 Months</EnrollmentPeriod><EnrollmentRate>13.81 Patients/Month</EnrollmentRate><DateFirstReceived>2005-09-13T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-02-16T11:51:39Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="85251"><TitleDisplay>A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer</TitleDisplay><TitleOfficial>A Randomized, Open-Label, Multicenter, Phase II Trial Comparing The Conventional 3-Weekly Schedule Of Cabazitaxel With A Weekly Regimen In Patients With Metastatic Castration Resistant Prostate Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">2011-004178-27</Identifier><Identifier type="NCT">NCT01541007</Identifier><Identifier type="Other">KS-01</Identifier><Identifier type="Trial Acronym">ConCab</Identifier></Identifiers><Indications><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="3664">Metastatic prostate cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cabazitaxel</Name><Drug id="28035">cabazitaxel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="28035">cabazitaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="1009547">Sanofi SA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="26093">Karolinska University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="28035" type="Drug"><TargetEntity id="287186" type="siDrug">Cabazitaxel</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="26093" type="Company"><TargetEntity id="5035524353" type="organizationId">Karolinska Universitetssjukhuset</TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity><SourceEntity id="3664" type="ciIndication"><TargetEntity id="10036909" type="MEDDRA"/><TargetEntity id="639" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="26093">Karolinska University Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1009547">Sanofi SA</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="852">Intravesical formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><PatientCountEvaluable>100</PatientCountEvaluable><DateStart>2012-04-30T00:00:00Z</DateStart><DateEnd type="actual">2015-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-24T11:57:16Z</DateChangeLast><DateAdded>2012-03-02T11:26:46Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Stockholm Läns Landsting</Affiliation><Email>johanna.vernersson@karolinska.se</Email><Name>Clinical Trials Unit</Name><Phone>468517-763 77</Phone></Contact><Contact type="Public contact"><Affiliation>Karolinska University Hosptial</Affiliation><Name>Jeffrey R Yachnin, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histological confirmed prostate cancer&lt;/li&gt;&lt;li&gt;Macroscopic metastatic disease&lt;/li&gt;&lt;li&gt;Prior treatment with docetaxel&lt;/li&gt;&lt;li&gt;Castration resistant disease defined as: serum testosterone (&amp;lt; 0.5 ng/ml) and:&lt;ul&gt;&lt;li&gt;Increase in measurable disease (RECIST 1.1)&lt;/li&gt;&lt;li&gt;For non-measurable disease, the appearance of at least one new lesion on nuclear             scintigraphy)&lt;/li&gt;&lt;li&gt;A rising prostate-specific antigen (PSA) from the previous reference value on two consecutive occasions at least             1 week apart&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Less than 21 days since prior treatment with chemotherapy&lt;/li&gt;&lt;li&gt;Less than 14 days since radiotherapy or surgery to the start of&lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Less             than 4 weeks after stopping endocrine therapies including antiandrogen, abiraterone             or other new agents&lt;/li&gt;&lt;li&gt;Prior isotope therapy or radiotherapy to&amp;gt; 30% of bone marrow (whole pelvic             radiotherapy is not an exclusion criteria)&lt;/li&gt;&lt;li&gt;Persistent adverse events from previous cancer therapies&amp;gt; grade 1 (CTCAE  - version             4.0) with the exception of alopecia (with respect to peripheral neuropathy and nail             changes grade 2 is acceptable)&lt;/li&gt;&lt;li&gt;Eastern oncology cooperative group (ECOG) performance status&amp;gt; 1&lt;/li&gt;&lt;li&gt;Known CNS malignancy&lt;/li&gt;&lt;li&gt;Within 6 months of randomization:&lt;ul&gt;&lt;li&gt;Myocardial infarction&lt;/li&gt;&lt;li&gt;Unstable angina&lt;/li&gt;&lt;li&gt;Angioplasty&lt;/li&gt;&lt;li&gt;Bypass surgery&lt;/li&gt;&lt;li&gt;Stroke&lt;/li&gt;&lt;li&gt;TIA&lt;/li&gt;&lt;li&gt;Congestive heart failure NYHA class III or IV&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Within 3 months prior to randomization:&lt;ul&gt;&lt;li&gt;Treatment resistant peptic ulcer disease&lt;/li&gt;&lt;li&gt;Infectious or inflammatory bowel disease&lt;/li&gt;&lt;li&gt;Pulmonary embolism&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Any severe acute or chronic medical condition that places the patient at                  increased risk of serious toxicity or interferes with the interpretation of                  study results&lt;/li&gt;&lt;li&gt;History of hypersensitivity to docetaxel or polysorbate 80&lt;/li&gt;&lt;li&gt;Inadequate organ and bone marrow function as evidenced by:&lt;ul&gt;&lt;li&gt;Hemoglobin&amp;lt; 9.0 g/dl&lt;/li&gt;&lt;li&gt;Absolute neutrophil count&amp;lt; 1.5 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelet count&amp;lt; 100 x 10(9)/l&lt;/li&gt;&lt;li&gt;AST/SGOT and/or ALT/SGPT&amp;gt; 1.5 x ULN&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;gt; 1.0 x ULN&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;gt; 1.5 x ULN. If creatinine 1.0 to 1.5 x ULN, creatinine                  clearance will be calculated according to CKD-EPI formula and patients with                  creatinine clearance &amp;lt; 60 ml/min should be excluded (http://mdrd.com/ for                  on-line calculation)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450             3A4/5. A 1 week wash-out period is necessary for patients who are already on these             treatments&lt;/li&gt;&lt;li&gt;Patients with reproductive potential not implementing accepted and effective method             of contraception&lt;/li&gt;&lt;li&gt;Unable to comply with study procedures&lt;/li&gt;&lt;li&gt;Age&amp;lt; 18 years  &lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Dose intensity</Description></Measure><Measure><Description>Relative cumulative dose of cabazitaxel at week 18: the primary end-point compares the cumulative dose of cabazitaxel that is received relative to the planned dose at 18 weeks of therapy. The cumulative dose of cabazitaxel in relation to the expected dose is a reflection of both tolerability and efficacy. Patients stopping treatment due to disease progression prior to week 18 will have lower relative cumulative doses as will patients with poor tolerability due to dose reductions and delays</Description><Timeframe>Week 18 after start of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disease Specific Survival</Description><Timeframe>When the last patient enrolled has either stopped treatment prior to week 18 or has reached the 18 th week of therapy all patients will be evlauated for all endpoints</Timeframe></Measure><Measure><Description>Quality of Life: quality of life will be assessed using the FACT-P-T self administered questionnaire. Patients will complete the questionnaire at baseline and the day before the 3 week general assessments. The questionnaire is to be answered at home</Description><Timeframe>When the last patient enrolled has either stopped treatment prior to week 18 or has reached the 18 th week of therapy all patients will be evlauated for all endpoints</Timeframe></Measure><Measure><Description>Dose Intensity at 24 and 36 weeks: dose intensity is defined in the same manner as for the primary endpoint</Description><Timeframe>When the last patient enrolled has either stopped treatment prior to week 18 or has reached the 18 th week of therapy all patients will be evlauated for all endpoints</Timeframe></Measure><Measure><Description>Tolerability: the primary endpoint in this protocol is chosen as a means of estimating tolerability. Another estimate of tolerability will be made by examining the frequency of patients requiring a dose reduction, a dose delay as well as patients. At each cycle of therapy evaluation, three questions will apply: is the patient stopping treatment for reasons of toxicity and not disease progression; is there a dose delay due to toxicity; or is there dose reduction; if the answer is yes to any of the three questions, this will be recorded as an event. A patient may subsequently have more than one event, (ie, dose delay [one event], dose reduction [one event], stopping treatment [one event])</Description><Timeframe>When the last patient enrolled has either stopped treatment prior to week 18 or has reached the 18 th week of therapy all patients will be evlauated for all endpoints</Timeframe></Measure><Measure><Description>Duration of Treatment: duration of treatment is defined as the length of time from the first day of treatment to the last day of treatment with cabazitaxel. Efficacy of cabazitaxel in relation to the total cumulative dose of prior treatment with docetaxel. Efficacy endpoints described above will be correlated to the cumulative dosage of docetaxel prior to study treatment</Description><Timeframe>When the last patient enrolled has either stopped treatment prior to week 18 or has reached the 18 th week of therapy all patients will be evlauated for all endpoints</Timeframe></Measure><Measure><Description>Frequency and time to skeletal related events</Description><Timeframe>When the last patient enrolled has either stopped treatment prior to week 18 or has reached the 18 th week of therapy all patients will be evlauated for all endpoints</Timeframe></Measure><Measure><Description>Pain progression</Description></Measure><Measure><Description>Overall survival: overall survival is defined as the length of time from randomization to death from any cause</Description><Timeframe>When the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date</Timeframe></Measure><Measure><Description>Progression free survival: progression free survival is defined as the length of time from randomization to the first documentation of one of the following: PSA progression or pain progression or death due to any cause or radiological disease progression</Description><Timeframe>When the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date</Timeframe></Measure><Measure><Description>PSA response: only considered after 12 weeks of treatment. PSA response is defined as a 50% or greater decline in serum PSA from baseline given that baseline PSA is at least 10 ng/ml</Description><Timeframe>When the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In July 2018, results were published. In arm B, more patients stopped treatment due to toxicity. Febrile neutropenia of grade 5 was noted in arm A. With weekly cabazitaxel, low-grade hematuria was found to be more prevalent (15 versus 5 events; p = 0.003). A total of three patients in arm B reported clinically significant inflammation of the ureters [&lt;ulink linkType="Reference" linkID="2056451"&gt;2056451&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study  examined another scheduling for      &lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt; to see if investigators could improve tolerability so that patients would receive a higher      percentage of the treatment as planned. This study aimed to      evaluate differences in the total received dose in relation to the planned dose as a measure      of which of the two treatment schedules was superior.&lt;/para&gt;&lt;para&gt;The main objective of the trial was to determine if a weekly regime improves tolerability of &lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt; compared to the standard 3 week regimen. &lt;/para&gt;&lt;para&gt;The secondary objectives of the trial was to compare drug efficacy, drug safety and patient quality of life in a weekly and three week scheduling of &lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;The study hypothesised that the experimental arm (arm B) would result in a 20% absolute increase in the relative cumulative dose by week 18 [&lt;ulink linkType="Reference" linkID="2056451"&gt;2056451&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In July 2018, results were published. In arms A and B, median doses of cabazitaxel were 276 and 257 mg, respectively, at week 18 (p = 0.13). In arm A versus B, median PFS and OS were 6 versus 6.4 months (hazard ratio [HR] 0.73; p = 0.156) and 14.6 and 15.6 months (HR 0.95; p = 0.85), respectively. In arms A and B, PSA responses &gt;/= 50% were noted in 52 and 46% of patients, respectively [&lt;ulink linkType="Reference" linkID="2056451"&gt;2056451&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study  would compare the standard treatment of &lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt; (25 mg/m2, q3w) with an      experimental scheduling of &lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt; (10 mg/m2) for 5 consecutive weeks of a 6-week cycle. In both study      arms, the planned cumulative dose of &lt;ulink linkType="Drug" linkID="28035"&gt;cabazitaxel&lt;/ulink&gt; at week 18 was 150 mg/m2. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomly assigned to arm A, cabazitaxel q3w, 25 mg/m2 or arm B, q1w, 10 mg/m2 5 of 6 weeks [&lt;ulink linkType="Reference" linkID="2056451"&gt;2056451&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>cabazitaxel</Name><Drug id="28035">cabazitaxel</Drug><Dose unit="milligram/m2 dose">10.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2291">Hematuria</Indication></AdverseEvent><AdverseEvent><Indication id="2949">Ureteral disease</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>cabazitaxel</Name><Drug id="28035">cabazitaxel</Drug><Dose unit="milligram/m2 dose">25.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2291">Hematuria</Indication></AdverseEvent><AdverseEvent><Indication id="3795">Febrile neutropenia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="210822">cabazitaxel</Intervention><Treatments><Treatment><Dose>10 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>25 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>150 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Sweden"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trials Unit</Name></Contact></Contacts></Site><Site><Name>Deapartment of Oncology Karolinska University Hospital</Name><Address1>Stockholm</Address1><Address3>171 76</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3565">Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3583">Subjects with Castrate Resistant Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3586">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="9106">Subjects with Rising PSA levels</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01541007</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Organisational Study">2011-004178-27</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7217"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7045"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7049"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7130">Assessment of PSA response</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3695"><Criterion>Subjects with Stage IV Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3704"><Criterion>Subjects with Progressive Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3705">Subjects with rising PSA levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3712"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3713"><Criterion>Subjects with Non-measurable Disease</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3717">Subjects with castrate level of testosterone</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3745"><Criterion>Subjects on Prior/Concurrent Therapy for Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3747">Subjects on prior/concurrent chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3755"><Criterion>Subjects with Castrate Resistant Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4876"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4888"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4871">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Prostate tumor" id="4884">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Prostate tumor" id="4921">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4943"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4947"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4966">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4967">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4968">Subjects on prior/concurrent radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4975"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4989"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2015-10-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>42.00 Months</EnrollmentPeriod><EnrollmentRate>2.38 Patients/Month</EnrollmentRate><DateFirstReceived>2012-02-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-03-02T11:26:46Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-05-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-11-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-07-25T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2018-07-25T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-25T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-25T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-25T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="95572"><TitleDisplay>Assessment Of Airway Obstruction In Infants With Lower Respiratory Infections</TitleDisplay><TitleOfficial>Assessment Of Airway Obstruction In Infants With Lower Respiratory Infections</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">0311-21</Identifier><Identifier type="NCT">NCT00435994</Identifier></Identifiers><Indications><Indication id="2976">Bronchiolitis</Indication><Indication id="511">Lower respiratory tract infection</Indication></Indications><BiomarkerNames><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2029" role="Therapeutic effect marker" type="Physiological">Forced expiratory flow </BiomarkerName><BiomarkerName id="11359" role="Therapeutic effect marker" type="Genomic;Proteomic">Vascular endothelial growth factors</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>primatene</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1037733" type="Company"><TargetEntity id="5011812131" type="organizationId">Thrasher Research Fund</TargetEntity></SourceEntity><SourceEntity id="1041898" type="Company"><TargetEntity id="5012759902" type="organizationId">Indiana University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="2976" type="ciIndication"><TargetEntity id="10006448" type="MEDDRA"/><TargetEntity id="D001988" type="MeSH"/><TargetEntity id="-414497616" type="omicsDisease"/><TargetEntity id="276" type="siCondition"/></SourceEntity><SourceEntity id="511" type="ciIndication"><TargetEntity id="10024968" type="MEDDRA"/><TargetEntity id="923" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1041898">Indiana University School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1037733">Thrasher Research Fund</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>59</PatientCountEnrollment><DateStart>2003-12-31T00:00:00Z</DateStart><DateEnd type="actual">2012-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-03-31T04:18:15Z</DateChangeLast><DateAdded>2012-10-25T10:55:08Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Indiana University</Affiliation><Name>Robert S. Tepper, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Group 1: infants between 2 and 24 months that are healthy&lt;/li&gt;&lt;li&gt;Group 2: infants between 2 and 24 months that have RSV or bronchiolitis and defined as             the first episode of wheezing&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Group 1 and 2:&lt;ul&gt;&lt;li&gt;No cardiac disease, no oxygen requirement, prematurity&amp;lt; 37 weeks,             and cannot be in the ICU&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Lung function: lung functions were obtained under sedation using chloral hydrate. Forced expiratory flows are a lung volume at which the airway pressure is equal to 30 cm H2O (V30). Forced expiratory flows are measured at 75% FVC (FEF75). Measurements were repeated post bronchodilator and again post epinephrine. A higher Z-score reflects better lung function</Description><Timeframe>Baseline, Post bronchodilator (up to 10 min, post-epinephrine up to 30 min)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Endothelial growth factor (VEGF): analysis for VEGF level by ELISA</Description><Timeframe>During nasal wash</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate how two different aerosol medications may improve      airway function in infants with respiratory illness.  This study  used  two different medications      and compared the difference in lung function after each medication.The investigators  took a nasal wash sample for VEGF. The investigators used this in comparing how infants respond to the aerosol medications as well. The study  hypothesized that vascular endothelial growth factor (VEGF) production was higher in children with RSV infection than in children with other viral infections and normal controls. In addition, the degree of VEGF production was related to severity of airway obstruction. The study also hypothesized  that infants with higher VEGF levels were more likely to improve lung function following racemic epinephrine than albuterol.    The study aimed to standardize medications used for infants with      bronchiolitis and  respiratory syncytial virus infections (RSV). &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Healthy and infants between the ages of 2 to 24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants would receive inhaled primatene (epinephrine) 0.5 ml of the 2.25% concentration once given as a breathing treatment.  Nasal washing would include 1 to 3 mls of normal saline would be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which would be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence. Infants 2  to 24 months who were diagnosed with bronchiolitis would received nasal wash only (1 to 3 mls of normal saline). Nasal wash sample for VEGF would be collected from  the infants and that would be used   in comparing how infants respond to the aerosol medications as well.&lt;br/&gt;While the  subject was being sedated, an inhaled mist of primetine mist would  be given to the patient. Infant pulmonary functions would follow the breathing treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Riley Hospital for Children</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3>46202</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00435994</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2009-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>67.03 Months</EnrollmentPeriod><EnrollmentRate>0.88 Patients/Month</EnrollmentRate><DateFirstReceived>2007-01-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-25T10:55:08Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="96350"><TitleDisplay>Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)</TitleDisplay><TitleOfficial>Impact of Regional Anesthesia Versus General Anesthesia on Immune Modulation and Clearance of Circulating Tumor Cells (CTC) in Subjects Undergoing Surgery for Primary Non-metastatic Breast Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">355841-17</Identifier><Identifier type="NCT">NCT01716065</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames><BiomarkerName id="2686" role="Disease marker" type="Cellular">Dendritic cells</BiomarkerName><BiomarkerName id="2706" role="Disease marker" type="Cellular">Natural killer cells</BiomarkerName><BiomarkerName id="6663" role="Disease marker" type="Cellular">B-lymphocytes</BiomarkerName><BiomarkerName id="36136" role="Disease marker" type="Genomic;Proteomic">Cytokines</BiomarkerName><BiomarkerName id="46506" role="Disease marker" type="Cellular">T-Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>general anesthesia</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>regional anesthesia</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1074616" type="Company"><TargetEntity id="5037940727" type="organizationId">Defense &amp; Veterans Center for Integrative Pain Management</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1074616">Defense and Veterans Center for Integrative Pain Management</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2012-06-30T00:00:00Z</DateStart><DateEnd type="actual">2013-05-31T00:00:00Z</DateEnd><DateChangeLast>2014-05-02T06:45:08Z</DateChangeLast><DateAdded>2012-11-02T11:05:58Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female  subjects should be  &gt;/= 18 years of age and capable of providing             informed consent indicating awareness of the investigational nature of this trial, in             keeping with institutional policy&lt;/li&gt;&lt;li&gt;Written informed consent must be obtained from each subject prior to entering the             study&lt;/li&gt;&lt;li&gt;Subjects with primary non-metastatic American Joint Committee on Cancer (AJCC)  stages I,  II or III, scheduled to undergo             either unilateral mastectomy with or without Sentinel lymph node biopsy or axillary             dissection, or unilateral lumpectomy with Sentinel lymph node biopsy or axillary             lymph node dissection&lt;/li&gt;&lt;li&gt;Able to stay overnight in the hospital post surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any subject&amp;lt; 18 years or &gt; 85 years of age&lt;/li&gt;&lt;li&gt;History of previous breast surgery (aside from biopsy), planned breast conserving             operation (isolated lumpectomy) or reconstruction (rectus or latissimus flap)&lt;/li&gt;&lt;li&gt;American Society of Anesthesia (ASA) classification of  four or greater, or any             contraindication to having regional anesthesia&lt;/li&gt;&lt;li&gt;Any subjects who receives an intraoperative or postoperative blood transfusion during             the period of venous blood sampling&lt;/li&gt;&lt;li&gt;Subjects who are pregnant. Exclusion of the possibility of pregnancy by testing             (urine HCG) or by history (tubal ligation, hysterectomy, or menopause) is required             prior to inclusion in the study&lt;/li&gt;&lt;li&gt;Subjects with active infectious process at the site of proposed paravertebral             injection&lt;/li&gt;&lt;li&gt;Subjects with significant allergy to local anesthetics&lt;/li&gt;&lt;li&gt;Subjects who convert from regional anesthesia (RA) to general anesthesia (GA) during surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Circulating Tumor Cells: blood will be drawn preoperative (&gt;/= 24 h before surgery), immediate prior to surgery, immediately postoperative, 12 to 24 h postoperative, and at postoperative appointment</Description><Timeframe>5 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Levels of cytokines</Description><Timeframe>5 days</Timeframe></Measure><Measure><Description>Breast cancer antibodies</Description><Timeframe>5 days</Timeframe></Measure><Measure><Description>Dendritic Cells</Description><Timeframe>5 days</Timeframe></Measure><Measure><Description>T and B lymphocytes</Description><Timeframe>5 days</Timeframe></Measure><Measure><Description>Natural Killer Cells (NK cells)</Description><Timeframe>5 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to determine whether the type of anesthesia during breast cancer      surgery has any impact on the way a patient's immune system functions for a brief period      after surgery. If the investigators find that one type of anesthesia versus the other was      more beneficial to a patient's immune system, then the investigators may use this      information to design a larger study to exam the effect of anesthesia better.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who received regional anesthesia  or general anesthesia would be enrolled in the study. Samples collected for circulating tumor cells (CTC) analysis (two tubes of 8 ml of blood) would be drawn at four time points: pre-operative (&gt;/= 24 h before surgery), immediate prior to surgery, 12 to 24 h post-operative, and 5 to 7 days post-operative.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Walter Reed National Military Medical Center</Name><Address1>Bethesda</Address1><Address2>Maryland</Address2><Address3>20889</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3943">Subjects with Stage I Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3944">Subjects with Stage II Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3945">Subjects with Stage III Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3950">Subjects with Early Stage Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3952">Subjects with Locally Advanced Breast Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="9010">Solid tumor subjects for supportive care</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01716065</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8728">Assessment of circulating tumor cell response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19411"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19412">Assessment of Other Treatment or Procedure Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8902"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8949">Assessment of Dendritic cells (DC)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8950"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8955">Assessment of lymphocytes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19329"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19330">Assessment of inflammatory/proinflammatory cytokine levels</SubEndpoint><SubEndpoint disease="Cancer supportive care" id="19332">Assessment of lymphocytes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19334"><Endpoint>Assessment of Antibodies</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4823"><Criterion>TNM Stage I Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4824"><Criterion>TNM Stage II Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4827"><Criterion>TNM Stage III Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4870"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4871">Subjects history/scheduled for mastectomy</SubCriterion><SubCriterion disease="Breast tumor" id="4873">Subjects history/scheduled for lumpectomy</SubCriterion><SubCriterion disease="Breast tumor" id="4875">Subjects history/scheduled for axillary lymphadenectomy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22417"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22418"><Criterion>Subjects with Early Breast Cancer</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="34403"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13377">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6272"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10882"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10900"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10908"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10914">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26891"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20290">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-02T11:05:58Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-05-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="97659"><TitleDisplay>Effects Of Pulsed Magnetic Pads On Rheumatoid Arthritis Symptoms In Postmenopausal Women</TitleDisplay><TitleOfficial>Pulsed Electromagnetic Field (PEMF) Efficacy In Reducing Rheumatoid Arthritis Symptoms</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">R21 AT001469-01A2</Identifier><Identifier type="NCT">NCT00110565</Identifier></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="781" role="Therapeutic effect marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName><BiomarkerName id="2613" role="Therapeutic effect marker" type="Biochemical">Norepinephrine</BiomarkerName><BiomarkerName id="6111" role="Therapeutic effect marker" type="Biochemical">Epinephrine</BiomarkerName><BiomarkerName id="11622" role="Therapeutic effect marker" type="Genomic">Interleukin 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Pulsed magnetic field pad</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1036410" type="Company"><TargetEntity id="5035525593" type="organizationId">National Center for Complementary and Integrative Health</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1036410">National Center for Complementary and Alternative Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>87</PatientCountEnrollment><DateStart>2005-01-31T00:00:00Z</DateStart><DateEnd type="actual">2007-07-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-23T12:00:39Z</DateChangeLast><DateAdded>2012-11-14T09:12:36Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Virginia</Affiliation><Name>Cheryl M. Bourguignon, PhD, RN</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of RA&lt;/li&gt;&lt;li&gt;Postmenopausal, defined by no menstrual period in at least  two  years prior to study             entry or a hysterectomy&lt;/li&gt;&lt;li&gt;Average pain of 2 or greater on a 0 to 10 pain scale&lt;/li&gt;&lt;li&gt;Sleep difficulty&lt;/li&gt;&lt;li&gt;Stable medication use related to RA for at least 4 weeks prior to study entry&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnoses of lupus, sleep apnea, or restless leg syndrome&lt;/li&gt;&lt;li&gt;High-dose prednisone (&gt; 10 mg/day) or equivalent&lt;/li&gt;&lt;li&gt;Pacemakers or other implanted devices&lt;/li&gt;&lt;li&gt;Epilepsy&lt;/li&gt;&lt;li&gt;Currently undergoing treatment for cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Fatigue</Description></Measure><Measure><Description>Sleep disturbances</Description></Measure><Measure><Description>Depression</Description></Measure><Measure><Description>Perceived stress</Description></Measure><Measure><Description>Stress hormones (norepinephrine and epinephrine)</Description></Measure><Measure><Description>Cortisol</Description></Measure><Measure><Description>Pro-inflammatory cytokines (IL-1, IL-6)</Description></Measure><Measure><Description>Erythrocyte sedimentation rate (ESR)</Description></Measure><Measure><Description>C-reactive protein (CRP)</Description></Measure><Measure><Description>Functional status</Description></Measure><Measure><Description>Feasibility of study</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether a pulsed magnetic field (PMF) pad will      improve symptoms of rheumatoid arthritis (RA) in postmenopausal female subjects.The study hypothesized that pulsed magnetic field pad would effectively reduce the symptoms of RA in      postmenopausal female subjects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would last 12 weeks. Subjects would  be randomly assigned to one of three groups:      &lt;br/&gt;Active PMF pad treatment, sham PMF pad treatment, or standard of care, which would include drug      therapy or physical therapy. Subjects in the active and sham PMF pad groups would be      treated with their assigned pad for approximately 8 min, twice a day for the duration of      the study. Questionnaires and self-report scales would be used to assess pain, fatigue, sleep      quality, mood, and inflammation episodes. Blood and urine collection would occur to assess      levels of stress hormones and certain proteins.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Virginia</Name><Address1>Charlottesville</Address1><Address2>Virginia</Address2><Address3>22903</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8388">Subjects with Mild to Moderate Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment><SubSegments><SubSegment id="8414">Subjects with arthritic pain</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Menopause</Disease><PatientSegments><PatientSegment><PatientSegment id="19017">Subjects with Protocol Specified Menstrual Status</PatientSegment><SubSegments><SubSegment id="11612">Postmenopausal Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00110565</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Rheumatoid arthritis" id="3955"><Endpoint>Assessment of pain</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Menopause" id="23541"><Endpoint>Assessment of pain</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25988"><Endpoint>Assessment of Underlying Conditions</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25992">Musculoskeletal disease related outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Rheumatoid arthritis" id="3924"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3952"><Endpoint>Symptomatic Assessment of Rheumatoid Arthritis Patients</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3954"><Endpoint>Assessment of Fatigue</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3999"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4000">Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</SubEndpoint><SubEndpoint disease="Rheumatoid arthritis" id="4001">Cytokines/Chemokines</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4112"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4240">Hormonal Assay</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4155"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4247">Feasibility/Performance of Therapy/Device</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Menopause" id="23534"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Menopause" id="23538">Assessment of psychological symptoms</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Menopause" id="23536"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Menopause" id="23550"><Endpoint>Assessment of Hormone Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25983"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26007"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26019">Assessment of hematological function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26024">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="44295"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4189">Assessment of sleep quality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Menopause" id="44992"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Menopause" id="23557">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="45616"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4017">Erythrocyte sedimentation rate (ESR)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Rheumatoid arthritis" id="1969"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1938">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="2014"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2015">Pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22091"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Pain" id="22092">Subjects with mild pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22191">Subjects with central nervous system disease/disorder associated pain</SubCriterion><SubCriterion disease="Pain" id="22196">Subjects with infectious/inflammatory/immunological disease/disorder associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Menopause" id="33715"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Menopause" id="20758">Postmenopausal subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Rheumatoid arthritis" id="2845"><Criterion>Subjects with History of Use of Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2849">Subjects with history of corticosteroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2885"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2906"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2833">Subjects with systemic lupus erythematosus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2915"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2931"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Menopause" id="18296"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Menopause" id="18300"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Menopause" id="18301"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18302"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18317"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20135">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2007-07-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2007-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>26.03 Months</EnrollmentPeriod><EnrollmentRate>3.34 Patients/Month</EnrollmentRate><DateFirstReceived>2005-05-10T00:00:00Z</DateFirstReceived><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-14T09:12:36Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>